1869,1810,OTVALA_ER_ERbERb_0480_CorCoef_up,0,0,,binding,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1870,1810,OTVALA_ER_ERbERb_0480_CorCoef_dn,0,0,,binding,percent_activity,negative,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1871,1811,OTVALA_ER_ERbERb_1440_CellCount_up,0,0,,binding,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1872,1811,OTVALA_ER_ERbERb_1440_CellCount_dn,0,0,,binding,percent_activity,negative,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1873,1812,OTVALA_ER_ERbERb_1440_CorCoef_up,0,0,,binding,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1874,1812,OTVALA_ER_ERbERb_1440_CorCoef_dn,0,0,,binding,percent_activity,negative,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1875,1813,OTVALA_AR_ARSRC1_0960_CellCount_up,0,0,,binding,percent_activity,positive,0,"4,5-alpha-Dihydrotestosterone",,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1876,1813,OTVALA_AR_ARSRC1_0960_CellCount_dn,0,0,,binding,percent_activity,negative,0,"4,5-alpha-Dihydrotestosterone",,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1877,1814,OTVALA_AR_ARSRC1_0960_CorCoef_up,0,0,,binding,percent_activity,positive,0,"4,5-alpha-Dihydrotestosterone",,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
2,1,ACEA_ER_80hr,1,1,"Data from the assay component ACEA_ER_80hr was analyzed into 2 assay endpoints. 
This assay endpoint, ACEA_ER_80hr_Positive, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",signaling,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
3,2,APR_HepG2_CellCycleArrest_1h_dn,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,cell cycle,proliferation,0,0,1
4,2,APR_HepG2_CellCycleArrest_1h_up,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,cell cycle,arrest,0,0,1
5,3,APR_HepG2_CellLoss_1h_dn,1,1,"Data from the assay component APR_HepG2_CellLoss_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
6,3,APR_HepG2_CellLoss_1h_up,1,1,"Data from the assay component APR_HepG2_CellLoss_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",viability,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,cellular,cell cycle,proliferation,0,0,1
7,4,APR_HepG2_MicrotubuleCSK_1h_dn,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,cellular,cell morphology,cell conformation,0,0,1
8,4,APR_HepG2_MicrotubuleCSK_1h_up,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,cellular,cell morphology,cell conformation,0,0,1
9,5,APR_HepG2_MitoMass_1h_dn,1,1,"Data from the assay component APR_HepG2_MitoMass_1hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
10,5,APR_HepG2_MitoMass_1h_up,1,1,"Data from the assay component APR_HepG2_MitoMass_1hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
11,6,APR_HepG2_MitoMembPot_1h_dn,1,1,"Data from the assay component APR_HepG2_MitoMembPot_1hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
12,6,APR_HepG2_MitoMembPot_1h_up,1,1,"Data from the assay component APR_HepG2_MitoMembPot_1hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
13,7,APR_HepG2_MitoticArrest_1h_dn,1,1,"Data from the assay component APR_HepG2_MitoticArrest_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,pathway,pathway-specified,cell cycle,proliferation,0,0,1
14,7,APR_HepG2_MitoticArrest_1h_up,1,1,"Data from the assay component APR_HepG2_MitoticArrest_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,pathway,pathway-specified,cell cycle,arrest,0,0,1
15,8,APR_HepG2_NuclearSize_1h_dn,1,1,"Data from the assay component APR_HepG2_NuclearSize_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,nucleus,cell morphology,organelle conformation,0,0,1
16,8,APR_HepG2_NuclearSize_1h_up,1,1,"Data from the assay component APR_HepG2_NuclearSize_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,nucleus,cell morphology,organelle conformation,0,0,1
17,9,APR_HepG2_P-H2AX_1h_dn,1,1,"Data from the assay component APR_HepG2_P-H2AX_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,dna binding,cellular response to DNA damage stimulus,0,0,1
18,9,APR_HepG2_P-H2AX_1h_up,1,1,"Data from the assay component APR_HepG2_P-H2AX_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,dna binding,cellular response to DNA damage stimulus,0,0,1
19,10,APR_HepG2_p53Act_1h_dn,1,1,"Data from the assay component APR_HepG2_p53Act_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
20,10,APR_HepG2_p53Act_1h_up,1,1,"Data from the assay component APR_HepG2_p53Act_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
21,11,APR_HepG2_StressKinase_1h_dn,1,1,"Data from the assay component APR_HepG2_StressKinase_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""stress response"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,cell cycle,stress response,0,0,1
22,11,APR_HepG2_StressKinase_1h_up,1,1,"Data from the assay component APR_HepG2_StressKinase_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""stress response"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,cell cycle,stress response,0,0,1
23,12,APR_HepG2_CellCycleArrest_24h_dn,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,cell cycle,proliferation,0,0,1
24,12,APR_HepG2_CellCycleArrest_24h_up,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,cell cycle,arrest,0,0,1
25,13,APR_HepG2_CellLoss_24h_dn,1,1,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log2_fold_induction,negative,1,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
26,13,APR_HepG2_CellLoss_24h_up,1,1,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",viability,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,cellular,cell cycle,proliferation,0,0,1
27,14,APR_HepG2_MicrotubuleCSK_24h_dn,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,cellular,cellular,cell morphology,cell conformation,0,0,1
28,14,APR_HepG2_MicrotubuleCSK_24h_up,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,cellular,cellular,cell morphology,cell conformation,0,0,1
29,15,APR_HepG2_MitoMass_24h_dn,1,1,"Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
30,15,APR_HepG2_MitoMass_24h_up,1,1,"Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
31,16,APR_HepG2_MitoMembPot_24h_dn,1,1,"Data from the assay component APR_HepG2_MitoMembPot_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
32,16,APR_HepG2_MitoMembPot_24h_up,1,1,"Data from the assay component APR_HepG2_MitoMembPot_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
33,17,APR_HepG2_MitoticArrest_24h_dn,1,1,"Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,pathway,pathway-specified,cell cycle,proliferation,0,0,1
34,17,APR_HepG2_MitoticArrest_24h_up,1,1,"Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,pathway,pathway-specified,cell cycle,arrest,0,0,1
35,18,APR_HepG2_NuclearSize_24h_dn,1,1,"Data from the assay component APR_HepG2_NuclearSize_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,nucleus,cell morphology,organelle conformation,0,0,1
36,18,APR_HepG2_NuclearSize_24h_up,1,1,"Data from the assay component APR_HepG2_NuclearSize_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,nucleus,cell morphology,organelle conformation,0,0,1
37,19,APR_HepG2_P-H2AX_24h_dn,1,1,"Data from the assay component APR_HepG2_P-H2AX_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,dna binding,cellular response to DNA damage stimulus,0,0,1
38,19,APR_HepG2_P-H2AX_24h_up,1,1,"Data from the assay component APR_HepG2_P-H2AX_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,dna binding,cellular response to DNA damage stimulus,0,0,1
39,20,APR_HepG2_p53Act_24h_dn,1,1,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
40,20,APR_HepG2_p53Act_24h_up,1,1,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
41,21,APR_HepG2_StressKinase_24h_dn,1,1,"Data from the assay component APR_HepG2_StressKinase_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""stress response"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,cell cycle,stress response,0,0,1
42,21,APR_HepG2_StressKinase_24h_up,1,1,"Data from the assay component APR_HepG2_StressKinase_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""stress response"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,cell cycle,stress response,0,0,1
43,22,APR_HepG2_CellCycleArrest_72h_dn,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,cell cycle,proliferation,0,0,1
44,22,APR_HepG2_CellCycleArrest_72h_up,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,cell cycle,arrest,0,0,1
45,23,APR_HepG2_CellLoss_72h_dn,1,1,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log2_fold_induction,negative,1,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
46,23,APR_HepG2_CellLoss_72h_up,1,1,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",viability,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,cellular,cell cycle,proliferation,0,0,1
47,24,APR_HepG2_MicrotubuleCSK_72h_dn,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,cellular,cellular,cell morphology,cell conformation,0,0,1
48,24,APR_HepG2_MicrotubuleCSK_72h_up,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,cellular,cellular,cell morphology,cell conformation,0,0,1
49,25,APR_HepG2_MitoMass_72h_dn,1,1,"Data from the assay component APR_HepG2_MitoMass_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
50,25,APR_HepG2_MitoMass_72h_up,1,1,"Data from the assay component APR_HepG2_MitoMass_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
51,26,APR_HepG2_MitoMembPot_72h_dn,1,1,"Data from the assay component APR_HepG2_MitoMembPot_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
52,26,APR_HepG2_MitoMembPot_72h_up,1,1,"Data from the assay component APR_HepG2_MitoMembPot_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
53,27,APR_HepG2_MitoticArrest_72h_dn,1,1,"Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,pathway,pathway-specified,cell cycle,proliferation,0,0,1
54,27,APR_HepG2_MitoticArrest_72h_up,1,1,"Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,pathway,pathway-specified,cell cycle,arrest,0,0,1
55,28,APR_HepG2_NuclearSize_72h_dn,1,1,"Data from the assay component APR_HepG2_NuclearSize_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,nucleus,cell morphology,organelle conformation,0,0,1
56,28,APR_HepG2_NuclearSize_72h_up,1,1,"Data from the assay component APR_HepG2_NuclearSize_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,nucleus,cell morphology,organelle conformation,0,0,1
57,29,APR_HepG2_P-H2AX_72h_dn,1,1,"Data from the assay component APR_HepG2_P-H2AX_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,dna binding,cellular response to DNA damage stimulus,0,0,1
58,29,APR_HepG2_P-H2AX_72h_up,1,1,"Data from the assay component APR_HepG2_P-H2AX_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,dna binding,cellular response to DNA damage stimulus,0,0,1
59,30,APR_HepG2_p53Act_72h_dn,1,1,"Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
60,30,APR_HepG2_p53Act_72h_up,1,1,"Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
61,31,APR_HepG2_StressKinase_72h_dn,1,1,"Data from the assay component APR_HepG2_StressKinase_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""stress response"".",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,cell cycle,stress response,0,0,1
62,31,APR_HepG2_StressKinase_72h_up,1,1,"Data from the assay component APR_HepG2_StressKinase_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""stress response"".",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,cell cycle,stress response,0,0,1
63,32,ATG_Ahr_CIS_up,1,1,"Data from the assay component ATG_Ahr_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Ahr_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AHR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",reporter gene,log2_fold_induction,positive,0,6-formylindolo carbazole,gain,protein,transcription factor,dna binding,basic helix-loop-helix protein,0,0,1
64,33,ATG_AP_1_CIS_up,1,1,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
65,34,ATG_AP_2_CIS_up,1,1,"Data from the assay component ATG_AP_2_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_2_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TFAP2A and TFAP2B and TFAP2D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-turn-helix leucine zipper.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,basic helix-turn-helix leucine zipper,0,0,1
66,35,ATG_BRE_CIS_up,1,1,"Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,Smad protein,0,0,1
67,36,ATG_C_EBP_CIS_up,1,1,"Data from the assay component ATG_C_EBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_C_EBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CEBPB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
68,37,ATG_CMV_CIS_up,1,1,"Data from the assay component ATG_CMV_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CMV_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
69,38,ATG_CRE_CIS_up,1,1,"Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",reporter gene,log2_fold_induction,positive,0,Forskolin,gain,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
70,39,ATG_DR4_LXR_CIS_up,1,1,"Data from the assay component ATG_DR4_LXR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR4_LXR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2 and NR1H3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
71,40,ATG_DR5_CIS_up,1,1,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,9-cis-Retinoic acid,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
72,41,ATG_E_Box_CIS_up,1,1,"Data from the assay component ATG_E_Box_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_E_Box_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene USF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,basic helix-loop-helix protein,0,0,1
73,42,ATG_E2F_CIS_up,1,1,"Data from the assay component ATG_E2F_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_E2F_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene E2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is E2F transcription factor.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,E2F transcription factor,0,0,1
74,43,ATG_EGR_CIS_up,1,1,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,zinc finger,0,0,1
75,44,ATG_ERE_CIS_up,1,1,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,17b-Estradiol,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
76,45,ATG_Ets_CIS_up,1,1,"Data from the assay component ATG_Ets_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Ets_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ETS1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is winged helix-turn-helix.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,winged helix-turn-helix,0,0,1
77,46,ATG_FoxA2_CIS_up,1,1,"Data from the assay component ATG_FoxA2_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FoxA2_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,forkhead box protein,0,0,1
78,47,ATG_FoxO_CIS_up,1,1,"Data from the assay component ATG_FoxO_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FoxO_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXO1 and FOXO3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,forkhead box protein,0,0,1
79,48,ATG_GATA_CIS_up,1,1,"Data from the assay component ATG_GATA_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GATA_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GATA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is GATA proteins.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,GATA proteins,0,0,1
80,49,ATG_GLI_CIS_up,1,1,"Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GLI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,zinc finger,0,0,1
81,50,ATG_GRE_CIS_up,1,1,"Data from the assay component ATG_GRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,Dexamethasone,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
82,51,ATG_HIF1a_CIS_up,1,1,"Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HIF1a_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,basic helix-loop-helix protein,0,0,1
83,52,ATG_HNF6_CIS_up,1,1,"Data from the assay component ATG_HNF6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HNF6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ONECUT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is homeobox protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,homeobox protein,0,0,1
84,53,ATG_HSE_CIS_up,1,1,"Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HSE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.",reporter gene,log2_fold_induction,positive,0,Geldanamycin,gain,protein,transcription factor,dna binding,heat shock protein,0,0,1
85,54,ATG_IR1_CIS_up,1,1,"Data from the assay component ATG_IR1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_IR1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
86,55,ATG_ISRE_CIS_up,1,1,"Data from the assay component ATG_ISRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ISRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene IRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is interferon regulatory factors.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,interferon regulatory factors,0,0,1
87,56,ATG_M_06_CIS_up,1,1,"Data from the assay component ATG_M_06_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_06_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
88,57,ATG_M_19_CIS_up,1,1,"Data from the assay component ATG_M_19_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_19_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
89,58,ATG_M_32_CIS_up,1,1,"Data from the assay component ATG_M_32_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_32_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
90,59,ATG_M_61_CIS_up,1,1,"Data from the assay component ATG_M_61_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_61_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
91,60,ATG_MRE_CIS_up,1,1,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,zinc finger,0,0,1
92,61,ATG_Myb_CIS_up,1,1,"Data from the assay component ATG_Myb_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Myb_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is MYB proteins.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,MYB proteins,0,0,1
93,62,ATG_Myc_CIS_up,1,1,"Data from the assay component ATG_Myc_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Myc_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,basic helix-loop-helix leucine zipper,0,0,1
94,63,ATG_NF_kB_CIS_up,1,1,"Data from the assay component ATG_NF_kB_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NF_kB_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFKB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is NF-kappa B.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,NF-kappa B,0,0,1
95,64,ATG_NFI_CIS_up,1,1,"Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NFI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,nuclear factor I,0,0,1
96,65,ATG_NRF1_CIS_up,1,1,"Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear respiratory factors.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,nuclear respiratory factors,0,0,1
97,66,ATG_NRF2_ARE_CIS_up,1,1,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
98,67,ATG_Oct_MLP_CIS_up,1,1,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,POU domain protein,0,0,1
99,68,ATG_p53_CIS_up,1,1,"Data from the assay component ATG_p53_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_p53_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,tumor suppressor,0,0,1
100,69,ATG_Pax6_CIS_up,1,1,"Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Pax6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is paired box protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,paired box protein,0,0,1
101,70,ATG_PBREM_CIS_up,1,1,"Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PBREM_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
102,71,ATG_PPRE_CIS_up,1,1,"Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,Rosiglitazone,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
103,72,ATG_PXRE_CIS_up,1,1,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,Rifampicin,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
104,73,ATG_RORE_CIS_up,1,1,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
105,74,ATG_Sox_CIS_up,1,1,"Data from the assay component ATG_Sox_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sox_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SOX1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,HMG box protein,0,0,1
106,75,ATG_Sp1_CIS_up,1,1,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,zinc finger,0,0,1
107,76,ATG_SREBP_CIS_up,1,1,"Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,basic helix-loop-helix leucine zipper,0,0,1
108,77,ATG_STAT3_CIS_up,1,1,"Data from the assay component ATG_STAT3_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_STAT3_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene STAT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is stat protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,stat protein,0,0,1
109,78,ATG_TA_CIS_up,1,1,"Data from the assay component ATG_TA_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TA_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
110,79,ATG_TAL_CIS_up,1,1,"Data from the assay component ATG_TAL_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TAL_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
111,80,ATG_TCF_b_cat_CIS_up,1,1,"Data from the assay component ATG_TCF_b_cat_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TCF_b_cat_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TCF7 and TCF7L2 and LEF1 and TCF7L1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,HMG box protein,0,0,1
112,81,ATG_TGFb_CIS_up,1,1,"Data from the assay component ATG_TGFb_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TGFb_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,growth factor,transforming growth factor beta,0,0,1
113,82,ATG_VDRE_CIS_up,1,1,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
114,83,ATG_Xbp1_CIS_up,1,1,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
115,84,ATG_AR_TRANS_up,1,1,"Data from the assay component ATG_AR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,6a-Fluorotestosterone,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
116,85,ATG_CAR_TRANS_up,1,1,"Data from the assay component ATG_CAR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CAR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
117,86,ATG_ERa_TRANS_up,1,1,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,17b-Estradiol,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
118,87,ATG_ERRa_TRANS_up,1,1,"Data from the assay component ATG_ERRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
119,88,ATG_ERRg_TRANS_up,1,1,"Data from the assay component ATG_ERRg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERRg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
120,89,ATG_FXR_TRANS_up,1,1,"Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,CDCA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
121,90,ATG_GAL4_TRANS_up,1,1,"Data from the assay component ATG_GAL4_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GAL4_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is baseline control.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,baseline control,0,0,1
122,91,ATG_GR_TRANS_up,1,1,"Data from the assay component ATG_GR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
123,92,ATG_HNF4a_TRANS_up,1,1,"Data from the assay component ATG_HNF4a_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HNF4a_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HNF4A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
124,93,ATG_Hpa5_TRANS_up,1,1,"Data from the assay component ATG_Hpa5_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Hpa5_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
125,94,ATG_LXRa_TRANS_up,1,1,"Data from the assay component ATG_LXRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_LXRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,T0901317,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
126,95,ATG_LXRb_TRANS_up,1,1,"Data from the assay component ATG_LXRb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_LXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,T0901317,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
127,96,ATG_M_06_TRANS_up,1,1,"Data from the assay component ATG_M_06_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_06_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
128,97,ATG_M_19_TRANS_up,1,1,"Data from the assay component ATG_M_19_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_19_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
129,98,ATG_M_32_TRANS_up,1,1,"Data from the assay component ATG_M_32_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_32_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
130,99,ATG_M_61_TRANS_up,1,1,"Data from the assay component ATG_M_61_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_61_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
131,100,ATG_NURR1_TRANS_up,1,1,"Data from the assay component ATG_NURR1_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NURR1_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
132,101,ATG_PPARa_TRANS_up,1,1,"Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,GW0742,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
133,102,ATG_PPARd_TRANS_up,1,1,"Data from the assay component ATG_PPARd_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARd_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,GW7647,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
134,103,ATG_PPARg_TRANS_up,1,1,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,Rosiglitazone,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
135,104,ATG_PXR_TRANS_up,1,1,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,T0901317,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
136,105,ATG_RARa_TRANS_up,1,1,"Data from the assay component ATG_RARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,Retinoic Acid,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
137,106,ATG_RARb_TRANS_up,1,1,"Data from the assay component ATG_RARb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,Retinoic Acid,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
138,107,ATG_RARg_TRANS_up,1,1,"Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,Retinoic Acid,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
139,108,ATG_RORb_TRANS_up,1,1,"Data from the assay component ATG_RORb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
140,109,ATG_RORg_TRANS_up,1,1,"Data from the assay component ATG_RORg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
141,110,ATG_RXRa_TRANS_up,1,1,"Data from the assay component ATG_RXRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RXRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,9-cis-Retinoic acid,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
142,111,ATG_RXRb_TRANS_up,1,1,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,9-cis-Retinoic acid,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
143,112,ATG_THRa1_TRANS_up,1,1,"Data from the assay component ATG_THRa1_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_THRa1_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene THRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,T3,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
144,113,ATG_VDR_TRANS_up,1,1,"Data from the assay component ATG_VDR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,"1a,25-Dihydroxyvitamin D3",gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
145,114,BSK_3C_Eselectin_down,1,1,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,selectins,0,0,1
146,114,BSK_3C_Eselectin_up,1,1,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,selectins,0,0,1
147,115,BSK_3C_HLADR_down,1,1,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,MHC Class II,0,0,1
148,115,BSK_3C_HLADR_up,1,1,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,MHC Class II,0,0,1
149,116,BSK_3C_ICAM1_down,1,1,"Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
150,116,BSK_3C_ICAM1_up,1,1,"Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
151,117,BSK_3C_IL8_down,1,1,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
152,117,BSK_3C_IL8_up,1,1,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
153,118,BSK_3C_MCP1_down,1,1,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
154,118,BSK_3C_MCP1_up,1,1,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
155,119,BSK_3C_MIG_down,1,1,"Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
156,119,BSK_3C_MIG_up,1,1,"Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
157,120,BSK_3C_Proliferation_down,1,1,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
158,120,BSK_3C_Proliferation_up,1,1,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,cell cycle,proliferation,0,0,1
159,121,BSK_3C_SRB_down,1,1,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
160,121,BSK_3C_SRB_up,1,1,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
161,122,BSK_3C_Thrombomodulin_down,1,1,"Data from the assay component BSK_3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Thrombomodulin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,gpcr,rhodopsin-like receptor,0,0,1
162,122,BSK_3C_Thrombomodulin_up,1,1,"Data from the assay component BSK_3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,gpcr,rhodopsin-like receptor,0,0,1
163,123,BSK_3C_TissueFactor_down,1,1,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,coagulation factor,0,0,1
164,123,BSK_3C_TissueFactor_up,1,1,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,coagulation factor,0,0,1
165,124,BSK_3C_uPAR_down,1,1,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,plasmogen activator,0,0,1
166,124,BSK_3C_uPAR_up,1,1,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,plasmogen activator,0,0,1
167,125,BSK_3C_VCAM1_down,1,1,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
168,125,BSK_3C_VCAM1_up,1,1,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
169,126,BSK_3C_Vis_down,1,1,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",background control,log10_fold_induction,negative,0,colchicine,loss,cellular,cellular,cell morphology,cell conformation,0,0,1
170,126,BSK_3C_Vis_up,1,1,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",background control,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,cell morphology,cell conformation,0,0,1
171,127,BSK_4H_Eotaxin3_down,1,1,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
172,127,BSK_4H_Eotaxin3_up,1,1,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
173,128,BSK_4H_MCP1_down,1,1,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
174,128,BSK_4H_MCP1_up,1,1,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
175,129,BSK_4H_Pselectin_down,1,1,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,selectins,0,0,1
176,129,BSK_4H_Pselectin_up,1,1,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,selectins,0,0,1
177,130,BSK_4H_SRB_down,1,1,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_4H_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
178,130,BSK_4H_SRB_up,1,1,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
179,131,BSK_4H_uPAR_down,1,1,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,plasmogen activator,0,0,1
180,131,BSK_4H_uPAR_up,1,1,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,plasmogen activator,0,0,1
181,132,BSK_4H_VCAM1_down,1,1,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
182,132,BSK_4H_VCAM1_up,1,1,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
183,133,BSK_4H_VEGFRII_down,1,1,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
184,133,BSK_4H_VEGFRII_up,1,1,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
185,134,BSK_BE3C_HLADR_down,1,1,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,MHC Class II,0,0,1
186,134,BSK_BE3C_HLADR_up,1,1,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,MHC Class II,0,0,1
187,135,BSK_BE3C_IL1a_down,1,1,"Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
188,135,BSK_BE3C_IL1a_up,1,1,"Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
189,136,BSK_BE3C_IP10_down,1,1,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
190,136,BSK_BE3C_IP10_up,1,1,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
191,137,BSK_BE3C_MIG_down,1,1,"Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
192,137,BSK_BE3C_MIG_up,1,1,"Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
193,138,BSK_BE3C_MMP1_down,1,1,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
194,138,BSK_BE3C_MMP1_up,1,1,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
195,139,BSK_BE3C_PAI1_down,1,1,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
196,139,BSK_BE3C_PAI1_up,1,1,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
197,140,BSK_BE3C_SRB_down,1,1,"Data from the assay component BSK_BE3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_BE3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
198,140,BSK_BE3C_SRB_up,1,1,"Data from the assay component BSK_BE3C_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
199,141,BSK_BE3C_TGFb1_down,1,1,"Data from the assay component BSK_BE3C_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,growth factor,transforming growth factor beta,0,0,1
200,141,BSK_BE3C_TGFb1_up,1,1,"Data from the assay component BSK_BE3C_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_TGFb1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,growth factor,transforming growth factor beta,0,0,1
201,142,BSK_BE3C_tPA_down,1,1,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,serine protease,0,0,1
202,142,BSK_BE3C_tPA_up,1,1,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,serine protease,0,0,1
203,143,BSK_BE3C_uPA_down,1,1,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,serine protease,0,0,1
204,143,BSK_BE3C_uPA_up,1,1,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,serine protease,0,0,1
205,144,BSK_BE3C_uPAR_down,1,1,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,plasmogen activator,0,0,1
206,144,BSK_BE3C_uPAR_up,1,1,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,plasmogen activator,0,0,1
207,145,BSK_CASM3C_HLADR_down,1,1,"Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,MHC Class II,0,0,1
208,145,BSK_CASM3C_HLADR_up,1,1,"Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,MHC Class II,0,0,1
209,146,BSK_CASM3C_IL6_down,1,1,"Data from the assay component BSK_CASM3C_IL6 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL6_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
210,146,BSK_CASM3C_IL6_up,1,1,"Data from the assay component BSK_CASM3C_IL6 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL6_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
211,147,BSK_CASM3C_IL8_down,1,1,"Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
212,147,BSK_CASM3C_IL8_up,1,1,"Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
213,148,BSK_CASM3C_LDLR_down,1,1,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""LDL receptor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,misc protein,LDL receptor,0,0,1
214,148,BSK_CASM3C_LDLR_up,1,1,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""LDL receptor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,misc protein,LDL receptor,0,0,1
215,149,BSK_CASM3C_MCP1_down,1,1,"Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
216,149,BSK_CASM3C_MCP1_up,1,1,"Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
217,150,BSK_CASM3C_MCSF_down,1,1,"Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,colony stimulating factor,0,0,1
218,150,BSK_CASM3C_MCSF_up,1,1,"Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,colony stimulating factor,0,0,1
219,151,BSK_CASM3C_MIG_down,1,1,"Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
220,151,BSK_CASM3C_MIG_up,1,1,"Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
221,152,BSK_CASM3C_Proliferation_down,1,1,"Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
222,152,BSK_CASM3C_Proliferation_up,1,1,"Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_Proliferation_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,cell cycle,proliferation,0,0,1
223,153,BSK_CASM3C_SAA_down,1,1,"Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""apolipoproteins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,apolipoproteins,0,0,1
224,153,BSK_CASM3C_SAA_up,1,1,"Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""apolipoproteins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,apolipoproteins,0,0,1
225,154,BSK_CASM3C_SRB_down,1,1,"Data from the assay component BSK_CASM3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
226,154,BSK_CASM3C_SRB_up,1,1,"Data from the assay component BSK_CASM3C_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
227,155,BSK_CASM3C_Thrombomodulin_down,1,1,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,gpcr,rhodopsin-like receptor,0,0,1
228,155,BSK_CASM3C_Thrombomodulin_up,1,1,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,gpcr,rhodopsin-like receptor,0,0,1
229,156,BSK_CASM3C_TissueFactor_down,1,1,"Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,coagulation factor,0,0,1
230,156,BSK_CASM3C_TissueFactor_up,1,1,"Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,coagulation factor,0,0,1
231,157,BSK_CASM3C_uPAR_down,1,1,"Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,plasmogen activator,0,0,1
232,157,BSK_CASM3C_uPAR_up,1,1,"Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,plasmogen activator,0,0,1
233,158,BSK_CASM3C_VCAM1_down,1,1,"Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
234,158,BSK_CASM3C_VCAM1_up,1,1,"Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
235,159,BSK_hDFCGF_CollagenIII_down,1,1,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,collagen,0,0,1
236,159,BSK_hDFCGF_CollagenIII_up,1,1,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,collagen,0,0,1
237,160,BSK_hDFCGF_EGFR_down,1,1,"Data from the assay component BSK_hDFCGF_EGFR was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_EGFR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
238,160,BSK_hDFCGF_EGFR_up,1,1,"Data from the assay component BSK_hDFCGF_EGFR was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_EGFR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
239,161,BSK_hDFCGF_IL8_down,1,1,"Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
240,161,BSK_hDFCGF_IL8_up,1,1,"Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
241,162,BSK_hDFCGF_IP10_down,1,1,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
242,162,BSK_hDFCGF_IP10_up,1,1,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
243,163,BSK_hDFCGF_MCSF_down,1,1,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,colony stimulating factor,0,0,1
244,163,BSK_hDFCGF_MCSF_up,1,1,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,colony stimulating factor,0,0,1
245,164,BSK_hDFCGF_MIG_down,1,1,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
246,164,BSK_hDFCGF_MIG_up,1,1,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
247,165,BSK_hDFCGF_MMP1_down,1,1,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
248,165,BSK_hDFCGF_MMP1_up,1,1,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
249,166,BSK_hDFCGF_PAI1_down,1,1,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
250,166,BSK_hDFCGF_PAI1_up,1,1,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
251,167,BSK_hDFCGF_Proliferation_down,1,1,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
252,167,BSK_hDFCGF_Proliferation_up,1,1,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,cell cycle,proliferation,0,0,1
253,168,BSK_hDFCGF_SRB_down,1,1,"Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
254,168,BSK_hDFCGF_SRB_up,1,1,"Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
255,169,BSK_hDFCGF_TIMP1_down,1,1,"Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease inhibitor,metalloproteinase inhibitor,0,0,1
256,169,BSK_hDFCGF_TIMP1_up,1,1,"Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease inhibitor,metalloproteinase inhibitor,0,0,1
257,170,BSK_hDFCGF_VCAM1_down,1,1,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
258,170,BSK_hDFCGF_VCAM1_up,1,1,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
259,171,BSK_KF3CT_ICAM1_down,1,1,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
260,171,BSK_KF3CT_ICAM1_up,1,1,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
261,172,BSK_KF3CT_IL1a_down,1,1,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
262,172,BSK_KF3CT_IL1a_up,1,1,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
263,173,BSK_KF3CT_IP10_down,1,1,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
264,173,BSK_KF3CT_IP10_up,1,1,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
265,174,BSK_KF3CT_MCP1_down,1,1,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
266,174,BSK_KF3CT_MCP1_up,1,1,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
267,175,BSK_KF3CT_MMP9_down,1,1,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
268,175,BSK_KF3CT_MMP9_up,1,1,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
269,176,BSK_KF3CT_SRB_down,1,1,"Data from the assay component BSK_KF3CT_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_KF3CT_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
270,176,BSK_KF3CT_SRB_up,1,1,"Data from the assay component BSK_KF3CT_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
271,177,BSK_KF3CT_TGFb1_down,1,1,"Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,growth factor,transforming growth factor beta,0,0,1
272,177,BSK_KF3CT_TGFb1_up,1,1,"Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TGFb1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,growth factor,transforming growth factor beta,0,0,1
273,178,BSK_KF3CT_TIMP2_down,1,1,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease inhibitor,metalloproteinase inhibitor,0,0,1
274,178,BSK_KF3CT_TIMP2_up,1,1,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease inhibitor,metalloproteinase inhibitor,0,0,1
275,179,BSK_KF3CT_uPA_down,1,1,"Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,serine protease,0,0,1
276,179,BSK_KF3CT_uPA_up,1,1,"Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,serine protease,0,0,1
277,180,BSK_LPS_CD40_down,1,1,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,inflammatory factor,0,0,1
278,180,BSK_LPS_CD40_up,1,1,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,inflammatory factor,0,0,1
279,181,BSK_LPS_Eselectin_down,1,1,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,selectins,0,0,1
280,181,BSK_LPS_Eselectin_up,1,1,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,selectins,0,0,1
281,182,BSK_LPS_IL1a_down,1,1,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
282,182,BSK_LPS_IL1a_up,1,1,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
283,183,BSK_LPS_IL8_down,1,1,"Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
284,183,BSK_LPS_IL8_up,1,1,"Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
285,184,BSK_LPS_MCP1_down,1,1,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
286,184,BSK_LPS_MCP1_up,1,1,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
287,185,BSK_LPS_MCSF_down,1,1,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,colony stimulating factor,0,0,1
288,185,BSK_LPS_MCSF_up,1,1,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,colony stimulating factor,0,0,1
289,186,BSK_LPS_PGE2_down,1,1,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,gpcr,rhodopsin-like receptor,0,0,1
290,186,BSK_LPS_PGE2_up,1,1,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,gpcr,rhodopsin-like receptor,0,0,1
291,187,BSK_LPS_SRB_down,1,1,"Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_LPS_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
292,187,BSK_LPS_SRB_up,1,1,"Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
293,188,BSK_LPS_TissueFactor_down,1,1,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,coagulation factor,0,0,1
294,188,BSK_LPS_TissueFactor_up,1,1,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,coagulation factor,0,0,1
295,189,BSK_LPS_TNFa_down,1,1,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,inflammatory factor,0,0,1
296,189,BSK_LPS_TNFa_up,1,1,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,inflammatory factor,0,0,1
297,190,BSK_LPS_VCAM1_down,1,1,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
298,190,BSK_LPS_VCAM1_up,1,1,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
299,191,BSK_SAg_CD38_down,1,1,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,other cytokine,0,0,1
300,191,BSK_SAg_CD38_up,1,1,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,other cytokine,0,0,1
301,192,BSK_SAg_CD40_down,1,1,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,inflammatory factor,0,0,1
302,192,BSK_SAg_CD40_up,1,1,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,inflammatory factor,0,0,1
303,193,BSK_SAg_CD69_down,1,1,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,inflammatory factor,0,0,1
304,193,BSK_SAg_CD69_up,1,1,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,inflammatory factor,0,0,1
305,194,BSK_SAg_Eselectin_down,1,1,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,selectins,0,0,1
306,194,BSK_SAg_Eselectin_up,1,1,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,selectins,0,0,1
307,195,BSK_SAg_IL8_down,1,1,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
308,195,BSK_SAg_IL8_up,1,1,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
309,196,BSK_SAg_MCP1_down,1,1,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
310,196,BSK_SAg_MCP1_up,1,1,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
311,197,BSK_SAg_MIG_down,1,1,"Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
312,197,BSK_SAg_MIG_up,1,1,"Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
313,198,BSK_SAg_PBMCCytotoxicity_down,1,1,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",signaling,log10_fold_induction,negative,0,colchicine,loss,cellular,cellular,cell cycle,proliferation,0,0,1
314,198,BSK_SAg_PBMCCytotoxicity_up,1,1,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
315,199,BSK_SAg_Proliferation_down,1,1,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
316,199,BSK_SAg_Proliferation_up,1,1,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,cell cycle,proliferation,0,0,1
317,200,BSK_SAg_SRB_down,1,1,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
318,200,BSK_SAg_SRB_up,1,1,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
319,201,NVS_ADME_hCYP19A1,1,1,"Data from the assay component NVS_ADME_hCYP19A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP19A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""steroidogenesis-related"".",enzymatic activity,percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,steroidogenesis-related,0,0,1
320,201,NVS_ADME_hCYP19A1_Activator,1,1,"Data from the assay component NVS_ADME_hCYP19A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP19A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""steroidogenesis-related"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,steroidogenesis-related,0,0,1
321,202,NVS_ADME_hCYP1A1,1,1,"Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Ketoconazole;Ketanserin,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
322,202,NVS_ADME_hCYP1A1_Activator,1,1,"Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ketoconazole;Ketanserin,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
323,203,NVS_ADME_hCYP1A2,1,1,"Data from the assay component NVS_ADME_hCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Furafylline,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
324,203,NVS_ADME_hCYP1A2_Activator,1,1,"Data from the assay component NVS_ADME_hCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Furafylline,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
325,204,NVS_ADME_hCYP1B1,1,1,"Data from the assay component NVS_ADME_hCYP1B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1B1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Alpha-Naphthoflavone,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
326,204,NVS_ADME_hCYP1B1_Activator,1,1,"Data from the assay component NVS_ADME_hCYP1B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1B1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Alpha-Naphthoflavone,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
327,205,NVS_ADME_hCYP2A6,1,1,"Data from the assay component NVS_ADME_hCYP2A6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2A6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2A6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Tranylcypromine,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
328,205,NVS_ADME_hCYP2A6_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2A6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2A6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2A6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Tranylcypromine,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
329,206,NVS_ADME_hCYP2B6,1,1,"Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2B6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Clotrimazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
330,206,NVS_ADME_hCYP2B6_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2B6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Clotrimazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
331,207,NVS_ADME_hCYP2C18,1,1,"Data from the assay component NVS_ADME_hCYP2C18 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C18, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C18. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Tranylcypromine,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
332,207,NVS_ADME_hCYP2C18_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2C18 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C18_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C18. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Tranylcypromine,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
333,208,NVS_ADME_hCYP2C19,1,1,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Tranylcypromine,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
334,208,NVS_ADME_hCYP2C19_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Tranylcypromine,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
335,209,NVS_ADME_hCYP2C8,1,1,"Data from the assay component NVS_ADME_hCYP2C8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C8, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,quercetin,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
336,209,NVS_ADME_hCYP2C8_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2C8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C8_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,quercetin,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
337,210,NVS_ADME_hCYP2C9,1,1,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Sulfaphenazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
338,210,NVS_ADME_hCYP2C9_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,sulfaphenazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
339,211,NVS_ADME_hCYP2D6,1,1,"Data from the assay component NVS_ADME_hCYP2D6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2D6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2D6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,quinidine,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
340,211,NVS_ADME_hCYP2D6_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2D6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2D6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2D6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,quinidine,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
341,212,NVS_ADME_hCYP2E1,1,1,"Data from the assay component NVS_ADME_hCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2E1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2E1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,chlormethiazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
342,212,NVS_ADME_hCYP2E1_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2E1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2E1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,chlormethiazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
343,213,NVS_ADME_hCYP2J2,1,1,"Data from the assay component NVS_ADME_hCYP2J2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2J2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2J2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
344,213,NVS_ADME_hCYP2J2_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2J2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2J2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2J2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
345,214,NVS_ADME_hCYP3A4,1,1,"Data from the assay component NVS_ADME_hCYP3A4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A4, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
346,214,NVS_ADME_hCYP3A4_Activator,1,1,"Data from the assay component NVS_ADME_hCYP3A4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A4_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
347,215,NVS_ADME_hCYP3A5,1,1,"Data from the assay component NVS_ADME_hCYP3A5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A5, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
348,215,NVS_ADME_hCYP3A5_Activator,1,1,"Data from the assay component NVS_ADME_hCYP3A5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A5_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
349,216,NVS_ADME_hCYP4F12,1,1,"Data from the assay component NVS_ADME_hCYP4F12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP4F12, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP4F12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
350,216,NVS_ADME_hCYP4F12_Activator,1,1,"Data from the assay component NVS_ADME_hCYP4F12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP4F12_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP4F12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
351,217,NVS_ADME_rCYP1A1,1,1,"Data from the assay component NVS_ADME_rCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,ellipticine,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
352,217,NVS_ADME_rCYP1A1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,ellipticine,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
353,218,NVS_ADME_rCYP1A2,1,1,"Data from the assay component NVS_ADME_rCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Alpha-Naphthoflavone,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
354,218,NVS_ADME_rCYP1A2_Activator,1,1,"Data from the assay component NVS_ADME_rCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Alpha-Naphthoflavone,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
355,219,NVS_ADME_rCYP2A1,1,1,"Data from the assay component NVS_ADME_rCYP2A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Clotrimazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
356,219,NVS_ADME_rCYP2A1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Clotrimazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
357,220,NVS_ADME_rCYP2A2,1,1,"Data from the assay component NVS_ADME_rCYP2A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Ketoconazole;Tranylcypromine,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
358,220,NVS_ADME_rCYP2A2_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ketoconazole;Tranylcypromine,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
359,221,NVS_ADME_rCYP2B1,1,1,"Data from the assay component NVS_ADME_rCYP2B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2B1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2b1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
360,221,NVS_ADME_rCYP2B1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2B1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2b1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
361,222,NVS_ADME_rCYP2C11,1,1,"Data from the assay component NVS_ADME_rCYP2C11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C11, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
362,222,NVS_ADME_rCYP2C11_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2C11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C11_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
363,223,NVS_ADME_rCYP2C12,1,1,"Data from the assay component NVS_ADME_rCYP2C12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C12, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Tranylcypromine,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
364,223,NVS_ADME_rCYP2C12_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2C12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C12_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Tranylcypromine,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
365,224,NVS_ADME_rCYP2C13,1,1,"Data from the assay component NVS_ADME_rCYP2C13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C13, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Clotrimazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
366,224,NVS_ADME_rCYP2C13_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2C13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C13_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Clotrimazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
367,225,NVS_ADME_rCYP2C6,1,1,"Data from the assay component NVS_ADME_rCYP2C6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c6v1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
368,225,NVS_ADME_rCYP2C6_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2C6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c6v1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
369,226,NVS_ADME_rCYP2D1,1,1,"Data from the assay component NVS_ADME_rCYP2D1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Propranolol HCl,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
370,226,NVS_ADME_rCYP2D1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2D1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Propranolol HCl,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
371,227,NVS_ADME_rCYP2D2,1,1,"Data from the assay component NVS_ADME_rCYP2D2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,Propranolol HCl,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
372,227,NVS_ADME_rCYP2D2_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2D2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Propranolol HCl,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
373,228,NVS_ADME_rCYP2E1,1,1,"Data from the assay component NVS_ADME_rCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2E1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2e1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,chlormethiazole,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
374,228,NVS_ADME_rCYP2E1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2E1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2e1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,chlormethiazole,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
375,229,NVS_ADME_rCYP3A1,1,1,"Data from the assay component NVS_ADME_rCYP3A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a23/3a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,(+/-) Verapamil HCl,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
376,229,NVS_ADME_rCYP3A1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP3A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a23/3a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,(+/-) Verapamil HCl,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
377,230,NVS_ADME_rCYP3A2,1,1,"Data from the assay component NVS_ADME_rCYP3A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",enzymatic activity,percent_activity,positive,0,(+/-) Verapamil HCl,loss,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
378,230,NVS_ADME_rCYP3A2_Activator,1,1,"Data from the assay component NVS_ADME_rCYP3A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,(+/-) Verapamil HCl,gain,protein,enzyme,cyp,xenobiotic metabolism,0,0,1
379,231,NVS_ENZ_hAbl,1,1,"Data from the assay component NVS_ENZ_hAbl was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAbl, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ABL1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
380,231,NVS_ENZ_hAbl_Activator,1,1,"Data from the assay component NVS_ENZ_hAbl was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAbl_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ABL1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
381,232,NVS_ENZ_hAChE,1,1,"Data from the assay component NVS_ENZ_hAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAChE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""acetylcholinesterase"".",enzymatic activity,percent_activity,positive,0,physostigmine,loss,protein,enzyme,esterase,acetylcholinesterase,0,0,1
382,232,NVS_ENZ_hAChE_Activator,1,1,"Data from the assay component NVS_ENZ_hAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAChE_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""acetylcholinesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,physostigmine,gain,protein,enzyme,esterase,acetylcholinesterase,0,0,1
383,233,NVS_ENZ_hACP1,1,1,"Data from the assay component NVS_ENZ_hACP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hACP1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""acid phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,acid phosphatase,0,0,1
384,233,NVS_ENZ_hACP1_Activator,1,1,"Data from the assay component NVS_ENZ_hACP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hACP1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""acid phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,acid phosphatase,0,0,1
385,234,NVS_ENZ_hAKT1,1,1,"Data from the assay component NVS_ENZ_hAKT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
386,234,NVS_ENZ_hAKT1_Activator,1,1,"Data from the assay component NVS_ENZ_hAKT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
387,235,NVS_ENZ_hAKT2,1,1,"Data from the assay component NVS_ENZ_hAKT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
388,235,NVS_ENZ_hAKT2_Activator,1,1,"Data from the assay component NVS_ENZ_hAKT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
389,236,NVS_ENZ_hAKT3,1,1,"Data from the assay component NVS_ENZ_hAKT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
390,236,NVS_ENZ_hAKT3_Activator,1,1,"Data from the assay component NVS_ENZ_hAKT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
391,237,NVS_ENZ_hAMPKa1,1,1,"Data from the assay component NVS_ENZ_hAMPKa1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAMPKa1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
392,237,NVS_ENZ_hAMPKa1_Activator,1,1,"Data from the assay component NVS_ENZ_hAMPKa1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAMPKa1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
393,238,NVS_ENZ_hAurA,1,1,"Data from the assay component NVS_ENZ_hAurA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAurA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AURKA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
394,238,NVS_ENZ_hAurA_Activator,1,1,"Data from the assay component NVS_ENZ_hAurA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAurA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AURKA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
395,239,NVS_ENZ_hBACE,1,1,"Data from the assay component NVS_ENZ_hBACE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBACE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BACE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""aspartate protease"".",enzymatic activity,percent_activity,positive,0,OM99-02,loss,protein,enzyme,protease,aspartate protease,0,0,1
396,239,NVS_ENZ_hBACE_Activator,1,1,"Data from the assay component NVS_ENZ_hBACE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBACE_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BACE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""aspartate protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,OM99-02,gain,protein,enzyme,protease,aspartate protease,0,0,1
397,240,NVS_ENZ_hBTK,1,1,"Data from the assay component NVS_ENZ_hBTK was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBTK, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BTK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
398,240,NVS_ENZ_hBTK_Activator,1,1,"Data from the assay component NVS_ENZ_hBTK was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBTK_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BTK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
399,241,NVS_ENZ_hCASP1,1,1,"Data from the assay component NVS_ENZ_hCASP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",enzymatic activity,percent_activity,positive,0,Ac-YVAD-CHO,loss,protein,enzyme,protease,cysteine protease,0,0,1
400,241,NVS_ENZ_hCASP1_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ac-YVAD-CHO,gain,protein,enzyme,protease,cysteine protease,0,0,1
401,242,NVS_ENZ_hCASP10,1,1,"Data from the assay component NVS_ENZ_hCASP10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP10, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",enzymatic activity,percent_activity,positive,0,Ac-DEVD-CHO,loss,protein,enzyme,protease,cysteine protease,0,0,1
402,242,NVS_ENZ_hCASP10_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP10_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ac-DEVD-CHO,gain,protein,enzyme,protease,cysteine protease,0,0,1
403,243,NVS_ENZ_hCASP2,1,1,"Data from the assay component NVS_ENZ_hCASP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",enzymatic activity,percent_activity,positive,0,z-VDVAD-CHO,loss,protein,enzyme,protease,cysteine protease,0,0,1
404,243,NVS_ENZ_hCASP2_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,z-VDVAD-CHO,gain,protein,enzyme,protease,cysteine protease,0,0,1
405,244,NVS_ENZ_hCASP3,1,1,"Data from the assay component NVS_ENZ_hCASP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",enzymatic activity,percent_activity,positive,0,Ac-DEVD-CHO,loss,protein,enzyme,protease,cysteine protease,0,0,1
406,244,NVS_ENZ_hCASP3_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ac-DEVD-CHO,gain,protein,enzyme,protease,cysteine protease,0,0,1
407,245,NVS_ENZ_hCASP4,1,1,"Data from the assay component NVS_ENZ_hCASP4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",enzymatic activity,percent_activity,positive,0,Ac-LEHD-CHO,loss,protein,enzyme,protease,cysteine protease,0,0,1
408,245,NVS_ENZ_hCASP4_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ac-LEHD-CHO,gain,protein,enzyme,protease,cysteine protease,0,0,1
409,246,NVS_ENZ_hCASP5,1,1,"Data from the assay component NVS_ENZ_hCASP5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",enzymatic activity,percent_activity,positive,0,Ac-LEHD-CHO,loss,protein,enzyme,protease,cysteine protease,0,0,1
410,246,NVS_ENZ_hCASP5_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP5_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ac-LEHD-CHO,gain,protein,enzyme,protease,cysteine protease,0,0,1
411,247,NVS_ENZ_hCASP8,1,1,"Data from the assay component NVS_ENZ_hCASP8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP8, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",enzymatic activity,percent_activity,positive,0,Ac-DEVD-CHO,loss,protein,enzyme,protease,cysteine protease,0,0,1
412,247,NVS_ENZ_hCASP8_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP8_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ac-DEVD-CHO,gain,protein,enzyme,protease,cysteine protease,0,0,1
413,248,NVS_ENZ_hCDK2,1,1,"Data from the assay component NVS_ENZ_hCDK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
414,248,NVS_ENZ_hCDK2_Activator,1,1,"Data from the assay component NVS_ENZ_hCDK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
415,249,NVS_ENZ_hCDK6,1,1,"Data from the assay component NVS_ENZ_hCDK6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
416,249,NVS_ENZ_hCDK6_Activator,1,1,"Data from the assay component NVS_ENZ_hCDK6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK6_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
417,250,NVS_ENZ_hCHK1,1,1,"Data from the assay component NVS_ENZ_hCHK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCHK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHEK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
418,250,NVS_ENZ_hCHK1_Activator,1,1,"Data from the assay component NVS_ENZ_hCHK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCHK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHEK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
419,251,NVS_ENZ_hCK1a,1,1,"Data from the assay component NVS_ENZ_hCK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,5-iodotubericidin,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
420,251,NVS_ENZ_hCK1a_Activator,1,1,"Data from the assay component NVS_ENZ_hCK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1a_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,5-iodotubericidin,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
421,252,NVS_ENZ_hCK1D,1,1,"Data from the assay component NVS_ENZ_hCK1D was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1D, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,5-iodotubericidin,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
422,252,NVS_ENZ_hCK1D_Activator,1,1,"Data from the assay component NVS_ENZ_hCK1D was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1D_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,5-iodotubericidin,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
423,253,NVS_ENZ_hCK2a2b2,1,1,"Data from the assay component NVS_ENZ_hCK2a2b2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK2a2b2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK2A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
424,253,NVS_ENZ_hCK2a2b2_Activator,1,1,"Data from the assay component NVS_ENZ_hCK2a2b2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK2a2b2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK2A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
425,254,NVS_ENZ_hCSF1R,1,1,"Data from the assay component NVS_ENZ_hCSF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCSF1R, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
426,254,NVS_ENZ_hCSF1R_Activator,1,1,"Data from the assay component NVS_ENZ_hCSF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCSF1R_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
427,255,NVS_ENZ_hDUSP3,1,1,"Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDUSP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,dual-specific phosphatase,0,0,1
428,255,NVS_ENZ_hDUSP3_Activator,1,1,"Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDUSP3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,dual-specific phosphatase,0,0,1
429,256,NVS_ENZ_hEGFR,1,1,"Data from the assay component NVS_ENZ_hEGFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEGFR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
430,256,NVS_ENZ_hEGFR_Activator,1,1,"Data from the assay component NVS_ENZ_hEGFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEGFR_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
431,257,NVS_ENZ_hElastase,1,1,"Data from the assay component NVS_ENZ_hElastase was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hElastase, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ELANE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",enzymatic activity,percent_activity,positive,0,Ursolic acid,loss,protein,enzyme,protease,serine protease,0,0,1
432,257,NVS_ENZ_hElastase_Activator,1,1,"Data from the assay component NVS_ENZ_hElastase was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hElastase_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ELANE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ursolic acid,gain,protein,enzyme,protease,serine protease,0,0,1
433,258,NVS_ENZ_hEphA1,1,1,"Data from the assay component NVS_ENZ_hEphA1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
434,258,NVS_ENZ_hEphA1_Activator,1,1,"Data from the assay component NVS_ENZ_hEphA1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
435,259,NVS_ENZ_hEphA2,1,1,"Data from the assay component NVS_ENZ_hEphA2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
436,259,NVS_ENZ_hEphA2_Activator,1,1,"Data from the assay component NVS_ENZ_hEphA2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
437,260,NVS_ENZ_hEphB1,1,1,"Data from the assay component NVS_ENZ_hEphB1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
438,260,NVS_ENZ_hEphB1_Activator,1,1,"Data from the assay component NVS_ENZ_hEphB1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
439,261,NVS_ENZ_hEphB2,1,1,"Data from the assay component NVS_ENZ_hEphB2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
440,261,NVS_ENZ_hEphB2_Activator,1,1,"Data from the assay component NVS_ENZ_hEphB2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
441,262,NVS_ENZ_hES,1,1,"Data from the assay component NVS_ENZ_hES was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hES, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BCHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""pseudocholinesterase"".",enzymatic activity,percent_activity,positive,0,physostigmine,loss,protein,enzyme,esterase,pseudocholinesterase,0,0,1
442,262,NVS_ENZ_hES_Activator,1,1,"Data from the assay component NVS_ENZ_hES was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hES_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BCHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""pseudocholinesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,physostigmine,gain,protein,enzyme,esterase,pseudocholinesterase,0,0,1
443,263,NVS_ENZ_hFGFR1,1,1,"Data from the assay component NVS_ENZ_hFGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,K252a,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
444,263,NVS_ENZ_hFGFR1_Activator,1,1,"Data from the assay component NVS_ENZ_hFGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,K252a,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
445,264,NVS_ENZ_hFGFR3,1,1,"Data from the assay component NVS_ENZ_hFGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
446,264,NVS_ENZ_hFGFR3_Activator,1,1,"Data from the assay component NVS_ENZ_hFGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
447,265,NVS_ENZ_hFyn,1,1,"Data from the assay component NVS_ENZ_hFyn was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFyn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
448,265,NVS_ENZ_hFyn_Activator,1,1,"Data from the assay component NVS_ENZ_hFyn was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFyn_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
449,266,NVS_ENZ_hGSK3b,1,1,"Data from the assay component NVS_ENZ_hGSK3b was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hGSK3b, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene GSK3B. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
450,266,NVS_ENZ_hGSK3b_Activator,1,1,"Data from the assay component NVS_ENZ_hGSK3b was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hGSK3b_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene GSK3B. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
451,267,NVS_ENZ_hHDAC3,1,1,"Data from the assay component NVS_ENZ_hHDAC3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""histone deacetylase"".",enzymatic activity,percent_activity,positive,0,trichostatin,loss,protein,enzyme,hydrolase,histone deacetylase,0,0,1
452,267,NVS_ENZ_hHDAC3_Activator,1,1,"Data from the assay component NVS_ENZ_hHDAC3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""histone deacetylase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,trichostatin,gain,protein,enzyme,hydrolase,histone deacetylase,0,0,1
453,268,NVS_ENZ_hHDAC6,1,1,"Data from the assay component NVS_ENZ_hHDAC6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""histone deacetylase"".",enzymatic activity,percent_activity,positive,0,trichostatin,loss,protein,enzyme,hydrolase,histone deacetylase,0,0,1
454,268,NVS_ENZ_hHDAC6_Activator,1,1,"Data from the assay component NVS_ENZ_hHDAC6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC6_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""histone deacetylase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,trichostatin,gain,protein,enzyme,hydrolase,histone deacetylase,0,0,1
455,269,NVS_ENZ_hIGF1R,1,1,"Data from the assay component NVS_ENZ_hIGF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIGF1R, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IGF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
456,269,NVS_ENZ_hIGF1R_Activator,1,1,"Data from the assay component NVS_ENZ_hIGF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIGF1R_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IGF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
457,270,NVS_ENZ_hIKKa,1,1,"Data from the assay component NVS_ENZ_hIKKa was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIKKa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHUK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
458,270,NVS_ENZ_hIKKa_Activator,1,1,"Data from the assay component NVS_ENZ_hIKKa was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIKKa_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHUK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
459,271,NVS_ENZ_hInsR,1,1,"Data from the assay component NVS_ENZ_hInsR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hInsR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene INSR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
460,271,NVS_ENZ_hInsR_Activator,1,1,"Data from the assay component NVS_ENZ_hInsR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hInsR_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene INSR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
461,272,NVS_ENZ_hIRAK4,1,1,"Data from the assay component NVS_ENZ_hIRAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIRAK4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IRAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
462,272,NVS_ENZ_hIRAK4_Activator,1,1,"Data from the assay component NVS_ENZ_hIRAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIRAK4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IRAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
463,273,NVS_ENZ_hJak2,1,1,"Data from the assay component NVS_ENZ_hJak2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJak2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene JAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
464,273,NVS_ENZ_hJak2_Activator,1,1,"Data from the assay component NVS_ENZ_hJak2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJak2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene JAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
465,274,NVS_ENZ_hJNK2,1,1,"Data from the assay component NVS_ENZ_hJNK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJNK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,SB203580,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
466,274,NVS_ENZ_hJNK2_Activator,1,1,"Data from the assay component NVS_ENZ_hJNK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJNK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,SB203580,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
467,275,NVS_ENZ_hLck,1,1,"Data from the assay component NVS_ENZ_hLck was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLck, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LCK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
468,275,NVS_ENZ_hLck_Activator,1,1,"Data from the assay component NVS_ENZ_hLck was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLck_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LCK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
469,276,NVS_ENZ_hLynA,1,1,"Data from the assay component NVS_ENZ_hLynA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
470,276,NVS_ENZ_hLynA_Activator,1,1,"Data from the assay component NVS_ENZ_hLynA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
471,277,NVS_ENZ_hLynB,1,1,"Data from the assay component NVS_ENZ_hLynB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
472,277,NVS_ENZ_hLynB_Activator,1,1,"Data from the assay component NVS_ENZ_hLynB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynB_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
473,278,NVS_ENZ_hMAPK1,1,1,"Data from the assay component NVS_ENZ_hMAPK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,K252a,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
474,278,NVS_ENZ_hMAPK1_Activator,1,1,"Data from the assay component NVS_ENZ_hMAPK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,K252a,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
475,279,NVS_ENZ_hMAPK11,1,1,"Data from the assay component NVS_ENZ_hMAPK11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK11, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,SB203580,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
476,279,NVS_ENZ_hMAPK11_Activator,1,1,"Data from the assay component NVS_ENZ_hMAPK11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK11_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,SB203580,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
477,280,NVS_ENZ_hMAPK3,1,1,"Data from the assay component NVS_ENZ_hMAPK3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
478,280,NVS_ENZ_hMAPK3_Activator,1,1,"Data from the assay component NVS_ENZ_hMAPK3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
479,281,NVS_ENZ_hMAPKAPK2,1,1,"Data from the assay component NVS_ENZ_hMAPKAPK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
480,281,NVS_ENZ_hMAPKAPK2_Activator,1,1,"Data from the assay component NVS_ENZ_hMAPKAPK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
481,282,NVS_ENZ_hMAPKAPK5,1,1,"Data from the assay component NVS_ENZ_hMAPKAPK5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
482,282,NVS_ENZ_hMAPKAPK5_Activator,1,1,"Data from the assay component NVS_ENZ_hMAPKAPK5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK5_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
483,283,NVS_ENZ_hMARK1,1,1,"Data from the assay component NVS_ENZ_hMARK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMARK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MARK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
484,283,NVS_ENZ_hMARK1_Activator,1,1,"Data from the assay component NVS_ENZ_hMARK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMARK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MARK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
485,284,NVS_ENZ_hMet,1,1,"Data from the assay component NVS_ENZ_hMet was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMet, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MET. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
486,284,NVS_ENZ_hMet_Activator,1,1,"Data from the assay component NVS_ENZ_hMet was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMet_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MET. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
487,285,NVS_ENZ_hMMP1,1,1,"Data from the assay component NVS_ENZ_hMMP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",enzymatic activity,percent_activity,positive,0,Galardin (GM6001),loss,protein,enzyme,protease,matrix metalloproteinase,0,0,1
488,285,NVS_ENZ_hMMP1_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Galardin (GM6001),gain,protein,enzyme,protease,matrix metalloproteinase,0,0,1
489,286,NVS_ENZ_hMMP13,1,1,"Data from the assay component NVS_ENZ_hMMP13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP13, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",enzymatic activity,percent_activity,positive,0,Tyr-Hydroxamic acid,loss,protein,enzyme,protease,matrix metalloproteinase,0,0,1
490,286,NVS_ENZ_hMMP13_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP13_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Tyr-Hydroxamic acid,gain,protein,enzyme,protease,matrix metalloproteinase,0,0,1
491,287,NVS_ENZ_hMMP2,1,1,"Data from the assay component NVS_ENZ_hMMP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",enzymatic activity,percent_activity,positive,0,Galardin (GM6001),loss,protein,enzyme,protease,matrix metalloproteinase,0,0,1
492,287,NVS_ENZ_hMMP2_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Galardin (GM6001),gain,protein,enzyme,protease,matrix metalloproteinase,0,0,1
493,288,NVS_ENZ_hMMP3,1,1,"Data from the assay component NVS_ENZ_hMMP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",enzymatic activity,percent_activity,positive,0,Galardin (GM6001),loss,protein,enzyme,protease,matrix metalloproteinase,0,0,1
494,288,NVS_ENZ_hMMP3_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Galardin (GM6001),gain,protein,enzyme,protease,matrix metalloproteinase,0,0,1
495,289,NVS_ENZ_hMMP7,1,1,"Data from the assay component NVS_ENZ_hMMP7 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP7, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",enzymatic activity,percent_activity,positive,0,Galardin (GM6001),loss,protein,enzyme,protease,matrix metalloproteinase,0,0,1
496,289,NVS_ENZ_hMMP7_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP7 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP7_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Galardin (GM6001),gain,protein,enzyme,protease,matrix metalloproteinase,0,0,1
497,290,NVS_ENZ_hMMP9,1,1,"Data from the assay component NVS_ENZ_hMMP9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP9, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",enzymatic activity,percent_activity,positive,0,Galardin (GM6001),loss,protein,enzyme,protease,matrix metalloproteinase,0,0,1
498,290,NVS_ENZ_hMMP9_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP9_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Galardin (GM6001),gain,protein,enzyme,protease,matrix metalloproteinase,0,0,1
499,291,NVS_ENZ_hMsk1,1,1,"Data from the assay component NVS_ENZ_hMsk1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMsk1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RPS6KA5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
500,291,NVS_ENZ_hMsk1_Activator,1,1,"Data from the assay component NVS_ENZ_hMsk1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMsk1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RPS6KA5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
501,292,NVS_ENZ_hNEK2,1,1,"Data from the assay component NVS_ENZ_hNEK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hNEK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NEK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
502,292,NVS_ENZ_hNEK2_Activator,1,1,"Data from the assay component NVS_ENZ_hNEK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hNEK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NEK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
503,293,NVS_ENZ_hPAK2,1,1,"Data from the assay component NVS_ENZ_hPAK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
504,293,NVS_ENZ_hPAK2_Activator,1,1,"Data from the assay component NVS_ENZ_hPAK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
505,294,NVS_ENZ_hPAK4,1,1,"Data from the assay component NVS_ENZ_hPAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
506,294,NVS_ENZ_hPAK4_Activator,1,1,"Data from the assay component NVS_ENZ_hPAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
507,295,NVS_ENZ_hPDE10,1,1,"Data from the assay component NVS_ENZ_hPDE10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE10, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE10A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",enzymatic activity,percent_activity,positive,0,trequinsin,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
508,295,NVS_ENZ_hPDE10_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE10_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE10A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,trequinsin,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
509,296,NVS_ENZ_hPDE4A1,1,1,"Data from the assay component NVS_ENZ_hPDE4A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE4A1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",enzymatic activity,percent_activity,positive,0,trequinsin,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
510,296,NVS_ENZ_hPDE4A1_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE4A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE4A1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,trequinsin,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
511,297,NVS_ENZ_hPDE5,1,1,"Data from the assay component NVS_ENZ_hPDE5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",enzymatic activity,percent_activity,positive,0,Dipyridamole,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
512,297,NVS_ENZ_hPDE5_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE5_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Dipyridamole,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
513,298,NVS_ENZ_hPI3Ka,1,1,"Data from the assay component NVS_ENZ_hPI3Ka was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPI3Ka, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PIK3CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""phosphoinositol kinase"".",enzymatic activity,percent_activity,positive,0,PI-103,loss,protein,enzyme,kinase,phosphoinositol kinase,0,0,1
514,298,NVS_ENZ_hPI3Ka_Activator,1,1,"Data from the assay component NVS_ENZ_hPI3Ka was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPI3Ka_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PIK3CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""phosphoinositol kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,PI-103,gain,protein,enzyme,kinase,phosphoinositol kinase,0,0,1
515,299,NVS_ENZ_hPKA,1,1,"Data from the assay component NVS_ENZ_hPKA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKACA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,H 89,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
516,299,NVS_ENZ_hPKA_Activator,1,1,"Data from the assay component NVS_ENZ_hPKA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKACA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,H 89,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
517,300,NVS_ENZ_hPKCz,1,1,"Data from the assay component NVS_ENZ_hPKCz was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKCz, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKCZ. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
518,300,NVS_ENZ_hPKCz_Activator,1,1,"Data from the assay component NVS_ENZ_hPKCz was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKCz_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKCZ. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
519,301,NVS_ENZ_hPKD2,1,1,"Data from the assay component NVS_ENZ_hPKD2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKD2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKD2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
520,301,NVS_ENZ_hPKD2_Activator,1,1,"Data from the assay component NVS_ENZ_hPKD2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKD2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKD2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
521,302,NVS_ENZ_hPPM1A,1,1,"Data from the assay component NVS_ENZ_hPPM1A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPM1A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPM1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"".",enzymatic activity,percent_activity,positive,0,sodium fluoride,loss,protein,enzyme,phosphatase,serine/threonine phosphatase,0,0,1
522,302,NVS_ENZ_hPPM1A_Activator,1,1,"Data from the assay component NVS_ENZ_hPPM1A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPM1A_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPM1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,sodium fluoride,gain,protein,enzyme,phosphatase,serine/threonine phosphatase,0,0,1
523,303,NVS_ENZ_hPPP1CA,1,1,"Data from the assay component NVS_ENZ_hPPP1CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP1CA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP1CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"".",enzymatic activity,percent_activity,positive,0,calyculin A,loss,protein,enzyme,phosphatase,serine/threonine phosphatase,0,0,1
524,303,NVS_ENZ_hPPP1CA_Activator,1,1,"Data from the assay component NVS_ENZ_hPPP1CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP1CA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP1CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,calyculin A,gain,protein,enzyme,phosphatase,serine/threonine phosphatase,0,0,1
525,304,NVS_ENZ_hPPP2CA,1,1,"Data from the assay component NVS_ENZ_hPPP2CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP2CA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP2CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"".",enzymatic activity,percent_activity,positive,0,calyculin A,loss,protein,enzyme,phosphatase,serine/threonine phosphatase,0,0,1
526,304,NVS_ENZ_hPPP2CA_Activator,1,1,"Data from the assay component NVS_ENZ_hPPP2CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP2CA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP2CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,calyculin A,gain,protein,enzyme,phosphatase,serine/threonine phosphatase,0,0,1
527,305,NVS_ENZ_hPTEN,1,1,"Data from the assay component NVS_ENZ_hPTEN was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTEN, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTEN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"".",enzymatic activity,percent_activity,positive,0,bpV (bipy),loss,protein,enzyme,phosphatase,dual-specific phosphatase,0,0,1
528,305,NVS_ENZ_hPTEN_Activator,1,1,"Data from the assay component NVS_ENZ_hPTEN was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTEN_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTEN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,bpV (bipy);Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,dual-specific phosphatase,0,0,1
529,306,NVS_ENZ_hPTPN1,1,1,"Data from the assay component NVS_ENZ_hPTPN1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
530,306,NVS_ENZ_hPTPN1_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
531,307,NVS_ENZ_hPTPN11,1,1,"Data from the assay component NVS_ENZ_hPTPN11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN11, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
532,307,NVS_ENZ_hPTPN11_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN11_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
533,308,NVS_ENZ_hPTPN12,1,1,"Data from the assay component NVS_ENZ_hPTPN12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN12, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
534,308,NVS_ENZ_hPTPN12_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN12_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
535,309,NVS_ENZ_hPTPN13,1,1,"Data from the assay component NVS_ENZ_hPTPN13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN13, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
536,309,NVS_ENZ_hPTPN13_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN13_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
537,310,NVS_ENZ_hPTPN14,1,1,"Data from the assay component NVS_ENZ_hPTPN14 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN14, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN14. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
538,310,NVS_ENZ_hPTPN14_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN14 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN14_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN14. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
539,311,NVS_ENZ_hPTPN2,1,1,"Data from the assay component NVS_ENZ_hPTPN2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
540,311,NVS_ENZ_hPTPN2_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
541,312,NVS_ENZ_hPTPN4,1,1,"Data from the assay component NVS_ENZ_hPTPN4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
542,312,NVS_ENZ_hPTPN4_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
543,313,NVS_ENZ_hPTPN6,1,1,"Data from the assay component NVS_ENZ_hPTPN6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
544,313,NVS_ENZ_hPTPN6_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN6_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
545,314,NVS_ENZ_hPTPN9,1,1,"Data from the assay component NVS_ENZ_hPTPN9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN9, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
546,314,NVS_ENZ_hPTPN9_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN9_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,non-receptor tyrosine phosphatase,0,0,1
547,315,NVS_ENZ_hPTPRB,1,1,"Data from the assay component NVS_ENZ_hPTPRB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,receptor tyrosine phosphatase,0,0,1
548,315,NVS_ENZ_hPTPRB_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPRB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRB_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,receptor tyrosine phosphatase,0,0,1
549,316,NVS_ENZ_hPTPRC,1,1,"Data from the assay component NVS_ENZ_hPTPRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,receptor tyrosine phosphatase,0,0,1
550,316,NVS_ENZ_hPTPRC_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,receptor tyrosine phosphatase,0,0,1
551,317,NVS_ENZ_hPTPRF,1,1,"Data from the assay component NVS_ENZ_hPTPRF was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,receptor tyrosine phosphatase,0,0,1
552,317,NVS_ENZ_hPTPRF_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPRF was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRF_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,receptor tyrosine phosphatase,0,0,1
553,318,NVS_ENZ_hPTPRM,1,1,"Data from the assay component NVS_ENZ_hPTPRM was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRM, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRM. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"".",enzymatic activity,percent_activity,positive,0,Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,phosphatase,receptor tyrosine phosphatase,0,0,1
554,318,NVS_ENZ_hPTPRM_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPRM was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRM_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRM. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,phosphatase,receptor tyrosine phosphatase,0,0,1
555,319,NVS_ENZ_hRAF1,1,1,"Data from the assay component NVS_ENZ_hRAF1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hRAF1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RAF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,SB203580,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
556,319,NVS_ENZ_hRAF1_Activator,1,1,"Data from the assay component NVS_ENZ_hRAF1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hRAF1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RAF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,SB203580,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
557,320,NVS_ENZ_hROCK1,1,1,"Data from the assay component NVS_ENZ_hROCK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hROCK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ROCK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
558,320,NVS_ENZ_hROCK1_Activator,1,1,"Data from the assay component NVS_ENZ_hROCK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hROCK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ROCK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
559,321,NVS_ENZ_hSGK1,1,1,"Data from the assay component NVS_ENZ_hSGK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSGK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SGK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
560,321,NVS_ENZ_hSGK1_Activator,1,1,"Data from the assay component NVS_ENZ_hSGK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSGK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SGK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,serine/threonine kinase,0,0,1
561,322,NVS_ENZ_hSIRT1,1,1,"Data from the assay component NVS_ENZ_hSIRT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"".",enzymatic activity,percent_activity,positive,0,Suramin;Ammonium Molybdate (NH4MoO4),loss,protein,enzyme,hydrolase,protein deacetylase,0,0,1
562,322,NVS_ENZ_hSIRT1_Activator,1,1,"Data from the assay component NVS_ENZ_hSIRT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Suramin;Ammonium Molybdate (NH4MoO4),gain,protein,enzyme,hydrolase,protein deacetylase,0,0,1
563,323,NVS_ENZ_hSIRT2,1,1,"Data from the assay component NVS_ENZ_hSIRT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"".",enzymatic activity,percent_activity,positive,0,Suramin,loss,protein,enzyme,hydrolase,protein deacetylase,0,0,1
564,323,NVS_ENZ_hSIRT2_Activator,1,1,"Data from the assay component NVS_ENZ_hSIRT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Suramin,gain,protein,enzyme,hydrolase,protein deacetylase,0,0,1
565,324,NVS_ENZ_hSIRT3,1,1,"Data from the assay component NVS_ENZ_hSIRT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"".",enzymatic activity,percent_activity,positive,0,Nicotinamide,loss,protein,enzyme,hydrolase,protein deacetylase,0,0,1
566,324,NVS_ENZ_hSIRT3_Activator,1,1,"Data from the assay component NVS_ENZ_hSIRT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Nicotinamide,gain,protein,enzyme,hydrolase,protein deacetylase,0,0,1
567,325,NVS_ENZ_hSRC,1,1,"Data from the assay component NVS_ENZ_hSRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSRC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
568,325,NVS_ENZ_hSRC_Activator,1,1,"Data from the assay component NVS_ENZ_hSRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSRC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
569,326,NVS_ENZ_hSyk,1,1,"Data from the assay component NVS_ENZ_hSyk was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSyk, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SYK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
570,326,NVS_ENZ_hSyk_Activator,1,1,"Data from the assay component NVS_ENZ_hSyk was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSyk_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SYK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
571,327,NVS_ENZ_hTie2,1,1,"Data from the assay component NVS_ENZ_hTie2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTie2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene TEK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
572,327,NVS_ENZ_hTie2_Activator,1,1,"Data from the assay component NVS_ENZ_hTie2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTie2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene TEK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
573,328,NVS_ENZ_hTrkA,1,1,"Data from the assay component NVS_ENZ_hTrkA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTrkA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NTRK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
574,328,NVS_ENZ_hTrkA_Activator,1,1,"Data from the assay component NVS_ENZ_hTrkA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTrkA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NTRK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
575,329,NVS_ENZ_hVEGFR1,1,1,"Data from the assay component NVS_ENZ_hVEGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
576,329,NVS_ENZ_hVEGFR1_Activator,1,1,"Data from the assay component NVS_ENZ_hVEGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
577,330,NVS_ENZ_hVEGFR2,1,1,"Data from the assay component NVS_ENZ_hVEGFR2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
578,330,NVS_ENZ_hVEGFR2_Activator,1,1,"Data from the assay component NVS_ENZ_hVEGFR2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
579,331,NVS_ENZ_hVEGFR3,1,1,"Data from the assay component NVS_ENZ_hVEGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
580,331,NVS_ENZ_hVEGFR3_Activator,1,1,"Data from the assay component NVS_ENZ_hVEGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
581,332,NVS_ENZ_hZAP70,1,1,"Data from the assay component NVS_ENZ_hZAP70 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hZAP70, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ZAP70. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
582,332,NVS_ENZ_hZAP70_Activator,1,1,"Data from the assay component NVS_ENZ_hZAP70 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hZAP70_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ZAP70. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
583,333,NVS_ENZ_oCOX1,1,1,"Data from the assay component NVS_ENZ_oCOX1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""cyclooxygenase"".",enzymatic activity,percent_activity,positive,0,SC-560,loss,protein,enzyme,oxidoreductase,cyclooxygenase,0,0,1
584,333,NVS_ENZ_oCOX1_Activator,1,1,"Data from the assay component NVS_ENZ_oCOX1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""cyclooxygenase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,SC-560,gain,protein,enzyme,oxidoreductase,cyclooxygenase,0,0,1
585,334,NVS_ENZ_oCOX2,1,1,"Data from the assay component NVS_ENZ_oCOX2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""cyclooxygenase"".",enzymatic activity,percent_activity,positive,0,DuP-697,loss,protein,enzyme,oxidoreductase,cyclooxygenase,0,0,1
586,334,NVS_ENZ_oCOX2_Activator,1,1,"Data from the assay component NVS_ENZ_oCOX2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""cyclooxygenase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,DuP-697,gain,protein,enzyme,oxidoreductase,cyclooxygenase,0,0,1
587,335,NVS_ENZ_pMTHFR,1,1,"Data from the assay component NVS_ENZ_pMTHFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_pMTHFR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MTHFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""methylenetetrahydrofolate reductase"".",enzymatic activity,percent_activity,positive,0,Sulfasalazine,loss,protein,enzyme,oxidoreductase,methylenetetrahydrofolate reductase,0,0,1
588,335,NVS_ENZ_pMTHFR_Activator,1,1,"Data from the assay component NVS_ENZ_pMTHFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_pMTHFR_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MTHFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""methylenetetrahydrofolate reductase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Sulfasalazine,gain,protein,enzyme,oxidoreductase,methylenetetrahydrofolate reductase,0,0,1
589,336,NVS_ENZ_rabI2C,1,1,"Data from the assay component NVS_ENZ_rabI2C was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rabI2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CKB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""imidazoline receptor"".",enzymatic activity,percent_activity,positive,0,2-BFI,loss,protein,receptor,oxidoreductase,imidazoline receptor,0,0,1
590,336,NVS_ENZ_rabI2C_Activator,1,1,"Data from the assay component NVS_ENZ_rabI2C was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rabI2C_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CKB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""imidazoline receptor"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,2-BFI,gain,protein,receptor,oxidoreductase,imidazoline receptor,0,0,1
591,337,NVS_ENZ_rACFSKBinding,1,1,"Data from the assay component NVS_ENZ_rACFSKBinding was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rACFSKBinding, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Adcy5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""lyase"" intended target family, where the subfamily is ""adenylyl cyclase"".",enzymatic activity,percent_activity,positive,0,Forskolin,loss,protein,enzyme,lyase,adenylyl cyclase,0,0,1
592,337,NVS_ENZ_rACFSKBinding_Activator,1,1,"Data from the assay component NVS_ENZ_rACFSKBinding was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rACFSKBinding_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Adcy5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""lyase"" intended target family, where the subfamily is ""adenylyl cyclase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Forskolin,gain,protein,enzyme,lyase,adenylyl cyclase,0,0,1
593,338,NVS_ENZ_rAChE,1,1,"Data from the assay component NVS_ENZ_rAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rAChE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Ache. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""acetylcholinesterase"".",enzymatic activity,percent_activity,positive,0,Physostigmine,loss,protein,enzyme,esterase,acetylcholinesterase,0,0,1
594,338,NVS_ENZ_rAChE_Activator,1,1,"Data from the assay component NVS_ENZ_rAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rAChE_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Ache. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""acetylcholinesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Physostigmine,gain,protein,enzyme,esterase,acetylcholinesterase,0,0,1
595,339,NVS_ENZ_rCNOS,1,1,"Data from the assay component NVS_ENZ_rCNOS was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCNOS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Nos1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""nitric oxide synthase"".",enzymatic activity,percent_activity,positive,0,Nitro-L-Arginine,loss,protein,enzyme,oxidoreductase,nitric oxide synthase,0,0,1
596,339,NVS_ENZ_rCNOS_Activator,1,1,"Data from the assay component NVS_ENZ_rCNOS was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCNOS_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Nos1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""nitric oxide synthase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Nitro-L-Arginine,gain,protein,enzyme,oxidoreductase,nitric oxide synthase,0,0,1
597,340,NVS_ENZ_rCOMT,1,1,"Data from the assay component NVS_ENZ_rCOMT was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCOMT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Comt. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""methyltransferase"" intended target family, where the subfamily is ""o-methyltransferase"".",enzymatic activity,percent_activity,positive,0,OR-486,loss,protein,enzyme,methyltransferase,o-methyltransferase,0,0,1
598,340,NVS_ENZ_rCOMT_Activator,1,1,"Data from the assay component NVS_ENZ_rCOMT was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCOMT_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Comt. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""methyltransferase"" intended target family, where the subfamily is ""o-methyltransferase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,OR-486,gain,protein,enzyme,methyltransferase,o-methyltransferase,0,0,1
599,341,NVS_ENZ_hDYRK1a,1,1,"Data from the assay component NVS_ENZ_hDYRK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDYRK1a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DYRK1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""dual-specific kinase"".",enzymatic activity,percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,dual-specific kinase,0,0,1
600,341,NVS_ENZ_hDYRK1a_Activator,1,1,"Data from the assay component NVS_ENZ_hDYRK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDYRK1a_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DYRK1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""dual-specific kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,dual-specific kinase,0,0,1
601,342,NVS_ENZ_rMAOAC,1,1,"Data from the assay component NVS_ENZ_rMAOAC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",enzymatic activity,percent_activity,positive,0,Ro 41-1049;Tetrindole mesylate,loss,protein,enzyme,oxidoreductase,monoamine oxidase,0,0,1
602,342,NVS_ENZ_rMAOAC_Activator,1,1,"Data from the assay component NVS_ENZ_rMAOAC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ro 41-1049;Tetrindole mesylate,gain,protein,enzyme,oxidoreductase,monoamine oxidase,0,0,1
603,343,NVS_ENZ_rMAOAP,1,1,"Data from the assay component NVS_ENZ_rMAOAP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAP, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",enzymatic activity,percent_activity,positive,0,Ro 41-1049;Tetrindole mesylate,loss,protein,enzyme,oxidoreductase,monoamine oxidase,0,0,1
604,343,NVS_ENZ_rMAOAP_Activator,1,1,"Data from the assay component NVS_ENZ_rMAOAP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAP_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ro 41-1049;Tetrindole mesylate,gain,protein,enzyme,oxidoreductase,monoamine oxidase,0,0,1
605,344,NVS_ENZ_rMAOBC,1,1,"Data from the assay component NVS_ENZ_rMAOBC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",enzymatic activity,percent_activity,positive,0,Ro 16-6491,loss,protein,enzyme,oxidoreductase,monoamine oxidase,0,0,1
606,344,NVS_ENZ_rMAOBC_Activator,1,1,"Data from the assay component NVS_ENZ_rMAOBC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ro 16-6491,gain,protein,enzyme,oxidoreductase,monoamine oxidase,0,0,1
607,345,NVS_ENZ_rMAOBP,1,1,"Data from the assay component NVS_ENZ_rMAOBP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBP, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",enzymatic activity,percent_activity,positive,0,Ro 16-6491,loss,protein,enzyme,oxidoreductase,monoamine oxidase,0,0,1
608,345,NVS_ENZ_rMAOBP_Activator,1,1,"Data from the assay component NVS_ENZ_rMAOBP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBP_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,Ro 16-6491,gain,protein,enzyme,oxidoreductase,monoamine oxidase,0,0,1
609,346,NVS_GPCR_bAdoR_NonSelective,1,1,"Data from the assay component NVS_GPCR_bAdoR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAdoR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,"5""-N-ethylcarboxamidoadenosine (NECA)",loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
610,347,NVS_GPCR_bAT2,1,1,"Data from the assay component NVS_GPCR_bAT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AGTR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Angiotensin II,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
611,348,NVS_GPCR_bDR_NonSelective,1,1,"Data from the assay component NVS_GPCR_bDR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bDR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Spiperone HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
612,349,NVS_GPCR_bH1,1,1,"Data from the assay component NVS_GPCR_bH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bH1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Tripolidine,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
613,350,NVS_GPCR_bNPY_NonSelective,1,1,"Data from the assay component NVS_GPCR_bNPY_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bNPY_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,porcine neuropeptide Y,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
614,351,NVS_GPCR_g5HT4,1,1,"Data from the assay component NVS_GPCR_g5HT4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_g5HT4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Serotonin,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
615,352,NVS_GPCR_gANPA,1,1,"Data from the assay component NVS_GPCR_gANPA was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gANPA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Nppa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""lyase"" intended target family, where the subfamily is ""guanylyl cyclase"".",binding,percent_activity,positive,0,rat ANP,loss,protein,receptor,lyase,guanylyl cyclase,0,0,1
616,353,NVS_GPCR_gBK2,1,1,"Data from the assay component NVS_GPCR_gBK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gBK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Bdkrb2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Bradykinin TFA salt,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
617,354,NVS_GPCR_gH2,1,1,"Data from the assay component NVS_GPCR_gH2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gH2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Hrh2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Tiotidine,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
618,355,NVS_GPCR_gLTB4,1,1,"Data from the assay component NVS_GPCR_gLTB4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTB4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ltb4r. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Leukotriene B4 (LTB4),loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
619,356,NVS_GPCR_gLTD4,1,1,"Data from the assay component NVS_GPCR_gLTD4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTD4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cysltr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Leukotriene D4 (LTD4),loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
620,357,NVS_GPCR_gMPeripheral_NonSelective,1,1,"Data from the assay component NVS_GPCR_gMPeripheral_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gMPeripheral_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Chrm3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Atropine sulfate,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
621,358,NVS_GPCR_gOpiateK,1,1,"Data from the assay component NVS_GPCR_gOpiateK was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gOpiateK, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprk1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,U-69593,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
622,359,NVS_GPCR_h5HT2A,1,1,"Data from the assay component NVS_GPCR_h5HT2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT2A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Ketanserin,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
623,360,NVS_GPCR_h5HT5A,1,1,"Data from the assay component NVS_GPCR_h5HT5A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT5A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Methiothepin mesylate,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
624,361,NVS_GPCR_h5HT6,1,1,"Data from the assay component NVS_GPCR_h5HT6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Methiothepin mesylate,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
625,362,NVS_GPCR_h5HT7,1,1,"Data from the assay component NVS_GPCR_h5HT7 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT7, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,5-carboxamidotryptamine,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
626,363,NVS_GPCR_hAdoRA1,1,1,"Data from the assay component NVS_GPCR_hAdoRA1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,2-chloroadenosine,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
627,364,NVS_GPCR_hAdoRA2a,1,1,"Data from the assay component NVS_GPCR_hAdoRA2a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA2a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,"5""-N-ethylcarboxamidoadenosine (NECA)",loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
628,365,NVS_GPCR_hAdra2A,1,1,"Data from the assay component NVS_GPCR_hAdra2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Oxymetazoline HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
629,366,NVS_GPCR_hAdra2C,1,1,"Data from the assay component NVS_GPCR_hAdra2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2C. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Oxymetazoline HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
630,367,NVS_GPCR_hAdrb1,1,1,"Data from the assay component NVS_GPCR_hAdrb1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Alprenolol HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
631,368,NVS_GPCR_hAdrb2,1,1,"Data from the assay component NVS_GPCR_hAdrb2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Alprenolol HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
632,369,NVS_GPCR_hAdrb3,1,1,"Data from the assay component NVS_GPCR_hAdrb3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Propranolol HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
633,370,NVS_GPCR_hAT1,1,1,"Data from the assay component NVS_GPCR_hAT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AGTR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Angiotensin II,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
634,371,NVS_GPCR_hC5a,1,1,"Data from the assay component NVS_GPCR_hC5a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hC5a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene C5AR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,human rC5a,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
635,372,NVS_GPCR_hDRD1,1,1,"Data from the assay component NVS_GPCR_hDRD1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,R(+)-SCH 23390,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
636,373,NVS_GPCR_hDRD2s,1,1,"Data from the assay component NVS_GPCR_hDRD2s was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD2s, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Haloperidol,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
637,374,NVS_GPCR_hDRD4.4,1,1,"Data from the assay component NVS_GPCR_hDRD4.4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD4.4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Haloperidol,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
638,375,NVS_GPCR_hETA,1,1,"Data from the assay component NVS_GPCR_hETA was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hETA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene EDNRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Endothelin-1,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
639,376,NVS_GPCR_hETB,1,1,"Data from the assay component NVS_GPCR_hETB was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hETB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene EDNRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Endothelin-1,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
640,377,NVS_GPCR_hH1,1,1,"Data from the assay component NVS_GPCR_hH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hH1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Tripolidine,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
641,378,NVS_GPCR_hLTB4_BLT1,1,1,"Data from the assay component NVS_GPCR_hLTB4_BLT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hLTB4_BLT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene LTB4R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Leukotriene B4 (LTB4),loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
642,379,NVS_GPCR_hM1,1,1,"Data from the assay component NVS_GPCR_hM1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Methylscopolamine bromide,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
643,380,NVS_GPCR_hM2,1,1,"Data from the assay component NVS_GPCR_hM2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Methylscopolamine bromide,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
644,381,NVS_GPCR_hM3,1,1,"Data from the assay component NVS_GPCR_hM3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Methylscopolamine bromide,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
645,382,NVS_GPCR_hM4,1,1,"Data from the assay component NVS_GPCR_hM4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Methylscopolamine bromide,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
646,383,NVS_GPCR_hM5,1,1,"Data from the assay component NVS_GPCR_hM5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Methylscopolamine bromide,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
647,384,NVS_GPCR_hNK2,1,1,"Data from the assay component NVS_GPCR_hNK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TACR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Neurokinin A,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
648,385,NVS_GPCR_hNPY1,1,1,"Data from the assay component NVS_GPCR_hNPY1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNPY1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,porcine neuropeptide Y,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
649,386,NVS_GPCR_hNPY2,1,1,"Data from the assay component NVS_GPCR_hNPY2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNPY2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY2R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,porcine neuropeptide Y,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
650,387,NVS_GPCR_hNTS,1,1,"Data from the assay component NVS_GPCR_hNTS was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNTS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NTSR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,neurotensin,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
651,388,NVS_GPCR_hOpiate_D1,1,1,"Data from the assay component NVS_GPCR_hOpiate_D1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_D1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Naltriben methanesulfonate,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
652,389,NVS_GPCR_hOpiate_mu,1,1,"Data from the assay component NVS_GPCR_hOpiate_mu was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_mu, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Naloxone HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
653,390,NVS_GPCR_hORL1,1,1,"Data from the assay component NVS_GPCR_hORL1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hORL1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRL1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Nociceptin,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
654,391,NVS_GPCR_hPY2,1,1,"Data from the assay component NVS_GPCR_hPY2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hPY2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene P2RY1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,ADPbS,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
655,392,NVS_GPCR_hTXA2,1,1,"Data from the assay component NVS_GPCR_hTXA2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hTXA2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TBXA2R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Pinane-thromboxane A2,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
656,393,NVS_GPCR_hV1A,1,1,"Data from the assay component NVS_GPCR_hV1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hV1A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AVPR1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,"(Phenyl[1]ac, D-Tyr(Me)[2],Arg[6,8],Lys-NH2[9])-vasopressin;Arg8-Vasopressin (AVP)",loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
657,394,NVS_GPCR_mCCKAPeripheral,1,1,"Data from the assay component NVS_GPCR_mCCKAPeripheral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCCKAPeripheral, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckar. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Cholecystokinin 8 (CCK-8) (26-33) sulfated,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
658,395,NVS_GPCR_mCKKBCentral,1,1,"Data from the assay component NVS_GPCR_mCKKBCentral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCKKBCentral, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckbr. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Cholecystokinin 8 (CCK-8) (26-33) sulfated,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
659,396,NVS_GPCR_p5HT2C,1,1,"Data from the assay component NVS_GPCR_p5HT2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_p5HT2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2C. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Mianserin HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
660,397,NVS_GPCR_r5HT_NonSelective,1,1,"Data from the assay component NVS_GPCR_r5HT_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_r5HT_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Methysergide maleate,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
661,398,NVS_GPCR_r5HT1_NonSelective,1,1,"Data from the assay component NVS_GPCR_r5HT1_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_r5HT1_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Serotonin,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
662,399,NVS_GPCR_rabPAF,1,1,"Data from the assay component NVS_GPCR_rabPAF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rabPAF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PTAFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,C16-PAF,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
663,400,NVS_GPCR_rAdra1_NonSelective,1,1,"Data from the assay component NVS_GPCR_rAdra1_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Phentolamine mesylate,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
664,401,NVS_GPCR_rAdra1A,1,1,"Data from the assay component NVS_GPCR_rAdra1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Phentolamine mesylate,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
665,402,NVS_GPCR_rAdra1B,1,1,"Data from the assay component NVS_GPCR_rAdra1B was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1B, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1b. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Phentolamine mesylate,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
666,403,NVS_GPCR_rAdra2_NonSelective,1,1,"Data from the assay component NVS_GPCR_rAdra2_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra2_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra2a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Phentolamine mesylate,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
667,404,NVS_GPCR_rAdrb_NonSelective,1,1,"Data from the assay component NVS_GPCR_rAdrb_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdrb_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adrb1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Alprenolol HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
668,405,NVS_GPCR_rCRF,1,1,"Data from the assay component NVS_GPCR_rCRF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rCRF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Crhr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""secretin receptor"".",binding,percent_activity,positive,0,Tyr0-oCRF,loss,protein,receptor,gpcr,secretin receptor,0,0,1
669,406,NVS_GPCR_rGABBR,1,1,"Data from the assay component NVS_GPCR_rGABBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGABBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabbr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""metabotropic glutamate receptor"".",binding,percent_activity,positive,0,(+/-)-Baclofen,loss,protein,receptor,gpcr,metabotropic glutamate receptor,0,0,1
670,407,NVS_GPCR_rGalanin,1,1,"Data from the assay component NVS_GPCR_rGalanin was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGalanin, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Galr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,porcine Galanin,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
671,408,NVS_GPCR_rGHB,1,1,"Data from the assay component NVS_GPCR_rGHB was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGHB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspan17. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""metabotropic glutamate receptor"".",binding,percent_activity,positive,0,NCS-382,loss,protein,receptor,gpcr,metabotropic glutamate receptor,0,0,1
672,409,NVS_GPCR_rH3,1,1,"Data from the assay component NVS_GPCR_rH3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rH3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Hrh3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,N-a-methylhistamine (NAMH),loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
673,410,NVS_GPCR_rmAdra2B,1,1,"Data from the assay component NVS_GPCR_rmAdra2B was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmAdra2B, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra2b. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Oxymetazoline HCl;Norepinephrine,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
674,411,NVS_GPCR_rmMGluR1,1,1,"Data from the assay component NVS_GPCR_rmMGluR1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmMGluR1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grm1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""metabotropic glutamate receptor"".",binding,percent_activity,positive,0,L-Glutamate,loss,protein,receptor,gpcr,metabotropic glutamate receptor,0,0,1
675,412,NVS_GPCR_rmMGluR5,1,1,"Data from the assay component NVS_GPCR_rmMGluR5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmMGluR5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grm5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""metabotropic glutamate receptor"".",binding,percent_activity,positive,0,MPEP,loss,protein,receptor,gpcr,metabotropic glutamate receptor,0,0,1
676,413,NVS_GPCR_rNK1,1,1,"Data from the assay component NVS_GPCR_rNK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tacr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Substance P,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
677,414,NVS_GPCR_rNK3,1,1,"Data from the assay component NVS_GPCR_rNK3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNK3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tacr3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Eledoisin,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
678,415,NVS_GPCR_rNTS,1,1,"Data from the assay component NVS_GPCR_rNTS was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNTS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ntsr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Neurotensin,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
679,416,NVS_GPCR_rOpiate_NonSelective,1,1,"Data from the assay component NVS_GPCR_rOpiate_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOpiate_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprm1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Naloxone HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
680,417,NVS_GPCR_rOpiate_NonSelectiveNa,1,1,"Data from the assay component NVS_GPCR_rOpiate_NonSelectiveNa was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOpiate_NonSelectiveNa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprm1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Naloxone HCl,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
681,418,NVS_GPCR_rOXT,1,1,"Data from the assay component NVS_GPCR_rOXT was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOXT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oxtr. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Oxytocin,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
682,419,NVS_GPCR_rSST,1,1,"Data from the assay component NVS_GPCR_rSST was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rSST, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sstr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,Somatostatin,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
683,420,NVS_GPCR_rTRH,1,1,"Data from the assay component NVS_GPCR_rTRH was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rTRH, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Trhr. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,TRH,loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
684,421,NVS_GPCR_rV1,1,1,"Data from the assay component NVS_GPCR_rV1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rV1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Avpr1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",binding,percent_activity,positive,0,"(Phenyl[1]ac, D-Tyr(Me)[2],Arg[6,8],Lys-NH2[9])-vasopressin;Arg8-Vasopressin (AVP)",loss,protein,receptor,gpcr,rhodopsin-like receptor,0,0,1
685,422,NVS_GPCR_rVIP_NonSelective,1,1,"Data from the assay component NVS_GPCR_rVIP_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rVIP_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Vipr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""secretin receptor"".",binding,percent_activity,positive,0,Vasoactive intestinal peptide (VIP),loss,protein,receptor,gpcr,secretin receptor,0,0,1
686,423,NVS_IC_hKhERGCh,1,1,"Data from the assay component NVS_IC_hKhERGCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_hKhERGCh, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene KCNH2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""potassium channel"".",binding,percent_activity,positive,0,Terfenadine,loss,protein,receptor,ion channel,potassium channel,0,0,1
687,424,NVS_IC_rCaBTZCHL,1,1,"Data from the assay component NVS_IC_rCaBTZCHL was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaBTZCHL, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""calcium channel"".",binding,percent_activity,positive,0,Diltiazem HCl,loss,protein,receptor,ion channel,calcium channel,0,0,1
688,425,NVS_IC_rCaChN,1,1,"Data from the assay component NVS_IC_rCaChN was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaChN, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1b. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""calcium channel"".",binding,percent_activity,positive,0,W-Conotoxin GVIA,loss,protein,receptor,ion channel,calcium channel,0,0,1
689,426,NVS_IC_rCaDHPRCh_L,1,1,"Data from the assay component NVS_IC_rCaDHPRCh_L was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaDHPRCh_L, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""calcium channel"".",binding,percent_activity,positive,0,Nifedipine,loss,protein,receptor,ion channel,calcium channel,0,0,1
690,427,NVS_IC_rKAR,1,1,"Data from the assay component NVS_IC_rKAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grik1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,Kainic acid,loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
691,428,NVS_IC_rKATPCh,1,1,"Data from the assay component NVS_IC_rKATPCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKATPCh, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Kcnj1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""potassium channel"".",binding,percent_activity,positive,0,Glibenclamide,loss,protein,receptor,ion channel,potassium channel,0,0,1
692,429,NVS_IC_rKCaCh,1,1,"Data from the assay component NVS_IC_rKCaCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKCaCh, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Kcnn1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""potassium channel"".",binding,percent_activity,positive,0,Apamin,loss,protein,receptor,ion channel,potassium channel,0,0,1
693,430,NVS_IC_rNaCh_site2,1,1,"Data from the assay component NVS_IC_rNaCh_site2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rNaCh_site2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Scn1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""sodium channel"".",binding,percent_activity,positive,0,Aconitine,loss,protein,receptor,ion channel,sodium channel,0,0,1
694,431,NVS_LGIC_bGABAR_Agonist,1,1,"Data from the assay component NVS_LGIC_bGABAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,GABA,loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
695,432,NVS_LGIC_bGABARa1,1,1,"Data from the assay component NVS_LGIC_bGABARa1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,Ro 15-1788 (Flumazenil),loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
696,433,NVS_LGIC_bGABARa5,1,1,"Data from the assay component NVS_LGIC_bGABARa5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,"L-655,708",loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
697,434,NVS_LGIC_h5HT3,1,1,"Data from the assay component NVS_LGIC_h5HT3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_h5HT3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR3A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,MDL-72222,loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
698,435,NVS_LGIC_hNNR_NBungSens,1,1,"Data from the assay component NVS_LGIC_hNNR_NBungSens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_hNNR_NBungSens, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRNA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,(+/-)-Epibatidine,loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
699,436,NVS_LGIC_rAMPA,1,1,"Data from the assay component NVS_LGIC_rAMPA was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rAMPA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gria1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,(+/-)-AMPA HBr,loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
700,437,NVS_LGIC_rGABAR_NonSelective,1,1,"Data from the assay component NVS_LGIC_rGABAR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABAR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,GABA,loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
701,438,NVS_LGIC_rGABARa6,1,1,"Data from the assay component NVS_LGIC_rGABARa6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABARa6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,"L-655,708",loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
702,439,NVS_LGIC_rGluNMDA_Agonist,1,1,"Data from the assay component NVS_LGIC_rGluNMDA_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGluNMDA_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grin1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,N-methyl-D-aspartate (NMDA),loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
703,440,NVS_LGIC_rGluNMDA_MK801_Agonist,1,1,"Data from the assay component NVS_LGIC_rGluNMDA_MK801_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGluNMDA_MK801_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grin1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,(+)-MK-801,loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
704,441,NVS_LGIC_rGlyRStrySens,1,1,"Data from the assay component NVS_LGIC_rGlyRStrySens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGlyRStrySens, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Glra1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,Strychnine nitrate,loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
705,442,NVS_LGIC_rNNR_BungSens,1,1,"Data from the assay component NVS_LGIC_rNNR_BungSens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rNNR_BungSens, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Chrna7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",binding,percent_activity,positive,0,Methyllycaconitine,loss,protein,receptor,ion channel,ligand-gated ion channel,0,0,1
706,443,NVS_MP_hPBR,1,1,"Data from the assay component NVS_MP_hPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_hPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TSPO. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""cholesterol transporter"".",binding,percent_activity,positive,0,PK11195,loss,protein,transporter,transporter,cholesterol transporter,0,0,1
707,444,NVS_MP_rPBR,1,1,"Data from the assay component NVS_MP_rPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_rPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspo. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""cholesterol transporter"".",binding,percent_activity,positive,0,PK11195,loss,protein,transporter,transporter,cholesterol transporter,0,0,1
708,445,NVS_NR_bER,1,1,"Data from the assay component NVS_NR_bER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bER, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,17b-Estradiol,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
709,446,NVS_NR_bPR,1,1,"Data from the assay component NVS_NR_bPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bPR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,Promegestone,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
710,447,NVS_NR_cAR,1,1,"Data from the assay component NVS_NR_cAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_cAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,Methyltrienolone,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
711,448,NVS_NR_hAR,1,1,"Data from the assay component NVS_NR_hAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,Methyltrienolone,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
712,449,NVS_NR_hCAR_Agonist,1,1,"Data from the assay component NVS_NR_hCAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,CITCO,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
713,450,NVS_NR_hCAR_Antagonist,1,1,"Data from the assay component NVS_NR_hCAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,Clotrimazole,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
714,451,NVS_NR_hER,1,1,"Data from the assay component NVS_NR_hER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hER, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,17b-Estradiol,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
715,452,NVS_NR_hFXR_Agonist,1,1,"Data from the assay component NVS_NR_hFXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,CDCA,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
716,453,NVS_NR_hFXR_Antagonist,1,1,"Data from the assay component NVS_NR_hFXR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,Guggulsterone,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
717,454,NVS_NR_hGR,1,1,"Data from the assay component NVS_NR_hGR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hGR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,Triamcinolone acetonide,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
718,455,NVS_NR_hPPARa,1,1,"Data from the assay component NVS_NR_hPPARa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,GW7647,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
719,456,NVS_NR_hPPARg,1,1,"Data from the assay component NVS_NR_hPPARg was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARg, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,Ciglitazone,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
720,457,NVS_NR_hPR,1,1,"Data from the assay component NVS_NR_hPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,Promegestone,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
721,458,NVS_NR_hPXR,1,1,"Data from the assay component NVS_NR_hPXR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPXR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,TO901317,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
722,459,NVS_NR_hRAR_Antagonist,1,1,"Data from the assay component NVS_NR_hRAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,RO415253,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
723,460,NVS_NR_hRARa_Agonist,1,1,"Data from the assay component NVS_NR_hRARa_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRARa_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,TTNPB,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
724,461,NVS_NR_hTRa_Antagonist,1,1,"Data from the assay component NVS_NR_hTRa_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hTRa_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene THRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,Bisphenol A,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
725,462,NVS_NR_mERa,1,1,"Data from the assay component NVS_NR_mERa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_mERa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Esr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,17b-Estradiol,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
726,463,NVS_NR_rAR,1,1,"Data from the assay component NVS_NR_rAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ar. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,Methyltrienolone,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
727,464,NVS_NR_rMR,1,1,"Data from the assay component NVS_NR_rMR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rMR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Nr3c2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,Spironolactone,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
728,465,NVS_OR_gSIGMA_NonSelective,1,1,"Data from the assay component NVS_OR_gSIGMA_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_gSIGMA_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sigmar1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""chaperone"".",binding,percent_activity,positive,0,Haloperidol,loss,protein,receptor,misc protein,chaperone,0,0,1
729,466,NVS_OR_hFKBP12,1,1,"Data from the assay component NVS_OR_hFKBP12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_hFKBP12, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene FKBP1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""chaperone"".",binding,percent_activity,positive,0,FK506,loss,protein,enzyme,misc protein,chaperone,0,0,1
730,467,NVS_TR_gDAT,1,1,"Data from the assay component NVS_TR_gDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_gDAT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",binding,percent_activity,positive,0,GBR-12909,loss,protein,transporter,transporter,neurotransmitter transporter,0,0,1
731,468,NVS_TR_hAdoT,1,1,"Data from the assay component NVS_TR_hAdoT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hAdoT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC29A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""nucleoside transporter"".",binding,percent_activity,positive,0,Nitrobenzylthioinosine (NBTI),loss,protein,transporter,transporter,nucleoside transporter,0,0,1
732,469,NVS_TR_hDAT,1,1,"Data from the assay component NVS_TR_hDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hDAT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",binding,percent_activity,positive,0,GBR-12909,loss,protein,transporter,transporter,neurotransmitter transporter,0,0,1
733,470,NVS_TR_hNET,1,1,"Data from the assay component NVS_TR_hNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hNET, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",binding,percent_activity,positive,0,Desipramine,loss,protein,transporter,transporter,neurotransmitter transporter,0,0,1
734,471,NVS_TR_hSERT,1,1,"Data from the assay component NVS_TR_hSERT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hSERT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",binding,percent_activity,positive,0,Imipramine HCl;Clomipramine HCl,loss,protein,transporter,transporter,neurotransmitter transporter,0,0,1
735,472,NVS_TR_rAdoT,1,1,"Data from the assay component NVS_TR_rAdoT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rAdoT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc29a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""nucleoside transporter"".",binding,percent_activity,positive,0,Nitrobenzylthioinosine (NBTI),loss,protein,transporter,transporter,nucleoside transporter,0,0,1
736,473,NVS_TR_rNET,1,1,"Data from the assay component NVS_TR_rNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rNET, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",binding,percent_activity,positive,0,Desipramine,loss,protein,transporter,transporter,neurotransmitter transporter,0,0,1
737,474,NVS_TR_rSERT,1,1,"Data from the assay component NVS_TR_rSERT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rSERT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",binding,percent_activity,positive,0,Imipramine HCl,loss,protein,transporter,transporter,neurotransmitter transporter,0,0,1
738,475,NVS_TR_rVMAT2,1,1,"Data from the assay component NVS_TR_rVMAT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rVMAT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc18a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""vesicular transporter"".",binding,percent_activity,positive,0,Reserpine,loss,protein,transporter,transporter,vesicular transporter,0,0,1
739,476,OT_AR_ARELUC_AG_1440,1,1,"Data from the assay component OT_AR_ARELUC_AG_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARELUC_AG_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",reporter gene,percent_activity,positive,0,6-alpha-Fluorotestosterone,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
740,477,OT_AR_ARSRC1_0480,1,1,"Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,"4,5-alpha-Dihydrotestosterone",gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
741,478,OT_AR_ARSRC1_0960,1,1,"Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,"4,5-alpha-Dihydrotestosterone",gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
742,479,OT_ER_ERaERa_0480,1,1,"Data from the assay component OT_ER_ERaERa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
743,480,OT_ER_ERaERa_1440,1,1,"Data from the assay component OT_ER_ERaERa_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
744,481,OT_ER_ERaERb_0480,1,1,"Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
745,482,OT_ER_ERaERb_1440,1,1,"Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
746,483,OT_ER_ERbERb_0480,1,1,"Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
747,484,OT_ER_ERbERb_1440,1,1,"Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
748,485,OT_ERa_ERELUC_AG_1440,0,0,OT_ERa_ERELUC_AG_1440,reporter gene,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
749,486,OT_ERa_ERELUC_ANT_1440,0,0,OT_ERa_ERELUC_ANT_1440,reporter gene,log2_fold_induction,positive,0,(Z)-4-Hydroxytamoxifen,loss,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
750,487,OT_ERa_EREGFP_0120,1,1,"Data from the assay component OT_ERa_GFPERaERE_0120 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ERa_EREGFP_0120, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",reporter gene,percent_activity,positive,0,(Z)-4-Hydroxytamoxifen,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
751,488,OT_ERa_EREGFP_0480,1,1,"Data from the assay component OT_ERa_GFPERaERE_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ERa_EREGFP_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",reporter gene,percent_activity,positive,0,(Z)-4-Hydroxytamoxifen,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
752,489,OT_ERb_ERELUC_ANT_1440,0,0,OT_ERb_ERELUC_ANT_1440,reporter gene,log2_fold_induction,positive,0,(Z)-4-Hydroxytamoxifen,loss,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
753,490,OT_FXR_FXRSRC1_0480,1,1,"Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,GW4064,gain,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
754,491,OT_FXR_FXRSRC1_1440,1,1,"Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,GW4064,gain,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
755,492,OT_NURR1_NURR1RXRa_0480,1,1,"Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,Isoproterenol;Fenoterol,gain,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
756,493,OT_NURR1_NURR1RXRa_1440,1,1,"Data from the assay component OT_NURR1_NURR1RXRa_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,Isoproterenol;Fenoterol,gain,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
757,494,OT_PPARg_PPARgSRC1_0480,1,1,"Data from the assay component OT_PPARg_PPARgSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_PPARg_PPARgSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,GW1929,gain,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
758,495,OT_PPARg_PPARgSRC1_1440,1,1,"Data from the assay component OT_PPARg_PPARgSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_PPARg_PPARgSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",binding,percent_activity,positive,0,GW1929,gain,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
759,496,TOX21_AR_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_AR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,R1881,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
760,497,TOX21_AR_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_AR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,R1881,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
761,498,TOX21_AR_BLA_Agonist_ratio,1,1,"Data from the assay component TOX21_AR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,R1881,gain,protein,receptor,nuclear receptor,steroidal,0,0,1
762,499,TOX21_AR_BLA_Antagonist_ratio,1,1,"Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,Cyproterone acetate,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
763,500,TOX21_AR_BLA_Antagonist_viability,1,1,"TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
764,501,TOX21_AR_LUC_MDAKB2_Agonist,1,1,"Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",agonist,percent_activity,positive,0,R1881,gain,protein,receptor,nuclear receptor,steroidal,0,0,1
765,502,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881,1,1,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",antagonist,percent_activity,positive,0,Nilutamide,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
766,503,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability,1,1,"TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
767,504,TOX21_Aromatase_Inhibition,1,1,"Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.",inducer,percent_activity,positive,0,Letrozole,loss,protein,enzyme,cyp,steroidogenesis-related,0,0,1
768,505,TOX21_Aromatase_Inhibition_viability,1,1,"TOX21_Aromatase_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
769,506,TOX21_AutoFluor_HEK293_Cell_blue,1,1,"Data from the assay component TOX21_AutoFluor_HEK293_Cell_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Cell_blue, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
770,507,TOX21_AutoFluor_HEK293_Cell_green,1,1,"Data from the assay component TOX21_AutoFluor_HEK293_Cell_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Cell_green, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
771,508,TOX21_AutoFluor_HEK293_Cell_red,1,1,"Data from the assay component TOX21_AutoFluor_HEK293_Cell_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Cell_red, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
772,509,TOX21_AutoFluor_HEK293_Media_blue,1,1,"Data from the assay component TOX21_AutoFluor_HEK293_Media_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Media_blue, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
773,510,TOX21_AutoFluor_HEK293_Media_green,1,1,"Data from the assay component TOX21_AutoFluor_HEK293_Media_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Media_green, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
774,511,TOX21_AutoFluor_HEK293_Media_red,1,1,"Data from the assay component TOX21_AutoFluor_HEK293_Media_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEK293_Media_red, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
775,512,TOX21_AutoFluor_HEPG2_Cell_blue,1,1,"Data from the assay component TOX21_AutoFluor_HEPG2_Cell_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Cell_blue, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
776,513,TOX21_AutoFluor_HEPG2_Cell_green,1,1,"Data from the assay component TOX21_AutoFluor_HEPG2_Cell_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Cell_green, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
777,514,TOX21_AutoFluor_HEPG2_Cell_red,1,1,"Data from the assay component TOX21_AutoFluor_HEPG2_Cell_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Cell_red, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
778,515,TOX21_AutoFluor_HEPG2_Media_blue,1,1,"Data from the assay component TOX21_AutoFluor_HEPG2_Media_blue was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Media_blue, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
779,516,TOX21_AutoFluor_HEPG2_Media_green,1,1,"Data from the assay component TOX21_AutoFluor_HEPG2_Media_green was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Media_green, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
780,517,TOX21_AutoFluor_HEPG2_Media_red,1,1,"Data from the assay component TOX21_AutoFluor_HEPG2_Media_red was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AutoFluor_HEPG2_Media_red, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is artifact fluorescence.",background control,percent_activity,positive,0,Fluorescein;Rose Bengal Sodium;Triamterene,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
781,518,TOX21_ELG1_LUC_Agonist,1,1,"Data from the assay component TOX21_ELG1_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ELG1_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATAD5.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is atpase.",agonist,percent_activity,positive,0,5-Fluorouridine,gain,protein,enzyme,hydrolase,atpase,0,0,1
782,519,TOX21_ELG1_LUC_Agonist_viability,1,1,"TOX21_ELG1_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
783,520,TOX21_ERa_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_ERa_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,17b-Estradiol,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
784,521,TOX21_ERa_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_ERa_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
785,522,TOX21_ERa_BLA_Agonist_ratio,1,1,"Data from the assay component TOX21_ERa_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,17b-Estradiol,gain,protein,receptor,nuclear receptor,steroidal,0,0,1
786,523,TOX21_ERa_BLA_Antagonist_ratio,1,1,"Data from the assay component TOX21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,4-hydroxytamoxifen,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
787,524,TOX21_ERa_BLA_Antagonist_viability,1,1,"TOX21_ERa_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
788,525,TOX21_ERa_LUC_VM7_Agonist,1,1,"Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",agonist,percent_activity,positive,0,17b-Estradiol,gain,protein,receptor,nuclear receptor,steroidal,0,0,1
789,526,TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2,1,1,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",antagonist,percent_activity,positive,0,4-hydroxytamoxifen,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
790,527,TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability,1,1,"TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
791,528,TOX21_GR_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_GR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Dexamethasone,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
792,529,TOX21_GR_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_GR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Dexamethasone,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
793,530,TOX21_GR_BLA_Agonist_ratio,1,1,"Data from the assay component TOX21_GR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,Dexamethasone,gain,protein,receptor,nuclear receptor,steroidal,0,0,1
794,531,TOX21_GR_BLA_Antagonist_ratio,1,1,"Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand gene activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",antagonist,percent_activity,positive,0,Mifeprostone,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
795,532,TOX21_GR_BLA_Antagonist_viability,1,1,"TOX21_GR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
796,533,TOX21_MMP_fitc,1,1,"TOX21_MMP_fitc is an assay readout measuring signaling via mitochondrial depolarization and designed using viability reporter (mitochondrial membrane potential) detected with immunofluorescence. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",signaling,percent_activity,positive,0,FCCP,gain,cellular,mitochondria,background measurement,baseline control,0,0,1
797,534,TOX21_MMP_ratio_down,1,1,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",signaling,percent_activity,positive,0,FCCP,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
798,535,TOX21_MMP_rhodamine,1,1,"TOX21_MMP_rhodamine is an assay readout measuring signaling via mitochondrial depolarization and designed using viability reporter (mitochondrial membrane potential) detected with immunofluorescence.  Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",signaling,percent_activity,positive,0,FCCP,loss,cellular,mitochondria,background measurement,baseline control,0,0,1
799,536,TOX21_MMP_viability,1,1,"TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
800,537,TOX21_PPARg_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_PPARg_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Rosiglitazone,loss,protein,receptor,channel 1,baseline control,0,0,1
801,538,TOX21_PPARg_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_PPARg_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Rosiglitazone,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
802,539,TOX21_PPARg_BLA_Agonist_ratio,1,1,"Data from the assay component TOX21_PPARg_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,Rosiglitazone,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
803,540,TOX21_TR_LUC_GH3_Agonist,1,1,"Data from the assay component TOX21_TR_LUC_GH3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,percent_activity,positive,0,0.092 uM T3,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
804,541,TOX21_TR_LUC_GH3_Antagonist,1,1,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",antagonist,percent_activity,positive,0,1 nM T3,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
805,542,TOX21_TR_LUC_GH3_Antagonist_viability,1,1,"TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
806,543,TOX21_AhR_LUC_Agonist,1,1,"Data from the assay component TOX21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AhR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic helix-loop-helix protein.",agonist,percent_activity,positive,0,Omeprazole,gain,protein,receptor,dna binding,basic helix-loop-helix protein,0,0,1
807,544,TOX21_AhR_LUC_Agonist_viability,1,1,"TOX21_AhR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
810,546,OT_Apoptosis_PARP1_1440_inh,0,1,viability reporter assay using Microscopy to monitor pathway in U-2 OS cell line: AEID810 -- OT_Apoptosis_PARP1_1440_inh,viability,percent_activity,negative,0,UCN-01,loss,pathway,pathway-specified,cell cycle,apoptosis,0,0,1
811,546,OT_Apoptosis_PARP1_1440_sti,0,1,viability reporter assay using Microscopy to monitor pathway in U-2 OS cell line: AEID811 -- OT_Apoptosis_PARP1_1440_sti,viability,percent_activity,positive,0,UCN-01,gain,pathway,pathway-specified,cell cycle,apoptosis,0,0,1
812,547,OT_ATR_Chk1Cdc25C_0480_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID812 -- OT_ATR_Chk1Cdc25C_0480_sti,binding,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
813,547,OT_ATR_Chk1Cdc25C_0480_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID813 -- OT_ATR_Chk1Cdc25C_0480_inh,binding,percent_activity,negative,0,17-AAG,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
814,548,OT_ATR_Chk1Cdc25C_1440_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID814 -- OT_ATR_Chk1Cdc25C_1440_sti,binding,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
815,548,OT_ATR_Chk1Cdc25C_1440_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID815 -- OT_ATR_Chk1Cdc25C_1440_inh,binding,percent_activity,negative,0,17-AAG,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
816,549,OT_ATR_Chk1Cdc25CCPT_1440_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID816 -- OT_ATR_Chk1Cdc25CCPT_1440_inh,binding,percent_activity,negative,0,Cadmium Chloride,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
817,549,OT_ATR_Chk1Cdc25CCPT_1440_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID817 -- OT_ATR_Chk1Cdc25CCPT_1440_sti,binding,percent_activity,positive,0,Cadmium Chloride,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
818,550,OT_b2AR_b2ARbARR2_0090_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID818 -- OT_b2AR_b2ARbARR2_0090_sti,binding,percent_activity,positive,0,Isoproterenol,gain,pathway,pathway-specified,gpcr,rhodopsin-like receptor,0,0,1
819,550,OT_b2AR_b2ARbARR2_0090_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID819 -- OT_b2AR_b2ARbARR2_0090_inh,binding,percent_activity,negative,0,Isoproterenol,loss,pathway,pathway-specified,gpcr,rhodopsin-like receptor,0,0,1
820,551,OT_b2AR_b2ARbARR2_0180_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID820 -- OT_b2AR_b2ARbARR2_0180_sti,binding,percent_activity,positive,0,Isoproterenol,gain,pathway,pathway-specified,gpcr,rhodopsin-like receptor,0,0,1
821,551,OT_b2AR_b2ARbARR2_0180_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID821 -- OT_b2AR_b2ARbARR2_0180_inh,binding,percent_activity,negative,0,Isoproterenol,loss,pathway,pathway-specified,gpcr,rhodopsin-like receptor,0,0,1
822,552,OT_b2AR_b2ARbARR2INN_0240_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID822 -- OT_b2AR_b2ARbARR2INN_0240_inh,binding,percent_activity,negative,0,Propranolol,loss,pathway,pathway-specified,gpcr,rhodopsin-like receptor,0,0,1
823,552,OT_b2AR_b2ARbARR2INN_0240_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID823 -- OT_b2AR_b2ARbARR2INN_0240_sti,binding,percent_activity,positive,0,Propranolol,gain,pathway,pathway-specified,gpcr,rhodopsin-like receptor,0,0,1
824,553,OT_CellCycle_Cdc2Cdc25C_0480_inh,0,1,binding reporter assay using Microscopy to monitor pathway in HEK293 cell line: AEID824 -- OT_CellCycle_Cdc2Cdc25C_0480_inh,binding,percent_activity,negative,0,17-AAG,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
825,553,OT_CellCycle_Cdc2Cdc25C_0480_sti,0,1,binding reporter assay using Microscopy to monitor pathway in HEK293 cell line: AEID825 -- OT_CellCycle_Cdc2Cdc25C_0480_sti,binding,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
826,554,OT_CellCycle_Cdc2Cdc25C_1440_inh,0,1,binding reporter assay using Microscopy to monitor pathway in HEK293 cell line: AEID826 -- OT_CellCycle_Cdc2Cdc25C_1440_inh,binding,percent_activity,negative,0,17-AAG,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
827,554,OT_CellCycle_Cdc2Cdc25C_1440_sti,0,1,binding reporter assay using Microscopy to monitor pathway in HEK293 cell line: AEID827 -- OT_CellCycle_Cdc2Cdc25C_1440_sti,binding,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
828,555,OT_CXCR4_CXCR4bARR2_0090_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID828 -- OT_CXCR4_CXCR4bARR2_0090_sti,binding,percent_activity,positive,0,CXCL12,gain,pathway,pathway-specified,cytokine,chemotactic factor,0,0,1
829,555,OT_CXCR4_CXCR4bARR2_0090_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID829 -- OT_CXCR4_CXCR4bARR2_0090_inh,binding,percent_activity,negative,0,CXCL12,loss,pathway,pathway-specified,cytokine,chemotactic factor,0,0,1
830,556,OT_CXCR4_CXCR4bARR2_0480_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID830 -- OT_CXCR4_CXCR4bARR2_0480_sti,binding,percent_activity,positive,0,CXCL12,gain,pathway,pathway-specified,cytokine,chemotactic factor,0,0,1
831,556,OT_CXCR4_CXCR4bARR2_0480_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID831 -- OT_CXCR4_CXCR4bARR2_0480_inh,binding,percent_activity,negative,0,CXCL12,loss,pathway,pathway-specified,cytokine,chemotactic factor,0,0,1
832,557,OT_CXCR4_CXCR4bARR2CXCL12_0240_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID832 -- OT_CXCR4_CXCR4bARR2CXCL12_0240_inh,binding,percent_activity,negative,0,AMD3100,loss,pathway,pathway-specified,cytokine,chemotactic factor,0,0,1
833,557,OT_CXCR4_CXCR4bARR2CXCL12_0240_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID833 -- OT_CXCR4_CXCR4bARR2CXCL12_0240_sti,binding,percent_activity,positive,0,AMD3100,gain,pathway,pathway-specified,cytokine,chemotactic factor,0,0,1
834,558,OT_ERStress_GRP78_1440_inh,0,0,,reporter gene,percent_activity,negative,0,Tunicamycin,loss,pathway,pathway-specified,misc protein,chaperone,0,0,1
835,558,OT_ERStress_GRP78_1440_sti,0,0,,reporter gene,percent_activity,positive,0,Tunicamycin,gain,pathway,pathway-specified,misc protein,chaperone,0,0,1
836,559,OT_H2AX_gH2AX_1440_sti,0,1,binding reporter assay using immunofluorescence assay to monitor pathway in U-2 OS cell line: AEID836 -- OT_H2AX_gH2AX_1440_sti,reporter gene,percent_activity,positive,0,Camptothecin,gain,pathway,pathway-specified,histones,H2A,0,0,1
837,559,OT_H2AX_gH2AX_1440_inh,0,1,binding reporter assay using immunofluorescence assay to monitor pathway in U-2 OS cell line: AEID837 -- OT_H2AX_gH2AX_1440_inh,reporter gene,percent_activity,negative,0,Camptothecin,loss,pathway,pathway-specified,histones,H2A,0,0,1
838,560,OT_HEK293T_LDH_2880_inh,0,1,viability reporter assay using Enzyme activity to monitor cellular process in HEK293T cell line: AEID838 -- OT_HEK293T_LDH_2880_inh,viability,percent_activity,negative,0,Cadmium Chloride,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
839,560,OT_HEK293T_LDH_2880_sti,0,1,viability reporter assay using Enzyme activity to monitor cellular process in HEK293T cell line: AEID839 -- OT_HEK293T_LDH_2880_sti,viability,percent_activity,positive,0,Cadmium Chloride,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
840,561,OT_Hepatocyte_LDH_2880_inh,0,1,viability reporter assay using Enzyme activity to monitor cellular process in hepatocyte cell line: AEID840 -- OT_Hepatocyte_LDH_2880_inh,viability,percent_activity,negative,0,Cadmium Chloride,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
841,561,OT_Hepatocyte_LDH_2880_sti,0,1,viability reporter assay using Enzyme activity to monitor cellular process in hepatocyte cell line: AEID841 -- OT_Hepatocyte_LDH_2880_sti,viability,percent_activity,positive,0,Cadmium Chloride,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
842,562,OT_NegCtrl_EmptyReporter_0240_sti,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID842 -- OT_NegCtrl_EmptyReporter_0240_sti,background control,percent_activity,positive,0,PMA,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
843,562,OT_NegCtrl_EmptyReporter_0240_inh,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID843 -- OT_NegCtrl_EmptyReporter_0240_inh,background control,percent_activity,negative,0,PMA,loss,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
844,563,OT_NegCtrl_EmptyReporter_0480_sti,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID844 -- OT_NegCtrl_EmptyReporter_0480_sti,background control,percent_activity,positive,0,PMA,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
845,563,OT_NegCtrl_EmptyReporter_0480_inh,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID845 -- OT_NegCtrl_EmptyReporter_0480_inh,background control,percent_activity,negative,0,PMA,loss,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
846,564,OT_NegCtrl_EmptyReporter_0960_sti,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID846 -- OT_NegCtrl_EmptyReporter_0960_sti,background control,percent_activity,positive,0,PMA,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
847,564,OT_NegCtrl_EmptyReporter_0960_inh,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID847 -- OT_NegCtrl_EmptyReporter_0960_inh,background control,percent_activity,negative,0,PMA,loss,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
848,565,OT_NegCtrl_EmptyReporter_1440_sti,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID848 -- OT_NegCtrl_EmptyReporter_1440_sti,background control,percent_activity,positive,0,PMA,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
849,565,OT_NegCtrl_EmptyReporter_1440_inh,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID849 -- OT_NegCtrl_EmptyReporter_1440_inh,background control,percent_activity,negative,0,PMA,loss,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
850,566,OT_NegCtrl_Fluorescence_0240_sti,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID850 -- OT_NegCtrl_Fluorescence_0240_sti,background control,percent_activity,positive,0,SU6656;Sunitinib,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
851,566,OT_NegCtrl_Fluorescence_0240_inh,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID851 -- OT_NegCtrl_Fluorescence_0240_inh,background control,percent_activity,negative,0,SU6656;Sunitinib,loss,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
852,567,OT_NegCtrl_Fluorescence_0480_sti,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID852 -- OT_NegCtrl_Fluorescence_0480_sti,background control,percent_activity,positive,0,SU6656;Sunitinib,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
853,567,OT_NegCtrl_Fluorescence_0480_inh,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID853 -- OT_NegCtrl_Fluorescence_0480_inh,background control,percent_activity,negative,0,SU6656;Sunitinib,loss,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
854,568,OT_NegCtrl_Fluorescence_0960_sti,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID854 -- OT_NegCtrl_Fluorescence_0960_sti,background control,percent_activity,positive,0,Sunitinib,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
855,568,OT_NegCtrl_Fluorescence_0960_inh,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID855 -- OT_NegCtrl_Fluorescence_0960_inh,background control,percent_activity,negative,0,Sunitinib,loss,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
856,569,OT_NegCtrl_Fluorescence_1440_sti,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID856 -- OT_NegCtrl_Fluorescence_1440_sti,background control,percent_activity,positive,0,SU6656;Sunitinib,gain,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
857,569,OT_NegCtrl_Fluorescence_1440_inh,0,1,background reporter assay using Microscopy to monitor physical feature in HEK293 cell line: AEID857 -- OT_NegCtrl_Fluorescence_1440_inh,background control,percent_activity,negative,0,SU6656;Sunitinib,loss,chemical,physical feature,background measurement,artifact fluorescence,0,0,1
858,570,OT_NFKb_p50p65_0480_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID858 -- OT_NFKb_p50p65_0480_sti,binding,percent_activity,positive,0,Tumor Necrosis Factor-alpha,gain,pathway,pathway-specified,cytokine,inflammatory factor,0,0,1
859,570,OT_NFKb_p50p65_0480_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID859 -- OT_NFKb_p50p65_0480_inh,binding,percent_activity,negative,0,Tumor Necrosis Factor-alpha,loss,pathway,pathway-specified,cytokine,inflammatory factor,0,0,1
860,571,OT_NFKb_p50p65_1440_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID860 -- OT_NFKb_p50p65_1440_sti,binding,percent_activity,positive,0,Tumor Necrosis Factor-alpha,gain,pathway,pathway-specified,cytokine,inflammatory factor,0,0,1
861,571,OT_NFKb_p50p65_1440_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID861 -- OT_NFKb_p50p65_1440_inh,binding,percent_activity,negative,0,Tumor Necrosis Factor-alpha,loss,pathway,pathway-specified,cytokine,inflammatory factor,0,0,1
862,572,OT_NFKb_p50p65TNFa_0090_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID862 -- OT_NFKb_p50p65TNFa_0090_inh,binding,percent_activity,negative,0,TPCA-1,loss,pathway,pathway-specified,cytokine,inflammatory factor,0,0,1
863,572,OT_NFKb_p50p65TNFa_0090_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID863 -- OT_NFKb_p50p65TNFa_0090_sti,binding,percent_activity,positive,0,TPCA-1,gain,pathway,pathway-specified,cytokine,inflammatory factor,0,0,1
864,573,OT_NFKb_p50p65TNFa_0480_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID864 -- OT_NFKb_p50p65TNFa_0480_inh,binding,percent_activity,negative,0,TPCA-1,loss,pathway,pathway-specified,cytokine,inflammatory factor,0,0,1
865,573,OT_NFKb_p50p65TNFa_0480_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID865 -- OT_NFKb_p50p65TNFa_0480_sti,binding,percent_activity,positive,0,TPCA-1,gain,pathway,pathway-specified,cytokine,inflammatory factor,0,0,1
866,574,OT_p38MAPK_Mnk1p38_0480_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID866 -- OT_p38MAPK_Mnk1p38_0480_sti,binding,percent_activity,positive,0,Forskolin,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
867,574,OT_p38MAPK_Mnk1p38_0480_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID867 -- OT_p38MAPK_Mnk1p38_0480_inh,binding,percent_activity,negative,0,Forskolin,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
868,575,OT_p38MAPK_Mnk1p38_1440_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID868 -- OT_p38MAPK_Mnk1p38_1440_sti,binding,percent_activity,positive,0,Forskolin,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
869,575,OT_p38MAPK_Mnk1p38_1440_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID869 -- OT_p38MAPK_Mnk1p38_1440_inh,binding,percent_activity,negative,0,Forskolin,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
870,576,OT_p53_Mdm2p53_0480_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID870 -- OT_p53_Mdm2p53_0480_sti,binding,percent_activity,positive,0,ALLN,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
871,576,OT_p53_Mdm2p53_0480_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID871 -- OT_p53_Mdm2p53_0480_inh,binding,percent_activity,negative,0,ALLN,loss,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
872,577,OT_p53_Mdm2p53_1440_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID872 -- OT_p53_Mdm2p53_1440_sti,binding,percent_activity,positive,0,ALLN,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
873,577,OT_p53_Mdm2p53_1440_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID873 -- OT_p53_Mdm2p53_1440_inh,binding,percent_activity,negative,0,ALLN,loss,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
874,578,OT_p53_Pin1p53_0480_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID874 -- OT_p53_Pin1p53_0480_inh,binding,percent_activity,negative,0,17-AAG,loss,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
875,578,OT_p53_Pin1p53_0480_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID875 -- OT_p53_Pin1p53_0480_sti,binding,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
876,579,OT_p53_Pin1p53_1440_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID876 -- OT_p53_Pin1p53_1440_inh,binding,percent_activity,negative,0,Camptothecin,loss,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
877,579,OT_p53_Pin1p53_1440_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID877 -- OT_p53_Pin1p53_1440_sti,binding,percent_activity,positive,0,Camptothecin,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
878,580,OT_p53_Pin1p53CPT_1440_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID878 -- OT_p53_Pin1p53CPT_1440_sti,binding,percent_activity,positive,0,Celastrol,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
879,580,OT_p53_Pin1p53CPT_1440_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID879 -- OT_p53_Pin1p53CPT_1440_inh,binding,percent_activity,negative,0,Celastrol,loss,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
880,581,OT_PI3K_Akt1PDk1_0090_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID880 -- OT_PI3K_Akt1PDk1_0090_inh,binding,percent_activity,negative,0,PI-103,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
881,581,OT_PI3K_Akt1PDk1_0090_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID881 -- OT_PI3K_Akt1PDk1_0090_sti,binding,percent_activity,positive,0,PI-103,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
882,582,OT_PI3K_Akt1PDk1_0480_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID882 -- OT_PI3K_Akt1PDk1_0480_inh,binding,percent_activity,negative,0,17-AAG,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
883,582,OT_PI3K_Akt1PDk1_0480_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID883 -- OT_PI3K_Akt1PDk1_0480_sti,binding,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
884,583,OT_PI3K_Akt1PDk1_1440_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID884 -- OT_PI3K_Akt1PDk1_1440_inh,binding,percent_activity,negative,0,17-AAG,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
885,583,OT_PI3K_Akt1PDk1_1440_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293 cell line: AEID885 -- OT_PI3K_Akt1PDk1_1440_sti,binding,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
886,584,OT_RhoRock_Limk2Cofilin1_0480_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID886 -- OT_RhoRock_Limk2Cofilin1_0480_inh,binding,percent_activity,negative,0,17-AAG,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
887,584,OT_RhoRock_Limk2Cofilin1_0480_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID887 -- OT_RhoRock_Limk2Cofilin1_0480_sti,binding,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
888,585,OT_RhoRock_Limk2Cofilin1_1440_inh,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID888 -- OT_RhoRock_Limk2Cofilin1_1440_inh,binding,percent_activity,negative,0,17-AAG,loss,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
889,585,OT_RhoRock_Limk2Cofilin1_1440_sti,0,1,binding reporter assay using Protein-fragment Complementation to monitor pathway in HEK293T cell line: AEID889 -- OT_RhoRock_Limk2Cofilin1_1440_sti,binding,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,kinase,serine/threonine kinase,0,0,1
890,586,CEETOX_H295R_11DCORT_dn,1,1,"Data from the assay component CEETOX_H295R_11DCORT was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_11DCORT_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,11-Deoxycortisol,steroid hormone,glucocorticoids,0,0,1
891,586,CEETOX_H295R_11DCORT_up,1,1,"Data from the assay component CEETOX_H295R_11DCORT was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_11DCORT_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,11-Deoxycortisol,steroid hormone,glucocorticoids,0,0,1
892,587,CEETOX_H295R_OHPREG_dn,1,1,"Data from the assay component CEETOX_H295R_OHPREG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPREG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,17alpha-hydroxypregnenolone,steroid hormone,progestagens,0,0,1
893,587,CEETOX_H295R_OHPREG_up,1,1,"Data from the assay component CEETOX_H295R_OHPREG_up was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPREG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,17alpha-hydroxypregnenolone,steroid hormone,progestagens,0,0,1
894,588,CEETOX_H295R_OHPROG_dn,1,1,"Data from the assay component CEETOX_H295R_OHPROG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPROG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,17alpha-hydroxyprogesterone,steroid hormone,progestagens,0,0,1
895,588,CEETOX_H295R_OHPROG_up,1,1,"Data from the assay component CEETOX_H295R_OHPROG_up was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPROG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,17alpha-hydroxyprogesterone,steroid hormone,progestagens,0,0,1
896,589,CEETOX_H295R_ANDR_dn,1,1,"Data from the assay component CEETOX_H295R_ANDR was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ANDR_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,Androstenedione,steroid hormone,androgens,0,0,1
897,589,CEETOX_H295R_ANDR_up,1,1,"Data from the assay component CEETOX_H295R_ANDR was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ANDR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,Androstenedione,steroid hormone,androgens,0,0,1
898,590,CEETOX_H295R_CORTIC_dn,1,1,"Data from the assay component CEETOX_H295R_CORTIC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTIC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,Corticosterone,steroid hormone,glucocorticoids,0,0,1
899,590,CEETOX_H295R_CORTIC_up,1,1,"Data from the assay component CEETOX_H295R_CORTIC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTIC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,Corticosterone,steroid hormone,glucocorticoids,0,0,1
900,591,CEETOX_H295R_CORTISOL_dn,1,1,"Data from the assay component CEETOX_H295R_CORTISOL was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTISOL_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Cortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,Cortisol,steroid hormone,glucocorticoids,0,0,1
901,591,CEETOX_H295R_CORTISOL_up,1,1,"Data from the assay component CEETOX_H295R_CORTISOL was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTISOL_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of Cortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,Cortisol,steroid hormone,glucocorticoids,0,0,1
902,592,CEETOX_H295R_DHEA_dn,0,1,"Data from the assay component CEETOX_H295R_DHEA was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_DHEA_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Dehydroepiandrosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,Dehydroepiandrosterone,steroid hormone,androgens,0,0,1
903,592,CEETOX_H295R_DHEA_up,0,1,"Data from the assay component CEETOX_H295R_DHEA was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_DHEA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of Dehydroepiandrosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,Dehydroepiandrosterone,steroid hormone,androgens,0,0,1
904,593,CEETOX_H295R_DOC_dn,1,1,"Data from the assay component CEETOX_H295R_DOC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_DOC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,11-Deoxycorticosterone,steroid hormone,glucocorticoids,0,0,1
905,593,CEETOX_H295R_DOC_up,1,1,"Data from the assay component CEETOX_H295R_DOC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_DOC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,11-Deoxycorticosterone,steroid hormone,glucocorticoids,0,0,1
906,594,CEETOX_H295R_ESTRADIOL_dn,1,1,"Data from the assay component CEETOX_H295R_ESTRADIOL was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ESTRADIOL_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Estradiol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,Estradiol,steroid hormone,estrogens,0,0,1
907,594,CEETOX_H295R_ESTRADIOL_up,1,1,"Data from the assay component CEETOX_H295R_ESTRADIOL was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ESTRADIOL_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Estradiol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,Estradiol,steroid hormone,estrogens,0,0,1
908,595,CEETOX_H295R_ESTRONE_dn,1,1,"Data from the assay component CEETOX_H295R_ESTRONE was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ESTRONE_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Estrone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,Estrone,steroid hormone,estrogens,0,0,1
909,595,CEETOX_H295R_ESTRONE_up,1,1,"Data from the assay component CEETOX_H295R_ESTRONE was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ESTRONE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Estrone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,Estrone,steroid hormone,estrogens,0,0,1
910,596,CEETOX_H295R_PREG_dn,0,1,"Data from the assay component CEETOX_H295R_PREG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_PREG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Pregnenolone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,Pregnenolone,steroid hormone,progestagens,0,0,1
911,596,CEETOX_H295R_PREG_up,0,1,"Data from the assay component CEETOX_H295R_PREG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_PREG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of Pregnenolone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,Pregnenolone,steroid hormone,progestagens,0,0,1
912,597,CEETOX_H295R_PROG_dn,1,1,"Data from the assay component CEETOX_H295R_PROG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_PROG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Progesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,Progesterone,steroid hormone,progestagens,0,0,1
913,597,CEETOX_H295R_PROG_up,1,1,"Data from the assay component CEETOX_H295R_PROG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_PROG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Progesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,Progesterone,steroid hormone,progestagens,0,0,1
914,598,CEETOX_H295R_TESTO_dn,1,1,"Data from the assay component CEETOX_H295R_TESTO was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_TESTO_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Testosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",detection of steroid hormone,log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,molecular messenger,Testosterone,steroid hormone,androgens,0,0,1
915,598,CEETOX_H295R_TESTO_up,1,1,"Data from the assay component CEETOX_H295R_TESTO was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_TESTO_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Testosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",detection of steroid hormone,log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,molecular messenger,Testosterone,steroid hormone,androgens,0,0,1
916,599,LTEA_HepaRG_ABCB1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,ABC transporter,0,0,1
917,599,LTEA_HepaRG_ABCB1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
918,600,LTEA_HepaRG_ABCB11_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,ABC transporter,0,0,1
919,600,LTEA_HepaRG_ABCB11_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
920,601,LTEA_HepaRG_ABCC2_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,ABC transporter,0,0,1
921,601,LTEA_HepaRG_ABCC2_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
922,602,LTEA_HepaRG_ABCC3_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,ABC transporter,0,0,1
923,602,LTEA_HepaRG_ABCC3_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
924,603,LTEA_HepaRG_ABCG2_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,ABC transporter,0,0,1
925,603,LTEA_HepaRG_ABCG2_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
926,604,LTEA_HepaRG_ACLY_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,lyase,steatosis,0,0,1
927,604,LTEA_HepaRG_ACLY_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,lyase,steatosis,0,0,1
928,605,LTEA_HepaRG_ACOX1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,oxidase,steatosis,0,0,1
929,605,LTEA_HepaRG_ACOX1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,oxidase,steatosis,0,0,1
930,606,LTEA_HepaRG_ADK_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,kinase,steatosis,0,0,1
931,606,LTEA_HepaRG_ADK_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,kinase,steatosis,0,0,1
932,607,LTEA_HepaRG_AFP_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,background measurement,assay control,0,0,1
933,607,LTEA_HepaRG_AFP_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,assay control,0,0,1
934,608,LTEA_HepaRG_ALPP_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,phosphatase,"Cell proliferation, survival, death",0,0,1
935,608,LTEA_HepaRG_ALPP_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,phosphatase,"Cell proliferation, survival, death",0,0,1
936,609,LTEA_HepaRG_APOA5_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,apolipoprotein,Steatosis,0,0,1
937,609,LTEA_HepaRG_APOA5_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,apolipoprotein,Steatosis,0,0,1
938,610,LTEA_HepaRG_BAD_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
939,610,LTEA_HepaRG_BAD_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
940,611,LTEA_HepaRG_BAX_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
941,611,LTEA_HepaRG_BAX_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
942,612,LTEA_HepaRG_BCL2_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
943,612,LTEA_HepaRG_BCL2_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
944,613,LTEA_HepaRG_BCL2L11_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
945,613,LTEA_HepaRG_BCL2L11_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
946,614,LTEA_HepaRG_BID_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
947,614,LTEA_HepaRG_BID_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
948,615,LTEA_HepaRG_CASP3_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,protease,cysteine protease,0,0,1
949,615,LTEA_HepaRG_CASP3_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,protease,cysteine protease,0,0,1
950,616,LTEA_HepaRG_CASP8_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,protease,cysteine protease,0,0,1
951,616,LTEA_HepaRG_CASP8_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,protease,cysteine protease,0,0,1
952,617,LTEA_HepaRG_CAT_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,catalase,oxidative stress,0,0,1
953,617,LTEA_HepaRG_CAT_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,catalase,oxidative stress,0,0,1
954,618,LTEA_HepaRG_CCND1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
955,618,LTEA_HepaRG_CCND1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
956,619,LTEA_HepaRG_CCND2_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
957,619,LTEA_HepaRG_CCND2_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
958,620,LTEA_HepaRG_CDKN1A_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
959,620,LTEA_HepaRG_CDKN1A_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
960,621,LTEA_HepaRG_CFLAR_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
961,621,LTEA_HepaRG_CFLAR_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell cycle,"Cell proliferation, survival, death",0,0,1
962,622,LTEA_HepaRG_CYP1A1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
963,622,LTEA_HepaRG_CYP1A1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
964,623,LTEA_HepaRG_CYP1A2_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
965,623,LTEA_HepaRG_CYP1A2_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
966,624,LTEA_HepaRG_CYP24A1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
967,624,LTEA_HepaRG_CYP24A1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
968,625,LTEA_HepaRG_CYP2B6_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
969,625,LTEA_HepaRG_CYP2B6_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
970,626,LTEA_HepaRG_CYP2C19_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
971,626,LTEA_HepaRG_CYP2C19_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
972,627,LTEA_HepaRG_CYP2C8_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
973,627,LTEA_HepaRG_CYP2C8_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
974,628,LTEA_HepaRG_CYP2C9_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
975,628,LTEA_HepaRG_CYP2C9_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
976,629,LTEA_HepaRG_CYP2E1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
977,629,LTEA_HepaRG_CYP2E1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
978,630,LTEA_HepaRG_CYP3A4_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
979,630,LTEA_HepaRG_CYP3A4_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
980,631,LTEA_HepaRG_CYP3A5_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
981,631,LTEA_HepaRG_CYP3A5_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
982,632,LTEA_HepaRG_CYP3A7_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
983,632,LTEA_HepaRG_CYP3A7_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
984,633,LTEA_HepaRG_CYP4A11_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
985,633,LTEA_HepaRG_CYP4A11_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
986,634,LTEA_HepaRG_CYP4A22_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
987,634,LTEA_HepaRG_CYP4A22_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
988,635,LTEA_HepaRG_CYP7A1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
989,635,LTEA_HepaRG_CYP7A1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
990,636,LTEA_HepaRG_DDIT3_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,basic leucine zipper,0,0,1
991,636,LTEA_HepaRG_DDIT3_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,basic leucine zipper,0,0,1
992,637,LTEA_HepaRG_EGF_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,growth factor,EGF-like domain,0,0,1
993,637,LTEA_HepaRG_EGF_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,growth factor,EGF-like domain,0,0,1
994,638,LTEA_HepaRG_EGR1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,zinc finger,0,0,1
995,638,LTEA_HepaRG_EGR1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,zinc finger,0,0,1
996,639,LTEA_HepaRG_EZR_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,membrane protein,Cellular remodeling,0,0,1
997,639,LTEA_HepaRG_EZR_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,membrane protein,Cellular remodeling,0,0,1
998,640,LTEA_HepaRG_FABP1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,fatty acid carrier protein,0,0,1
999,640,LTEA_HepaRG_FABP1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,fatty acid carrier protein,0,0,1
1000,641,LTEA_HepaRG_FAS_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cytokine receptor,TNF receptor,0,0,1
1001,641,LTEA_HepaRG_FAS_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cytokine receptor,TNF receptor,0,0,1
1002,642,LTEA_HepaRG_FASN_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,lyase,fatty acid synthase,0,0,1
1003,642,LTEA_HepaRG_FASN_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,lyase,fatty acid synthase,0,0,1
1004,643,LTEA_HepaRG_FMO3_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,oxidoreductase,dioxygenase,0,0,1
1005,643,LTEA_HepaRG_FMO3_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,oxidoreductase,dioxygenase,0,0,1
1006,644,LTEA_HepaRG_FOXO1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,forkhead box protein,0,0,1
1007,644,LTEA_HepaRG_FOXO1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,forkhead box protein,0,0,1
1008,645,LTEA_HepaRG_FOXO3_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,forkhead box protein,0,0,1
1009,645,LTEA_HepaRG_FOXO3_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,forkhead box protein,0,0,1
1010,646,LTEA_HepaRG_GADD45A_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell cycle,Oxidative Stress,0,0,1
1011,646,LTEA_HepaRG_GADD45A_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell cycle,Oxidative Stress,0,0,1
1012,647,LTEA_HepaRG_GADD45B_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,mutagenicity response,"Cell proliferation, survival, death",0,0,1
1013,647,LTEA_HepaRG_GADD45B_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,mutagenicity response,"Cell proliferation, survival, death",0,0,1
1014,648,LTEA_HepaRG_GADD45G_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,mutagenicity response,"Cell proliferation, survival, death",0,0,1
1015,648,LTEA_HepaRG_GADD45G_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,mutagenicity response,"Cell proliferation, survival, death",0,0,1
1016,649,LTEA_HepaRG_GCLC_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,ligase,C-N ligase,0,0,1
1017,649,LTEA_HepaRG_GCLC_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,ligase,C-N ligase,0,0,1
1018,650,LTEA_HepaRG_GCLM_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,ligase,C-N ligase,0,0,1
1019,650,LTEA_HepaRG_GCLM_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,ligase,C-N ligase,0,0,1
1020,651,LTEA_HepaRG_GE_ACTB_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,background control,log2_fold_induction,negative,0,,loss,rna,mRNA,background measurement,baseline control,0,0,1
1021,651,LTEA_HepaRG_GE_ACTB_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,1
1022,652,LTEA_HepaRG_GE_GAPDH_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,background control,log2_fold_induction,negative,0,,loss,rna,mRNA,background measurement,baseline control,0,0,1
1023,652,LTEA_HepaRG_GE_GAPDH_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,1
1024,653,LTEA_HepaRG_GE_POLR2A_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,background control,log2_fold_induction,negative,0,,loss,rna,mRNA,background measurement,baseline control,0,0,1
1025,653,LTEA_HepaRG_GE_POLR2A_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,1
1026,654,LTEA_HepaRG_GSTA2_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transferase,alkyl and aryl transferase,0,0,1
1027,654,LTEA_HepaRG_GSTA2_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,alkyl and aryl transferase,0,0,1
1028,655,LTEA_HepaRG_GSTM3_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transferase,alkyl and aryl transferase,0,0,1
1029,655,LTEA_HepaRG_GSTM3_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,alkyl and aryl transferase,0,0,1
1030,656,LTEA_HepaRG_HGF_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,growth factor,hepatocyte growth factor,0,0,1
1031,656,LTEA_HepaRG_HGF_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,growth factor,hepatocyte growth factor,0,0,1
1032,657,LTEA_HepaRG_HIF1A_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,basic helix-loop-helix protein,0,0,1
1033,657,LTEA_HepaRG_HIF1A_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,basic helix-loop-helix protein,0,0,1
1034,658,LTEA_HepaRG_HMGCS2_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,lyase,HMG-CoA synthase,0,0,1
1035,658,LTEA_HepaRG_HMGCS2_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,lyase,HMG-CoA synthase,0,0,1
1036,659,LTEA_HepaRG_HSPA1A_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,heat shock protein,0,0,1
1037,659,LTEA_HepaRG_HSPA1A_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,heat shock protein,0,0,1
1038,660,LTEA_HepaRG_ICAM1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cell adhesion molecules,Immunoglobulin CAM,0,0,1
1039,660,LTEA_HepaRG_ICAM1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cell adhesion molecules,Immunoglobulin CAM,0,0,1
1040,661,LTEA_HepaRG_IGF1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,growth factor,insulin-like,0,0,1
1041,661,LTEA_HepaRG_IGF1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,growth factor,insulin-like,0,0,1
1042,662,LTEA_HepaRG_IGFBP1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,hormone carrier protein,0,0,1
1043,662,LTEA_HepaRG_IGFBP1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,hormone carrier protein,0,0,1
1044,663,LTEA_HepaRG_IL6_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cytokine,interleukins,0,0,1
1045,663,LTEA_HepaRG_IL6_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cytokine,interleukins,0,0,1
1046,664,LTEA_HepaRG_IL6R_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cytokine receptor,JAK-STAT cytokine receptor,0,0,1
1047,664,LTEA_HepaRG_IL6R_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cytokine receptor,JAK-STAT cytokine receptor,0,0,1
1048,665,LTEA_HepaRG_JUN_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,basic leucine zipper,0,0,1
1049,665,LTEA_HepaRG_JUN_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,basic leucine zipper,0,0,1
1050,666,LTEA_HepaRG_KCNK1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,ion channel,potassium channel,0,0,1
1051,666,LTEA_HepaRG_KCNK1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,ion channel,potassium channel,0,0,1
1052,667,LTEA_HepaRG_KRT19_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,filaments,keratin,0,0,1
1053,667,LTEA_HepaRG_KRT19_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,filaments,keratin,0,0,1
1054,668,LTEA_HepaRG_LIPC_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,esterase,lipase,0,0,1
1055,668,LTEA_HepaRG_LIPC_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,esterase,lipase,0,0,1
1056,669,LTEA_HepaRG_LPL_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,esterase,lipase,0,0,1
1057,669,LTEA_HepaRG_LPL_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,esterase,lipase,0,0,1
1058,670,LTEA_HepaRG_MIR122_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,miRNA,microrna,post-transcriptional regulation,0,0,1
1059,670,LTEA_HepaRG_MIR122_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,miRNA,microrna,post-transcriptional regulation,0,0,1
1060,671,LTEA_HepaRG_MMP10_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,protease,matrix metalloproteinase,0,0,1
1061,671,LTEA_HepaRG_MMP10_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,protease,matrix metalloproteinase,0,0,1
1062,672,LTEA_HepaRG_MMP3_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,protease,matrix metalloproteinase,0,0,1
1063,672,LTEA_HepaRG_MMP3_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,protease,matrix metalloproteinase,0,0,1
1064,673,LTEA_HepaRG_MYC_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,basic helix-loop-helix leucine zipper,0,0,1
1065,673,LTEA_HepaRG_MYC_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,basic helix-loop-helix leucine zipper,0,0,1
1066,674,LTEA_HepaRG_NFE2L2_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,basic leucine zipper,0,0,1
1067,674,LTEA_HepaRG_NFE2L2_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,basic leucine zipper,0,0,1
1068,675,LTEA_HepaRG_NFKB1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,NF-kappa B,0,0,1
1069,675,LTEA_HepaRG_NFKB1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,NF-kappa B,0,0,1
1070,676,LTEA_HepaRG_NQO1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,oxidoreductase,quinone-acceptor,0,0,1
1071,676,LTEA_HepaRG_NQO1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,oxidoreductase,quinone-acceptor,0,0,1
1072,677,LTEA_HepaRG_PDK4_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,kinase,serine/threonine kinase,0,0,1
1073,677,LTEA_HepaRG_PDK4_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,kinase,serine/threonine kinase,0,0,1
1074,678,LTEA_HepaRG_PEG10_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,xenobiotic metabolism,0,0,1
1075,678,LTEA_HepaRG_PEG10_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,xenobiotic metabolism,0,0,1
1076,679,LTEA_HepaRG_PPP2R4_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,phosphatase,serine/threonine phosphatase,0,0,1
1077,679,LTEA_HepaRG_PPP2R4_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,phosphatase,serine/threonine phosphatase,0,0,1
1078,680,LTEA_HepaRG_PTEN_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,phosphatase,dual-specific phosphatase,0,0,1
1079,680,LTEA_HepaRG_PTEN_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,phosphatase,dual-specific phosphatase,0,0,1
1080,681,LTEA_HepaRG_SDHB_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,oxidoreductase,ubiquinone,0,0,1
1081,681,LTEA_HepaRG_SDHB_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,oxidoreductase,ubiquinone,0,0,1
1082,682,LTEA_HepaRG_SLC22A1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,organic cation transporter,0,0,1
1083,682,LTEA_HepaRG_SLC22A1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,organic cation transporter,0,0,1
1084,683,LTEA_HepaRG_SLCO1B1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,organic anion transporter,0,0,1
1085,683,LTEA_HepaRG_SLCO1B1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,organic anion transporter,0,0,1
1086,684,LTEA_HepaRG_STAT3_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,stat protein,0,0,1
1087,684,LTEA_HepaRG_STAT3_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,stat protein,0,0,1
1088,685,LTEA_HepaRG_SULT2A1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transferase,sulfotransferase,0,0,1
1089,685,LTEA_HepaRG_SULT2A1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,sulfotransferase,0,0,1
1090,686,LTEA_HepaRG_TGFA_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,growth factor,EGF-like domain,0,0,1
1091,686,LTEA_HepaRG_TGFA_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,growth factor,EGF-like domain,0,0,1
1092,687,LTEA_HepaRG_TGFB1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,growth factor,transforming growth factor beta,0,0,1
1093,687,LTEA_HepaRG_TGFB1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,growth factor,transforming growth factor beta,0,0,1
1094,688,LTEA_HepaRG_THRSP_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,growth factor,NR mediated metabolism,0,0,1
1095,688,LTEA_HepaRG_THRSP_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,growth factor,NR mediated metabolism,0,0,1
1096,689,LTEA_HepaRG_TIMP1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,protease inhibitor,metalloproteinase inhibitor,0,0,1
1097,689,LTEA_HepaRG_TIMP1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,protease inhibitor,metalloproteinase inhibitor,0,0,1
1098,690,LTEA_HepaRG_TNFRSF1A_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cytokine receptor,TNF receptor,0,0,1
1099,690,LTEA_HepaRG_TNFRSF1A_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cytokine receptor,TNF receptor,0,0,1
1100,691,LTEA_HepaRG_TP53_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,tumor suppressor,0,0,1
1101,691,LTEA_HepaRG_TP53_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,tumor suppressor,0,0,1
1102,692,LTEA_HepaRG_UGT1A1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transferase,glucuronosyltransferase,0,0,1
1103,692,LTEA_HepaRG_UGT1A1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,glucuronosyltransferase,0,0,1
1104,693,LTEA_HepaRG_UGT1A6_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transferase,glucuronosyltransferase,0,0,1
1105,693,LTEA_HepaRG_UGT1A6_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,glucuronosyltransferase,0,0,1
1106,694,LTEA_HepaRG_XBP1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,dna binding,basic leucine zipper,0,0,1
1107,694,LTEA_HepaRG_XBP1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,dna binding,basic leucine zipper,0,0,1
1108,695,TOX21_ARE_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_ARE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Beta-Naphthoflavone,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1109,696,TOX21_ARE_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_ARE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Beta-Naphthoflavone,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1110,697,TOX21_ARE_BLA_agonist_ratio,1,1,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",ratio,percent_activity,positive,0,Beta-Naphthoflavone,gain,pathway,pathway-specified,dna binding,basic leucine zipper,0,0,1
1111,698,TOX21_HSE_BLA_agonist_ch1,1,1,"Data from the assay component TOX21_HSE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,17-AAG,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1112,699,TOX21_HSE_BLA_agonist_ch2,1,1,"Data from the assay component TOX21_HSE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1113,700,TOX21_HSE_BLA_agonist_ratio,1,1,"Data from the assay component TOX21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_HSE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is heat shock protein.",ratio,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,dna binding,heat shock protein,0,0,1
1114,701,TOX21_p53_BLA_p1_ch1,1,1,"Data from the assay component TOX21_p53_BLA_p1_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Mitomycin C,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1115,702,TOX21_p53_BLA_p1_ch2,1,1,"Data from the assay component TOX21_p53_BLA_p1_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Mitomycin C;Nutlin3,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1116,703,TOX21_p53_BLA_p1_ratio,1,1,"Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",ratio,percent_activity,positive,0,Mitomycin C;Nutlin3,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
1117,704,TOX21_FXR_BLA_agonist_ch1,1,1,"Data from the assay component TOX21_FXR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Chenodeoxycholic acid,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1118,705,TOX21_FXR_BLA_agonist_ch2,1,1,"Data from the assay component TOX21_FXR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Chenodeoxycholic acid,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1119,706,TOX21_FXR_BLA_agonist_ratio,1,1,"Data from the assay component TOX21_FXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,Chenodeoxycholic acid,gain,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
1120,707,TOX21_FXR_BLA_antagonist_ratio,1,1,"Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,Guggulsterone,loss,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
1121,708,TOX21_FXR_BLA_antagonist_viability,1,1,"TOX21_FXR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1122,709,TOX21_PPARd_BLA_agonist_ch1,1,1,"Data from the assay component TOX21_PPARd_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,"L-165,041",loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1123,710,TOX21_PPARd_BLA_agonist_ch2,1,1,"Data from the assay component TOX21_PPARd_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,"L-165,041",gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1124,711,TOX21_PPARd_BLA_agonist_ratio,1,1,"Data from the assay component TOX21_PPARd_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,"L-165,041",gain,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
1125,712,TOX21_PPARd_BLA_antagonist_ratio,1,1,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,MK886,loss,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
1126,713,TOX21_PPARd_BLA_antagonist_viability,1,1,"TOX21_PPARd_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1127,714,TOX21_PPARg_BLA_antagonist_ratio,1,1,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,GW9662,loss,pathway,pathway-specified,nuclear receptor,non-steroidal,0,0,1
1128,715,TOX21_PPARg_BLA_antagonist_viability,1,1,"TOX21_PPARg_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1129,716,TOX21_VDR_BLA_agonist_ch1,1,1,"Data from the assay component TOX21_VDR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Calcitriol,loss,protein,receptor,channel 1,baseline control,0,0,1
1130,717,TOX21_VDR_BLA_agonist_ch2,1,1,"Data from the assay component TOX21_VDR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Calcitriol,gain,protein,receptor,channel 2,baseline control,0,0,1
1131,718,TOX21_VDR_BLA_agonist_ratio,1,1,"Data from the assay component TOX21_VDR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,Calcitriol,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
1132,719,TOX21_VDR_BLA_antagonist_ratio,1,1,"Data from the assay component TOX21_VDR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,"1alpha,25-Dihydroxy vitamin D3",loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
1133,720,TOX21_VDR_BLA_antagonist_viability,1,1,"TOX21_VDR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1134,721,TOX21_DT40,1,1,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",viability,percent_activity,positive,0,Tetraoctyl ammonium bromide,loss,pathway,pathway-specified,cell cycle,DNA repair,0,0,1
1136,722,LTEA_HepaRG_LDH_cytotoxicity,1,1,LDH leakage activity as a measure of membrane integrity and cytotoxicity in the cells.,viability,percent_activity,positive,0,,gain,cellular,cellular,cell cycle,proliferation,0,0,1
1137,723,APR_Hepat_Apoptosis_1hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1137 -- APR_Hepat_Apoptosis_1hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,proliferation,0,0,1
1138,723,APR_Hepat_Apoptosis_1hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1138 -- APR_Hepat_Apoptosis_1hr_up,signaling,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,cell cycle,apoptosis,0,0,1
1139,724,APR_Hepat_CellLoss_1hr_dn,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1139 -- APR_Hepat_CellLoss_1hr_dn,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1140,724,APR_Hepat_CellLoss_1hr_up,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1140 -- APR_Hepat_CellLoss_1hr_up,viability,log2_fold_induction,positive,0,,gain,cellular,cellular,cell cycle,proliferation,0,0,1
1141,725,APR_Hepat_DNADamage_1hr_dn,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1141 -- APR_Hepat_DNADamage_1hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,cellular,cell morphology,dna conformation,0,0,1
1142,725,APR_Hepat_DNADamage_1hr_up,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1142 -- APR_Hepat_DNADamage_1hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,cellular,cell morphology,dna conformation,0,0,1
1143,726,APR_Hepat_DNATexture_1hr_dn,0,1,conformation reporter assay using HCS Fluorescent Imaging to monitor dna-unspecified in hepatocyte cell line: AEID1143 -- APR_Hepat_DNATexture_1hr_dn,signaling,log2_fold_induction,negative,0,,loss,dna,dna-unspecified,cell morphology,dna conformation,0,0,1
1144,726,APR_Hepat_DNATexture_1hr_up,0,1,conformation reporter assay using HCS Fluorescent Imaging to monitor dna-unspecified in hepatocyte cell line: AEID1144 -- APR_Hepat_DNATexture_1hr_up,signaling,log2_fold_induction,positive,0,,gain,dna,dna-unspecified,cell morphology,dna conformation,0,0,1
1145,727,APR_Hepat_LysosomalMass_1hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor lysosome in hepatocyte cell line: AEID1145 -- APR_Hepat_LysosomalMass_1hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,lysosome,cell morphology,organelle conformation,0,0,1
1146,727,APR_Hepat_LysosomalMass_1hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor lysosome in hepatocyte cell line: AEID1146 -- APR_Hepat_LysosomalMass_1hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,lysosome,cell morphology,organelle conformation,0,0,1
1147,728,APR_Hepat_MitoFxnI_1hr_dn,0,1,membrane potential reporter assay using HCS Fluorescent Imaging to monitor mitochondria in hepatocyte cell line: AEID1147 -- APR_Hepat_MitoFxnI_1hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1148,728,APR_Hepat_MitoFxnI_1hr_up,0,1,membrane potential reporter assay using HCS Fluorescent Imaging to monitor mitochondria in hepatocyte cell line: AEID1148 -- APR_Hepat_MitoFxnI_1hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1149,729,APR_Hepat_NuclearSize_1hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor nucleus in hepatocyte cell line: AEID1149 -- APR_Hepat_NuclearSize_1hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,nucleus,cell morphology,organelle conformation,0,0,1
1150,729,APR_Hepat_NuclearSize_1hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor nucleus in hepatocyte cell line: AEID1150 -- APR_Hepat_NuclearSize_1hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,nucleus,cell morphology,organelle conformation,0,0,1
1151,730,APR_Hepat_Steatosis_1hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1151 -- APR_Hepat_Steatosis_1hr_dn,signaling,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,cell morphology,cell conformation,0,0,1
1152,730,APR_Hepat_Steatosis_1hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1152 -- APR_Hepat_Steatosis_1hr_up,signaling,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,cell morphology,cell conformation,0,0,1
1153,731,APR_Hepat_Apoptosis_24hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1153 -- APR_Hepat_Apoptosis_24hr_dn,signaling,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,cell cycle,proliferation,0,0,1
1154,731,APR_Hepat_Apoptosis_24hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1154 -- APR_Hepat_Apoptosis_24hr_up,signaling,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,cell morphology,cell conformation,0,0,1
1155,732,APR_Hepat_CellLoss_24hr_dn,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1155 -- APR_Hepat_CellLoss_24hr_dn,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1156,732,APR_Hepat_CellLoss_24hr_up,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1156 -- APR_Hepat_CellLoss_24hr_up,viability,log2_fold_induction,positive,0,,gain,cellular,cellular,cell cycle,proliferation,0,0,1
1157,733,APR_Hepat_DNADamage_24hr_dn,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1157 -- APR_Hepat_DNADamage_24hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,cellular,cell morphology,dna conformation,0,0,1
1158,733,APR_Hepat_DNADamage_24hr_up,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1158 -- APR_Hepat_DNADamage_24hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,cellular,cell morphology,dna conformation,0,0,1
1159,734,APR_Hepat_DNATexture_24hr_dn,0,1,conformation reporter assay using HCS Fluorescent Imaging to monitor dna-unspecified in hepatocyte cell line: AEID1159 -- APR_Hepat_DNATexture_24hr_dn,signaling,log2_fold_induction,negative,0,,loss,dna,dna-unspecified,cell morphology,dna conformation,0,0,1
1160,734,APR_Hepat_DNATexture_24hr_up,0,1,conformation reporter assay using HCS Fluorescent Imaging to monitor dna-unspecified in hepatocyte cell line: AEID1160 -- APR_Hepat_DNATexture_24hr_up,signaling,log2_fold_induction,positive,0,,gain,dna,dna-unspecified,cell morphology,dna conformation,0,0,1
1161,735,APR_Hepat_LysosomalMass_24hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor lysosome in hepatocyte cell line: AEID1161 -- APR_Hepat_LysosomalMass_24hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,lysosome,cell morphology,organelle conformation,0,0,1
1162,735,APR_Hepat_LysosomalMass_24hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor lysosome in hepatocyte cell line: AEID1162 -- APR_Hepat_LysosomalMass_24hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,lysosome,cell morphology,organelle conformation,0,0,1
1163,736,APR_Hepat_MitoFxnI_24hr_dn,0,1,membrane potential reporter assay using HCS Fluorescent Imaging to monitor mitochondria in hepatocyte cell line: AEID1163 -- APR_Hepat_MitoFxnI_24hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1164,736,APR_Hepat_MitoFxnI_24hr_up,0,1,membrane potential reporter assay using HCS Fluorescent Imaging to monitor mitochondria in hepatocyte cell line: AEID1164 -- APR_Hepat_MitoFxnI_24hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1165,737,APR_Hepat_NuclearSize_24hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor nucleus in hepatocyte cell line: AEID1165 -- APR_Hepat_NuclearSize_24hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,nucleus,cell morphology,organelle conformation,0,0,1
1166,737,APR_Hepat_NuclearSize_24hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor nucleus in hepatocyte cell line: AEID1166 -- APR_Hepat_NuclearSize_24hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,nucleus,cell morphology,organelle conformation,0,0,1
1167,738,APR_Hepat_Steatosis_24hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1167 -- APR_Hepat_Steatosis_24hr_dn,signaling,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,cell morphology,cell conformation,0,0,1
1168,738,APR_Hepat_Steatosis_24hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1168 -- APR_Hepat_Steatosis_24hr_up,signaling,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,cell morphology,cell conformation,0,0,1
1169,739,APR_Hepat_Apoptosis_48hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1169 -- APR_Hepat_Apoptosis_48hr_dn,signaling,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,cell cycle,proliferation,0,0,1
1170,739,APR_Hepat_Apoptosis_48hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1170 -- APR_Hepat_Apoptosis_48hr_up,signaling,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,cell morphology,cell conformation,0,0,1
1171,740,APR_Hepat_CellLoss_48hr_dn,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1171 -- APR_Hepat_CellLoss_48hr_dn,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1172,740,APR_Hepat_CellLoss_48hr_up,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1172 -- APR_Hepat_CellLoss_48hr_up,viability,log2_fold_induction,positive,0,,gain,cellular,cellular,cell cycle,proliferation,0,0,1
1173,741,APR_Hepat_DNADamage_48hr_dn,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1173 -- APR_Hepat_DNADamage_48hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,cellular,cell morphology,dna conformation,0,0,1
1174,741,APR_Hepat_DNADamage_48hr_up,0,1,viability reporter assay using HCS Fluorescent Imaging to monitor cellular process in hepatocyte cell line: AEID1174 -- APR_Hepat_DNADamage_48hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,cellular,cell morphology,dna conformation,0,0,1
1175,742,APR_Hepat_DNATexture_48hr_dn,0,1,conformation reporter assay using HCS Fluorescent Imaging to monitor dna-unspecified in hepatocyte cell line: AEID1175 -- APR_Hepat_DNATexture_48hr_dn,signaling,log2_fold_induction,negative,0,,loss,dna,dna-unspecified,cell morphology,dna conformation,0,0,1
1176,742,APR_Hepat_DNATexture_48hr_up,0,1,conformation reporter assay using HCS Fluorescent Imaging to monitor dna-unspecified in hepatocyte cell line: AEID1176 -- APR_Hepat_DNATexture_48hr_up,signaling,log2_fold_induction,positive,0,,gain,dna,dna-unspecified,cell morphology,dna conformation,0,0,1
1177,743,APR_Hepat_LysosomalMass_48hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor lysosome in hepatocyte cell line: AEID1177 -- APR_Hepat_LysosomalMass_48hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,lysosome,cell morphology,organelle conformation,0,0,1
1178,743,APR_Hepat_LysosomalMass_48hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor lysosome in hepatocyte cell line: AEID1178 -- APR_Hepat_LysosomalMass_48hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,lysosome,cell morphology,organelle conformation,0,0,1
1179,744,APR_Hepat_MitoFxnI_48hr_dn,0,1,membrane potential reporter assay using HCS Fluorescent Imaging to monitor mitochondria in hepatocyte cell line: AEID1179 -- APR_Hepat_MitoFxnI_48hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1180,744,APR_Hepat_MitoFxnI_48hr_up,0,1,membrane potential reporter assay using HCS Fluorescent Imaging to monitor mitochondria in hepatocyte cell line: AEID1180 -- APR_Hepat_MitoFxnI_48hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1181,745,APR_Hepat_NuclearSize_48hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor nucleus in hepatocyte cell line: AEID1181 -- APR_Hepat_NuclearSize_48hr_dn,signaling,log2_fold_induction,negative,0,,loss,cellular,nucleus,cell morphology,organelle conformation,0,0,1
1182,745,APR_Hepat_NuclearSize_48hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor nucleus in hepatocyte cell line: AEID1182 -- APR_Hepat_NuclearSize_48hr_up,signaling,log2_fold_induction,positive,0,,gain,cellular,nucleus,cell morphology,organelle conformation,0,0,1
1183,746,APR_Hepat_Steatosis_48hr_dn,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1183 -- APR_Hepat_Steatosis_48hr_dn,signaling,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,cell morphology,cell conformation,0,0,1
1184,746,APR_Hepat_Steatosis_48hr_up,0,1,morphology reporter assay using HCS Fluorescent Imaging to monitor pathway in hepatocyte cell line: AEID1184 -- APR_Hepat_Steatosis_48hr_up,signaling,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,cell morphology,cell conformation,0,0,1
1185,747,TOX21_ARE_BLA_agonist_viability,1,1,"TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1186,748,TOX21_HSE_BLA_agonist_viability,1,1,"TOX21_HSE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1187,749,TOX21_p53_BLA_p1_viability,1,1,"TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1188,750,TOX21_FXR_BLA_agonist_viability,1,1,"TOX21_FXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1189,751,TOX21_ERa_BLA_Antagonist_ch1,1,1,"Data from the assay component TOX21_ERa_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,4-hydroxytamoxifen,gain,pathway,pathway-specified,channel 1,baseline control,0,0,1
1190,752,TOX21_ERa_BLA_Antagonist_ch2,1,1,"Data from the assay component TOX21_ERa_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,4-hydroxytamoxifen,loss,pathway,pathway-specified,channel 2,baseline control,0,0,1
1191,753,TOX21_FXR_BLA_Antagonist_ch1,1,1,"Data from the assay component TOX21_FXR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Guggulsterone,gain,pathway,pathway-specified,channel 1,baseline control,0,0,1
1192,754,TOX21_FXR_BLA_Antagonist_ch2,1,1,"Data from the assay component TOX21_FXR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Guggulsterone,loss,pathway,pathway-specified,channel 2,baseline control,0,0,1
1193,755,TOX21_GR_BLA_Antagonist_ch1,1,1,"Data from the assay component TOX21_GR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Mifepristone,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1194,756,TOX21_GR_BLA_Antagonist_ch2,1,1,"Data from the assay component TOX21_GR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Mifepristone,loss,pathway,pathway-specified,channel 2,baseline control,0,0,1
1195,757,TOX21_PPARd_BLA_Agonist_viability,1,1,"TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1196,758,TOX21_PPARd_BLA_Antagonist_ch1,1,1,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,MK886,gain,pathway,pathway-specified,channel 1,baseline control,0,0,1
1197,759,TOX21_PPARd_BLA_Antagonist_ch2,1,1,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,MK886,loss,pathway,pathway-specified,channel 2,baseline control,0,0,1
1198,760,TOX21_PPARg_BLA_Antagonist_ch1,1,1,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,GW9662,gain,pathway,pathway-specified,channel 1,baseline control,0,0,1
1199,761,TOX21_PPARg_BLA_Antagonist_ch2,1,1,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,GW9662,loss,pathway,pathway-specified,channel 2,baseline control,0,0,1
1200,762,TOX21_VDR_BLA_Antagonist_ch1,1,1,"Data from the assay component TOX21_VDR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Tetraoctyl ammonium bromide,gain,protein,receptor,channel 1,baseline control,0,0,1
1201,763,TOX21_VDR_BLA_Antagonist_ch2,1,1,"Data from the assay component TOX21_VDR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,"1alpha,25-Dihydroxy vitamin D3",loss,protein,receptor,channel 2,baseline control,0,0,1
1202,764,TOX21_AR_BLA_Antagonist_ch1,1,1,"Data from the assay component TOX21_AR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Cyproterone acetate,gain,pathway,pathway-specified,channel 1,baseline control,0,0,1
1203,765,TOX21_AR_BLA_Antagonist_ch2,1,1,"Data from the assay component TOX21_AR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Cyproterone acetate,loss,pathway,pathway-specified,channel 2,baseline control,0,0,1
1204,766,ATG_XTT_Cytotoxicity_up,1,1,"Data from the assay component ATG_XTT_Cytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, ATG_XTT_Cytotoxicity_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,NA,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1315,890,TOX21_p53_BLA_p2_ch1,1,1,"Data from the assay component TOX21_p53_BLA_p2_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Mitomycin C;Nutlin3,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1316,891,TOX21_p53_BLA_p2_ch2,1,1,"Data from the assay component TOX21_p53_BLA_p2_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Mitomycin C;Nutlin3,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1317,892,TOX21_p53_BLA_p2_ratio,1,1,"Data from the assay component TOX21_p53_BLA_p2_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",ratio,percent_activity,positive,0,Mitomycin C;Nutlin3,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
1318,893,TOX21_p53_BLA_p2_viability,1,1,"TOX21_p53_BLA_p2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1319,894,TOX21_p53_BLA_p3_ch1,1,1,"Data from the assay component TOX21_p53_BLA_p3_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Mitomycin C;Nutlin3,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1320,895,TOX21_p53_BLA_p3_ch2,1,1,"Data from the assay component TOX21_p53_BLA_p3_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Mitomycin C;Nutlin3,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1321,896,TOX21_p53_BLA_p3_ratio,1,1,"Data from the assay component TOX21_p53_BLA_p3_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_p53_BLA_p3_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter,  gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",ratio,percent_activity,positive,0,Mitomycin C;Nutlin3,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
1322,897,TOX21_p53_BLA_p3_viability,1,1,"TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1323,898,TOX21_p53_BLA_p4_ch1,1,1,"Data from the assay component TOX21_p53_BLA_p4_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Mitomycin C;Nutlin3,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1324,899,TOX21_p53_BLA_p4_ch2,1,1,"Data from the assay component TOX21_p53_BLA_p4_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Mitomycin C;Nutlin3,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1325,900,TOX21_p53_BLA_p4_ratio,1,1,"Data from the assay component TOX21_p53_BLA_p4_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",ratio,percent_activity,positive,0,Mitomycin C;Nutlin3,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
1326,901,TOX21_p53_BLA_p4_viability,1,1,"TOX21_p53_BLA_p4_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1327,902,TOX21_p53_BLA_p5_ch1,1,1,"Data from the assay component TOX21_p53_BLA_p5_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Mitomycin C;Nutlin3,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1328,903,TOX21_p53_BLA_p5_ch2,1,1,"Data from the assay component TOX21_p53_BLA_p5_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Mitomycin C;Nutlin3,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1329,904,TOX21_p53_BLA_p5_ratio,1,1,"Data from the assay component TOX21_p53_BLA_p5_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",ratio,percent_activity,positive,0,Mitomycin C;Nutlin3,gain,pathway,pathway-specified,dna binding,tumor suppressor,0,0,1
1330,905,TOX21_p53_BLA_p5_viability,1,1,"TOX21_p53_BLA_p5_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1331,906,TOX21_VDR_BLA_Agonist_viability,1,1,"TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1332,886,APR_Hepat_MitoFxnI_1hr_MEAN_up,0,0,,signaling,log2_fold_induction,positive,0,,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1333,887,APR_Hepat_MitoFxnI_24hr_MEAN_up,0,0,,signaling,log2_fold_induction,positive,0,,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1334,888,APR_Hepat_MitoFxnI_48hr_MEAN_up,0,0,,signaling,log2_fold_induction,positive,0,,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1335,889,APR_Hepat_Steatosis_48hr_TotalArea_up,0,0,,signaling,log2_fold_induction,positive,0,,gain,cellular,lysosome,cell morphology,organelle conformation,0,0,1
1336,886,APR_Hepat_MitoFxnI_1hr_MEAN_dn,0,0,,signaling,log2_fold_induction,negative,0,,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1337,887,APR_Hepat_MitoFxnI_24hr_MEAN_dn,0,0,,signaling,log2_fold_induction,negative,0,,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1338,888,APR_Hepat_MitoFxnI_48hr_MEAN_dn,0,0,,signaling,log2_fold_induction,negative,0,,loss,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1339,889,APR_Hepat_Steatosis_48hr_TotalArea_dn,0,0,,signaling,log2_fold_induction,negative,0,,loss,cellular,lysosome,cell morphology,organelle conformation,0,0,1
1340,907,TOX21_ESRE_BLA_ch1,1,1,"Data from the assay component TOX21_ESRE_BLA_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,17-AAG,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1341,908,TOX21_ESRE_BLA_ch2,1,1,"Data from the assay component TOX21_ESRE_BLA_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1342,909,TOX21_ESRE_BLA_ratio,1,1,"Data from the assay component TOX21_ESRE_BLA_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ATF6.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.",ratio,percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,dna binding,basic leucine zipper,0,0,1
1343,910,TOX21_ESRE_BLA_viability,1,1,"TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1344,911,TOX21_NFkB_BLA_agonist_ch1,1,1,"Data from the assay component TOX21_NFkB_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,TNFa,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1345,912,TOX21_NFkB_BLA_agonist_ch2,1,1,"Data from the assay component TOX21_NFkB_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,TNFa,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1346,913,TOX21_NFkB_BLA_agonist_ratio,1,1,"Data from the assay component TOX21_NFkB_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_NFkB_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is NF-kappa B.",ratio,percent_activity,positive,0,TNFa,gain,pathway,pathway-specified,dna binding,NF-kappa B,0,0,1
1347,914,TOX21_NFkB_BLA_agonist_viability,1,1,"TOX21_NFkB_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1348,915,ATG_NUR77_TRANS2_up,1,1,"The assay endpoint, ATG_NUR77_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1349,916,ATG_GCNF_TRANS2_up,1,1,"The assay endpoint ATG_GCNF_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR6A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1350,917,ATG_COUP_TF2_TRANS2_up,1,1,"The assay endpoint ATG_COUP_TF2_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2F2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1351,918,ATG_PNR_TRANS2_up,1,1,"The assay endpoint ATG_PNR_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2E3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1352,919,ATG_LRH1_TRANS2_up,1,1,"The assay endpoint ATG_LRH1_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR5A2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1353,920,ATG_Rev_ERB_A_TRANS2_up,1,1,"The assay endpoint ATG_Rev_ERB_A_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1D1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1354,921,ATG_HNF4g_TRANS2_up,1,1,"The assay endpoint ATG_HNF4g_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HNF4G. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1355,922,ATG_ERRb_TRANS2_up,1,1,"The assay endpoint ATG_ERRb_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1356,923,ATG_MR_TRANS2_up,1,1,"The assay endpoint ATG_MR_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1357,924,ATG_COUP_TF1_TRANS2_up,1,1,"The assay endpoint ATG_COUP_TF1_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2F1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1358,925,ATG_NOR1_TRANS2_up,1,1,"The assay endpoint ATG_NOR1_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1359,926,ATG_TR4_TRANS2_up,1,1,"The assay endpoint ATG_TR4_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2C2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1360,927,ATG_DAX1_TRANS2_up,1,1,"The assay endpoint ATG_DAX1_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR0B1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1361,928,ATG_Rev_ERB_B_TRANS2_up,1,1,"The assay endpoint ATG_Rev_ERB_B_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1D2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1362,929,ATG_RORa_TRANS2_up,1,1,"The assay endpoint ATG_RORa_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is  orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1363,930,ATG_PR_TRANS2_up,1,1,"The assay endpoint ATG_PR_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PGR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1364,931,ATG_RXRg_TRANS2_up,1,1,"The assay endpoint ATG_RXRg_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1365,932,ATG_SF_1_TRANS2_up,1,1,"The assay endpoint ATG_SF_1_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR5A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1366,933,ATG_SHP_TRANS2_up,1,1,"The assay endpoint ATG_SHP_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR0B2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1367,934,ATG_ERb_TRANS2_up,1,1,"The assay endpoint ATG_ERb_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1368,935,ATG_TLX_TRANS2_up,1,1,"The assay endpoint ATG_TLX_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2E1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1369,936,ATG_THRb_TRANS2_up,1,1,"The assay endpoint ATG_THRb_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1370,937,ATG_EAR2_TRANS2_up,1,1,"The assay endpoint ATG_EAR2_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2F6. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1371,938,ATG_TR2_TRANS2_up,1,1,"The assay endpoint ATG_TR2_TRANS2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR2C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,orphan,0,0,1
1372,939,Tanguay_ZF_120hpf_MORT_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_MORT_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_MORT_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1373,940,Tanguay_ZF_120hpf_YSE_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_YSE_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_YSE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1374,941,Tanguay_ZF_120hpf_AXIS_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_AXIS_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_AXIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1375,942,Tanguay_ZF_120hpf_EYE_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_EYE_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_EYE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1376,943,Tanguay_ZF_120hpf_SNOU_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_SNOU_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SNOU_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1377,944,Tanguay_ZF_120hpf_JAW_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_JAW_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_JAW_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1378,945,Tanguay_ZF_120hpf_OTIC_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_OTIC_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_OTIC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1379,946,Tanguay_ZF_120hpf_PE_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_PE_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1380,947,Tanguay_ZF_120hpf_BRAI_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_BRAI_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_BRAI_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1381,948,Tanguay_ZF_120hpf_SOMI_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_SOMI_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SOMI_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1382,949,Tanguay_ZF_120hpf_PFIN_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_PFIN_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PFIN_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1383,950,Tanguay_ZF_120hpf_CFIN_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_CFIN_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_CFIN_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1384,951,Tanguay_ZF_120hpf_PIG_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_PIG_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1385,952,Tanguay_ZF_120hpf_CIRC_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_CIRC_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_CIRC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1386,953,Tanguay_ZF_120hpf_TRUN_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_TRUN_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_TRUN_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1387,954,Tanguay_ZF_120hpf_SWIM_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_SWIM_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SWIM_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1388,955,Tanguay_ZF_120hpf_NC_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_NC_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_NC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1389,956,Tanguay_ZF_120hpf_TR_up,1,1,"Data from the assay component Tanguay_ZF_120hpf_TR_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_TR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,NA,0,0,1
1390,957,LTEA_HepaRG_SLC22A6_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,organic anion transporter,0,0,1
1391,957,LTEA_HepaRG_SLC22A6_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,organic anion transporter,0,0,1
1392,958,LTEA_HepaRG_KLK3_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,protease,Cellular remodeling,0,0,1
1393,958,LTEA_HepaRG_KLK3_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,protease,Cellular remodeling,0,0,1
1394,959,LTEA_HepaRG_SLC10A1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,transporter,sodium/bile acid cotransporter,0,0,1
1395,959,LTEA_HepaRG_SLC10A1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,sodium/bile acid cotransporter,0,0,1
1396,960,LTEA_HepaRG_MMP1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,protease,matrix metalloproteinase,0,0,1
1397,960,LTEA_HepaRG_MMP1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,protease,matrix metalloproteinase,0,0,1
1398,961,LTEA_HepaRG_CYP24A1_1_dn,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,reporter gene,log2_fold_induction,negative,0,,loss,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1399,961,LTEA_HepaRG_CYP24A1_1_up,1,1,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1400,32,ATG_Ahr_CIS_dn,1,1,ATG_Ahr_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,6-formylindolo carbazole,loss,protein,transcription factor,dna binding,basic helix-loop-helix protein,0,0,1
1401,33,ATG_AP_1_CIS_dn,1,1,ATG_AP_1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
1402,34,ATG_AP_2_CIS_dn,1,1,ATG_AP_2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,basic helix-turn-helix leucine zipper,0,0,1
1403,84,ATG_AR_TRANS_dn,1,1,ATG_AR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1404,35,ATG_BRE_CIS_dn,1,1,ATG_BRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,Smad protein,0,0,1
1405,85,ATG_CAR_TRANS_dn,1,1,ATG_CAR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1406,37,ATG_CMV_CIS_dn,1,1,ATG_CMV_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1407,924,ATG_COUP_TF1_TRANS2_dn,1,1,ATG_COUP_TF1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1408,917,ATG_COUP_TF2_TRANS2_dn,1,1,ATG_COUP_TF2_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1409,38,ATG_CRE_CIS_dn,1,1,ATG_CRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
1410,36,ATG_C_EBP_CIS_dn,1,1,ATG_C_EBP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
1411,927,ATG_DAX1_TRANS2_dn,1,1,ATG_DAX1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1412,39,ATG_DR4_LXR_CIS_dn,1,1,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1413,40,ATG_DR5_CIS_dn,1,1,ATG_DR5_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1414,42,ATG_E2F_CIS_dn,1,1,ATG_E2F_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,E2F transcription factor,0,0,1
1415,937,ATG_EAR2_TRANS2_dn,1,1,ATG_EAR2_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1416,43,ATG_EGR_CIS_dn,1,1,ATG_EGR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,zinc finger,0,0,1
1417,86,ATG_ERa_TRANS_dn,1,1,ATG_ERa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,4-hydroxytamoxifen,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1418,934,ATG_ERb_TRANS2_dn,1,1,ATG_ERb_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1419,44,ATG_ERE_CIS_dn,1,1,ATG_ERE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,4-hydroxytamoxifen,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1420,87,ATG_ERRa_TRANS_dn,1,1,ATG_ERRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1421,922,ATG_ERRb_TRANS2_dn,1,1,ATG_ERRb_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1422,88,ATG_ERRg_TRANS_dn,1,1,ATG_ERRg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1423,45,ATG_Ets_CIS_dn,1,1,ATG_Ets_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,winged helix-turn-helix,0,0,1
1424,41,ATG_E_Box_CIS_dn,1,1,ATG_E_Box_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,basic helix-loop-helix protein,0,0,1
1425,46,ATG_FoxA2_CIS_dn,1,1,ATG_FoxA2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,forkhead box protein,0,0,1
1426,47,ATG_FoxO_CIS_dn,1,1,ATG_FoxO_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,forkhead box protein,0,0,1
1427,89,ATG_FXR_TRANS_dn,1,1,ATG_FXR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1428,90,ATG_GAL4_TRANS_dn,1,1,ATG_GAL4_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,baseline control,0,0,1
1429,48,ATG_GATA_CIS_dn,1,1,ATG_GATA_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,GATA proteins,0,0,1
1430,916,ATG_GCNF_TRANS2_dn,1,1,ATG_GCNF_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1431,49,ATG_GLI_CIS_dn,1,1,ATG_GLI_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,zinc finger,0,0,1
1432,50,ATG_GRE_CIS_dn,1,1,ATG_GRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1433,91,ATG_GR_TRANS_dn,1,1,ATG_GR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1434,51,ATG_HIF1a_CIS_dn,1,1,ATG_HIF1a_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,basic helix-loop-helix protein,0,0,1
1435,92,ATG_HNF4a_TRANS_dn,1,1,ATG_HNF4a_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1436,921,ATG_HNF4g_TRANS2_dn,1,1,ATG_HNF4g_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1437,52,ATG_HNF6_CIS_dn,1,1,ATG_HNF6_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,homeobox protein,0,0,1
1438,93,ATG_Hpa5_TRANS_dn,1,1,ATG_Hpa5_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1439,53,ATG_HSE_CIS_dn,1,1,ATG_HSE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,heat shock protein,0,0,1
1440,54,ATG_IR1_CIS_dn,1,1,ATG_IR1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1441,55,ATG_ISRE_CIS_dn,1,1,ATG_ISRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,interferon regulatory factors,0,0,1
1442,919,ATG_LRH1_TRANS2_dn,1,1,ATG_LRH1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1443,94,ATG_LXRa_TRANS_dn,1,1,ATG_LXRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1444,95,ATG_LXRb_TRANS_dn,1,1,ATG_LXRb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1445,60,ATG_MRE_CIS_dn,1,1,ATG_MRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,zinc finger,0,0,1
1446,923,ATG_MR_TRANS2_dn,1,1,ATG_MR_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1447,61,ATG_Myb_CIS_dn,1,1,ATG_Myb_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,MYB proteins,0,0,1
1448,62,ATG_Myc_CIS_dn,1,1,ATG_Myc_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,basic helix-loop-helix leucine zipper,0,0,1
1449,56,ATG_M_06_CIS_dn,1,1,ATG_M_06_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1450,96,ATG_M_06_TRANS_dn,1,1,ATG_M_06_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1451,57,ATG_M_19_CIS_dn,1,1,ATG_M_19_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1452,97,ATG_M_19_TRANS_dn,1,1,ATG_M_19_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1453,58,ATG_M_32_CIS_dn,1,1,ATG_M_32_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1454,98,ATG_M_32_TRANS_dn,1,1,ATG_M_32_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1455,59,ATG_M_61_CIS_dn,1,1,ATG_M_61_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1456,99,ATG_M_61_TRANS_dn,1,1,ATG_M_61_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1457,64,ATG_NFI_CIS_dn,1,1,ATG_NFI_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,nuclear factor I,0,0,1
1458,63,ATG_NF_kB_CIS_dn,1,1,ATG_NF_kB_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,NF-kappa B,0,0,1
1459,925,ATG_NOR1_TRANS2_dn,1,1,ATG_NOR1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1460,65,ATG_NRF1_CIS_dn,1,1,ATG_NRF1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,nuclear respiratory factors,0,0,1
1461,66,ATG_NRF2_ARE_CIS_dn,1,1,ATG_NRF2_ARE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
1462,915,ATG_NUR77_TRANS2_dn,1,1,ATG_NUR77_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1463,100,ATG_NURR1_TRANS_dn,1,1,ATG_NURR1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1464,67,ATG_Oct_MLP_CIS_dn,1,1,ATG_Oct_MLP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,POU domain protein,0,0,1
1465,68,ATG_p53_CIS_dn,1,1,ATG_p53_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,tumor suppressor,0,0,1
1466,69,ATG_Pax6_CIS_dn,1,1,ATG_Pax6_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,paired box protein,0,0,1
1467,70,ATG_PBREM_CIS_dn,1,1,ATG_PBREM_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1468,918,ATG_PNR_TRANS2_dn,1,1,ATG_PNR_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1469,101,ATG_PPARa_TRANS_dn,1,1,ATG_PPARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1470,102,ATG_PPARd_TRANS_dn,1,1,ATG_PPARd_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1471,103,ATG_PPARg_TRANS_dn,1,1,ATG_PPARg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1472,71,ATG_PPRE_CIS_dn,1,1,ATG_PPRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1473,930,ATG_PR_TRANS2_dn,1,1,ATG_PR_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1474,72,ATG_PXRE_CIS_dn,1,1,ATG_PXRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1475,104,ATG_PXR_TRANS_dn,1,1,ATG_PXR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1476,105,ATG_RARa_TRANS_dn,1,1,ATG_RARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1477,106,ATG_RARb_TRANS_dn,1,1,ATG_RARb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1478,107,ATG_RARg_TRANS_dn,1,1,ATG_RARg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1479,920,ATG_Rev_ERB_A_TRANS2_dn,1,1,ATG_Rev_ERB_A_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1480,928,ATG_Rev_ERB_B_TRANS2_dn,1,1,ATG_Rev_ERB_B_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1481,929,ATG_RORa_TRANS2_dn,1,1,ATG_RORa_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1482,108,ATG_RORb_TRANS_dn,1,1,ATG_RORb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1483,73,ATG_RORE_CIS_dn,1,1,ATG_RORE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1484,109,ATG_RORg_TRANS_dn,1,1,ATG_RORg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1485,110,ATG_RXRa_TRANS_dn,1,1,ATG_RXRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1486,111,ATG_RXRb_TRANS_dn,1,1,ATG_RXRb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1487,931,ATG_RXRg_TRANS2_dn,1,1,ATG_RXRg_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1488,932,ATG_SF_1_TRANS2_dn,1,1,ATG_SF_1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1489,933,ATG_SHP_TRANS2_dn,1,1,ATG_SHP_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1490,74,ATG_Sox_CIS_dn,1,1,ATG_Sox_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,HMG box protein,0,0,1
1491,75,ATG_Sp1_CIS_dn,1,1,ATG_Sp1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,zinc finger,0,0,1
1492,76,ATG_SREBP_CIS_dn,1,1,ATG_SREBP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,basic helix-loop-helix leucine zipper,0,0,1
1493,77,ATG_STAT3_CIS_dn,1,1,ATG_STAT3_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,stat protein,0,0,1
1494,79,ATG_TAL_CIS_dn,1,1,ATG_TAL_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1495,78,ATG_TA_CIS_dn,1,1,ATG_TA_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1496,80,ATG_TCF_b_cat_CIS_dn,1,1,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,HMG box protein,0,0,1
1497,81,ATG_TGFb_CIS_dn,1,1,ATG_TGFb_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,growth factor,transforming growth factor beta,0,0,1
1498,112,ATG_THRa1_TRANS_dn,1,1,ATG_THRa1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1499,936,ATG_THRb_TRANS2_dn,1,1,ATG_THRb_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1500,935,ATG_TLX_TRANS2_dn,1,1,ATG_TLX_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1501,938,ATG_TR2_TRANS2_dn,1,1,ATG_TR2_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1502,926,ATG_TR4_TRANS2_dn,1,1,ATG_TR4_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,orphan,0,0,1
1503,82,ATG_VDRE_CIS_dn,1,1,ATG_VDRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1504,113,ATG_VDR_TRANS_dn,1,1,ATG_VDR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1505,83,ATG_Xbp1_CIS_dn,1,1,ATG_Xbp1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
1506,766,ATG_XTT_Cytotoxicity_dn,0,0,ATG_XTT_Cytotoxicity_dn was not developed or optimized to detect loss of signal. Use data with caution.,viability,percent_activity,negative,0,NA,gain,cellular,cellular,cell cycle,proliferation,0,0,0
1507,962,CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,1,1,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",developmental defect,percent_activity,positive,0,NA,gain,organism,malformation,malformation,total,0,0,1
1508,963,CCTE_Simmons_AUR_TPO_dn,1,1,"Data from the assay component CCTE_Simmons_AUR_TPO was analyzed at the endpoint, CCTE_Simmons_AUR_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, the Amplex UltraRed assay, loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",binding,percent_activity,positive,0,methimazole (MMI),loss,protein,enzyme,oxidoreductase,peroxidase,0,0,1
1509,964,CCTE_Simmons_CellTiterGLO_HEK293T,1,1,"Data from the assay component CCTE_Simmons_CellTiterGLO_HEK293T was analyzed at the endpoint, CCTE_Simmons_CellTiterGLO_HEK293T_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. This assay was run in parallel with aeid 1508 as a means of indicating the range of chemical cytotoxicity or reactivity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,LUCINH1;LUCINH2,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1510,965,CCTE_Simmons_QuantiLum_inhib_dn,0,1,"Data from the assay component CCTE_Simmons_QuantiLum_inhib was analyzed at the endpoint, CCTE_Simmons_QuantiLum_inhib_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, measures of enzyme activity for loss-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene TPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monooxygenase. The assay was replaced by aeid 1848 which uses a higher concentration of luciferase enzyme.",binding,percent_activity,positive,0,b-naphthoquinone,loss,protein,enzyme,oxidoreductase,monooxygenase,0,0,1
1512,966,Vala_A1_LipidPxlInt_up,0,1,,,log2_fold_induction,positive,0,Rosiglitazone,gain,pathway,pathway-specified,a1,,0,0,1
1513,966,Vala_A1_LipidPxlInt_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,a1,,0,0,1
1514,967,Vala_A1_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1515,968,Vala_A1_PctDifferenCells_up,0,1,,,log2_fold_induction,positive,0,Rosiglitazone,gain,pathway,pathway-specified,a1,,0,0,1
1516,968,Vala_A1_PctDifferenCells_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,a1,,0,0,1
1517,969,Vala_A1_K2_ADFPvLipid_up,0,1,,,log2_fold_induction,positive,0,Rosiglitazone,gain,pathway,pathway-specified,a1,,0,0,1
1518,969,Vala_A1_K2_ADFPvLipid_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,a1,,0,0,1
1519,970,Vala_A1_LipidDropletDiam_up,0,1,,,log2_fold_induction,positive,0,Rosiglitazone,gain,pathway,pathway-specified,a1,,0,0,1
1520,970,Vala_A1_LipidDropletDiam_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,a1,,0,0,1
1521,971,Vala_A1_PCC_ADFPvLipid_up,0,1,,,log2_fold_induction,positive,0,Rosiglitazone,gain,pathway,pathway-specified,a1,,0,0,1
1522,971,Vala_A1_PCC_ADFPvLipid_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,a1,,0,0,1
1523,972,Vala_A1_PCC_PerilipinvLipid_up,0,1,,,log2_fold_induction,positive,0,Rosiglitazone,gain,pathway,pathway-specified,a1,,0,0,1
1524,972,Vala_A1_PCC_PerilipinvLipid_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,a1,,0,0,1
1525,973,Vala_A2_LipidPxlInt_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,a2,,0,0,1
1526,973,Vala_A2_LipidPxlInt_dn,0,1,,,log2_fold_induction,negative,0,TNFalpha,loss,pathway,pathway-specified,a2,,0,0,1
1527,974,Vala_A2_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1528,975,Vala_A2_PctDifferenCells_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,a2,,0,0,1
1529,975,Vala_A2_PctDifferenCells_dn,0,1,,,log2_fold_induction,negative,0,TNFalpha,loss,pathway,pathway-specified,a2,,0,0,1
1530,976,Vala_A2_K2_LipidvADFP_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,a2,,0,0,1
1531,976,Vala_A2_K2_LipidvADFP_dn,0,1,,,log2_fold_induction,negative,0,TNFalpha,loss,pathway,pathway-specified,a2,,0,0,1
1532,977,Vala_A2_K1_ADFPvLipid_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,a2,,0,0,1
1533,977,Vala_A2_K1_ADFPvLipid_dn,0,1,,,log2_fold_induction,negative,0,TNFalpha,loss,pathway,pathway-specified,a2,,0,0,1
1534,978,Vala_A2_LipidDropletDiam_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,a2,,0,0,1
1535,978,Vala_A2_LipidDropletDiam_dn,0,1,,,log2_fold_induction,negative,0,TNFalpha,loss,pathway,pathway-specified,a2,,0,0,1
1536,979,Vala_A2_PCC_LipidvPerilipin_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,a2,,0,0,1
1537,979,Vala_A2_PCC_LipidvPerilipin_dn,0,1,,,log2_fold_induction,negative,0,TNFalpha,loss,pathway,pathway-specified,a2,,0,0,1
1538,980,Vala_BC1_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1539,981,Vala_BC1_PCC_betacateninvNucleus_up,0,1,,,log2_fold_induction,positive,0,BIO-acetoxime,gain,pathway,pathway-specified,bc1,,0,0,1
1540,981,Vala_BC1_PCC_betacateninvNucleus_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,bc1,,0,0,1
1541,982,Vala_ECAD_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1542,983,Vala_ECAD_ECADMembraneInt_up,0,1,,,log2_fold_induction,positive,0,MG 132,gain,pathway,pathway-specified,ecad,,0,0,1
1543,983,Vala_ECAD_ECADMembraneInt_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,ecad,,0,0,1
1544,984,Vala_ECAD_ECADCellInt_up,0,1,,,log2_fold_induction,positive,0,MG 132,gain,pathway,pathway-specified,ecad,,0,0,1
1545,984,Vala_ECAD_ECADCellInt_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,ecad,,0,0,1
1546,985,Vala_ECAD_TSA_up,0,1,,,log2_fold_induction,positive,0,MG 132,gain,pathway,pathway-specified,ecad,,0,0,1
1547,985,Vala_ECAD_TSA_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,ecad,,0,0,1
1548,986,Vala_L2_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1549,987,Vala_L2_PctDifferenCells_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,l2,,0,0,1
1550,987,Vala_L2_PctDifferenCells_dn,0,1,,,log2_fold_induction,negative,0,Propranolol,loss,pathway,pathway-specified,l2,,0,0,1
1551,988,Vala_L2_LipidDropletDiam_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,l2,,0,0,1
1552,988,Vala_L2_LipidDropletDiam_dn,0,1,,,log2_fold_induction,negative,0,Propranolol,loss,pathway,pathway-specified,l2,,0,0,1
1553,989,Vala_L2_PCC_pHSLvLipid_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,l2,,0,0,1
1554,989,Vala_L2_PCC_pHSLvLipid_dn,0,1,,,log2_fold_induction,negative,0,Propranolol,loss,pathway,pathway-specified,l2,,0,0,1
1555,990,Vala_L2_PCC_pPerilipinvLipid_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,l2,,0,0,1
1556,990,Vala_L2_PCC_pPerilipinvLipid_dn,0,1,,,log2_fold_induction,negative,0,Propranolol,loss,pathway,pathway-specified,l2,,0,0,1
1557,991,Vala_LD1_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1558,992,Vala_LD1_M2_ADFPvLipid_m_up,0,1,,,log2_fold_induction,positive,0,Oleic Acid,gain,pathway,pathway-specified,ld1,,0,0,1
1559,992,Vala_LD1_M2_ADFPvLipid_m_dn,0,1,,,log2_fold_induction,negative,0,Triacsin C,loss,pathway,pathway-specified,ld1,,0,0,1
1560,993,Vala_LD1_LipidDropletArea_up,0,1,,,log2_fold_induction,positive,0,Oleic Acid,gain,pathway,pathway-specified,ld1,,0,0,1
1561,993,Vala_LD1_LipidDropletArea_dn,0,1,,,log2_fold_induction,negative,0,Triacsin C,loss,pathway,pathway-specified,ld1,,0,0,1
1562,994,Vala_LD1_LipidDropletDiam_up,0,1,,,log2_fold_induction,positive,0,Oleic Acid,gain,pathway,pathway-specified,ld1,,0,0,1
1563,994,Vala_LD1_LipidDropletDiam_dn,0,1,,,log2_fold_induction,negative,0,Triacsin C,loss,pathway,pathway-specified,ld1,,0,0,1
1564,995,Vala_MEF1_Flk1Int_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,mef1,,0,0,1
1565,995,Vala_MEF1_Flk1Int_dn,0,1,,,log2_fold_induction,negative,0,Activin A,loss,pathway,pathway-specified,mef1,,0,0,1
1566,996,Vala_MEF1_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1567,997,Vala_MEF1_MOC_NucleusFoxA2_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,mef1,,0,0,1
1568,997,Vala_MEF1_MOC_NucleusFoxA2_dn,0,1,,,log2_fold_induction,negative,0,Activin A,loss,pathway,pathway-specified,mef1,,0,0,1
1569,998,Vala_MEF1_PCC_NucleusvFlk1_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,mef1,,0,0,1
1570,998,Vala_MEF1_PCC_NucleusvFlk1_dn,0,1,,,log2_fold_induction,negative,0,Activin A,loss,pathway,pathway-specified,mef1,,0,0,1
1571,999,Vala_MEF1_PCC_NucleusvFoxA2_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,mef1,,0,0,1
1572,999,Vala_MEF1_PCC_NucleusvFoxA2_dn,0,1,,,log2_fold_induction,negative,0,Activin A,loss,pathway,pathway-specified,mef1,,0,0,1
1573,1000,Vala_NO1_NeuriteArea_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,no1,,0,0,1
1574,1000,Vala_NO1_NeuriteArea_dn,0,1,,,log2_fold_induction,negative,0,Brefeldin A,loss,pathway,pathway-specified,no1,,0,0,1
1575,1001,Vala_NO1_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1576,1002,Vala_NO1_M1_PrePostSynapticImage_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,no1,,0,0,1
1577,1002,Vala_NO1_M1_PrePostSynapticImage_dn,0,1,,,log2_fold_induction,negative,0,Brefeldin A,loss,pathway,pathway-specified,no1,,0,0,1
1578,1003,Vala_NO1_M2_PrePostNeuriteImage_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,no1,,0,0,1
1579,1003,Vala_NO1_M2_PrePostNeuriteImage_dn,0,1,,,log2_fold_induction,negative,0,Brefeldin A,loss,pathway,pathway-specified,no1,,0,0,1
1580,1004,Vala_PBCD_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1581,1005,Vala_PBCD_FractionCellsGFPabvbgd_up,0,1,,,log2_fold_induction,positive,0,Tamoxifen,gain,pathway,pathway-specified,pbcd,,0,0,1
1582,1005,Vala_PBCD_FractionCellsGFPabvbgd_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,pbcd,,0,0,1
1583,1006,Vala_PBCD_GFPNucleusInt_up,0,1,,,log2_fold_induction,positive,0,Tamoxifen,gain,pathway,pathway-specified,pbcd,,0,0,1
1584,1006,Vala_PBCD_GFPNucleusInt_dn,0,1,,,log2_fold_induction,negative,0,,loss,pathway,pathway-specified,pbcd,,0,0,1
1585,1007,Vala_SCP1_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1586,1008,Vala_SCP1_PCC_Oct3vNucleus_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,scp1,,0,0,1
1587,1008,Vala_SCP1_PCC_Oct3vNucleus_dn,0,1,,,log2_fold_induction,negative,0,Retinoic Acid,loss,pathway,pathway-specified,scp1,,0,0,1
1588,1009,Vala_VECAD_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1589,1010,Vala_VECAD_WholeCellInt_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,vecad,,0,0,1
1590,1010,Vala_VECAD_WholeCellInt_dn,0,1,,,log2_fold_induction,negative,0,Cycloheximide,loss,pathway,pathway-specified,vecad,,0,0,1
1591,1011,Vala_VECAD_TSAMiMm_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,vecad,,0,0,1
1592,1011,Vala_VECAD_TSAMiMm_dn,0,1,,,log2_fold_induction,negative,0,Cycloheximide,loss,pathway,pathway-specified,vecad,,0,0,1
1593,1012,Vala_VECAD_TSA_up,0,1,,,log2_fold_induction,positive,0,,gain,pathway,pathway-specified,vecad,,0,0,1
1594,1012,Vala_VECAD_TSA_dn,0,1,,,log2_fold_induction,negative,0,Cycloheximide,loss,pathway,pathway-specified,vecad,,0,0,1
1595,822,CLD_ABCB1_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,0
1596,823,CLD_ABCB11_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,0
1597,824,CLD_ABCG2_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,0
1598,825,CLD_ACTIN_0hr_negctrl,0,0,,background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,0
1599,826,CLD_CYP1A1_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,0
1600,827,CLD_CYP1A2_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,0
1601,828,CLD_CYP2B6_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,0
1602,829,CLD_CYP2C19_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,0
1603,830,CLD_CYP2C9_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,0
1604,831,CLD_CYP3A4_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,0
1605,832,CLD_GAPDH_0hr_negctrl,0,0,,background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,0
1606,833,CLD_GSTA2_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,alkyl and aryl transferase,0,0,0
1607,834,CLD_HMGCS2_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,lyase,HMG-CoA synthase,0,0,0
1608,835,CLD_SLCO1B1_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,organic anion transporter,0,0,0
1609,836,CLD_SULT2A_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,sulfotransferase,0,0,0
1610,837,CLD_UGT1A1_0hr_negctrl,0,0,,reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,glucuronosyltransferase,0,0,0
1611,838,CLD_ABCB1_6hr,1,1,"Data from the assay component CLD_ABCB1_6hr was analyzed at the endpoint, CLD_ABCB1_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
1612,839,CLD_ABCB11_6hr,1,1,"Data from the assay component CLD_ABCB11_6hr was analyzed at the endpoint, CLD_ABCB11_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB11. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
1613,840,CLD_ABCG2_6hr,1,1,"Data from the assay component CLD_ABCG2_6hr was analyzed at the endpoint, CLD_ABCG2_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCG2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
1614,841,CLD_ACTIN_6hr,1,1,"Data from the assay component CLD_ACTIN_6hr was analyzed at the endpoint, CLD_ACTIN_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ACTA1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.",background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,1
1615,842,CLD_CYP1A1_6hr,1,1,"Data from the assay component CLD_CYP1A1_6hr was analyzed at the endpoint, CLD_CYP1A1_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1616,843,CLD_CYP1A2_6hr,1,1,"Data from the assay component CLD_CYP1A2_6hr was analyzed at the endpoint, CLD_CYP1A2_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1617,844,CLD_CYP2B6_6hr,1,1,"Data from the assay component CLD_CYP2B6_6hr was analyzed at the endpoint, CLD_CYP2B6_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1618,845,CLD_CYP2C19_6hr,1,1,"Data from the assay component CLD_CYP2C19_6hr was analyzed at the endpoint, CLD_CYP2C19_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C19. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1619,846,CLD_CYP2C9_6hr,1,1,"Data from the assay component CLD_CYP2C9_6hr was analyzed at the endpoint, CLD_CYP2C9_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C9. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1620,847,CLD_CYP3A4_6hr,1,1,"Data from the assay component CLD_CYP3A4_6hr was analyzed at the endpoint, CLD_CYP3A4_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1621,848,CLD_GAPDH_6hr,1,1,"Data from the assay component CLD_GAPDH_6hr was analyzed at the endpoint, CLD_GAPDH_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GAPDH. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.",background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,1
1622,849,CLD_GSTA2_6hr,1,1,"Data from the assay component CLD_GSTA2_6hr was analyzed at the endpoint, CLD_GSTA2_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GSTA2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is alkyl and aryl transferase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,alkyl and aryl transferase,0,0,1
1623,850,CLD_HMGCS2_6hr,1,1,"Data from the assay component CLD_HMGCS2_6hr was analyzed at the endpoint, CLD_HMGCS2_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HMGCS2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where subfamily is HMG-CoA synthase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,lyase,HMG-CoA synthase,0,0,1
1624,851,CLD_SLCO1B1_6hr,1,1,"Data from the assay component CLD_SLCO1B1_6hr was analyzed at the endpoint, CLD_SLCO1B1_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SLCO1B1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is organic anion transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,organic anion transporter,0,0,1
1625,852,CLD_SULT2A_6hr,1,1,"Data from the assay component CLD_SULT2A_6hr was analyzed at the endpoint, CLD_SULT2A_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,sulfotransferase,0,0,1
1626,853,CLD_UGT1A1_6hr,1,1,"Data from the assay component CLD_UGT1A1_6hr was analyzed at the endpoint, CLD_UGT1A1_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,glucuronosyltransferase,0,0,1
1627,854,CLD_ABCB1_24hr,1,1,"Data from the assay component CLD_ABCB1_24hr was analyzed at the endpoint, CLD_ABCB1_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
1628,855,CLD_ABCB11_24hr,1,1,"Data from the assay component CLD_ABCB11_24hr was analyzed at the endpoint, CLD_ABCB11_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB11. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
1629,856,CLD_ABCG2_24hr,1,1,"Data from the assay component CLD_ABCG2_24hr was analyzed at the endpoint, CLD_ABCG2_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCG2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
1630,857,CLD_ACTIN_24hr,1,1,"Data from the assay component CLD_ACTIN_24hr was analyzed at the endpoint, CLD_ACTIN_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ACTA1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.",background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,1
1631,858,CLD_CYP1A1_24hr,1,1,"Data from the assay component CLD_CYP1A1_24hr was analyzed at the endpoint, CLD_CYP1A1_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1632,859,CLD_CYP1A2_24hr,1,1,"Data from the assay component CLD_CYP1A2_24hr was analyzed at the endpoint, CLD_CYP1A2_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1633,860,CLD_CYP2B6_24hr,1,1,"Data from the assay component CLD_CYP2B6_24hr was analyzed at the endpoint, CLD_CYP2B6_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1634,861,CLD_CYP2C19_24hr,1,1,"Data from the assay component CLD_CYP2C19_24hr was analyzed at the endpoint, CLD_CYP2C19_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C19. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1635,862,CLD_CYP2C9_24hr,1,1,"Data from the assay component CLD_CYP2C9_24hr was analyzed at the endpoint, CLD_CYP2C9_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C9. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1636,863,CLD_CYP3A4_24hr,1,1,"Data from the assay component CLD_CYP3A4_24hr was analyzed at the endpoint, CLD_CYP3A4_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1637,864,CLD_GAPDH_24hr,1,1,"Data from the assay component CLD_GAPDH_24hr was analyzed at the endpoint, CLD_GAPDH_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GAPDH. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.",background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,1
1638,865,CLD_GSTA2_24hr,1,1,"Data from the assay component CLD_GSTA2_24hr was analyzed at the endpoint, CLD_GSTA2_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GSTA2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is alkyl and aryl transferase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,alkyl and aryl transferase,0,0,1
1639,866,CLD_HMGCS2_24hr,1,1,"Data from the assay component CLD_HMGCS2_24hr was analyzed at the endpoint, CLD_HMGCS2_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HMGCS2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where subfamily is HMG-CoA synthase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,lyase,HMG-CoA synthase,0,0,1
1640,867,CLD_SLCO1B1_24hr,1,1,"Data from the assay component CLD_SLCO1B1_24hr was analyzed at the endpoint, CLD_SLCO1B1_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SLCO1B1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is organic anion transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,organic anion transporter,0,0,1
1641,868,CLD_SULT2A_24hr,1,1,"Data from the assay component CLD_SULT2A_24hr was analyzed at the endpoint, CLD_SULT2A_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,sulfotransferase,0,0,1
1642,869,CLD_UGT1A1_24hr,1,1,"Data from the assay component CLD_UGT1A1_24hr was analyzed at the endpoint, CLD_UGT1A1_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,glucuronosyltransferase,0,0,1
1643,870,CLD_ABCB1_48hr,1,1,"Data from the assay component CLD_ABCB1_48hr was analyzed at the endpoint, CLD_ABCB1_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
1644,871,CLD_ABCB11_48hr,1,1,"Data from the assay component CLD_ABCB11_48hr was analyzed at the endpoint, CLD_ABCB11_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCB11. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
1645,872,CLD_ABCG2_48hr,1,1,"Data from the assay component CLD_ABCG2_48hr was analyzed at the endpoint, CLD_ABCG2_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ABCG2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is ABC transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,ABC transporter,0,0,1
1646,873,CLD_ACTIN_48hr,1,1,"Data from the assay component CLD_ACTIN_48hr was analyzed at the endpoint, CLD_ACTIN_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ACTA1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.",background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,1
1647,874,CLD_CYP1A1_48hr,1,1,"Data from the assay component CLD_CYP1A1_48hr was analyzed at the endpoint, CLD_CYP1A1_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1648,875,CLD_CYP1A2_48hr,1,1,"Data from the assay component CLD_CYP1A2_48hr was analyzed at the endpoint, CLD_CYP1A2_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1649,876,CLD_CYP2B6_48hr,1,1,"Data from the assay component CLD_CYP2B6_48hr was analyzed at the endpoint, CLD_CYP2B6_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1650,877,CLD_CYP2C19_48hr,1,1,"Data from the assay component CLD_CYP2C19_48hr was analyzed at the endpoint, CLD_CYP2C19_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C19. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1651,878,CLD_CYP2C9_48hr,1,1,"Data from the assay component CLD_CYP2C9_48hr was analyzed at the endpoint, CLD_CYP2C9_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C9. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1652,879,CLD_CYP3A4_48hr,1,1,"Data from the assay component CLD_CYP3A4_48hr was analyzed at the endpoint, CLD_CYP3A4_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,cyp,xenobiotic metabolism,0,0,1
1653,880,CLD_GAPDH_48hr,1,1,"Data from the assay component CLD_GAPDH_48hr was analyzed at the endpoint, CLD_GAPDH_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GAPDH. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where subfamily is baseline control.",background control,log2_fold_induction,positive,0,,gain,rna,mRNA,background measurement,baseline control,0,0,1
1654,881,CLD_GSTA2_48hr,1,1,"Data from the assay component CLD_GSTA2_48hr was analyzed at the endpoint, CLD_GSTA2_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GSTA2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is alkyl and aryl transferase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,alkyl and aryl transferase,0,0,1
1655,882,CLD_HMGCS2_48hr,1,1,"Data from the assay component CLD_HMGCS2_48hr was analyzed at the endpoint, CLD_HMGCS2_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HMGCS2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where subfamily is HMG-CoA synthase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,lyase,HMG-CoA synthase,0,0,1
1656,883,CLD_SLCO1B1_48hr,1,1,"Data from the assay component CLD_SLCO1B1_48hr was analyzed at the endpoint, CLD_SLCO1B1_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SLCO1B1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where subfamily is organic anion transporter.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transporter,organic anion transporter,0,0,1
1657,884,CLD_SULT2A_48hr,1,1,"Data from the assay component CLD_SULT2A_48hr was analyzed at the endpoint, CLD_SULT2A_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,sulfotransferase,0,0,1
1658,885,CLD_UGT1A1_48hr,1,1,"Data from the assay component CLD_UGT1A1_48hr was analyzed at the endpoint, CLD_UGT1A1_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.",reporter gene,log2_fold_induction,positive,0,,gain,rna,mRNA,transferase,glucuronosyltransferase,0,0,1
1659,1013,TOX21_RAR_LUC_Agonist,1,1,"Data from the assay component TOX21_RAR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",agonist,percent_activity,positive,0,Retinol,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
1660,1014,TOX21_RAR_LUC_Agonist_viability,1,1,"TOX21_RAR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1661,1015,TOX21_RORg_LUC_CHO_Antagonist,1,1,"Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",antagonist,percent_activity,positive,0,TO-901317,loss,protein,receptor,nuclear receptor,orphan,0,0,1
1662,1016,TOX21_RORg_LUC_CHO_Antagonist_viability,1,1,"TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1663,1017,CEETOX_H295R_MTT_cell_viability_up,1,1,"The assay component endpoint CEETOX_H295R_MTT_cell_viability_up was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter in the MTT cytotoxicity assay, loss-of-signal activity can be used to monitor cellular processes to understand changes in cytotoxicity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
1664,1017,CEETOX_H295R_MTT_cell_viability_dn,1,1,"The assay component endpoint CEETOX_H295R_MTT_cell_viability_dn was analyzed in the negative fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter in the MTT cytotoxicity assay, gain-of-signal activity can be used to monitor cellular processes to understand changes in proliferation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is proliferation.",viability,percent_activity,negative,0,,gain,cellular,cellular,cell cycle,proliferation,0,1,1
1665,1018,Vala_LD2_CellCount_dn,0,1,,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1666,1019,Vala_LD2_PCC_ADFPvlipid_up,0,1,,,log2_fold_induction,positive,0,,loss,pathway,pathway-specified,ld2,,0,0,1
1667,1019,Vala_LD2_PCC_ADFPvlipid_dn,0,1,,,log2_fold_induction,negative,0,,gain,pathway,pathway-specified,ld2,,0,0,1
1668,1020,Vala_LD2_LipidDropletDiam_up,0,1,,,log2_fold_induction,positive,0,,loss,pathway,pathway-specified,ld2,,0,0,1
1669,1020,Vala_LD2_LipidDropletDiam_dn,0,1,,,log2_fold_induction,negative,0,,gain,pathway,pathway-specified,ld2,,0,0,1
1670,1021,Vala_LD2_M2_ADFPvLipid_up,0,1,,,log2_fold_induction,positive,0,,loss,pathway,pathway-specified,ld2,,0,0,1
1671,1021,Vala_LD2_M2_ADFPvLipid_dn,0,1,,,log2_fold_induction,negative,0,,gain,pathway,pathway-specified,ld2,,0,0,1
1672,1022,Vala_LD2_LipidPxlInt_up,0,1,,,log2_fold_induction,positive,0,,loss,pathway,pathway-specified,ld2,,0,0,1
1673,1022,Vala_LD2_LipidPxlInt_dn,0,1,,,log2_fold_induction,negative,0,,gain,pathway,pathway-specified,ld2,,0,0,1
1674,1023,STM_H9_C13Cystine_area_up,0,1,"Data from the STM_H9_C13Cystine_area was analyzed at the assay endpoint STM_H9_C13Cystine_area_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,positive,0,Methotrexate,gain,protein,secretome metabolite,metabolite,Cystine,0,0,1
1675,1023,STM_H9_C13Cystine_area_dn,0,1,"Data from the STM_H9_C13Cystine_area was analyzed at the assay endpoint STM_H9_C13Cystine_area_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,negative,0,Methotrexate,loss,protein,secretome metabolite,metabolite,Cystine,0,0,1
1676,1024,STM_H9_C13Ornithine_area_up,0,1,"Data from the STM_H9_C13Ornithine_area was analyzed at the assay endpoint STM_H9_C13Ornithine_area_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,positive,0,Methotrexate,gain,protein,secretome metabolite,metabolite,Ornithine,0,0,1
1677,1024,STM_H9_C13Ornithine_area_dn,0,1,"Data from the STM_H9_C13Ornithine_area was analyzed at the assay endpoint STM_H9_C13Ornithine_area_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,negative,0,Methotrexate,loss,protein,secretome metabolite,metabolite,Ornithine,0,0,1
1678,1025,STM_H9_Cystine_area_up,0,1,"Data from the STM_H9_Cystine_area was analyzed at the assay endpoint STM_H9_Cystine_area_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,positive,0,Methotrexate,gain,protein,secretome metabolite,metabolite,Cystine,0,0,1
1679,1025,STM_H9_Cystine_area_dn,0,1,"Data from the STM_H9_Cystine_area was analyzed at the assay endpoint STM_H9_Cystine_area_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,negative,0,Methotrexate,loss,protein,secretome metabolite,metabolite,Cystine,0,0,1
1680,1026,STM_H9_CystineISnorm_up,0,1,"Data from the STM_H9_CystineISnorm was analyzed at the assay endpoint STM_H9_CystineISnorm_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,positive,0,Methotrexate,gain,protein,secretome metabolite,metabolite,Cystine,0,0,1
1681,1026,STM_H9_CystineISnorm_dn,0,1,"Data from the STM_H9_CystineISnorm was analyzed at the assay endpoint STM_H9_CystineISnorm_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,negative,0,Methotrexate,loss,protein,secretome metabolite,metabolite,Cystine,0,0,1
1682,1027,STM_H9_CystineISnorm_perc_up,1,1,"Data from the STM_H9_CystineISnorm_perc was analyzed at the assay endpoint STM_H9_CystineISnorm_perc_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,positive,0,Methotrexate,gain,protein,secretome metabolite,metabolite,Cystine,0,0,1
1683,1027,STM_H9_CystineISnorm_perc_dn,1,1,"Data from the STM_H9_CystineISnorm_perc was analyzed at the assay endpoint STM_H9_CystineISnorm_perc_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,negative,0,Methotrexate,loss,protein,secretome metabolite,metabolite,Cystine,0,0,1
1684,1028,STM_H9_Ornithine_area_up,0,1,"Data from the STM_H9_Ornithine_area was analyzed at the assay endpoint STM_H9_Ornithine_area_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,positive,0,Methotrexate,gain,protein,secretome metabolite,metabolite,Ornithine,0,0,1
1685,1028,STM_H9_Ornithine_area_dn,0,1,"Data from the STM_H9_Ornithine_area was analyzed at the assay endpoint STM_H9_Ornithine_area_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,negative,0,Methotrexate,loss,protein,secretome metabolite,metabolite,Ornithine,0,0,1
1686,1029,STM_H9_OrnithineISnorm_up,0,1,"Data from the STM_H9_OrnithineISnorm was analyzed at the assay endpoint STM_H9_OrnithineISnorm_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,positive,0,Methotrexate,gain,protein,secretome metabolite,metabolite,Ornithine,0,0,1
1687,1029,STM_H9_OrnithineISnorm_dn,0,1,"Data from the STM_H9_OrnithineISnorm was analyzed at the assay endpoint STM_H9_OrnithineISnorm_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,negative,0,Methotrexate,loss,protein,secretome metabolite,metabolite,Ornithine,0,0,1
1688,1030,STM_H9_OrnithineISnorm_perc_up,1,1,"Data from the STM_H9_OrnithineISnorm_perc was analyzed at the assay endpoint STM_H9_OrnithineISnorm_perc_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,positive,0,Methotrexate,gain,protein,secretome metabolite,metabolite,Ornithine,0,0,1
1689,1030,STM_H9_OrnithineISnorm_perc_dn,1,1,"Data from the STM_H9_OrnithineISnorm_perc was analyzed at the assay endpoint STM_H9_OrnithineISnorm_perc_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,negative,0,Methotrexate,loss,protein,secretome metabolite,metabolite,Ornithine,0,0,1
1690,1031,STM_H9_OrnCyssISnorm_ratio_up,0,1,"Data from the STM_H9_OrnCyssISnorm_ratio was analyzed at the assay endpoint STM_H9_OrnCyssISnorm_ratio_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,positive,0,Methotrexate,gain,protein,secretome metabolite,metabolite,Ornithine/Cystine,0,0,1
1691,1031,STM_H9_OrnCyssISnorm_ratio_dn,1,1,"Data from the STM_H9_OrnCyssISnorm_ratio was analyzed at the assay endpoint STM_H9_OrnCyssISnorm_ratio_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,negative,0,Methotrexate,loss,protein,secretome metabolite,metabolite,Ornithine/Cystine,0,0,1
1692,1032,STM_H9_OrnCyssISnorm_prediction_up,0,1,"Data from the STM_H9_OrnCyssISnorm_prediction was analyzed at the assay endpoint STM_H9_OrnCyssISnorm_prediction_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,positive,0,Methotrexate,gain,protein,secretome metabolite,metabolite,Ornithine/Cystine,0,0,1
1693,1032,STM_H9_OrnCyssISnorm_prediction_dn,0,1,"Data from the STM_H9_OrnCyssISnorm_prediction was analyzed at the assay endpoint STM_H9_OrnCyssISnorm_prediction_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand relative metabolite change.",relative metabolite change,log2_fold_induction,negative,0,Methotrexate,loss,protein,secretome metabolite,metabolite,Ornithine/Cystine,0,0,1
1742,1033,Vala_LD1_LipidPxlInt_up,0,1,,,log2_fold_induction,positive,0,,loss,pathway,pathway-specified,ld1,,0,0,1
1743,1033,Vala_LD1_LipidPxlInt_dn,0,1,,,log2_fold_induction,negative,0,,gain,pathway,pathway-specified,ld1,,0,0,1
1744,1034,NVS_ENZ_hPPP3CA,1,1,"Data from the assay component NVS_ENZ_hPPP3CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP3CA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP3CA.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"".",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,phosphatase,serine/threonine phosphatase,0,0,1
1745,1035,ATG_GPCR_ADORA2A_TRANS_dn,1,1,ATG_GPCR_ADORA2A_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1746,1035,ATG_GPCR_ADORA2A_TRANS_up,1,1,"The assay endpoint ATG_GPCR_ADORA2A_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADORA2A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1747,1036,ATG_GPCR_ADORA2B_TRANS_dn,1,1,ATG_GPCR_ADORA2B_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1748,1036,ATG_GPCR_ADORA2B_TRANS_up,1,1,"The assay endpoint ATG_GPCR_ADORA2B_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADORA2B. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1749,1037,ATG_GPCR_ADRA1A_TRANS_dn,1,1,ATG_GPCR_ADRA1A_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1750,1037,ATG_GPCR_ADRA1A_TRANS_up,1,1,"The assay endpoint ATG_GPCR_ADRA1A_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRA1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1751,1038,ATG_GPCR_ADRA2B_TRANS_dn,1,1,ATG_GPCR_ADRA2B_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1752,1038,ATG_GPCR_ADRA2B_TRANS_up,1,1,"The assay endpoint ATG_GPCR_ADRA2B_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRA2B. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1753,1039,ATG_GPCR_ADRB2_TRANS_dn,1,1,ATG_GPCR_ADRB2_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1754,1039,ATG_GPCR_ADRB2_TRANS_up,1,1,"The assay endpoint ATG_GPCR_ADRB2_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRB2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1755,1040,ATG_GPCR_ADRB3_TRANS_dn,1,1,ATG_GPCR_ADRB3_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1756,1040,ATG_GPCR_ADRB3_TRANS_up,1,1,"The assay endpoint ATG_GPCR_ADRB3_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRB3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1757,1041,ATG_GPCR_CHRM3_TRANS_dn,1,1,ATG_GPCR_CHRM3_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1758,1041,ATG_GPCR_CHRM3_TRANS_up,1,1,"The assay endpoint ATG_GPCR_CHRM3_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CHRM3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1759,1042,ATG_GPCR_DRD1_TRANS_dn,1,1,ATG_GPCR_DRD1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1760,1042,ATG_GPCR_DRD1_TRANS_up,1,1,"The assay endpoint ATG_GPCR_DRD1_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene DRD1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1761,1043,ATG_GPCR_DRD5_TRANS_dn,1,1,ATG_GPCR_DRD5_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1762,1043,ATG_GPCR_DRD5_TRANS_up,1,1,"The assay endpoint ATG_GPCR_DRD5_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene DRD5. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1763,1044,ATG_GPCR_EDNRA_TRANS_dn,1,1,ATG_GPCR_EDNRA_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1764,1044,ATG_GPCR_EDNRA_TRANS_up,1,1,"The assay endpoint ATG_GPCR_EDNRA_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EDNRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1765,1045,ATG_GPCR_GCGR_TRANS_dn,1,1,ATG_GPCR_GCGR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1766,1045,ATG_GPCR_GCGR_TRANS_up,1,1,"The assay endpoint ATG_GPCR_GCGR_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GCGR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1767,1046,ATG_GPCR_GPBAR1_TRANS_dn,1,1,ATG_GPCR_GPBAR1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1768,1046,ATG_GPCR_GPBAR1_TRANS_up,1,1,"The assay endpoint ATG_GPCR_GPBAR1_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GPBAR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1769,1047,ATG_GPCR_GPR40_TRANS_dn,1,1,ATG_GPCR_GPR40_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1770,1047,ATG_GPCR_GPR40_TRANS_up,1,1,"The assay endpoint ATG_GPCR_GPR40_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GPR40. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1771,1048,ATG_GPCR_GQ_TRANS_dn,1,1,ATG_GPCR_GQ_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1772,1048,ATG_GPCR_GQ_TRANS_up,1,1,"The assay endpoint ATG_GPCR_GQ_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GNAQ. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1773,1049,ATG_GPCR_GS1_TRANS_dn,1,1,ATG_GPCR_GS1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1774,1049,ATG_GPCR_GS1_TRANS_up,1,1,"The assay endpoint ATG_GPCR_GS1_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GNAS. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1775,1050,ATG_GPCR_GS_TRANS_dn,1,1,ATG_GPCR_GS_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1776,1050,ATG_GPCR_GS_TRANS_up,1,1,"The assay endpoint ATG_GPCR_GS_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GNAS. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1777,1051,ATG_GPCR_HRH1_TRANS_dn,1,1,ATG_GPCR_HRH1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1778,1051,ATG_GPCR_HRH1_TRANS_up,1,1,"The assay endpoint ATG_GPCR_HRH1_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HRH1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1779,1052,ATG_GPCR_HTR6_TRANS_dn,1,1,ATG_GPCR_HTR6_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1780,1052,ATG_GPCR_HTR6_TRANS_up,1,1,"The assay endpoint ATG_GPCR_HTR6_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HTR6. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1781,1053,ATG_GPCR_HTR7_TRANS_dn,1,1,ATG_GPCR_HTR7_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1782,1053,ATG_GPCR_HTR7_TRANS_up,1,1,"The assay endpoint ATG_GPCR_HTR7_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HTR7. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1783,1054,ATG_GPCR_LPAR4_TRANS_dn,1,1,ATG_GPCR_LPAR4_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1784,1054,ATG_GPCR_LPAR4_TRANS_up,1,1,"The assay endpoint ATG_GPCR_LPAR4_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene LPAR4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1785,1055,ATG_GPCR_MC1R_TRANS_dn,1,1,ATG_GPCR_MC1R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1786,1055,ATG_GPCR_MC1R_TRANS_up,1,1,"The assay endpoint ATG_GPCR_MC1R_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC1R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1787,1056,ATG_GPCR_MC2R_TRANS_dn,1,1,ATG_GPCR_MC2R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1788,1056,ATG_GPCR_MC2R_TRANS_up,1,1,"The assay endpoint ATG_GPCR_MC2R_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC2R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1789,1057,ATG_GPCR_MC3R_TRANS_dn,1,1,ATG_GPCR_MC3R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1790,1057,ATG_GPCR_MC3R_TRANS_up,1,1,"The assay endpoint ATG_GPCR_MC3R_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC3R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1791,1058,ATG_GPCR_MC4R_TRANS_dn,1,1,ATG_GPCR_MC4R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1792,1058,ATG_GPCR_MC4R_TRANS_up,1,1,"The assay endpoint ATG_GPCR_MC4R_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC4R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1793,1059,ATG_GPCR_PTGDR_TRANS_dn,1,1,ATG_GPCR_PTGDR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1794,1059,ATG_GPCR_PTGDR_TRANS_up,1,1,"The assay endpoint ATG_GPCR_PTGDR_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PTGDR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1795,1060,ATG_GPCR_PTGIR_TRANS_dn,1,1,ATG_GPCR_PTGIR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
1796,1060,ATG_GPCR_PTGIR_TRANS_up,1,1,"The assay endpoint ATG_GPCR_PTGIR_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PTGIR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
1797,1061,Tanguay_ZF_120hpf_ActivityScore,1,1,"Data from the assay component Tanguay_ZF_120hpf_ActivityScore was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_ActivityScore, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",NA,percent_activity,NA,0,NA,NA,organism,malformation,malformation,total,0,0,1
1798,1062,BRL_CHO_micronucleus_freq_up,0,0,,,log2_fold_induction,positive,0,mitomycin C,gain,dna,micronuclei,dna damage,clastogenicity,0,0,1
1799,1063,BRL_CHO_hypodiploid_freq_up,0,0,,,log2_fold_induction,positive,0,cyclophosphamide,gain,dna,whole chromosome,dna damage,aneugenicity,0,0,1
1800,1064,BRL_CHO_relative_survival_dn,0,0,,viability,percent_activity,negative,0,,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1801,1065,BRL_CHO_S9_micronucleus_freq_up,0,0,,,log2_fold_induction,positive,0,mitomycin C,gain,dna,micronuclei,dna damage,clastogenicity,0,0,1
1802,1066,BRL_CHO_S9_hypodiploid_freq_up,0,0,,,log2_fold_induction,positive,0,cyclophosphamide,gain,dna,whole chromosome,dna damage,aneugenicity,0,0,1
1803,1067,BRL_CHO_S9_relative_survival_dn,0,0,,viability,percent_activity,negative,0,,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1804,1112,Vala_LD1_M2_ADFPvLipid_md_up,0,1,,,log2_fold_induction,positive,0,Oleic Acid,gain,pathway,pathway-specified,ld1,,0,0,1
1805,1112,Vala_LD1_M2_ADFPvLipid_md_dn,0,1,,,log2_fold_induction,negative,0,Triacsin C,loss,pathway,pathway-specified,ld1,,0,0,1
1806,1115,CCTE_Hunter_MHC_CellCount_dn,0,1,viability reporter assay using In-Cell Western assay with Infrared Imaging System to monitor cellular process in J1 embryonic stem cells cell line: AEID1806,viability,log2_fold_induction,negative,0,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1807,1115,CCTE_Hunter_MHC_CellCount_up,0,1,viability reporter assay using In-Cell Western assay with Infrared Imaging System to monitor cellular process in J1 embryonic stem cells cell line: AEID1807,viability,log2_fold_induction,positive,0,,gain,cellular,cellular,cell cycle,proliferation,0,0,1
1808,1116,CCTE_Hunter_MHC_MHCvCellCount_dn,0,1,morphology reporter assay using In-Cell Western assay with Infrared Imaging System to monitor differentiation event in J1 embryonic stem cells cell line: AEID1808,signaling,log2_fold_induction,negative,0,,loss,biosystem,differentiation event,cell morphology,cell differentiation,0,0,1
1809,1116,CCTE_Hunter_MHC_MHCvCellCount_up,0,1,morphology reporter assay using In-Cell Western assay with Infrared Imaging System to monitor differentiation event in J1 embryonic stem cells cell line: AEID1809,signaling,log2_fold_induction,positive,0,,gain,biosystem,differentiation event,cell morphology,cell differentiation,0,0,1
1810,1117,CCTE_Hunter_GSC_CellCount_dn,0,1,NULL,viability,log2_fold_induction,negative,1,,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1811,1117,CCTE_Hunter_GSC_CellCount_up,0,1,NULL,viability,log2_fold_induction,positive,0,,gain,cellular,cellular,cell cycle,proliferation,0,0,1
1812,1118,CCTE_Hunter_GSC_GSCvCellCount_dn,0,1,NULL,signaling,log2_fold_induction,negative,0,,loss,biosystem,differentiation event,cell morphology,cell differentiation,0,0,1
1813,1118,CCTE_Hunter_GSC_GSCvCellCount_up,0,1,NULL,signaling,log2_fold_induction,positive,0,,gain,biosystem,differentiation event,cell morphology,cell differentiation,0,0,1
1866,1808,OTVALA_ER_ERaERa_1440_CorCoef_dn,0,0,,binding,percent_activity,negative,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1867,1809,OTVALA_ER_ERbERb_0480_CellCount_up,0,0,,binding,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1868,1809,OTVALA_ER_ERbERb_0480_CellCount_dn,0,0,,binding,percent_activity,negative,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1850,1802,ACEA_AR_agonist_AUC_viability,1,1,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,percent_activity,negative,1,MG 132,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1816,1120,TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,1,1,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",antagonist,percent_activity,positive,0,Nilutamide,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
1817,1121,TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability,1,1,"TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1818,1122,TOX21_RXR_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_RXR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,9-cis-Retinoic acid,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1819,1123,TOX21_RXR_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_RXR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,9-cis-Retinoic acid,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1820,1124,TOX21_RXR_BLA_Agonist_ratio,1,1,"Data from the assay component TOX21_RXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where subfamily is NF-kappa B.",ratio,percent_activity,positive,0,9-cis-Retinoic acid,gain,pathway,pathway-specified,dna binding,NF-kappa B,0,0,1
1821,1125,TOX21_RXR_BLA_Agonist_viability,1,1,"TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,Cyproterone acetate,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1822,1126,TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide,1,1,"Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of backgound reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",background control,percent_activity,positive,0,R1881,gain,protein,receptor,nuclear receptor,steroidal,0,0,1
1823,1127,TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability,1,1,"TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1824,1128,CCTE_Simmons_GUA_TPO_dn,1,1,"Data from the assay component CCTE_Simmons_GUA_TPO was analyzed at the endpoint, CCTE_Simmons_GUA_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, measures of enzyme activity for loss-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene TPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",binding,percent_activity,positive,0,,loss,protein,enzyme,oxidoreductase,peroxidase,0,0,1
1825,1129,ArunA_hNP_CT_dn,0,0,,,log2_fold_induction,,0,,,,,,,0,0,1
1826,1130,ArunA_hNC_CT_dn,0,0,,viability,log2_fold_induction,,0,,,,,,,0,0,1
1827,1131,ArunA_hNP_MG_dn,0,0,,,log2_fold_induction,negative,0,,,,,,,0,0,1
1829,1132,ArunA_hNC_MG_dn,0,0,,,log2_fold_induction,negative,0,,,,,,,0,0,1
1831,1133,ArunA_hNN_NC_dn,0,0,,,log2_fold_induction,negative,0,,,,,,,0,0,1
1833,1134,ArunA_hNN_NL_dn,0,0,,,log2_fold_induction,negative,0,,,,,,,0,0,1
1835,1135,ArunA_hNN_NN_dn,0,0,,,log2_fold_induction,negative,0,,,,,,,0,0,1
1837,1136,ArunA_hNN_BN_dn,0,0,,,log2_fold_induction,negative,0,,,,,,,0,0,1
1839,1137,TOX21_RAR_LUC_Antagonist,1,1,"Data from the assay component TOX21_RAR_LUC_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.",antagonist,percent_activity,positive,0,ER50891,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
1840,1138,TOX21_RAR_LUC_Antagonist_viability,1,1,"TOX21_RAR_LUC_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
3023,2809,VALA_TUBIPS1_CellCount_dn,0,0,,,log2_fold_induction,,0,,,,,,,0,0,1
3022,2808,VALA_TUBHUV2_TubuleLength_dn,0,0,,,percent_activity,,0,,,,,,,0,0,1
3021,2807,VALA_TUBHUV2_CellCount_dn,0,0,,,log2_fold_induction,,0,,,,,,,0,0,1
3020,2806,VALA_TUBHUV1_TubuleLength_up,0,0,,,percent_activity,,0,,,,,,,0,0,1
3019,2805,VALA_TUBHUV1_CellCount_dn,0,0,,,log2_fold_induction,,0,,,,,,,0,0,1
1838,1136,ArunA_hNN_BN_up,0,0,,,log2_fold_induction,positive,0,,,,,,,0,0,1
1841,1139,TOX21_H2AX_HTRF_CHO_Agonist_ch1,1,1,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Etoposide,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1842,1140,TOX21_H2AX_HTRF_CHO_Agonist_ch2,1,1,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Etoposide,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1843,1141,TOX21_H2AX_HTRF_CHO_Agonist_ratio,1,1,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.",ratio,percent_activity,positive,0,Etoposide,gain,pathway,pathway-specified,dna binding,histone H2A,0,0,1
1844,1142,TOX21_AP1_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,EGF,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
1845,1143,TOX21_AP1_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,EGF,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
1846,1144,TOX21_AP1_BLA_Agonist_ratio,1,1,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",ratio,percent_activity,positive,0,EGF,gain,protein,transcription factor,dna binding,basic leucine zipper,0,0,1
1847,1145,TOX21_AP1_BLA_Agonist_viability,1,1,"TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1848,1146,CCTE_Simmons_QuantiLum_inhib_2_dn,1,1,"Data from the assay component CCTE_Simmons_QuantiLum_inhib_2 was analyzed at the endpoint, CCTE_Simmons_QuantiLum_inhib_2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, measures of enzyme activity for loss-of-signal activity can be used to understand inhibition of firefly luciferase. This is an assay endpoint to indicate nonspecific protein inhibition for comparison to aeid 1508 for thyroperoxidase inhibition. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is monooxygenase.",binding,percent_activity,positive,0,b-naphthoquinone,loss,protein,enzyme,oxidoreductase,monooxygenase,0,0,1
1852,1804,ACEA_ER_AUC_viability,1,1,"Data from the assay component ACEA_ER_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,percent_activity,negative,1,MG 132,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1857,1831,ACEA_AR_antagonist_AUC_viability,1,1,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",viability,percent_activity,negative,1,MG 132,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1858,1114,STM_H9_Viability_norm,1,1,"Data from the STM_H9_Viability was analyzed at the assay endpoint STM_H9_Viability_Norm in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability.",viability,percent activity,positive,0,NA,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
1859,1805,OTVALA_ER_ERaERa_0480_CellCount_up,0,0,,binding,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1860,1805,OTVALA_ER_ERaERa_0480_CellCount_dn,0,0,,binding,percent_activity,negative,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1861,1806,OTVALA_ER_ERaERa_0480_CorCoef_up,0,0,,binding,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1862,1806,OTVALA_ER_ERaERa_0480_CorCoef_dn,0,0,,binding,percent_activity,negative,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1863,1807,OTVALA_ER_ERaERa_1440_CellCount_up,0,0,,binding,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1864,1807,OTVALA_ER_ERaERa_1440_CellCount_dn,0,0,,binding,percent_activity,negative,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1865,1808,OTVALA_ER_ERaERa_1440_CorCoef_up,0,0,,binding,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1854,534,TOX21_MMP_ratio_up,1,1,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. The assay endpoin, TOX21_MMP_ratio_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",signaling,percent_activity,negative,0,FCCP,gain,cellular,mitochondria,cell morphology,organelle conformation,0,0,1
1855,1829,ACEA_AR_agonist_80hr,1,1,"Data from the assay component ACEA_AR_agonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the geneAR 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",signaling,percent_activity,positive,0,testosterone,gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
1856,1830,ACEA_AR_antagonist_80hr,1,1,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",signaling,log2_fold_induction,positive,0,NA,loss,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
1878,1814,OTVALA_AR_ARSRC1_0960_CorCoef_dn,0,0,,binding,percent_activity,negative,0,"4,5-alpha-Dihydrotestosterone",,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1879,1815,OTVALA_AR_ARSRC1_0480_CellCount_up,0,0,,binding,percent_activity,positive,0,"4,5-alpha-Dihydrotestosterone",,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1880,1815,OTVALA_AR_ARSRC1_0480_CellCount_dn,0,0,,binding,percent_activity,negative,0,"4,5-alpha-Dihydrotestosterone",,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1881,1816,OTVALA_AR_ARSRC1_0480_CorCoef_up,0,0,,binding,percent_activity,positive,0,"4,5-alpha-Dihydrotestosterone",,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1882,1816,OTVALA_AR_ARSRC1_0480_CorCoef_dn,0,0,,binding,percent_activity,negative,0,"4,5-alpha-Dihydrotestosterone",,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1883,1817,OTVALA_ERa_GFPERaERE_0060_CellCount_up,0,0,,reporter gene,percent_activity,positive,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1884,1817,OTVALA_ERa_GFPERaERE_0060_CellCount_dn,0,0,,reporter gene,percent_activity,negative,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1885,1818,OTVALA_ERa_GFPERaERE_0060_DotArea_up,0,0,,reporter gene,percent_activity,positive,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1886,1818,OTVALA_ERa_GFPERaERE_0060_DotArea_dn,0,0,,reporter gene,percent_activity,negative,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1887,1819,OTVALA_ERa_GFPERaERE_0060_DotApi_up,0,0,,reporter gene,percent_activity,positive,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1888,1819,OTVALA_ERa_GFPERaERE_0060_DotApi_dn,0,0,,reporter gene,percent_activity,negative,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1889,1820,OTVALA_ERa_GFPERaERE_0480_CellCount_up,0,0,,reporter gene,percent_activity,positive,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1890,1820,OTVALA_ERa_GFPERaERE_0480_CellCount_dn,0,0,,reporter gene,percent_activity,negative,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1891,1821,OTVALA_ERa_GFPERaERE_0480_DotArea_up,0,0,,reporter gene,percent_activity,positive,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1892,1821,OTVALA_ERa_GFPERaERE_0480_DotArea_dn,0,0,,reporter gene,percent_activity,negative,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1893,1822,OTVALA_ERa_GFPERaERE_0480_DotApi_up,0,0,,reporter gene,percent_activity,positive,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1894,1822,OTVALA_ERa_GFPERaERE_0480_DotApi_dn,0,0,,reporter gene,percent_activity,negative,0,,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1895,1823,OTVALA_AR_GFPhyperspec_0360_CellCount_up,0,0,,reporter gene,percent_activity,positive,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1896,1823,OTVALA_AR_GFPhyperspec_0360_CellCount_dn,0,0,,reporter gene,percent_activity,negative,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1897,1824,OTVALA_AR_GFPhyperspec_0360_ARTransloc_up,0,0,,reporter gene,percent_activity,positive,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1898,1824,OTVALA_AR_GFPhyperspec_0360_ARTransloc_dn,0,0,,reporter gene,percent_activity,negative,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1899,1825,OTVALA_AR_GFPhyperspec_0360_Hyperspec_up,0,0,,reporter gene,percent_activity,positive,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1900,1825,OTVALA_AR_GFPhyperspec_0360_Hyperspec_dn,0,0,,reporter gene,percent_activity,negative,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1901,1826,OTVALA_AR_GFPhyperspec_1080_CellCount_up,0,0,,reporter gene,percent_activity,positive,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1902,1826,OTVALA_AR_GFPhyperspec_1080_CellCount_dn,0,0,,reporter gene,percent_activity,negative,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1903,1827,OTVALA_AR_GFPhyperspec_1080_ARTransloc_up,0,0,,reporter gene,percent_activity,positive,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1904,1827,OTVALA_AR_GFPhyperspec_1080_ARTransloc_dn,0,0,,reporter gene,percent_activity,negative,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1905,1828,OTVALA_AR_GFPhyperspec_1080_Hyperspec_up,0,0,,reporter gene,percent_activity,positive,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1906,1828,OTVALA_AR_GFPhyperspec_1080_Hyperspec_dn,0,0,,reporter gene,percent_activity,negative,0,Casodex,,protein,transcription factor,nuclear receptor,steroidal,0,0,0
1907,1832,ACEA_SERM_Agonist_ECC-1_72hr,0,0,,signaling,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1908,1833,ACEA_SERM_Agonist_Ishikawa_72hr,0,0,,signaling,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1909,1834,ACEA_SERM_Agonist_LNCaP_72hr,0,0,,signaling,percent_activity,positive,0,17b-Estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1910,1835,ACEA_SERM_Antagonist_ECC-1_72hr,0,0,,signaling,percent_activity,negative,0,40 pM 17b-estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1911,1836,ACEA_SERM_Antagonist_Ishikawa_72hr,0,0,,signaling,percent_activity,negative,0,100 pM 17b-estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1912,1837,ACEA_SERM_Antagonist_LNCaP_72hr,0,0,,signaling,percent_activity,negative,0,10 nM 17b-estradiol,,pathway,pathway-specified,nuclear receptor,steroidal,0,0,0
1913,1856,ATG_chAR_XSP1_up,1,1,"The assay endpoint ATG_chAR_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1914,1856,ATG_chAR_XSP1_dn,1,1,"The assay endpoint ATG_chAR_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1915,1857,ATG_frAR_XSP1_up,1,1,"The assay endpoint ATG_frAR_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1916,1857,ATG_frAR_XSP1_dn,1,1,"The assay endpoint ATG_frAR_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1917,1858,ATG_hAR_XSP1_up,1,1,"The assay endpoint ATG_hAR_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1918,1858,ATG_hAR_XSP1_dn,1,1,"The assay endpoint ATG_hAR_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1919,1859,ATG_trAR_XSP1_up,1,1,"The assay endpoint ATG_trAR_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1920,1859,ATG_trAR_XSP1_dn,1,1,"The assay endpoint ATG_trAR_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1921,1860,ATG_zfAR_XSP1_up,1,1,"The assay endpoint ATG_zfAR_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1922,1860,ATG_zfAR_XSP1_dn,1,1,"The assay endpoint ATG_zfAR_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1923,1861,ATG_frER1_XSP1_up,1,1,"The assay endpoint ATG_frER1_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1924,1861,ATG_frER1_XSP1_dn,1,1,"The assay endpoint ATG_frER1_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1925,1862,ATG_zfER1_XSP1_up,1,1,"The assay endpoint ATG_zfER1_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1926,1862,ATG_zfER1_XSP1_dn,1,1,"The assay endpoint ATG_zfER1_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1927,1863,ATG_zfER2a_XSP1_up,1,1,"The assay endpoint ATG_zfER2a_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1928,1863,ATG_zfER2a_XSP1_dn,1,1,"The assay endpoint ATG_zfER2a_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1929,1864,ATG_zfER2b_XSP1_up,1,1,"The assay endpoint ATG_zfER2b_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1930,1864,ATG_zfER2b_XSP1_dn,1,1,"The assay endpoint ATG_zfER2b_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1931,1865,ATG_frER2_XSP1_up,1,1,"The assay endpoint ATG_frER2_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1932,1865,ATG_frER2_XSP1_dn,1,1,"The assay endpoint ATG_frER2_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1933,1866,ATG_chERa_XSP1_up,1,1,"The assay endpoint ATG_chERa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1934,1866,ATG_chERa_XSP1_dn,1,1,"The assay endpoint ATG_chERa_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1935,1867,ATG_hERa_XSP1_up,1,1,"The assay endpoint ATG_hERa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1936,1867,ATG_hERa_XSP1_dn,1,1,"ATG_hERa_XSP1_dnThe assay endpoint ATG_hERa_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1937,1868,ATG_trERa_XSP1_up,1,1,"The assay endpoint ATG_trERa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1938,1868,ATG_trERa_XSP1_dn,1,1,"The assay endpoint ATG_trERa_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1939,1869,ATG_hERb_XSP1_up,1,1,"The assay endpoint ATG_hERb_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1940,1869,ATG_hERb_XSP1_dn,1,1,"The assay endpoint ATG_hERb_XSP1_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1941,1870,ATG_GAL4_XSP1_up,1,1,"This assay endpoint, ATG_GAL4_XSP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is baseline control.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,baseline control,0,0,1
1942,1870,ATG_GAL4_XSP1_dn,1,1,ATG_GAL4_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,baseline control,0,0,1
1943,1871,ATG_M_06_XSP1_up,1,1,"This assay endpoint, ATG_M_06_XSP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
1944,1871,ATG_M_06_XSP1_dn,1,1,ATG_M_06_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1945,1872,ATG_M_19_XSP1_up,1,1,"This assay endpoint, ATG_M_19_XSP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
1946,1872,ATG_M_19_XSP1_dn,1,1,ATG_M_19_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1947,1873,ATG_M_32_XSP1_up,1,1,"This assay endpoint, ATG_M_32_XSP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
1948,1873,ATG_M_32_XSP1_dn,1,1,ATG_M_32_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1949,1874,ATG_M_61_XSP1_up,1,1,"This assay endpoint, ATG_M_61_XSP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
1950,1874,ATG_M_61_XSP1_dn,1,1,ATG_M_61_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1951,1875,ATG_hPPARg_XSP1_up,1,1,"The assay endpoint ATG_hPPARg_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1952,1875,ATG_hPPARg_XSP1_dn,1,1,ATG_hPPARg_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1953,1876,ATG_mPPARg_XSP1_up,1,1,"The assay endpoint ATG_mPPARg_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1954,1876,ATG_mPPARg_XSP1_dn,1,1,ATG_mPPARg_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1955,1877,ATG_zfPPARg_XSP1_up,1,1,"The assay endpoint ATG_zfPPARg_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1956,1877,ATG_zfPPARg_XSP1_dn,1,1,ATG_zfPPARg_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1957,1878,ATG_mPXR_XSP1_up,1,1,"The assay endpoint ATG_mPXR_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PXR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1958,1878,ATG_mPXR_XSP1_dn,1,1,ATG_mPXR_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1959,1879,ATG_frTRa_XSP1_up,1,1,"The assay endpoint ATG_frTRa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1960,1879,ATG_frTRa_XSP1_dn,1,1,ATG_frTRa_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1961,1880,ATG_hTRa_XSP1_up,1,1,"The assay endpoint ATG_hTRa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1962,1880,ATG_hTRa_XSP1_dn,1,1,ATG_hTRa_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1963,1881,ATG_trTRa_XSP1_up,1,1,"The assay endpoint ATG_trTRa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1964,1881,ATG_trTRa_XSP1_dn,1,1,ATG_trTRa_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1965,1882,ATG_zfTRa_XSP1_up,1,1,"The assay endpoint ATG_zfTRa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1966,1882,ATG_zfTRa_XSP1_dn,1,1,ATG_zfTRa_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1967,1883,ATG_hTRb_XSP1_up,1,1,"The assay endpoint ATG_hTRb_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1968,1883,ATG_hTRb_XSP1_dn,1,1,ATG_hTRb_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1969,1884,ATG_zfTRb_XSP1_up,1,1,"The assay endpoint ATG_zfTRb_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1970,1884,ATG_zfTRb_XSP1_dn,1,1,ATG_zfTRb_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
1971,1885,ATG_XTT_Cytotoxicity_XSP1_up,1,1,"This assay endpoint, ATG_XTT_Cytotoxicity_XSP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,NA,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
1972,1885,ATG_XTT_Cytotoxicity_XSP1_dn,0,0,ATG_XTT_Cytotoxicity_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,viability,percent_activity,negative,0,NA,loss,cellular,cellular,cell cycle,proliferation,0,0,0
1973,1886,ATG_M_06_XSP2_up,1,1,"This assay endpoint, ATG_M_06_XSP2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
1974,1886,ATG_M_06_XSP2_dn,1,1,ATG_M_06_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
1975,1887,ATG_trERa_XSP2_up,1,1,"The assay endpoint ATG_trERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1976,1887,ATG_trERa_XSP2_dn,1,1,ATG_trERa_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1977,1888,ATG_hERb_XSP2_up,1,1,"The assay endpoint ATG_hERb_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1978,1888,ATG_hERb_XSP2_dn,1,1,"The assay endpoint ATG_hERb_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1979,1889,ATG_trAR_XSP2_up,1,1,"The assay endpoint ATG_trAR_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1980,1889,ATG_trAR_XSP2_dn,1,1,"The assay endpoint ATG_trAR_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1981,1890,ATG_GAL4_XSP2_up,1,1,"This assay endpoint, ATG_GAL4_XSP2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is baseline control.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,baseline control,0,0,1
1982,1890,ATG_GAL4_XSP2_dn,1,1,ATG_GAL4_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,baseline control,0,0,1
1983,1891,ATG_zfER1_XSP2_up,1,1,"The assay endpoint ATG_zfER1_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1984,1891,ATG_zfER1_XSP2_dn,1,1,"The assay endpoint ATG_zfER1_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1985,1892,ATG_chERa_XSP2_up,1,1,"The assay endpoint ATG_chERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1986,1892,ATG_chERa_XSP2_dn,1,1,"The assay endpoint ATG_chERa_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1987,1893,ATG_zfER2a_XSP2_up,1,1,"The assay endpoint ATG_zfER2a_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1988,1893,ATG_zfER2a_XSP2_dn,1,1,"The assay endpoint ATG_zfER2a_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1989,1894,ATG_hAR_XSP2_up,1,1,"The assay endpoint ATG_hAR_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1990,1894,ATG_hAR_XSP2_dn,1,1,"The assay endpoint ATG_hAR_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1991,1895,ATG_chAR_XSP2_up,1,1,"The assay endpoint ATG_chAR_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1992,1895,ATG_chAR_XSP2_dn,1,1,"The assay endpoint ATG_chAR_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1993,1896,ATG_frER1_XSP2_up,1,1,"The assay endpoint ATG_frER1_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1994,1896,ATG_frER1_XSP2_dn,1,1,"The assay endpoint ATG_frER1_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1995,1897,ATG_frAR_XSP2_up,1,1,"The assay endpoint ATG_frAR_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1996,1897,ATG_frAR_XSP2_dn,1,1,"The assay endpoint ATG_frAR_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1997,1898,ATG_zfAR_XSP2_up,1,1,"The assay endpoint ATG_zfAR_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1998,1898,ATG_zfAR_XSP2_dn,1,1,"The assay endpoint ATG_zfAR_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
1999,1899,ATG_zfER2b_XSP2_up,1,1,"The assay endpoint ATG_zfER2b_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2000,1899,ATG_zfER2b_XSP2_dn,1,1,"The assay endpoint ATG_zfER2b_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2001,1900,ATG_hERa_XSP2_up,1,1,"The assay endpoint ATG_hERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2002,1900,ATG_hERa_XSP2_dn,1,1,"The assay endpoint ATG_hERa_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2003,1901,ATG_M_19_XSP2_up,1,1,"This assay endpoint, ATG_M_19_XSP2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
2004,1901,ATG_M_19_XSP2_dn,1,1,ATG_M_19_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
2005,1902,ATG_M_32_XSP2_up,1,1,"This assay endpoint, ATG_M_32_XSP2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
2006,1902,ATG_M_32_XSP2_dn,1,1,ATG_M_32_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
2007,1903,ATG_frER2_XSP2_up,1,1,"The assay endpoint ATG_frER2_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2008,1903,ATG_frER2_XSP2_dn,1,1,"The assay endpoint ATG_frER2_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2009,1904,ATG_mPPARg_XSP2_up,1,1,"The assay endpoint ATG_mPPARg_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2010,1904,ATG_mPPARg_XSP2_dn,1,1,ATG_mPPARg_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2011,1905,ATG_zfPPARg_XSP2_up,1,1,"The assay endpoint ATG_zfPPARg_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2012,1905,ATG_zfPPARg_XSP2_dn,1,1,ATG_zfPPARg_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2013,1906,ATG_hPPARg_XSP2_up,1,1,"The assay endpoint ATG_hPPARg_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2014,1906,ATG_hPPARg_XSP2_dn,1,1,ATG_hPPARg_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2015,1907,ATG_mPXR_XSP2_up,1,1,"The assay endpoint ATG_mPXR_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PXR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2016,1907,ATG_mPXR_XSP2_dn,1,1,ATG_mPXR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2017,1908,ATG_trTRa_XSP2_up,1,1,"The assay endpoint ATG_trTRa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2018,1908,ATG_trTRa_XSP2_dn,1,1,ATG_trTRa_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2019,1909,ATG_zfTRa_XSP2_up,1,1,"The assay endpoint ATG_zfTRa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2020,1909,ATG_zfTRa_XSP2_dn,1,1,ATG_zfTRa_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2021,1910,ATG_zfTRb_XSP2_up,1,1,"The assay endpoint ATG_zfTRb_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2022,1910,ATG_zfTRb_XSP2_dn,1,1,ATG_zfTRb_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2023,1911,ATG_M_61_XSP2_up,1,1,"This assay endpoint, ATG_M_61_XSP2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
2024,1911,ATG_M_61_XSP2_dn,1,1,ATG_M_61_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
2025,1912,ATG_frTRa_XSP2_up,1,1,"The assay endpoint ATG_frTRa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2026,1912,ATG_frTRa_XSP2_dn,1,1,ATG_frTRa_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2027,1913,ATG_hTRa_XSP2_up,1,1,"The assay endpoint ATG_hTRa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2028,1913,ATG_hTRa_XSP2_dn,1,1,ATG_hTRa_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2029,1914,ATG_hTRb_XSP2_up,1,1,"The assay endpoint ATG_hTRb_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2030,1914,ATG_hTRb_XSP2_dn,1,1,ATG_hTRb_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,nuclear receptor,non-steroidal,0,0,1
2031,1915,ATG_XTT_Cytotoxicity_XSP2_up,1,1,"Data from the assay component ATG_XTT_Cytotoxicity_XSP2 was analyzed into 1 assay endpoint. This assay endpoint, ATG_XTT_Cytotoxicity_XSP2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,log2_fold_induction,positive,0,NA,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
2032,1915,ATG_XTT_Cytotoxicity_XSP2_dn,0,0,ATG_XTT_Cytotoxicity_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,viability,log2_fold_induction,negative,0,NA,gain,cellular,cellular,cell cycle,proliferation,0,0,0
2033,1916,CCTE_Shafer_MEA_MFR_up,0,1,NULL,,log2_fold_induction,positive,0,bicuculline methiodide,,,,,,0,0,1
2034,1916,CCTE_Shafer_MEA_MFR_dn,0,1,NULL,,log2_fold_induction,negative,0,bicuculline methiodide,,,,,,0,0,1
2035,1917,CCTE_Shafer_MEA_LDH,0,1,NULL,viability,percent_activity,positive,0,,,,,,,0,0,1
2036,1918,CCTE_Shafer_MEA_AB,0,1,NULL,viability,percent_activity,negative,0,,,,,,,0,0,1
2037,1919,CPHEA_Stoker_NIS_Inhibition_RAIU,1,1,enzyme reporter assay using MicroBeta radioactivity plate reader to monitor enzyme in HEK293T cell line: AEID2037,binding,percent_activity,positive,0,NaClO4,loss,protein,enzyme,transporter,transporter,0,0,1
2038,1920,TOX21_TSHR_HTRF_Agonist_ch1,1,1,"Data from the assay component TOX21_TSHR_HTRF_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,TSH,loss,pathway,pathway-specified,background measurement,baseline control,0,0,1
2039,1921,TOX21_TSHR_HTRF_Agonist_ch2,1,1,"Data from the assay component TOX21_TSHR_HTRF_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,TSH,gain,pathway,pathway-specified,background measurement,baseline control,0,0,1
2040,1922,TOX21_TSHR_HTRF_Agonist_ratio,1,1,"Data from the assay component TOX21_TSHR_HTRF_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",ratio,percent_activity,positive,0,TSH,gain,protein,receptor,gpcr,thyrotropin-releasing hormone receptor,0,0,1
2041,1923,TOX21_TSHR_HTRF_Antagonist_ch1,1,1,"Data from the assay component TOX21_TSHR_HTRF_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,no TSH stimulation,gain,pathway,pathway-specified,channel 1,baseline control,0,0,1
2042,1924,TOX21_TSHR_HTRF_Antagonist_ch2,1,1,"Data from the assay component TOX21_TSHR_HTFR_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTFR_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,no TSH stimulation,loss,pathway,pathway-specified,channel 2,baseline control,0,0,1
2043,1925,TOX21_TSHR_HTRF_Antagonist_ratio,1,1,"Data from the assay component TOX21_TSHR_HTRF_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this one serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",ratio,percent_activity,positive,0,no TSH stimulation,loss,protein,receptor,gpcr,thyrotropin-releasing hormone receptor,0,0,1
2044,1926,TOX21_TSHR_HTRF_wt_ch1,1,1,"Data from the assay component TOX21_TSHR_HTRF_wt_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss of signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Forskolin,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
2045,1927,TOX21_TSHR_HTRF_wt_ch2,1,1,"Data from the assay component TOX21_TSHR_HTRF_wt_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Forskolin,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
2046,1928,TOX21_TSHR_HTRF_wt_ratio,1,1,"Data from the assay component TOX21_TSHR_HTRF_wt_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",ratio,percent_activity,positive,0,Forskolin,gain,pathway,pathway-specified,gpcr,thyrotropin-releasing hormone receptor,0,0,1
2047,1929,TOX21_CAR_Agonist,1,1,"Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",agonist,percent_activity,positive,0,CITCO,gain,protein,receptor,nuclear receptor,xenobiotic,0,0,1
2048,1930,TOX21_CAR_Agonist_viabillity,1,1,"TOX21_CAR_Agonist_viabillity used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2049,1931,TOX21_CAR_Antagonist,1,1,"Data from the assay component TOX21_CAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",antagonist,percent_activity,positive,0,PK11195,loss,protein,receptor,nuclear receptor,xenobiotic,0,0,1
2050,1932,TOX21_CAR_Antagonist_viability,1,1,"TOX21_CAR_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2053,1935,TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2,1,1,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",antagonist,percent_activity,positive,0,4-hydroxytamoxifen,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
2054,1936,TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability,1,1,"TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2055,1937,TOX21_ERR_Agonist,1,1,"Data from the assay component TOX21_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",agonist,percent_activity,positive,0,Genistein,gain,protein,receptor,nuclear receptor,orphan,0,0,1
2057,1939,TOX21_ERR_Antagonist,1,1,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",antagonist,percent_activity,positive,0,XCT790,loss,protein,receptor,nuclear receptor,orphan,0,0,1
2059,1941,TOX21_ERR_viability,1,1,"TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2060,1942,TOX21_H2AX_HTRF_CHO_viability,1,1,"TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2061,1943,TOX21_HDAC_Inhibition,1,1,"Data from the assay component TOX21_HDAC_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HDAC_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HDAC1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",reporter gene,percent_activity,positive,0,Trichostatin A,loss,pathway,pathway-specified,hydrolase,NA,0,0,1
2062,1944,TOX21_HDAC_Inhibition_viability,1,1,"TOX21_HDAC_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2063,1945,TOX21_HRE_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_HRE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,Cobalt(II)chloride hexahydrate,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
2064,1946,TOX21_HRE_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_HRE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,Cobalt(II)chloride hexahydrate,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
2065,1947,TOX21_HRE_BLA_Agonist_ratio,1,1,"Data from the assay component TOX21_HRE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is hypoxia-response element.",ratio,percent_activity,positive,0,Cobalt(II)chloride hexahydrate,gain,pathway,pathway-specified,dna binding,hypoxia-response element,0,0,1
2066,1948,TOX21_HRE_BLA_Agonist_viability,1,1,"TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2067,1949,TOX21_LUC_Biochem,1,1,"TOX21_LUC_Biochem used a type of viability reporter where loss-of-signal activity can be used to understand inhibition of luciferase enzymatic activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the enzyme intended target family, where the subfamily is luciferase.",reporter gene,percent_activity,positive,0,PTC124,loss,protein,enzyme,enzyme,luciferase,0,0,1
2068,1950,TOX21_PGC_ERR_Agonist,1,1,"Data from the assay component TOX21_PGC_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",agonist,percent_activity,positive,0,Genistein,gain,protein,receptor,nuclear receptor,orphan,0,0,1
2070,1952,TOX21_PGC_ERR_Antagonist,1,1,"Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",antagonist,percent_activity,positive,0,XCT790,loss,protein,receptor,nuclear receptor,orphan,0,0,1
2072,1954,TOX21_PGC_ERR_viability,1,1,"TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2074,1956,TOX21_RT_HEK293_FLO_00hr_viability,1,1,"TOX21_RT_HEK293_FLO_00hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,0,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2075,1957,TOX21_RT_HEK293_FLO_08hr_viability,1,1,"TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2077,1959,TOX21_RT_HEK293_FLO_16hr_viability,1,1,"TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2078,1960,TOX21_RT_HEK293_FLO_24hr_viability,1,1,"TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2080,1962,TOX21_RT_HEK293_FLO_32hr_viability,1,1,"TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2082,1964,TOX21_RT_HEK293_FLO_40hr_viability,1,1,"TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2084,1966,TOX21_RT_HEK293_GLO_00hr_viability,1,1,"TOX21_RT_HEK293_GLO_00hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2086,1968,TOX21_RT_HEK293_GLO_08hr_viability,1,1,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2088,1970,TOX21_RT_HEK293_GLO_16hr_viability,1,1,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2089,1971,TOX21_RT_HEK293_GLO_24hr_viability,1,1,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2091,1973,TOX21_RT_HEK293_GLO_32hr_viability,1,1,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2093,1975,TOX21_RT_HEK293_GLO_40hr_viability,1,1,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2094,1976,TOX21_RT_HEPG2_FLO_00hr_ctrl_viability,1,1,"TOX21_RT_HEPG2_FLO_00hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,0,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2095,1977,TOX21_RT_HEPG2_FLO_08hr_viability,1,1,"TOX21_RT_HEPG2_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2096,1978,TOX21_RT_HEPG2_FLO_16hr_ctrl_viability,1,1,"TOX21_RT_HEPG2_FLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2097,1979,TOX21_RT_HEPG2_FLO_24hr_viability,1,1,"TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2098,1980,TOX21_RT_HEPG2_FLO_32hr_ctrl_viability,1,1,"TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2099,1981,TOX21_RT_HEPG2_FLO_40hr_ctrl_viability,1,1,"TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2100,1982,TOX21_RT_HEPG2_GLO_00hr_ctrl_viability,1,1,"TOX21_RT_HEPG2_GLO_00hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2101,1983,TOX21_RT_HEPG2_GLO_08hr_ctrl_viability,1,1,"TOX21_RT_HEPG2_GLO_08hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2102,1984,TOX21_RT_HEPG2_GLO_16hr_ctrl_viability,1,1,"TOX21_RT_HEPG2_GLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2103,1985,TOX21_RT_HEPG2_GLO_32hr_ctrl_viability,1,1,"TOX21_RT_HEPG2_GLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2105,1987,TOX21_RT_HEPG2_GLO_40hr_viability,1,1,"TOX21_RT_HEPG2_GLO_40hr_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2106,1988,TOX21_SHH_3T3_GLI3_Agonist,1,1,"Data from the assay component TOX21_SHH_3T3_GLI3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",agonist,percent_activity,positive,0,SAG,gain,pathway,pathway-specified,dna binding,zinc finger,0,0,1
2107,1989,TOX21_SHH_3T3_GLI3_Agonist_viability,1,1,"TOX21_SHH_3T3_GLI3_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2108,1990,TOX21_SHH_3T3_GLI3_Antagonist,1,1,"Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",antagonist,percent_activity,positive,0,Cyclopamine,loss,pathway,pathway-specified,dna binding,zinc finger,0,0,1
2109,1991,TOX21_SHH_3T3_GLI3_Antagonist_viability,1,1,"TOX21_SHH_3T3_GLI3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2110,1992,CPHEA_Stoker_NIS_Cytotoxicity,1,1,viability reporter assay using Luciferase-coupled ATP quantitation to monitor cellular process in HEK293T cell line: AEID2110 ,viability,percent_activity,positive,0,b-naphthoquinone,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2112,1993,TOX21_AChE_Inhibition_Fluor,1,1,"Data from the assay component TOX21_AChE_Inhibition_Fluor was normalized to the positive control, BW284C51, and fit as percent of the positive control in the positive direction. Data are used in conjuction with the fluorescent version of this assay, TOX21_AChE_Inhibition_Colormetric, to identify inhibitors of acetylcholinesterase.",reporter gene,percent_activity,positive,0,BW284C51,loss,protein,protein-specified,esterase,acetylcholinesterase,0,0,0
2113,1999,TOX21_ERb_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_ERb_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,17b-Estradiol,loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
2114,2000,TOX21_ERb_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_ERb_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
2115,2001,TOX21_ERb_BLA_Agonist_ratio,1,1,"Data from the assay component TOX21_ERb_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,17b-Estradiol,gain,protein,receptor,nuclear receptor,steroidal,0,0,1
2116,2002,TOX21_ERb_BLA_Agonist_viability,1,1,"TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2117,1995,TOX21_ERb_BLA_Antagonist_ch1,1,1,"Data from the assay component TOX21_ERb_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,4-hydroxytamoxifen,gain,pathway,pathway-specified,channel 1,baseline control,0,0,1
2118,1996,TOX21_ERb_BLA_Antagonist_ch2,1,1,"Data from the assay component TOX21_ERb_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,4-hydroxytamoxifen,loss,pathway,pathway-specified,channel 2,baseline control,0,0,1
2119,1997,TOX21_ERb_BLA_Antagonist_ratio,1,1,"Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,4-hydroxytamoxifen,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
2120,1998,TOX21_ERb_BLA_Antagonist_viability,1,1,"TOX21_ERb_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2121,2003,TOX21_PR_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_PR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,promegestone (R5020),loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
2122,2004,TOX21_PR_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_PR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,promegestone (R5020),gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
2123,2005,TOX21_PR_BLA_Agonist_ratio,1,1,"Data from the assay component TOX21_PR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,promegestone (R5020),gain,protein,receptor,nuclear receptor,steroidal,0,0,1
2124,2006,TOX21_PR_BLA_Agonist_viability,1,1,"TOX21_PR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2125,2007,TOX21_PR_BLA_Antagonist_ch1,1,1,"Data from the assay component TOX21_PR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,RU486,gain,pathway,pathway-specified,channel 1,baseline control,0,0,1
2126,2008,TOX21_PR_BLA_Antagonist_ch2,1,1,"Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,RU486,loss,pathway,pathway-specified,channel 2,baseline control,0,0,1
2127,2009,TOX21_PR_BLA_Antagonist_ratio,1,1,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,RU486,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
2128,2010,TOX21_PR_BLA_Antagonist_viability,1,1,"TOX21_PR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2130,2012,TOX21_DT40_100,1,1,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",viability,percent_activity,positive,0,Tetraoctyl ammonium bromide,loss,pathway,pathway-specified,cell cycle,DNA repair,0,0,1
2131,2013,TOX21_DT40_657,1,1,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",viability,percent_activity,positive,0,Tetraoctyl ammonium bromide,loss,pathway,pathway-specified,cell cycle,DNA repair,0,0,1
2142,2023,CEETOX_H295R_11DCORT_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_11DCORT_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_11DCORT_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,11-Deoxycortisol,steroid hormone,glucocorticoids,0,0,1
2141,2022,MCT8_inhibition,0,0,,,percent_activity,,0,,,,,,,0,0,0
2143,2023,CEETOX_H295R_11DCORT_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_11DCORT_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_11DCORT_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,11-Deoxycortisol,steroid hormone,glucocorticoids,0,0,1
2144,2024,CEETOX_H295R_OHPREG_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_OHPREG_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPREG_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,17alpha-hydroxypregnenolone,steroid hormone,progestagens,0,0,1
2145,2024,CEETOX_H295R_OHPREG_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_OHPREG_noMTC_up was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPREG_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,17alpha-hydroxypregnenolone,steroid hormone,progestagens,0,0,1
2146,2025,CEETOX_H295R_OHPROG_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_OHPROG_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPROG_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,17alpha-hydroxyprogesterone,steroid hormone,progestagens,0,0,1
2147,2025,CEETOX_H295R_OHPROG_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_OHPROG_noMTC_up was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPROG_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,17alpha-hydroxyprogesterone,steroid hormone,progestagens,0,0,1
2148,2026,CEETOX_H295R_ANDR_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_ANDR_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ANDR_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,Androstenedione,steroid hormone,androgens,0,0,1
2149,2026,CEETOX_H295R_ANDR_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_ANDR_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ANDR_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,Androstenedione,steroid hormone,androgens,0,0,1
2150,2027,CEETOX_H295R_CORTIC_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_CORTIC_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTIC_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,Corticosterone,steroid hormone,glucocorticoids,0,0,1
2151,2027,CEETOX_H295R_CORTIC_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_CORTIC_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTIC_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,Corticosterone,steroid hormone,glucocorticoids,0,0,1
2152,2028,CEETOX_H295R_CORTISOL_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_CORTISOL_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTISOL_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Cortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,Cortisol ,steroid hormone,glucocorticoids,0,0,1
2153,2028,CEETOX_H295R_CORTISOL_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_CORTISOL_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTISOL_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of Cortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,Cortisol ,steroid hormone,glucocorticoids,0,0,1
2154,2029,CEETOX_H295R_DHEA_noMTC_dn,0,0,NA,NA,log2 fold change,NA,0,NA,loss,NA,NA,na,NA,0,0,1
2155,2029,CEETOX_H295R_DHEA_noMTC_up,0,0,NA,NA,log2 fold change,NA,0,NA,gain,NA,NA,na,NA,0,0,1
2156,2030,CEETOX_H295R_DOC_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_DOC_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_DOC_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,11-Deoxycorticosterone,steroid hormone,glucocorticoids,0,0,1
2157,2030,CEETOX_H295R_DOC_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_DOC_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_DOC_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,11-Deoxycorticosterone,steroid hormone,glucocorticoids,0,0,1
2158,2031,CEETOX_H295R_ESTRADIOL_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_ESTRADIOL_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ESTRADIOL_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Estradiol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,Estradiol,steroid hormone,estrogens,0,0,1
2159,2031,CEETOX_H295R_ESTRADIOL_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_ESTRADIOL_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ESTRADIOL_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Estradiol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,Estradiol,steroid hormone,estrogens,0,0,1
2160,2032,CEETOX_H295R_ESTRONE_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_ESTRONE_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ESTRONE_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Estrone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,Estrone,steroid hormone,estrogens,0,0,1
2161,2032,CEETOX_H295R_ESTRONE_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_ESTRONE_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ESTRONE_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Estrone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,Estrone,steroid hormone,estrogens,0,0,1
2162,2033,CEETOX_H295R_PREG_noMTC_dn,0,0,"assay system using HPLC-MS-MS to monitor synthesis of Pregnenolone  in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,Pregnenolone,steroid hormone,NA,0,0,1
2163,2033,CEETOX_H295R_PREG_noMTC_up,0,0,"assay system using HPLC-MS-MS to monitor synthesis of Pregnenolone  in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,Pregnenolone,steroid hormone,NA,0,0,1
2164,2034,CEETOX_H295R_PROG_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_PROG_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_PROG_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Progesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,Progesterone,steroid hormone,progestagens,0,0,1
2165,2034,CEETOX_H295R_PROG_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_PROG_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_PROG_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Progesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,Progesterone,steroid hormone,progestagens,0,0,1
2166,2035,CEETOX_H295R_TESTO_noMTC_dn,1,1,"Data from the assay component CEETOX_H295R_TESTO_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_TESTO_noMTC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Testosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",detection of steroid hormone,log2 fold change,negative,0,prochloraz; forskolin,loss,molecular messenger,Testosterone,steroid hormone,androgens,0,0,1
2167,2035,CEETOX_H295R_TESTO_noMTC_up,1,1,"Data from the assay component CEETOX_H295R_TESTO_noMTC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_TESTO_noMTC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Testosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",detection of steroid hormone,log2 fold change,positive,0,prochloraz; forskolin,gain,molecular messenger,Testosterone,steroid hormone,androgens,0,0,1
2168,2036,Alb_HumA_ABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2169,2037,Alb_HumA_ABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2170,2038,Alb_HumA_ABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2171,2039,Alb_HumA_noABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2172,2040,Alb_HumA_noABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2173,2041,Alb_HumA_noABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2174,2042,Alb_HumB_ABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2175,2043,Alb_HumB_ABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2176,2044,Alb_HumB_ABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2177,2045,Alb_HumB_noABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2178,2046,Alb_HumB_noABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2179,2047,Alb_HumB_noABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2180,2048,Alb_HumC_ABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2181,2049,Alb_HumC_ABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2182,2050,Alb_HumC_ABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2183,2051,Alb_HumC_noABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2184,2052,Alb_HumC_noABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2185,2053,Alb_HumC_noABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2186,2054,Alb_RatA_ABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2187,2055,Alb_RatA_ABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2188,2056,Alb_RatA_ABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2189,2057,Alb_RatA_noABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2190,2058,Alb_RatA_noABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2191,2059,Alb_RatA_noABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2192,2060,Alb_RatB_ABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2193,2061,Alb_RatB_ABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2194,2062,Alb_RatB_ABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2195,2063,Alb_RatB_noABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2196,2064,Alb_RatB_noABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2197,2065,Alb_RatB_noABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2198,2066,Alb_RatC_ABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2199,2067,Alb_RatC_ABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2200,2068,Alb_RatC_ABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2201,2069,Alb_RatC_noABT_02d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2202,2070,Alb_RatC_noABT_07d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2203,2071,Alb_RatC_noABT_14d,0,0,,,percent_activity,,0,,,,,,,0,0,0
2210,2072,TOX21_AChE_Inhibition_Colormetric,1,1,"Data from the assay component TOX21_AChE_Inhibition_Colormetric was normalized to the positive control, BW284C51, and fit as percent of the positive control in the positive direction. Data are used in conjuction with the fluorescent version of this assay, TOX21_AChE_Inhibition_Fluor, to identify inhibitors of acetylcholinesterase.",reporter gene,percent_activity,positive,0,BW284C51,loss,protein,protein-specified,esterase,acetylcholinesterase,0,0,0
2211,2073,TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780,1,1,"Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",agonist,percent_activity,positive,0,17b-Estradiol,gain,protein,receptor,nuclear receptor,steroidal,0,0,1
2212,2074,TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability,1,1,"TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2213,2075,TOX21_RT_HEPG2_GLO_24hr_ctrl_viability,1,1,"TOX21_RT_HEPG2_GLO_24hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,NA,cell cycle,cytotoxicity,0,1,1
2214,2275,TOX21_PR_BLA_Followup_Agonist_ch1,1,1,"Data from the assay component TOX21_PR_BLA_Followup_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,promegestone (R5020),loss,pathway,pathway-specified,channel 1,baseline control,0,0,1
2215,2276,TOX21_PR_BLA_Followup_Antagonist_ch1,1,1,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,RU486,gain,pathway,pathway-specified,channel 1,baseline control,0,0,1
2216,2277,TOX21_PR_BLA_Followup_Agonist_ch2,1,1,"Data from the assay component TOX21_PR_BLA_Followup_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,promegestone (R5020),gain,pathway,pathway-specified,channel 2,baseline control,0,0,1
2217,2278,TOX21_PR_BLA_Followup_Antagonist_ch2,1,1,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,RU486,loss,protein,receptor,channel 2,baseline control,0,0,1
2218,2279,TOX21_PR_BLA_Followup_Agonist_ratio,1,1,"Data from the assay component TOX21_PR_BLA_Followup_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,promegestone (R5020),gain,protein,receptor,nuclear receptor,steroidal,0,0,1
2219,2280,TOX21_PR_BLA_Followup_Antagonist_ratio,1,1,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",ratio,percent_activity,positive,0,RU486,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
2220,2281,TOX21_PR_BLA_Followup_Agonist_viability,1,1,"TOX21_PR_BLA_Followup_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
2221,2282,TOX21_PR_BLA_Followup_Antagonist_viability,1,1,"TOX21_PR_BLA_Followup_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
2222,2283,TOX21_PR_LUC_Followup_Agonist,1,1,"Data from the assay component TOX21_PR_LUC_Followup_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_LUC_Followup_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is steroidal.",agonist,percent_activity,positive,0,promegestone (R5020),gain,protein,receptor,nuclear receptor,steroidal,0,0,1
2223,2284,TOX21_PR_LUC_Followup_Antagonist,1,1,"Data from the assay component TOX21_PR_LUC_Followup_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_LUC_Followup_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is steroidal.",antagonist,percent_activity,positive,0,RU486,loss,protein,receptor,nuclear receptor,steroidal,0,0,1
2224,2285,TOX21_PR_LUC_Followup_Agonist_viability,1,1,"TOX21_PR_LUC_Followup_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
2225,2286,TOX21_PR_LUC_Followup_Antagonist_viability,1,1,"TOX21_PR_LUC_Followup_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
2226,2287,TOX21_TR_LUC_GH3_Agonist_Followup,1,1,"Data from the assay component TOX21_TR_LUC_GH3_Agonist_Followup was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist_Followup, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB in the GH3 cell line using a luciferase reporter. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. This assay endpoint is designated followup because it was a confirmatory screen following the primary qHTS assay.",agonist,percent_activity,positive,0,T3,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2227,2288,TOX21_TR_LUC_GH3_Antagonist_Followup,1,1,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist_Followup was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist_Followup, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB in the GH3 cell line using a luciferase reporter. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. This assay endpoint is designated followup because it was a confirmatory screen following the primary qHTS assay.",antagonist,percent_activity,positive,0,T3,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2228,2289,TOX21_TRA_COA_Agonist_Followup_ch1,1,1,"Data from the assay component TOX21_TRA_COA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Agonist_Followup_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,T3,loss,protein,receptor,channel 1,baseline control,0,0,1
2229,2290,TOX21_TRA_COA_Agonist_Followup_ch2,1,1,"Data from the assay component TOX21_TRA_COA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Agonist_Followup_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,T3,gain,protein,receptor,channel 2,baseline control,0,0,1
2230,2291,TOX21_TRA_COA_Agonist_Followup_ratio,1,1,"Data from the assay component TOX21_TRA_COA_Agonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Agonist_Followup_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a primary readout,  because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,T3,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2231,2292,TOX21_TRA_COA_Antagonist_Followup_ch1,1,1,"Data from the assay component TOX21_TRA_COA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Antagonist_Followup_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,T3,gain,protein,receptor,channel 1,baseline control,0,0,1
2232,2293,TOX21_TRA_COA_Antagonist_Followup_ch2,1,1,"Data from the assay component TOX21_TRA_COA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Antagonist_Followup_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,T3,loss,protein,receptor,channel 2,baseline control,0,0,1
2233,2294,TOX21_TRA_COA_Antagonist_Followup_ratio,1,1,"Data from the assay component TOX21_TRA_COA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRA_COA_Antagonist_Followup_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA. 
Furthermore, this assay endpoint can be referred to as a primary readout,  because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,T3,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2234,2295,TOX21_TRB_BLA_Agonist_Followup_ch1,1,1,"Data from the assay component TOX21_TRB_BLA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Agonist_Followup_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,T3,loss,protein,receptor,channel 1,baseline control,0,0,1
2235,2296,TOX21_TRB_BLA_Agonist_Followup_ch2,1,1,"Data from the assay component TOX21_TRB_BLA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Agonist_Followup_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,T3,gain,protein,receptor,channel 2,baseline control,0,0,1
2236,2297,TOX21_TRB_BLA_Agonist_Followup_ratio,1,1,"Data from the assay component TOX21_TRB_BLA_Agonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Agonist_Followup_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.",ratio,percent_activity,positive,0,T3,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2237,2298,TOX21_TRB_BLA_Agonist_Followup_viability,1,1,"The assay component endpoint  TOX21_TRB_BLA_Agonist_Followup_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
2238,2299,TOX21_TRB_BLA_Antagonist_Followup_ch1,1,1,"Data from the assay component TOX21_TRB_BLA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Antagonist_Followup_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,T3,gain,protein,receptor,channel 1,baseline control,0,0,1
2239,2300,TOX21_TRB_BLA_Antagonist_Followup_ch2,1,1,"Data from the assay component TOX21_TRB_BLA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Antagonist_Followup_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,T3,loss,protein,receptor,channel 2,baseline control,0,0,1
2240,2301,TOX21_TRB_BLA_Antagonist_Followup_ratio,1,1,"Data from the assay component TOX21_TRB_BLA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_BLA_Antagonist_Followup_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout,  because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,T3,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2241,2302,TOX21_TRB_BLA_Antagonist_Followup_viability,1,1,"TOX21_TRB_BLA_Antagonist_Followup_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
2242,2303,TOX21_TRB_COA_Agonist_Followup_ch1,1,1,"Data from the assay component TOX21_TRB_COA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Agonist_Followup_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,T3,loss,protein,receptor,channel 1,baseline control,0,0,1
2243,2304,TOX21_TRB_COA_Agonist_Followup_ch2,1,1,"Data from the assay component TOX21_TRB_COA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,T3,gain,protein,receptor,channel 2,baseline control,0,0,1
2244,2305,TOX21_TRB_COA_Agonist_Followup_ratio,1,1,"Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a primary readout,  because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,T3,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2245,2306,TOX21_TRB_COA_Antagonist_Followup_ch1,1,1,"Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,T3,gain,protein,receptor,channel 1,baseline control,0,0,1
2246,2307,TOX21_TRB_COA_Antagonist_Followup_ch2,1,1,"Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,T3,loss,protein,receptor,channel 2,baseline control,0,0,1
2247,2308,TOX21_TRB_COA_Antagonist_Followup_ratio,1,1,"Data from the assay component TOX21_TRB_COA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TRB_COA_Antagonist_Followup_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout,  because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,T3,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2248,2309,TOX21_TR_COA_Antagonist_Followup_ch1,0,0,"Data from the assay component TOX21_TR_COA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_COA_Antagonist_Followup_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the genes THRA and THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,NA,gain,protein,receptor,channel 1,baseline control,0,0,1
2249,2310,TOX21_TR_COA_Antagonist_Followup_ch2,0,0,"Data from the assay component TOX21_TR_COA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_COA_Antagonist_Followup_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the genes THRA and THRB. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,NA,loss,protein,receptor,channel 2,baseline control,0,0,1
2250,2311,TOX21_TR_COA_Antagonist_Followup_ratio,0,0,"Data from the assay component TOX21_TR_COA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_COA_Antagonist_Followup_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the genes THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout,  because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",ratio,percent_activity,positive,0,NA,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2251,2312,TOX21_TR_RXR_BLA_Agonist_Followup_ch1,1,1,"Data from the assay component TOX21_TR_RXR_BLA_Agonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Agonist_Followup_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,9-cis-Retinoic acid,loss,protein,receptor,channel 1,baseline control,0,0,1
2252,2313,TOX21_TR_RXR_BLA_Agonist_Followup_ch2,1,1,"Data from the assay component TOX21_TR_RXR_BLA_Agonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Agonist_Followup_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,9-cis-Retinoic acid,gain,protein,receptor,channel 2,baseline control,0,0,1
2253,2314,TOX21_TR_RXR_BLA_Agonist_Followup_ratio,1,1,"Data from the assay component TOX21_TR_RXR_BLA_Agonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Agonist_Followup_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.",ratio,percent_activity,positive,0,9-cis-Retinoic acid,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2254,2315,TOX21_TR_RXR_BLA_Agonist_Followup_viability,1,1,"The assay component endpoint  TOX21_TR_RXR_BLA_Agonist_Followup_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
2255,2316,TOX21_TR_RXR_BLA_Antagonist_Followup_ch1,1,1,"Data from the assay component TOX21_TR_RXR_BLA_Antagonist_Followup_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Antagonist_Followup_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,1 nM TA_Antagonist,gain,protein,receptor,channel 1,baseline control,0,0,1
2256,2317,TOX21_TR_RXR_BLA_Antagonist_Followup_ch2,1,1,"Data from the assay component TOX21_TR_RXR_BLA_Antagonist_Followup_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Antagonist_Followup_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,1 nM TA_Antagonist,loss,protein,receptor,channel 2,baseline control,0,0,1
2257,2318,TOX21_TR_RXR_BLA_Antagonist_Followup_ratio,1,1,"Data from the assay component TOX21_TR_RXR_BLA_Antagonist_Followup_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_RXR_BLA_Antagonist_Followup_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.",ratio,percent_activity,positive,0,1 nM T21_TR_RXR_BLA_Antagonist,loss,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2258,2319,TOX21_TR_RXR_BLA_Antagonist_Followup_viability,1,1,"The assay component endpoint  TOX21_TR_RXR_BLA_Antagonist_Followup_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,0,1
2259,1852,ACEA_HuRELrat_AUC_Con_309h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2260,1850,ACEA_HuRELrat_AUC_ABT_309h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2261,1854,HuRELmouseFibroblast_AUC_Con_309h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2262,1840,ACEA_HuRELhumanA_AUC_Con_309h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2263,1838,ACEA_HuRELhumanA_AUC_ABT_309h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2264,1844,ACEA_HuRELhumanB_AUC_Con_309h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2265,1842,ACEA_HuRELhumanB_AUC_ABT_309h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2266,1848,ACEA_HuRELhumanC_AUC_Con_309h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2267,1846,ACEA_HuRELhumanC_AUC_ABT_309h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2268,1853,ACEA_HuRELrat_AUC_Con_48h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2269,1851,ACEA_HuRELrat_AUC_ABT_48h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2270,1855,HuRELmouseFibroblast_AUC_Con_48h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2271,1841,ACEA_HuRELhumanA_AUC_Con_48h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2272,1839,ACEA_HuRELhumanA_AUC_ABT_48h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2273,1845,ACEA_HuRELhumanB_AUC_Con_48h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2274,1843,ACEA_HuRELhumanB_AUC_ABT_48h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2275,1849,ACEA_HuRELhumanC_AUC_Con_48h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2276,1847,ACEA_HuRELhumanC_AUC_ABT_48h,0,0,,,percent_activity,,0,,,,,,,0,0,0
2277,2320,NVS_ENZ_hPDE1A1,1,1,"Data from the assay component NVS_ENZ_hPDE1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE1A1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2278,2320,NVS_ENZ_hPDE1A1_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE1A1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the genePDE1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase. Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,NA,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
2279,2321,NVS_ENZ_hPDE1B1,1,1,"Data from the assay component NVS_ENZ_hPDE1B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE1B1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE1B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2280,2321,NVS_ENZ_hPDE1B1_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE1A1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the genePDE1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase. Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,NA,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
2281,2322,NVS_ENZ_hPDE2A,1,1,"Data from the assay component NVS_ENZ_hPDE2A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE2A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2282,2322,NVS_ENZ_hPDE2A_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE2A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE2A_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase. Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,NA,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
2283,2323,NVS_ENZ_hPDE3A,1,1,"Data from the assay component NVS_ENZ_hPDE3A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE3A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD3A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2284,2323,NVS_ENZ_hPDE3A_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE3A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE3A_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE3A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase. Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,NA,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
2285,2324,NVS_ENZ_hPDE4B1,1,1,"Data from the assay component NVS_ENZ_hPDE4B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPD4B1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD4B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2286,2324,NVS_ENZ_hPDE4B1_Activator,1,1,"Data from the assay component NVS_ENZ_hPD4B1_Activator was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPD4B1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD4B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase. Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,NA,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
2287,2325,NVS_ENZ_hPDE4C1,1,1,"Data from the assay component NVS_ENZ_hPD4C1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPD4C1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2288,2325,NVS_ENZ_hPDE4C1_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE4C1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPD4C1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4C1.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase. Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,NA,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
2289,2326,NVS_ENZ_hPDE4D3,1,1,"Data from the assay component NVS_ENZ_hPDE4D3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE4D3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4D3.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2290,2326,NVS_ENZ_hPDE4D3_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE4D3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE4D3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4D3.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase. Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,NA,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
2291,2327,NVS_ENZ_hPDE7A,1,1,"Data from the assay component NVS_ENZ_hPDE7A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE7A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE7A.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2292,2327,NVS_ENZ_hPDE7A_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE10_Activator was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE7A_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE7A.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase. Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,NA,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
2293,2328,NVS_ENZ_hPDE8A1,1,1,"Data from the assay component NVS_ENZ_hPDE8A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE8A1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE8A1.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2294,2328,NVS_ENZ_hPDE8A1_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE8A1_Activator was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE8A1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE8A1.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase. Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,NA,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
2295,2329,NVS_ENZ_hPDE9A2,1,1,"Data from the assay component NVS_ENZ_hPDE9A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE9A2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE9A2.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent_activity,positive,0,NA,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2296,2329,NVS_ENZ_hPDE9A2_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE9A2_Activator was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE9A2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE9A2.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase. Assay was not developed or optimized to detect gain of signal. Use data with caution.",enzymatic activity,percent_activity,negative,0,NA,gain,protein,enzyme,esterase,phosphodiesterase,0,0,1
2297,2330,CCTE_Harrill_HTTr_Viability_DMEM_6hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Viability_DMEM_6hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter  to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,1 nM Nlity,gain,cell,cellular,cell cycle,cytotoxicity,0,0,1
2298,2334,CCTE_Harrill_HTTr_Viability_DMEM_12hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Viability_DMEM_12hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter  to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,1 nM Nlity,gain,cell,cellular,cell cycle,cytotoxicity,0,0,1
2299,2335,CCTE_Harrill_HTTr_Viability_DMEM_24hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Viability_DMEM_24hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter  to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,1 nM Nlity,gain,cell,cellular,cell cycle,cytotoxicity,0,0,1
2300,2331,CCTE_Harrill_HTTr_Viability_PRF_DMEM_6hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Viability_PRF_DMEM_6hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter  to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,1 nM N6,gain,cell,cellular,cell cycle,cytotoxicity,0,0,1
2301,2336,CCTE_Harrill_HTTr_Viability_PRF_DMEM_12hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Viability_PRF_DMEM_12hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter  to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,1 nM N12,gain,cell,cellular,cell cycle,cytotoxicity,0,0,1
2302,2337,CCTE_Harrill_HTTr_Viability_PRF_DMEM_24hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Viability_PRF_DMEM_24hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter  to understand changes in cytotoxicity, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,1 nM N24,gain,cell,cellular,cell cycle,cytotoxicity,0,0,1
2303,2332,CCTE_Harrill_HTTr_Apoptosis_DMEM_6hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_DMEM_6hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.",viability,percent_activity,positive,0,1 nM Nosis,gain,cell,cellular,cell cycle,apoptosis,0,0,1
2304,2338,CCTE_Harrill_HTTr_Apoptosis_DMEM_12hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_DMEM_12hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.",viability,percent_activity,positive,0,1 nM Nosis,gain,cell,cellular,cell cycle,apoptosis,0,0,1
2305,2339,CCTE_Harrill_HTTr_Apoptosis_DMEM_24hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_DMEM_24hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.",viability,percent_activity,positive,0,1 nM Nosis,gain,cell,cellular,cell cycle,apoptosis,0,0,1
2306,2333,CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_6hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_6hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.",viability,percent_activity,positive,0,1 nM N6,gain,cell,cellular,cell cycle,apoptosis,0,0,1
2307,2340,CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_12hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_12hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.",viability,percent_activity,positive,0,1 nM N12,gain,cell,cellular,cell cycle,apoptosis,0,0,1
2308,2341,CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_24hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_PRF_DMEM_24hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.",viability,percent_activity,positive,0,1 nM N24,gain,cell,cellular,cell cycle,apoptosis,0,0,1
2309,2342,CCTE_GLTED_hDIO1_dn,1,1,"Data from the assay component CCTE_GLTED_hDIO1 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO1_dn, was analyzed in the down fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 1'.",enzymatic activity,% inhibition,negative,0,6-propyl-thiouracil (PTU),loss,protein,enzyme,deiodinase,deiodinase Type 1,0,0,1
2525,2486,CCTE_Shafer_MEA_dev_correlation_coefficient_mean_up,1,1,"Data from the CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_correlation_coefficient_mean_up  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2524,2486,CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2523,2485,CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_up,1,1,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2522,2485,CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2521,2484,CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_up,1,1,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2520,2484,CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2519,2483,CCTE_Shafer_MEA_dev_per_network_spike_interspike_interval_mean_up,1,1,"Data from the CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2518,2483,CCTE_Shafer_MEA_dev_per_network_spike_interspike_interval_mean_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2517,2482,CCTE_Shafer_MEA_dev_network_spike_duration_std_up,1,1,"Data from the CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_duration_std_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2516,2482,CCTE_Shafer_MEA_dev_network_spike_duration_std_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_duration_std_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2515,2481,CCTE_Shafer_MEA_dev_spike_duration_mean_up,1,1,"Data from the CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_spike_duration_mean_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2514,2481,CCTE_Shafer_MEA_dev_spike_duration_mean_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_spike_duration_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2513,2480,CCTE_Shafer_MEA_dev_network_spike_peak_up,1,1,"Data from the CCTE_Shafer_MEA_dev_network_spike_peak was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_peak_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2512,2480,CCTE_Shafer_MEA_dev_network_spike_peak_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_network_spike_peak was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_peak_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2511,2479,CCTE_Shafer_MEA_dev_network_spike_number_up,1,1,"Data from the CCTE_Shafer_MEA_dev_network_spike_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_number_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2510,2479,CCTE_Shafer_MEA_dev_network_spike_number_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_network_spike_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2509,2478,CCTE_Shafer_MEA_dev_interburst_interval_mean_up,1,1,"Data from the CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_interburst_interval_mean_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: bursting activity,0,0,1
2508,2478,CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_interburst_interval_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: bursting activity,0,0,1
2507,2477,CCTE_Shafer_MEA_dev_burst_duration_mean_up,1,1,"Data from the CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_burst_duration_mean_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: bursting activity,0,0,1
2506,2477,CCTE_Shafer_MEA_dev_burst_duration_mean_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_burst_duration_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: bursting activity,0,0,1
2505,2476,CCTE_Shafer_MEA_dev_per_burst_spike_percent_up,1,1,"Data from the CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_spike_percent_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: bursting activity,0,0,1
2504,2476,CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: bursting activity,0,0,1
2503,2475,CCTE_Shafer_MEA_dev_per_burst_interspike_interval_up,1,1,"Data from the CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_interspike_interval_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: bursting activity,0,0,1
2502,2475,CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: bursting activity,0,0,1
2501,2474,CCTE_Shafer_MEA_dev_bursting_electrodes_number_up,1,1,"Data from the CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_bursting_electrodes_number_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: activity,0,0,1
2500,2474,CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: activity,0,0,1
2499,2473,CCTE_Shafer_MEA_dev_active_electrodes_number_up,1,1,"Data from the CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_active_electrodes_number_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: activity,0,0,1
2498,2473,CCTE_Shafer_MEA_dev_active_electrodes_number_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_active_electrodes_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: activity,0,0,1
2497,2472,CCTE_Shafer_MEA_dev_burst_rate_up,1,1,"Data from the CCTE_Shafer_MEA_dev_burst_rate was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_burst_rate_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: activity,0,0,1
2496,2472,CCTE_Shafer_MEA_dev_burst_rate_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_burst_rate was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_burst_rate_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: activity,0,0,1
2495,2471,CCTE_Shafer_MEA_dev_firing_rate_mean_up,1,1,"Data from the CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_firing_rate_mean_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: activity,0,0,1
2494,2471,CCTE_Shafer_MEA_dev_firing_rate_mean_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_firing_rate_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: activity,0,0,1
2362,2369,TOX21_PXR_viability,1,1,"The assay component endpoint  TOX21_PXR_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,46 uM rifampicin ,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2363,2370,TOX21_PXR_Agonist,1,1,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",agonist,percent_activity,positive,0,46 uM rifampicin ,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2364,2371,TOX21_TRHR_HEK293_Agonist,1,1,"TOX21_TRHR_HEK293_Agonist  used a type of biochemical reporter where gain-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",agonist,percent_activity,positive,0,TRH,gain,protein,receptor,gpcr,thyrotropin-releasing hormone receptor,0,0,1
2365,2372,TOX21_TRHR_HEK293_Antagonist,1,1,"TOX21_TRHR_HEK293_Antagonist  used a type of biochemical reporter where loss-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",antagonist,percent_activity,positive,0,1 nM T293,loss,protein,receptor,gpcr,thyrotropin-releasing hormone receptor,0,0,1
2366,2373,TOX21_CASP3_HEPG2,1,1,"The assay component endpoint  TOX21_CASP3_HEPG2 was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_HEPG2 assay is a homogeneous, luminescent assay that measures caspase-3 activity following compound treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.",inducer,percent_activity,positive,0,Staurosporine,gain,cellular,cellular,apoptosis,caspase,0,0,1
2367,2374,TOX21_CASP3_HEPG2_viability,1,1,"The assay component endpoint  TOX21_CASP3_HEPG2_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2368,2375,TOX21_CASP3_CHO,1,1,"The assay component endpoint  TOX21_CASP3_CHO was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_CHO assay is a homogeneous, luminescent assay that measures caspase-3 activity following chemical treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.",inducer,percent_activity,positive,0,Staurosporine,gain,cellular,cellular,apoptosis,caspase,0,0,1
2369,2376,TOX21_CASP3_CHO_viability,1,1,"The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2370,2377,TOX21_SBE_BLA_Antagonist_ch1,1,1,"Data from the assay component TOX21_SBE_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,NA,gain,protein,receptor,channel 1,baseline control,0,0,1
2371,2378,TOX21_SBE_BLA_Antagonist_ch2,1,1,"Data from the assay component TOX21_SBE_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,NA,loss,protein,receptor,channel 2,baseline control,0,0,1
2372,2379,TOX21_SBE_BLA_Antagonist_ratio,1,1,"Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.",ratio,percent_activity,positive,0,NA,loss,protein,receptor,growth factor receptor,transforming growth factor beta,0,0,1
2373,2380,TOX21_SBE_BLA_Antagonist_viability,1,1,"The assay component endpoint  TOX21_SBE_BLA_Antagonist_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,1,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2943,2766,IUF_NPC2c_oligodendrocyte_migration_120hr_up,0,0,"Data from the IUF_NPC2c_oligodendrocyte_migration_120hr component was analyzed at the endpoint IUF_NPC2c_oligodendrocyte_migration_120hr_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,NA,gain,cellular,cellular,neurodevelopment,neural progenitor cell migration,0,0,1
2944,2766,IUF_NPC2c_oligodendrocyte_migration_120hr_dn,0,0,"Data from the IUF_NPC2c_oligodendrocyte_migration_120hr component was analyzed at the endpoint IUF_NPC2c_oligodendrocyte_migration_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,NA,loss,cellular,cellular,neurodevelopment,neural progenitor cell migration,0,0,1
2945,2767,IUF_NPC3_neuron_diff_120hr_up,0,0,"Data from the IUF_NPC3_neuron_diff_120hr component was analyzed at the endpoint IUF_NPC3_neuron_diff_120hr_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,EGF,gain,cellular,cellular,neurodevelopment,neural progenitor differentiation,0,0,1
2946,2767,IUF_NPC3_neuron_diff_120hr_dn,0,0,"Data from the IUF_NPC3_neuron_diff_120hr component was analyzed at the endpoint IUF_NPC3_neuron_diff_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,EGF,loss,cellular,cellular,neurodevelopment,neural progenitor differentiation,0,0,1
2947,2768,IUF_NPC4_neurite_length_120hr_up,0,0,"Data from the IUF_NPC4_neurite_length_120hr component was analyzed at the endpoint IUF_NPC4_neurite_length_120hr_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,NA,gain,cellular,cellular,neurodevelopment,neural progenitor differentiation,0,0,1
2374,2381,TOX21_SBE_BLA_Agonist_ch1,1,1,"Data from the assay component TOX21_SBE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",substrate,percent_activity,positive,0,TGFb,loss,protein,receptor,channel 1,baseline control,0,0,1
2375,2382,TOX21_SBE_BLA_Agonist_ch2,1,1,"Data from the assay component TOX21_SBE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_SBE_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",product,percent_activity,positive,0,TGFb,gain,protein,receptor,channel 2,baseline control,0,0,1
2376,2383,TOX21_SBE_BLA_Agonist_ratio,1,1,"Data from the assay component TOX21_SBE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.",ratio,percent_activity,positive,0,TGFb,gain,protein,receptor,growth factor receptor,transforming growth factor beta,0,0,1
2377,2384,TOX21_SBE_BLA_Agonist_viability,1,1,"The assay component endpoint  TOX21_SBE_BLA_Agonist_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent_activity,positive,0,tetraoctylammonium bromide,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2937,2763,IUF_NPC2a_glia_migration_72hr_up,0,0,"Data from the IUF_NPC2a_glia_migration_72hr component was analyzed at the endpoint IUF_NPC2a_glia_migration_72hr_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,SRC kinase inhibitor PP2,gain,cellular,cellular,neurodevelopment,neural progenitor cell migration,0,0,1
2938,2763,IUF_NPC2a_glia_migration_72hr_dn,0,0,"Data from the IUF_NPC2a_glia_migration_72hr component was analyzed at the endpoint IUF_NPC2a_glia_migration_72hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,SRC kinase inhibitor PP2,loss,cellular,cellular,neurodevelopment,neural progenitor cell migration,0,0,1
2939,2764,IUF_NPC2a_ glia_migration_120hr_up,0,0,"Data from the IUF_NPC2a_glia_migration_120hr component was analyzed at the endpoint IUF_NPC2a_ glia_migration_120hr_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,NA,gain,cellular,cellular,neurodevelopment,neural progenitor cell migration,0,0,1
2940,2764,IUF_NPC2a_ glia_migration_120hr_dn,0,0,"Data from the IUF_NPC2a_glia_migration_120hr component was analyzed at the endpoint IUF_NPC2a_ glia_migration_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,NA,loss,cellular,cellular,neurodevelopment,neural progenitor cell migration,0,0,1
2941,2765,IUF_NPC2b_neuron_migration_120hr_up,0,0,"Data from the IUF_NPC2b_neuron_migration_120hr component was analyzed at the endpoint IUF_NPC2b_neuron_migration_120hr_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,NA,gain,cellular,cellular,neurodevelopment,neural progenitor cell migration,0,0,1
2942,2765,IUF_NPC2b_neuron_migration_120hr_dn,0,0,"Data from the IUF_NPC2b_neuron_migration_120hr component was analyzed at the endpoint IUF_NPC2b_neuron_migration_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,NA,loss,cellular,cellular,neurodevelopment,neural progenitor cell migration,0,0,1
2378,2385,UPITT_compartments_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2379,2386,UPITT_compartments_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2380,2387,UPITT_mean.compartment.average.intensity_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2381,2388,UPITT_mean.compartment.average.intensity_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2382,2389,UPITT_integrated.inner.intensity_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2383,2390,UPITT_integrated.inner.intensity_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2384,2391,UPITT_integrated.outer.intensity_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2385,2392,UPITT_integrated.outer.intensity_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2386,2393,UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist,1,1,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",binding,percent_activity,positive,0,DMSO,loss,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
2387,2394,UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist,1,1,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist, was analyzed in the positive fitting direction relative to DMSO as the baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",binding,percent_activity,positive,0,dihydroxytestosterone (DHT),gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
2388,2395,UPITT_average.outer.intensity_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2389,2396,UPITT_average.outer.intensity_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2390,2397,UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist,1,1,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",binding,percent_activity,positive,0,DMSO,loss,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
2391,2398,UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist,1,1,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist, was analyzed in the positive fitting direction relative to DMSO as the baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",binding,percent_activity,positive,0,dihydroxytestosterone (DHT),gain,pathway,pathway-specified,nuclear receptor,steroidal,0,0,1
2392,2399,UPITT_outer.inner.intensity.ratio_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2393,2400,UPITT_outer.inner.intensity.ratio_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2394,2401,UPITT_Total.Cells_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2395,2402,UPITT_Total.Cells_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2396,2403,UPITT_All.Nuclei.Mean.Average.Itensity_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2397,2404,UPITT_All.Nuclei.Mean.Average.Itensity_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2398,2405,UPITT_All.Nuclei.Mean.Integr.Itensity_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2399,2406,UPITT_All.Nuclei.Mean.Integr.Itensity_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2400,2407,UPITT_All.W2.Mean.Nucl.Integr.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2401,2408,UPITT_All.W2.Mean.Nucl.Integr.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2402,2409,UPITT_All.W2.Mean.Nucl.Aver.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2403,2410,UPITT_All.W2.Mean.Nucl.Aver.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2404,2411,UPITT_All.W2.Mean.Cyto.Integr.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2405,2412,UPITT_All.W2.Mean.Cyto.Integr.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2406,2413,UPITT_All.W2.Mean.Cyto.Aver.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2407,2414,UPITT_All.W2.Mean.Cyto.Aver.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2408,2415,UPITT_All.W2.Mean.Cell.Integr.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2409,2416,UPITT_All.W2.Mean.Cell.Integr.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2410,2417,UPITT_All.W2.Mean.Cell.Aver.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2411,2418,UPITT_All.W2.Mean.Cell.Aver.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2412,2419,UPITT_All.W3.Mean.Nucl.Integr.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2413,2420,UPITT_All.W3.Mean.Nucl.Integr.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2414,2421,UPITT_All.W3.Mean.Nucl.Aver.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2415,2422,UPITT_All.W3.Mean.Nucl.Aver.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2416,2423,UPITT_All.W3.Mean.Cyto.Integr.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2417,2424,UPITT_All.W3.Mean.Cyto.Integr.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2418,2425,UPITT_All.W3.Mean.Cyto.Aver.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2419,2426,UPITT_All.W3.Mean.Cyto.Aver.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2420,2427,UPITT_All.W3.Mean.Cell.Integr.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2421,2428,UPITT_All.W3.Mean.Cell.Integr.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2422,2429,UPITT_All.W3.Mean.Cell.Aver.Intens_Antagonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2423,2430,UPITT_All.W3.Mean.Cell.Aver.Intens_Agonist,0,0,,,percent_activity,,0,,,,,,,0,0,0
2424,2431,ATG_GPCR_M_06_TRANS_dn,0,0,ATG_GPCR_M_06_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
2425,2431,ATG_GPCR_M_06_TRANS_up,0,0,"This assay endpoint, ATG_GPCR_M_06_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
2426,2432,ATG_GPCR_CHRM1_TRANS_dn,0,0,ATG_GPCR_CHRM1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
2427,2432,ATG_GPCR_CHRM1_TRANS_up,0,0,"The assay endpoint ATG_GPCR_CHRM1_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CHRM1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
2428,2433,ATG_GPCR_PTGER2_TRANS_dn,0,0,ATG_GPCR_PTGER2_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
2429,2433,ATG_GPCR_PTGER2_TRANS_up,0,0,"The assay endpoint ATG_GPCR_PTGER2_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PTGER2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
2430,2434,ATG_GPCR_ADRB1_TRANS_dn,0,0,ATG_GPCR_ADRB1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
2431,2434,ATG_GPCR_ADRB1_TRANS_up,0,0,"The assay endpoint ATG_GPCR_ADRB1_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ADRB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
2432,2435,ATG_GPCR_HTR2B_TRANS_dn,0,0,ATG_GPCR_HTR2B_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
2433,2435,ATG_GPCR_HTR2B_TRANS_up,0,0,"The assay endpoint ATG_GPCR_HTR2B_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HTR2B. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
2434,2436,ATG_GPCR_M_19_TRANS_dn,0,0,ATG_GPCR_M_19_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,reporter gene,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
2435,2436,ATG_GPCR_M_19_TRANS_up,0,0,"This assay endpoint, ATG_GPCR_M_19_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
2436,2437,ATG_GPCR_MC5R_TRANS_dn,0,0,ATG_GPCR_MC5R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,gpcr,NA,0,0,1
2437,2437,ATG_GPCR_MC5R_TRANS_up,0,0,"The assay endpoint ATG_GPCR_MC5R_TRANS_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MC5R. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family.",reporter gene,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,gpcr,NA,0,0,1
2438,2438,ATG_GPCR_M_32_TRANS_dn,0,0,ATG_GPCR_M_32_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
2439,2438,ATG_GPCR_M_32_TRANS_up,0,0,"This assay endpoint, ATG_GPCR_M_32_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
2440,2439,ATG_GPCR_M_61_TRANS_dn,0,0,ATG_GPCR_M_61_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,background control,log2_fold_induction,negative,0,NA,loss,protein,transcription factor,background measurement,internal marker,0,0,1
2441,2439,ATG_GPCR_M_61_TRANS_up,0,0,"This assay endpoint, ATG_GPCR_M_61_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the background measurement intended target family, where the subfamily is internal marker.",background control,log2_fold_induction,positive,0,NA,gain,protein,transcription factor,background measurement,internal marker,0,0,1
2442,2440,CCTE_Simmons_MITO_basal_resp_rate_OCR_dn,1,1,"Data from the assay component CCTE_Simmons_MITO_basal_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_basal_resp_rate_OCR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of basal respiration for loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",cellular respiration,fold change,negative,0,Fenpyroximate,loss,cellular,cellular,mitochondria,respiration,0,0,1
2443,2440,CCTE_Simmons_MITO_basal_resp_rate_OCR_up,1,1,"Data from the assay component CCTE_Simmons_MITO_basal_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_basal_resp_rate_OCR_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of basal respiration for gain-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",cellular respiration,fold change,positive,0,"2,4-Dinitrophenol",gain,cellular,cellular,mitochondria,respiration,0,0,1
2444,2441,CCTE_Simmons_MITO_max_resp_rate_OCR_dn,1,1,"Data from the assay component CCTE_Simmons_MITO_max_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_max_resp_rate_OCR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of maximal respiration for loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",cellular respiration,fold change,negative,0,Fenpyroximate,loss,cellular,cellular,mitochondria,respiration,0,0,1
2445,2441,CCTE_Simmons_MITO_max_resp_rate_OCR_up,1,1,"Data from the assay component CCTE_Simmons_MITO_max_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_max_resp_rate_OCR_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of maximal respiration for gain-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",cellular respiration,fold change,positive,0,none,gain,cellular,cellular,mitochondria,respiration,0,0,1
2446,2442,CCTE_Simmons_MITO_inhib_resp_rate_OCR_dn,1,1,"Data from the assay component CCTE_Simmons_MITO_inhib_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_inhib_resp_rate_OCR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of inhibited respiration for loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",cellular respiration,fold change,negative,0,none,loss,cellular,cellular,mitochondria,respiration,0,0,1
2447,2442,CCTE_Simmons_MITO_inhib_resp_rate_OCR_up,1,1,"Data from the assay component CCTE_Simmons_MITO_inhib_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_inhib_resp_rate_OCR_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of inhibited respiration for gain-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",cellular respiration,fold change,positive,0,none,gain,cellular,cellular,mitochondria,respiration,0,0,1
2450,2443,CCTE_Simmons_MITO_viability,1,1,"Data from the assay component CCTE_Simmons_MITO_viability was analyzed at the endpoint, CCTE_Simmons_MITO_viability, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",viability,percent activity,negative,0,blank wells,loss,cellular,cellular,cell proliferation,cytotoxicity,0,1,1
2451,2445,CCTE_Harrill_HTTr_Viability_MCF7_DMEM_6hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Viability_MCF7_DMEM_6hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion to understand changes in cytotoxicity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",viability,percent activity,positive,0,1 nM N6,gain,cell,cellular,cell cycle,cytotoxicity,0,0,1
2452,2446,CCTE_Harrill_HTTr_Apoptosis_MCF7_DMEM_6hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_MCF7_DMEM_6hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.",viability,percent activity,positive,0,1 nM N6,gain,cell,cellular,cell cycle,apoptosis,0,0,1
2453,2444,CCTE_Harrill_HTTr_CellCount_MCF7_DMEM_6hr,1,1,"The assay component endpoint CCTE_Harrill_HTTr_CellCount_MCF7_DMEM_6hr was analyzed in the negative fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in cell count. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cell count.",viability,percent activity,negative,0,1 nM N6,loss,cell,cellular,cell cycle,cell count,0,0,1
2454,2447,CCTE_Shafer_MEA_acute_spike_number_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2455,2447,CCTE_Shafer_MEA_acute_spike_number_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2456,2448,CCTE_Shafer_MEA_acute_firing_rate_mean_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2457,2448,CCTE_Shafer_MEA_acute_firing_rate_mean_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2458,2449,CCTE_Shafer_MEA_acute_burst_number_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2459,2449,CCTE_Shafer_MEA_acute_burst_number_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2460,2450,CCTE_Shafer_MEA_acute_burst_duration_mean_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2461,2450,CCTE_Shafer_MEA_acute_burst_duration_mean_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2462,2451,CCTE_Shafer_MEA_acute_per_burst_spike_number_mean_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2463,2451,CCTE_Shafer_MEA_acute_per_burst_spike_number_mean_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2464,2452,CCTE_Shafer_MEA_acute_interburst_interval_mean_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2465,2452,CCTE_Shafer_MEA_acute_interburst_interval_mean_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2466,2453,CCTE_Shafer_MEA_acute_burst_percentage_mean_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2467,2453,CCTE_Shafer_MEA_acute_burst_percentage_mean_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2468,2454,CCTE_Shafer_MEA_acute_burst_percentage_std_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2469,2454,CCTE_Shafer_MEA_acute_burst_percentage_std_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2470,2455,CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2471,2455,CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2472,2456,CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2473,2456,CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2474,2457,CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2475,2457,CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2476,2458,CCTE_Shafer_MEA_acute_network_burst_percentage_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2477,2458,CCTE_Shafer_MEA_acute_network_burst_percentage_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2478,2459,CCTE_Shafer_MEA_acute_cross_correlation_area_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2479,2459,CCTE_Shafer_MEA_acute_cross_correlation_area_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2480,2460,CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2481,2460,CCTE_Shafer_MEA_acute_cross_correlation_HWHM_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2482,2461,CCTE_Shafer_MEA_acute_synchrony_index_dn,0,0,NULL,,response,,0,,,,,,,0,0,1
2483,2461,CCTE_Shafer_MEA_acute_synchrony_index_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2484,2462,CCTE_Deisenroth_AIME_96WELL_LUC_Active_up,1,1,"CCTE_Deisenroth_AIME_96WELL_LUC_Active_up is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism positive mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_LUC_Active_up, was analyzed in the positive fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,percent_activity,positive,0,17b-Estradiol,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2485,2463,CCTE_Deisenroth_AIME_96WELL_CTox_Active_dn,1,1,"CCTE_Deisenroth_AIME_96WELL_CTox_Active_dn is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism positive mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_CTox_Active_dn, was analyzed in the positive fitting direction in the ERTA assay. ",viability,log2,positive,0,NA,loss,protein,protein-unspecified,protease,NA,0,1,1
2486,2464,CCTE_Deisenroth_AIME_96WELL_LUC_Inactive_up,1,1,"CCTE_Deisenroth_AIME_96WELL_LUC_Inactive_up is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism negative mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_LUC_Inactive_up, was analyzed in the positive fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,percent_activity,positive,0,17b-Estradiol,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2487,2465,CCTE_Deisenroth_AIME_96WELL_CTox_Inactive_dn,1,1,"CCTE_Deisenroth_AIME_96WELL_CTox_Inactive_dn is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism negative mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_96WELL_CTox_Inactive_dn, was analyzed in the positive fitting direction in the ERTA assay. ",viability,log2,positive,0,NA,loss,protein,protein-unspecified,protease,NA,0,1,1
2488,2466,CCTE_Deisenroth_AIME_384WELL_LUC_Active_up,0,0,"CCTE_Deisenroth_AIME_384WELL_LUC_Active_up is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism positive mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_LUC_Active_up, was analyzed in the positive fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,percent_activity,positive,0,17b-Estradiol,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2489,2467,CCTE_Deisenroth_AIME_384WELL_CTox_Active_dn,0,0,"CCTE_Deisenroth_AIME_384WELL_CTox_Active_dn is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism positive mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_CTox_Active_dn, was analyzed in the positive fitting direction in the ERTA assay. ",viability,log2,positive,0,NA,loss,protein,protein-unspecified,protease,NA,0,0,1
2490,2468,CCTE_Deisenroth_AIME_384WELL_LUC_Inactive_up,0,0,"CCTE_Deisenroth_AIME_384WELL_LUC_Inactive_up is a component of the CCTE_Deisenroth_AIME_96WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism negative mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_LUC_Inactive_up, was analyzed in the positive fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",reporter gene,percent_activity,positive,0,17b-Estradiol,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2491,2469,CCTE_Deisenroth_AIME_384WELL_CTox_Inactive_dn,0,0,"CCTE_Deisenroth_AIME_384WELL_CTox_Inactive_dn is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism negative mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_CTox_Inactive_dn, was analyzed in the positive fitting direction in the ERTA assay. ",viability,log2,positive,0,NA,loss,protein,protein-unspecified,protease,NA,0,0,1
2492,2470,CCTE_Deisenroth_AIME_384WELL_LUC_Shift_up,0,0,NA,reporter gene,percent_activity,positive,0,17b-Estradiol,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2493,2470,CCTE_Deisenroth_AIME_384WELL_LUC_Shift_dn,0,0,NA,reporter gene,percent_activity,positive,0,17b-Estradiol,gain,protein,transcription factor,nuclear receptor,steroidal,0,0,1
2526,2487,CCTE_Shafer_MEA_dev_mutual_information_norm_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_mutual_information_norm_dn  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,loss,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2527,2487,CCTE_Shafer_MEA_dev_mutual_information_norm_up,1,1,"Data from the CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_mutual_information_norm_up  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",electrical activity,percent activity,positive,0,NA,gain,extracellular,action potential,neurodevelopment,neural network function: network connectivity,0,0,1
2529,2488,CCTE_Shafer_MEA_dev_LDH_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_LDH was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_LDH_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand cell viability.",cell viability,percent activity,positive,0,NA,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2530,2489,CCTE_Shafer_MEA_dev_AB_dn,1,1,"Data from the CCTE_Shafer_MEA_dev_AB was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_AB_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand cell viability.",cell viability,percent activity,negative,0,NA,loss,cellular,mitochondria,cell cycle,cytotoxicity,0,1,1
2532,2490,CCTE_GLTED_hDIO2_dn,1,1,"Data from the assay component CCTE_GLTED_hDIO2 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO2_dn, was analyzed in the down fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 2'.",enzymatic activity,% inhibition,negative,0,xanthohumol,loss,protein,enzyme,deiodinase,deiodinase Type 2,1,0,1
2533,2491,CCTE_GLTED_hDIO3_dn,1,1,"Data from the assay component CCTE_GLTED_hDIO3 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO3_dn, was analyzed in the down fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 3'.",enzymatic activity,% inhibition,negative,0,xanthohumol,loss,protein,enzyme,deiodinase,deiodinase Type 3,1,0,1
2534,2492,CW_HCS_iPCS_Oligo_DAPI_cellcount_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2535,2492,CW_HCS_iPCS_Oligo_DAPI_cellcount_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2536,2493,CW_HCS_iPCS_Oligo_O1_glycolipid_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2537,2493,CW_HCS_iPCS_Oligo_O1_glycolipid_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2538,2494,CW_HCS_iPCS_Oligo_MBP_protein_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2539,2494,CW_HCS_iPCS_Oligo_MBP_protein_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2540,2495,CCTE_Shafer_MEA_acute_LDH_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2541,2496,CCTE_Shafer_MEA_acute_AB_up,0,0,NULL,,response,,0,,,,,,,0,0,1
2542,2497,TOX21_msti_p2_activity_n,0,0,TOX21_msti_p2_activity_n was run as an assay to identify chemicals with have inherent fluorescence that may interfere with the assay TOX21_msti_p2_activity. TOX21_msti_p2_activity_n assay was performed in parallel consisting of the identical assay protocol to TOX21_msti_p2_activity but lacking the MSTI substrate.,background control,percent_activity,positive,0,NA,loss,chemical,fluorescence,fluorescence,fluorescence,0,0,1
2543,2498,TOX21_msti_p2_activity,0,0,"TOX21_msti_p2_activity used a chemical substrate, (E)-2-(4-mercaptostyryl)-1,3,3-trimethyl-3H-indol-1-ium (MSTI), to identify thiol-reactive chemicals in a chemical reaction format. Covalent binding of the test chemical with MSTI results in a decreased fluorescence intensity of the substrate. Thiol-reactive chemicals are associated with cell stress through effects on proteins and cellular membranes. To identify chemicals with have inherent fluorescence that may interfere with the assay, the TOX21_msti_p2_activity_n assay was performed in parallel consisting of the identical assay protocol but lacking the MSTI substrate.",chemical reporter,percent_activity,positive,0,MLS001163887,loss,chemical,chemical reactivity,NA,stress,0,0,1
2544,2499,TOX21_p450_3a4_p1,0,0,TOX21_p450_3a4_p1 used a fluorescent substrate for CYP3A4 to measure the inhibition of enzymatic activity of human CYP3A4.,inhibitor,percent_activity,positive,0,Ketoconazole,loss,protein,protein-specified,cyp,cyp3a4,0,0,1
2545,2500,UKN_HCS_SBAD2_UKN5_neurite_outgrowth_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2546,2500,UKN_HCS_SBAD2_UKN5_neurite_outgrowth_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2547,2501,UKN_HCS_SBAD2_UKN5_cell_viability_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2548,2501,UKN_HCS_SBAD2_UKN5_cell_viability_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2549,2502,ERF_ADME_hCYP2A6_dn,1,1,"Data from the assay component ERF_ADME_hCYP2A6 was analyzed at the assay endpoint, ERF_ADME_hCYP2A6_dn, in the positive fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2A6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp  intended target family, where the subfamily is steroidogenesis-related.",enzymatic activity,percent activity,positive,0,NA,loss,protein,enzyme,cyp ,steroidogenesis-related,0,0,1
2550,2503,ERF_ADME_hCYP2B6_dn,1,1,"Data from the assay component ERF_ADME_hCYP2B6 was analyzed at the assay endpoint, ERF_ADME_hCYP2B6_dn, in the positive fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2B6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp  intended target family, where the subfamily is steroidogenesis-related.",enzymatic activity,percent activity,positive,0,NA,loss,protein,enzyme,cyp ,steroidogenesis-related,0,0,1
2551,2504,ERF_ADME_hCYP2C19_CEC_dn,1,1,"Data from the assay component ERF_ADME_hCYP2C19_CEC was analyzed at the assay endpoint, ERF_ADME_hCYP2C19_CEC_dn, in the positive fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C19. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp  intended target family, where the subfamily is steroidogenesis-related.",enzymatic activity,percent activity,positive,0,NA,loss,protein,enzyme,cyp ,steroidogenesis-related,0,0,1
2552,2505,ERF_ADME_hCYP2C19_Omeprazole_dn,1,1,"Data from the assay component ERF_ADME_hCYP2C19_Omeprazole was analyzed at the assay endpoint, ERF_ADME_hCYP2C19_Omeprazole_dn, in the positive fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C19. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp  intended target family, where the subfamily is steroidogenesis-related.",enzymatic activity,percent activity,positive,0,NA,loss,protein,enzyme,cyp ,steroidogenesis-related,0,0,1
2553,2506,ERF_ADME_hCYP2C8_dn,1,1,"Data from the assay component ERF_ADME_hCYP2C8 was analyzed at the assay endpoint, ERF_ADME_hCYP2C8_dn, in the positive fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C8. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp  intended target family, where the subfamily is steroidogenesis-related.",enzymatic activity,percent activity,positive,0,NA,loss,protein,enzyme,cyp ,steroidogenesis-related,0,0,1
2554,2507,ERF_ADME_hCYP2C9_dn,1,1,"Data from the assay component ERF_ADME_hCYP2C9 was analyzed at the assay endpoint, ERF_ADME_hCYP2C9_dn, in the positive fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2C9. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp  intended target family, where the subfamily is steroidogenesis-related.",enzymatic activity,percent activity,positive,0,NA,loss,protein,enzyme,cyp ,steroidogenesis-related,0,0,1
2555,2508,ERF_ADME_hCYP2E1_dn,1,1,"Data from the assay component ERF_ADME_hCYP2E1 was analyzed at the assay endpoint, ERF_ADME_hCYP2E1_dn, in the positive fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP2E1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp  intended target family, where the subfamily is steroidogenesis-related.",enzymatic activity,percent activity,positive,0,NA,loss,protein,enzyme,cyp ,steroidogenesis-related,0,0,1
2556,2509,ERF_ADME_hCYP3A4_dn,1,1,"Data from the assay component ERF_ADME_hCYP3A4 was analyzed at the assay endpoint, ERF_ADME_hCYP3A4_dn, in the positive fitting direction relative to acetonitrile as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP3A4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp  intended target family, where the subfamily is steroidogenesis-related.",enzymatic activity,percent activity,positive,0,NA,loss,protein,enzyme,cyp ,steroidogenesis-related,0,0,1
2557,2510,ERF_ENZ_bPDE1_dn,1,1,"Data from the assay component ERF_ENZ_bPDE1 was analyzed at the assay endpoint, ERF_ENZ_bPDE1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphodiesterase intended target family, where the subfamily is cyclic nucleotide signaling.",enzymatic activity,percent activity,positive,0,3-Isobutyl-1-methylxanthine,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2558,2511,ERF_ENZ_hABL1_dn,1,1,"Data from the assay component ERF_ENZ_hABL1 was analyzed at the assay endpoint, ERF_ENZ_hABL1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ABL1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2559,2512,ERF_ENZ_hAKT2_dn,1,1,"Data from the assay component ERF_ENZ_hAKT2 was analyzed at the assay endpoint, ERF_ENZ_hAKT2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene AKT2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2560,2513,ERF_ENZ_hAKT3_dn,1,1,"Data from the assay component ERF_ENZ_hAKT3 was analyzed at the assay endpoint, ERF_ENZ_hAKT3_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene AKT3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2561,2514,ERF_ENZ_hAURKA_dn,1,1,"Data from the assay component ERF_ENZ_hAURKA was analyzed at the assay endpoint, ERF_ENZ_hAURKA_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene AURKA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,receptor,kinase,serine/threonine kinase,0,0,1
2562,2515,ERF_ENZ_hBTK_dn,1,1,"Data from the assay component ERF_ENZ_hBTK was analyzed at the assay endpoint, ERF_ENZ_hBTK_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene BTK. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is  tyrosine kinase (tk).",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase, tyrosine kinase (tk),0,0,1
2563,2516,ERF_ENZ_hCDK2_dn,1,1,"Data from the assay component ERF_ENZ_hCDK2 was analyzed at the assay endpoint, ERF_ENZ_hCDK2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CDK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2564,2517,ERF_ENZ_hCHK1_dn,1,1,"Data from the assay component ERF_ENZ_hCHK1 was analyzed at the assay endpoint, ERF_ENZ_hCHK1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CHEK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2565,2518,ERF_ENZ_hCHLE_dn,1,1,"Data from the assay component ERF_ENZ_hCHLE was analyzed at the assay endpoint, ERF_ENZ_hCHLE_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene BCHE. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is butylcholinesterase.",enzymatic activity,percent activity,positive,0,physostigmine,loss,protein,enzyme,esterase,butylcholinesterase,0,0,1
2566,2519,ERF_ENZ_hCSF1R_dn,1,1,"Data from the assay component ERF_ENZ_hCSF1R was analyzed at the assay endpoint, ERF_ENZ_hCSF1R_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSF1R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2567,2520,ERF_ENZ_hCSNK1A1_dn,1,1,"Data from the assay component ERF_ENZ_hCSNK1A1 was analyzed at the assay endpoint, ERF_ENZ_hCSNK1A1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSNK1A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,IC 261,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2568,2521,ERF_ENZ_hCSNK1D_dn,1,1,"Data from the assay component ERF_ENZ_hCSNK1D was analyzed at the assay endpoint, ERF_ENZ_hCSNK1D_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSNK1D. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,IC 261,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2569,2522,ERF_ENZ_hCSNK2A1_dn,1,1,"Data from the assay component ERF_ENZ_hCSNK2A1 was analyzed at the assay endpoint, ERF_ENZ_hCSNK2A1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CSNK2A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,hypericin,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2570,2523,ERF_ENZ_hCYP19A1_dn,1,1,"Data from the assay component ERF_ENZ_hCYP19A1 was analyzed at the assay endpoint, ERF_ENZ_hCYP19A1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene CYP19A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.",enzymatic activity,percent activity,positive,0,testosterone,loss,protein,enzyme,cyp ,steroidogenesis-related,0,0,1
2571,2524,ERF_ENZ_hDUSP3_dn,1,1,"Data from the assay component ERF_ENZ_hDUSP3 was analyzed at the assay endpoint, ERF_ENZ_hDUSP3_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene DUSP3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is dual-specific kinase.",enzymatic activity,percent activity,positive,0,sodium orthovanadate,loss,protein,enzyme,kinase,dual-specific kinase,0,0,1
2572,2525,ERF_ENZ_hDYRK1A_dn,1,1,"Data from the assay component ERF_ENZ_hDYRK1A was analyzed at the assay endpoint, ERF_ENZ_hDYRK1A_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene DYRK1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2573,2526,ERF_ENZ_hEGFR_dn,1,1,"Data from the assay component ERF_ENZ_hEGFR was analyzed at the assay endpoint, ERF_ENZ_hEGFR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EGFR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,hydrochloride,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2574,2527,ERF_ENZ_hELANE_dn,1,1,"Data from the assay component ERF_ENZ_hELANE was analyzed at the assay endpoint, ERF_ENZ_hELANE_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ELANE. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine peptidase.",enzymatic activity,percent activity,positive,0,"3',4'dichloroisocoumarin",loss,protein,enzyme,protease,serine peptidase,0,0,1
2575,2528,ERF_ENZ_hEPHA1_dn,1,1,"Data from the assay component ERF_ENZ_hEPHA1 was analyzed at the assay endpoint, ERF_ENZ_hEPHA1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EPHA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2576,2529,ERF_ENZ_hEPHA2_dn,1,1,"Data from the assay component ERF_ENZ_hEPHA2 was analyzed at the assay endpoint, ERF_ENZ_hEPHA2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EPHA2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2577,2530,ERF_ENZ_hEPHB2_dn,1,1,"Data from the assay component ERF_ENZ_hEPHB2 was analyzed at the assay endpoint, ERF_ENZ_hEPHB2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene EPHB2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,PP2,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2578,2531,ERF_ENZ_hFGFR1_dn,1,1,"Data from the assay component ERF_ENZ_hFGFR1 was analyzed at the assay endpoint, ERF_ENZ_hFGFR1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FGFR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2579,2532,ERF_ENZ_hFGFR3_dn,1,1,"Data from the assay component ERF_ENZ_hFGFR3 was analyzed at the assay endpoint, ERF_ENZ_hFGFR3_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FGFR3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2580,2533,ERF_ENZ_hFLT1_dn,1,1,"Data from the assay component ERF_ENZ_hFLT1 was analyzed at the assay endpoint, ERF_ENZ_hFLT1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FLT1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2581,2534,ERF_ENZ_hFLT4_dn,1,1,"Data from the assay component ERF_ENZ_hFLT4 was analyzed at the assay endpoint, ERF_ENZ_hFLT4_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FLT4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2582,2535,ERF_ENZ_hFYN_dn,1,1,"Data from the assay component ERF_ENZ_hFYN was analyzed at the assay endpoint, ERF_ENZ_hFYN_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene FYN. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine phosphatase.",enzymatic activity,percent activity,positive,0,PP1,loss,protein,enzyme,kinase,non-receptor tyrosine phosphatase,0,0,1
2583,2536,ERF_ENZ_hGSK3b_dn,1,1,"Data from the assay component ERF_ENZ_hGSK3b was analyzed at the assay endpoint, ERF_ENZ_hGSK3b_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene GSK3B. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2584,2537,ERF_ENZ_hHDAC6_dn,1,1,"Data from the assay component ERF_ENZ_hHDAC6 was analyzed at the assay endpoint, ERF_ENZ_hHDAC6_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene HDAC6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the epigenetic enzyme intended target family, where the subfamily is histone deacetylase.",enzymatic activity,percent activity,positive,0,trichostatin A,loss,protein,enzyme,epigenetic enzyme,histone deacetylase,0,0,1
2585,2538,ERF_ENZ_hIRAK4_dn,1,1,"Data from the assay component ERF_ENZ_hIRAK4 was analyzed at the assay endpoint, ERF_ENZ_hIRAK4_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene IRAK4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2586,2539,ERF_ENZ_hJAK2_dn,1,1,"Data from the assay component ERF_ENZ_hJAK2 was analyzed at the assay endpoint, ERF_ENZ_hJAK2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene JAK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
2587,2540,ERF_ENZ_hKDR_dn,1,1,"Data from the assay component ERF_ENZ_hKDR was analyzed at the assay endpoint, ERF_ENZ_hKDR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene KDR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2588,2541,ERF_ENZ_hLCK_dn,1,1,"Data from the assay component ERF_ENZ_hLCK was analyzed at the assay endpoint, ERF_ENZ_hLCK_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene LCK. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
2589,2542,ERF_ENZ_hLYN_dn,1,1,"Data from the assay component ERF_ENZ_hLYN was analyzed at the assay endpoint, ERF_ENZ_hLYN_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene LYN. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
2590,2543,ERF_ENZ_hMAOA_dn,1,1,"Data from the assay component ERF_ENZ_hMAOA was analyzed at the assay endpoint, ERF_ENZ_hMAOA_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAOA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the stress response intended target family, where the subfamily is monoamine oxidase.",enzymatic activity,percent activity,positive,0,clorgiline,loss,protein,enzyme,stress response,monoamine oxidase,0,0,1
2591,2544,ERF_ENZ_hMAOB_dn,1,1,"Data from the assay component ERF_ENZ_hMAOB was analyzed at the assay endpoint, ERF_ENZ_hMAOB_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAOB. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the stress response intended target family, where the subfamily is monoamine oxidase.",enzymatic activity,percent activity,positive,0,deprenyl,loss,protein,enzyme,stress response,monoamine oxidase,0,0,1
2592,2545,ERF_ENZ_hMAPK1_dn,1,1,"Data from the assay component ERF_ENZ_hMAPK1 was analyzed at the assay endpoint, ERF_ENZ_hMAPK1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2593,2546,ERF_ENZ_hMAPK11_dn,1,1,"Data from the assay component ERF_ENZ_hMAPK11 was analyzed at the assay endpoint, ERF_ENZ_hMAPK11_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPK11. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,PP1 Analog II. 1NM-PP1,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2594,2547,ERF_ENZ_hMAPKAPK2_dn,1,1,"Data from the assay component ERF_ENZ_hMAPKAPK2 was analyzed at the assay endpoint, ERF_ENZ_hMAPKAPK2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPKAPK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2595,2548,ERF_ENZ_hMAPKAPK5_dn,1,1,"Data from the assay component ERF_ENZ_hMAPKAPK5 was analyzed at the assay endpoint, ERF_ENZ_hMAPKAPK5_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MAPKAPK5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2596,2549,ERF_ENZ_hMARK1_dn,1,1,"Data from the assay component ERF_ENZ_hMARK1 was analyzed at the assay endpoint, ERF_ENZ_hMARK1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MARK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2597,2550,ERF_ENZ_hMET_dn,1,1,"Data from the assay component ERF_ENZ_hMET was analyzed at the assay endpoint, ERF_ENZ_hMET_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MET. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2598,2551,ERF_ENZ_hMMP3_dn,1,1,"Data from the assay component ERF_ENZ_hMMP3 was analyzed at the assay endpoint, ERF_ENZ_hMMP3_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MMP3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metallopeptidase.",enzymatic activity,percent activity,positive,0,Ilomastat,loss,protein,enzyme,protease,matrix metallopeptidase,0,0,1
2599,2552,ERF_ENZ_hMMP9_dn,1,1,"Data from the assay component ERF_ENZ_hMMP9 was analyzed at the assay endpoint, ERF_ENZ_hMMP9_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MMP9. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metallopeptidase.",enzymatic activity,percent activity,positive,0,Ilomastat,loss,protein,enzyme,protease,matrix metallopeptidase,0,0,1
2600,2553,ERF_ENZ_hMSK1_dn,1,1,"Data from the assay component ERF_ENZ_hMSK1 was analyzed at the assay endpoint, ERF_ENZ_hMSK1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene MSK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2601,2554,ERF_ENZ_hNEK2_dn,1,1,"Data from the assay component ERF_ENZ_hNEK2 was analyzed at the assay endpoint, ERF_ENZ_hNEK2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NEK2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2602,2555,ERF_ENZ_hNTRK1_dn,1,1,"Data from the assay component ERF_ENZ_hNTRK1 was analyzed at the assay endpoint, ERF_ENZ_hNTRK1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NTRK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,receptor tyrosine kinase,0,0,1
2603,2556,ERF_ENZ_hPAK4_dn,1,1,"Data from the assay component ERF_ENZ_hPAK4 was analyzed at the assay endpoint, ERF_ENZ_hPAK4_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PAK4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2604,2557,ERF_ENZ_hPDE10A_dn,1,1,"Data from the assay component ERF_ENZ_hPDE10A was analyzed at the assay endpoint, ERF_ENZ_hPDE10A_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE10A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphodiesterase intended target family, where the subfamily is cyclic nucleotide signaling.",enzymatic activity,percent activity,positive,0,papaverine,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2605,2558,ERF_ENZ_hPDE4A_dn,1,1,"Data from the assay component ERF_ENZ_hPDE4A was analyzed at the assay endpoint, ERF_ENZ_hPDE4A_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE4A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphodiesterase intended target family, where the subfamily is cyclic nucleotide signaling.",enzymatic activity,percent activity,positive,0,Ro 20-1724,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2606,2559,ERF_ENZ_hPDE4D2_dn,1,1,"Data from the assay component ERF_ENZ_hPDE4D2 was analyzed at the assay endpoint, ERF_ENZ_hPDE4D2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PDE4D. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is phosphodiesterase.",enzymatic activity,percent activity,positive,0,rolipram,loss,protein,enzyme,esterase,phosphodiesterase,0,0,1
2607,2560,ERF_ENZ_hPKD2_dn,1,1,"Data from the assay component ERF_ENZ_hPKD2 was analyzed at the assay endpoint, ERF_ENZ_hPKD2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKD2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2608,2561,ERF_ENZ_hPRKAA1_dn,1,1,"Data from the assay component ERF_ENZ_hPRKAA1 was analyzed at the assay endpoint, ERF_ENZ_hPRKAA1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKAA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2609,2562,ERF_ENZ_hPRKACA_dn,1,1,"Data from the assay component ERF_ENZ_hPRKACA was analyzed at the assay endpoint, ERF_ENZ_hPRKACA_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKACA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,1-(5-ISOQUINOLINESULFONYL)-2-M,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2610,2563,ERF_ENZ_hPRKCZ_dn,1,1,"Data from the assay component ERF_ENZ_hPRKCZ was analyzed at the assay endpoint, ERF_ENZ_hPRKCZ_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PRKCZ. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2611,2564,ERF_ENZ_hPTEN_dn,1,1,"Data from the assay component ERF_ENZ_hPTEN was analyzed at the assay endpoint, ERF_ENZ_hPTEN_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PTEN. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is dual-specific phosphatase.",enzymatic activity,percent activity,positive,0,(NH4)6Mo7O24,loss,protein,enzyme,phosphatase,dual-specific phosphatase,0,0,1
2612,2565,ERF_ENZ_hPTGS2_dn,1,1,"Data from the assay component ERF_ENZ_hPTGS2 was analyzed at the assay endpoint, ERF_ENZ_hPTGS2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene PTGS2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the stress response intended target family, where the subfamily is cyclooxygenase.",binding,percent activity,positive,0,ns-398,loss,protein,enzyme,stress response,cyclooxygenase,0,0,1
2613,2566,ERF_ENZ_hPTPN11_dn,1,1,"Data from the assay component ERF_ENZ_hPTPN11 was analyzed at the assay endpoint, ERF_ENZ_hPTPN11_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PTPN11. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is protein tyrosine phosphatase.",enzymatic activity,percent activity,positive,0,sodium orthovanadate,loss,protein,enzyme,phosphatase,protein tyrosine phosphatase,0,0,1
2614,2567,ERF_ENZ_hPTPRB_dn,1,1,"Data from the assay component ERF_ENZ_hPTPRB was analyzed at the assay endpoint, ERF_ENZ_hPTPRB_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene PTPRB. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is protein tyrosine phosphatase.",binding,percent activity,positive,0,NA,loss,protein,receptor,phosphatase,protein tyrosine phosphatase,0,0,1
2615,2568,ERF_ENZ_hPTPRF_dn,1,1,"Data from the assay component ERF_ENZ_hPTPRF was analyzed at the assay endpoint, ERF_ENZ_hPTPRF_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene PTPRF. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is receptorÂ tyrosine phosphatase.",enzymatic activity,percent activity,positive,0,(NH4)6Mo7O24,loss,protein,enzyme,phosphatase,receptorÂ tyrosine phosphatase,0,0,1
2616,2569,ERF_ENZ_hPTPRM_dn,1,1,"Data from the assay component ERF_ENZ_hPTPRM was analyzed at the assay endpoint, ERF_ENZ_hPTPRM_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene PTPRM. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is protein tyrosine phosphatase.",binding,percent activity,positive,0,(NH4)6Mo7O24Â ,loss,protein,receptor,phosphatase,protein tyrosine phosphatase,0,0,1
2617,2570,ERF_ENZ_hRAF1,1,1,"Data from the assay component ERF_ENZ_hRAF1 was analyzed at the assay endpoint, ERF_ENZ_hRAF1, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene RAF1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2618,2571,ERF_ENZ_hROCK1_dn,1,1,"Data from the assay component ERF_ENZ_hROCK1 was analyzed at the assay endpoint, ERF_ENZ_hROCK1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ROCK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2619,2572,ERF_ENZ_hSGK1_dn,1,1,"Data from the assay component ERF_ENZ_hSGK1 was analyzed at the assay endpoint, ERF_ENZ_hSGK1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SGK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,serine/threonine kinase,0,0,1
2620,2573,ERF_ENZ_hSIRT3_dn,1,1,"Data from the assay component ERF_ENZ_hSIRT3 was analyzed at the assay endpoint, ERF_ENZ_hSIRT3_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SIRT3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the epigenetic enzyme intended target family, where the subfamily is histone deacetylase.",enzymatic activity,percent activity,positive,0,nicotinamide,loss,protein,enzyme,epigenetic enzyme,histone deacetylase,0,0,1
2621,2574,ERF_ENZ_hSRC_dn,1,1,"Data from the assay component ERF_ENZ_hSRC was analyzed at the assay endpoint, ERF_ENZ_hSRC_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SRC. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is non-receptor tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,non-receptor tyrosine kinase,0,0,1
2622,2575,ERF_ENZ_hSYK_dn,1,1,"Data from the assay component ERF_ENZ_hSYK was analyzed at the assay endpoint, ERF_ENZ_hSYK_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SYK. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is spleen tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,spleen tyrosine kinase,0,0,1
2623,2576,ERF_ENZ_hZAP70_dn,1,1,"Data from the assay component ERF_ENZ_hZAP70 was analyzed at the assay endpoint, ERF_ENZ_hZAP70_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene ZAP70. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is protein tyrosine kinase.",enzymatic activity,percent activity,positive,0,staurosporine,loss,protein,enzyme,kinase,protein tyrosine kinase,0,0,1
2624,2577,ERF_ENZ_rACFSK_Agonist,1,1,"Data from the assay component ERF_ENZ_rACFSK_Agonist was analyzed at the assay endpoint, ERF_ENZ_rACFSK_Agonist, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene ADCY5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenylyl cyclase.",binding,percent activity,positive,0,cAMP,gain,protein,receptor,gpcr,adenylyl cyclase,0,0,1
2625,2578,ERF_ENZ_rACFSK_Antagonist,1,1,"Data from the assay component ERF_ENZ_rACFSK_Antagonist was analyzed at the assay endpoint, ERF_ENZ_rACFSK_Antagonist, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ADCY5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenylyl cyclase.",binding,percent activity,positive,0,cAMP,loss,protein,receptor,gpcr,adenylyl cyclase,0,0,1
2626,2579,ERF_GPCR_binding_g5HT4_dn,1,1,"Data from the assay component ERF_GPCR_binding_g5HT4 was analyzed at the assay endpoint, ERF_GPCR_binding_g5HT4_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene HTR4 (homolog). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.",radioligand binding,percent activity,positive,0,CHEMBL83954,loss,protein,receptor,gpcr,serotonin,0,0,1
2627,2580,ERF_GPCR_binding_gANPA_dn,1,1,"Data from the assay component ERF_GPCR_binding_gANPA was analyzed at the assay endpoint, ERF_GPCR_binding_gANPA_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ANPA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is guanylyl cyclase.",binding,percent activity,positive,0,ANF (rat),loss,protein,receptor,gpcr,guanylyl cyclase,0,0,1
2628,2581,ERF_GPCR_binding_hADORA1_up,1,1,"Data from the assay component ERF_GPCR_binding_hADORA1 was analyzed at the assay endpoint, ERF_GPCR_binding_hADORA1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene ADORA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenosine.",binding,percent activity,positive,0,CPA,gain,protein,receptor,gpcr,adenosine,0,0,1
2629,2582,ERF_GPCR_binding_hADORA2A_up,1,1,"Data from the assay component ERF_GPCR_binding_hADORA2A was analyzed at the assay endpoint, ERF_GPCR_binding_hADORA2A_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene ADORA2A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adenosine.",binding,percent activity,positive,0,NECA,gain,protein,receptor,gpcr,adenosine,0,0,1
2630,2583,ERF_GPCR_binding_hADRA1A_dn,1,1,"Data from the assay component ERF_GPCR_binding_hADRA1A was analyzed at the assay endpoint, ERF_GPCR_binding_hADRA1A_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ADRA1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.",binding,percent activity,positive,0,WB-4101,loss,protein,receptor,gpcr,adrenoceptor,0,0,1
2631,2584,ERF_GPCR_binding_hADRA2A_dn,1,1,"Data from the assay component ERF_GPCR_binding_hADRA2A was analyzed at the assay endpoint, ERF_GPCR_binding_hADRA2A_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRA2A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.",radioligand binding,percent activity,positive,0,yohimbine,loss,protein,receptor  ,gpcr,adrenoceptor,0,0,1
2632,2585,ERF_GPCR_binding_hADRA2C_dn,1,1,"Data from the assay component ERF_GPCR_binding_hADRA2C was analyzed at the assay endpoint, ERF_GPCR_binding_hADRA2C_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRA2C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.",radioligand binding,percent activity,positive,0,yohimbine,loss,protein,receptor  ,gpcr,adrenoceptor,0,0,1
2633,2586,ERF_GPCR_binding_hADRB1_dn,1,1,"Data from the assay component ERF_GPCR_binding_hADRB1 was analyzed at the assay endpoint, ERF_GPCR_binding_hADRB1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRB1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.",radioligand binding,percent activity,positive,0,S(-)-Propranolol,loss,protein,receptor  ,gpcr,adrenoceptor,0,0,1
2634,2587,ERF_GPCR_binding_hADRB2_dn,1,1,"Data from the assay component ERF_GPCR_binding_hADRB2 was analyzed at the assay endpoint, ERF_GPCR_binding_hADRB2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene ADRB2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.",binding,percent activity,positive,0,ICI 118551,loss,protein,receptor,gpcr,adrenoceptor,0,0,1
2635,2588,ERF_GPCR_binding_hADRB3_dn,1,1,"Data from the assay component ERF_GPCR_binding_hADRB3 was analyzed at the assay endpoint, ERF_GPCR_binding_hADRB3_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene ADRB3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is adrenoceptor.",radioligand binding,percent activity,positive,0,alprenolol ,loss,protein,receptor  ,gpcr,adrenoceptor,0,0,1
2636,2589,ERF_GPCR_binding_hAGTR1_up,1,1,"Data from the assay component ERF_GPCR_binding_hAGTR1_up was analyzed at the assay endpoint, ERF_GPCR_binding_hAGTR1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene AGTR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is angiotensin.",radioligand binding,percent activity,positive,0,saralasin,gain,protein,receptor  ,gpcr,angiotensin,0,0,1
2637,2590,ERF_GPCR_binding_hAGTR2_up,1,1,"Data from the assay component ERF_GPCR_binding_hAGTR2 was analyzed at the assay endpoint, ERF_GPCR_binding_hAGTR2_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene AGTR2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is angiotensin.",radioligand binding,percent activity,positive,0,saralasin,gain,protein,receptor  ,gpcr,angiotensin,0,0,1
2638,2591,ERF_GPCR_binding_hAVPR1A_up,1,1,"Data from the assay component ERF_GPCR_binding_hAVPR1A was analyzed at the assay endpoint, ERF_GPCR_binding_hAVPR1A_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene AVPR1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is vasopressin and oxytocin.",binding,percent activity,positive,0,"[d(CH2)51,Tyr(Me)2]-AVP",gain,protein,receptor,gpcr,vasopressin and oxytocin,0,0,1
2639,2592,ERF_GPCR_binding_hBDKRB2_up,1,1,"Data from the assay component ERF_GPCR_binding_hBDKRB2 was analyzed at the assay endpoint, ERF_GPCR_binding_hBDKRB2_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene BDKRB2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is bradykinin.",binding,percent activity,positive,0,Npc 567,gain,protein,receptor,gpcr,bradykinin,0,0,1
2640,2593,ERF_GPCR_binding_hCCKAR_dn,1,1,"Data from the assay component ERF_GPCR_binding_hCCKAR was analyzed at the assay endpoint, ERF_GPCR_binding_hCCKAR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CCKAR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is cholecystokinin.",binding,percent activity,positive,0,devazepide,loss,protein,receptor,gpcr,cholecystokinin,0,0,1
2641,2594,ERF_GPCR_binding_hCCKBR_up,1,1,"Data from the assay component ERF_GPCR_binding_hCCKBR was analyzed at the assay endpoint, ERF_GPCR_binding_hCCKBR_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene CCKBR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is cholecystokinin.",binding,percent activity,positive,0,CCK-8s,gain,protein,receptor,gpcr,cholecystokinin,0,0,1
2642,2595,ERF_GPCR_binding_hCHRM1_dn,1,1,"Data from the assay component ERF_GPCR_binding_hCHRM1 was analyzed at the assay endpoint, ERF_GPCR_binding_hCHRM1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).",binding,percent activity,positive,0,pirenzepine,loss,protein,receptor,gpcr,acetylcholine (Muscarinic),0,0,1
2643,2596,ERF_GPCR_binding_hCHRM2_dn,1,1,"Data from the assay component ERF_GPCR_binding_hCHRM2 was analyzed at the assay endpoint, ERF_GPCR_binding_hCHRM2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).",binding,percent activity,positive,0,methoctramine,loss,protein,receptor,gpcr,acetylcholine (Muscarinic),0,0,1
2644,2597,ERF_GPCR_binding_hCHRM3_dn,1,1,"Data from the assay component ERF_GPCR_binding_hCHRM3 was analyzed at the assay endpoint, ERF_GPCR_binding_hCHRM3_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).",binding,percent activity,positive,0,4-Damp methiodide,loss,protein,receptor,gpcr,acetylcholine (Muscarinic),0,0,1
2645,2598,ERF_GPCR_binding_hCHRM4_dn,1,1,"Data from the assay component ERF_GPCR_binding_hCHRM4 was analyzed at the assay endpoint, ERF_GPCR_binding_hCHRM4_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).",binding,percent activity,positive,0,4-Damp methiodide,loss,protein,receptor,gpcr,acetylcholine (Muscarinic),0,0,1
2646,2599,ERF_GPCR_binding_hCHRM5_dn,1,1,"Data from the assay component ERF_GPCR_binding_hCHRM5 was analyzed at the assay endpoint, ERF_GPCR_binding_hCHRM5_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CHRM5. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is acetylcholine (Muscarinic).",binding,percent activity,positive,0,4-Damp methiodide,loss,protein,receptor,gpcr,acetylcholine (Muscarinic),0,0,1
2647,2600,ERF_GPCR_binding_hCYSLTR1_up,1,1,"Data from the assay component ERF_GPCR_binding_hCYSLTR1 was analyzed at the assay endpoint, ERF_GPCR_binding_hCYSLTR1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene CYSLTR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is leukotriene.",binding,percent activity,positive,0,leukotriene D4,gain,protein,receptor,gpcr,leukotriene,0,0,1
2648,2601,ERF_GPCR_binding_hDRD1_dn,1,1,"Data from the assay component ERF_GPCR_binding_hDRD1 was analyzed at the assay endpoint, ERF_GPCR_binding_hDRD1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene DRD1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is dopamine.",binding,percent activity,positive,0,SCH 23390,loss,protein,receptor,gpcr,dopamine,0,0,1
2649,2602,ERF_GPCR_binding_hDRD2_dn,1,1,"Data from the assay component ERF_GPCR_binding_hDRD2 was analyzed at the assay endpoint, ERF_GPCR_binding_hDRD2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene DRD2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is dopamine.",binding,percent activity,positive,0,butaclamol,loss,protein,receptor,gpcr,dopamine,0,0,1
2650,2603,ERF_GPCR_binding_hDRD4_dn,1,1,"Data from the assay component ERF_GPCR_binding_hDRD4 was analyzed at the assay endpoint, ERF_GPCR_binding_hDRD4_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene DRD4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is dopamine.",binding,percent activity,positive,0,spiperone,loss,protein,receptor,gpcr,dopamine,0,0,1
2651,2604,ERF_GPCR_binding_hGALR1_up,1,1,"Data from the assay component ERF_GPCR_binding_hGALR1 was analyzed at the assay endpoint, ERF_GPCR_binding_hGALR1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene GALR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is galanin.",binding,percent activity,positive,0,galanin,gain,protein,receptor,gpcr,galanin,0,0,1
2652,2605,ERF_GPCR_binding_hHRH1_dn,1,1,"Data from the assay component ERF_GPCR_binding_hHRH1 was analyzed at the assay endpoint, ERF_GPCR_binding_hHRH1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene HRH1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is histamine.",binding,percent activity,positive,0,pyrilamine,loss,protein,receptor,gpcr,histamine,0,0,1
2653,2606,ERF_GPCR_binding_hHTR1A_up,1,1,"Data from the assay component ERF_GPCR_binding_hHTR1A was analyzed at the assay endpoint, ERF_GPCR_binding_hHTR1A_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.",binding,percent activity,positive,0,8-OH-DPAT,gain,protein,receptor,gpcr,serotonin,0,0,1
2654,2607,ERF_GPCR_binding_hHTR5A_up,1,1,"Data from the assay component ERF_GPCR_binding_hHTR5A was analyzed at the assay endpoint, ERF_GPCR_binding_hHTR5A_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR5A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.",binding,percent activity,positive,0,serotonin,gain,protein,receptor,gpcr,serotonin,0,0,1
2655,2608,ERF_GPCR_binding_hHTR6_up,1,1,"Data from the assay component ERF_GPCR_binding_hHTR6 was analyzed at the assay endpoint, ERF_GPCR_binding_hHTR6_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR6. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.",binding,percent activity,positive,0,serotonin,gain,protein,receptor,gpcr,serotonin,0,0,1
2656,2609,ERF_GPCR_binding_hHTR7_up,1,1,"Data from the assay component ERF_GPCR_binding_hHTR7 was analyzed at the assay endpoint, ERF_GPCR_binding_hHTR7_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene HTR7. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.",binding,percent activity,positive,0,serotonin,gain,protein,receptor,gpcr,serotonin,0,0,1
2657,2610,ERF_GPCR_binding_hLTB4R_up,1,1,"Data from the assay component ERF_GPCR_binding_hLTB4R was analyzed at the assay endpoint, ERF_GPCR_binding_hLTB4R_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene LTB4R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is leukotriene.",binding,percent activity,positive,0,LTB4,gain,protein,receptor,gpcr,leukotriene,0,0,1
2658,2611,ERF_GPCR_binding_hNPY1R_up,1,1,"Data from the assay component ERF_GPCR_binding_hNPY1R was analyzed at the assay endpoint, ERF_GPCR_binding_hNPY1R_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NPY1R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is neuropeptide Y.",binding,percent activity,positive,0,NPY,gain,protein,receptor,gpcr,neuropeptide Y,0,0,1
2659,2612,ERF_GPCR_binding_hNPY2R_up,1,1,"Data from the assay component ERF_GPCR_binding_hNPY2R was analyzed at the assay endpoint, ERF_GPCR_binding_hNPY2R_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NPY2R. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is neuropeptide Y.",binding,percent activity,positive,0,NPY,gain,protein,receptor,gpcr,neuropeptide Y,0,0,1
2660,2613,ERF_GPCR_binding_hNTSR1_up,1,1,"Data from the assay component ERF_GPCR_binding_hNTSR1 was analyzed at the assay endpoint, ERF_GPCR_binding_hNTSR1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NTSR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is neurotensin.",binding,percent activity,positive,0,neurotensin,gain,protein,receptor,gpcr,neurotensin,0,0,1
2661,2614,ERF_GPCR_binding_hOPRD1_up,1,1,"Data from the assay component ERF_GPCR_binding_hOPRD1 was analyzed at the assay endpoint, ERF_GPCR_binding_hOPRD1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OPRD1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is opioid.",binding,percent activity,positive,0,DPDPE,gain,protein,receptor,gpcr,opioid,0,0,1
2662,2615,ERF_GPCR_binding_hOPRL1_up,1,1,"Data from the assay component ERF_GPCR_binding_hOPRL1 was analyzed at the assay endpoint, ERF_GPCR_binding_hOPRL1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OPRL1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is opioid.",binding,percent activity,positive,0,nociceptin,gain,protein,receptor,gpcr,opioid,0,0,1
2663,2616,ERF_GPCR_binding_hOPRM1_up,1,1,"Data from the assay component ERF_GPCR_binding_hOPRM1 was analyzed at the assay endpoint, ERF_GPCR_binding_hOPRM1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OPRM1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is opioid.",binding,percent activity,positive,0,DAMGO,gain,protein,receptor,gpcr,opioid,0,0,1
2664,2617,ERF_GPCR_binding_hOXTR_up,1,1,"Data from the assay component ERF_GPCR_binding_hOXTR was analyzed at the assay endpoint, ERF_GPCR_binding_hOXTR_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene OXTR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is vasopressin and oxytocin.",binding,percent activity,positive,0,oxytocin,gain,protein,receptor,gpcr,vasopressin and oxytocin,0,0,1
2665,2618,ERF_GPCR_binding_hTACR1_up,1,1,"Data from the assay component ERF_GPCR_binding_hTACR1 was analyzed at the assay endpoint, ERF_GPCR_binding_hTACR1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene TACR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is tachykinin.",radioligand binding,percent activity,positive,0,L-703606,gain,protein,receptor,gpcr,tachykinin,0,0,1
2666,2619,ERF_GPCR_binding_hTACR2_dn,1,1,"Data from the assay component ERF_GPCR_binding_hTACR2 was analyzed at the assay endpoint, ERF_GPCR_binding_hTACR2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene TACR2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is tachykinin.",radioligand binding,percent activity,positive,0,MEN-10376,loss,protein,receptor,gpcr,tachykinin,0,0,1
2667,2620,ERF_GPCR_binding_hVIPR1_up,1,1,"Data from the assay component ERF_GPCR_binding_hVIPR1 was analyzed at the assay endpoint, ERF_GPCR_binding_hVIPR1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene VIPR1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is VIP and PACAP.",binding,percent activity,positive,0,VIP ,gain,protein,receptor,gpcr,VIP and PACAP,0,0,1
2668,2621,ERF_GPCR_binding_rGHB_dn,1,1,"Data from the assay component ERF_GPCR_binding_rGHB was analyzed at the assay endpoint, ERF_GPCR_binding_rGHB_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene TSPAN17. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is ghb  .",binding,percent activity,positive,0,NCS382,loss,protein,receptor,gpcr,ghb  ,0,0,1
2669,2622,ERF_GPCR_binding_rPY2_up,1,1,"Data from the assay component ERF_GPCR_binding_rPY2 was analyzed at the assay endpoint, ERF_GPCR_binding_rPY2_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene P2RY1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is P2Y.",binding,percent activity,positive,0,datpalphas,gain,protein,receptor,gpcr,P2Y,0,0,1
2670,2623,ERF_IC_binding_rCACNA1C_Dihydropyridine_dn,1,1,"Data from the assay component ERF_IC_binding_rCACNA1C_Dihydropyridine was analyzed at the assay endpoint, ERF_IC_binding_rCACNA1C_Dihydropyridine_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CACNA1C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Calcium).",binding,percent activity,positive,0,nitrendipine,loss,protein,transporter,ion channel,voltage gated (Calcium),0,0,1
2671,2624,ERF_IC_binding_rCACNA1C_Diltiazem_dn,1,1,"Data from the assay component ERF_IC_binding_rCACNA1C_Diltiazem was analyzed at the assay endpoint, ERF_IC_binding_rCACNA1C_Diltiazem_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene CACNA1C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Calcium).",binding,percent activity,positive,0,diltiazem,loss,protein,transporter,ion channel,voltage gated (Calcium),0,0,1
2672,2625,ERF_IC_binding_rKCNJ1_dn,1,1,"Data from the assay component ERF_IC_binding_rKCNJ1 was analyzed at the assay endpoint, ERF_IC_binding_rKCNJ1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene KCNJ1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Potassium).",binding,percent activity,positive,0,glyburide potassium salt,loss,protein,transporter,ion channel,voltage gated (Potassium),0,0,1
2673,2626,ERF_IC_binding_rKCNN1_dn,1,1,"Data from the assay component ERF_IC_binding_rKCNN1  was analyzed at the assay endpoint, ERF_IC_binding_rKCNN1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene Kcnn1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Potassium).",binding,percent activity,positive,0,apamin,loss,protein,transporter,ion channel,voltage gated (Potassium),0,0,1
2674,2627,ERF_IC_binding_rSCN1A_dn,1,1,"Data from the assay component ERF_IC_binding_rSCN1A was analyzed at the assay endpoint, ERF_IC_binding_rSCN1A_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene SCN1A. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is voltage gated (Sodium).",binding,percent activity,positive,0,veratridine,loss,protein,transporter,ion channel,voltage gated (Sodium),0,0,1
2675,2628,ERF_LGIC_binding_hGABRA1_up,1,1,"Data from the assay component ERF_LGIC_binding_hGABRA1 was analyzed at the assay endpoint, ERF_LGIC_binding_hGABRA1_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene GABRA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated.",binding,percent activity,positive,0,muscimol,gain,protein,transporter,ion channel,ligand-gated ion channel,0,0,1
2676,2629,ERF_LGIC_binding_rGLRA1_dn,1,1,"Data from the assay component ERF_LGIC_binding_rGLRA1 was analyzed at the assay endpoint, ERF_LGIC_binding_rGLRA1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GLRA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glycine).",binding,percent activity,positive,0,strychnine,loss,protein,transporter,ion channel,ligand-gated (glycine),0,0,1
2677,2630,ERF_LGIC_binding_rGRIA1_dn,1,1,"Data from the assay component ERF_LGIC_binding_rGRIA1 was analyzed at the assay endpoint, ERF_LGIC_binding_rGRIA1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GRIA1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glutamate, Ionotropic).",binding,percent activity,positive,0,L-Glutamate,loss,protein,transporter,ion channel,"ligand-gated (glutamate, Ionotropic)",0,0,1
2678,2631,ERF_LGIC_binding_rGRIK1_dn,1,1,"Data from the assay component ERF_LGIC_binding_rGRIK1 was analyzed at the assay endpoint, ERF_LGIC_binding_rGRIK1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GRIK1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glutamate, Ionotropic).",binding,percent activity,positive,0,kainic acid,loss,protein,transporter,ion channel,"ligand-gated (glutamate, Ionotropic)",0,0,1
2679,2632,ERF_LGIC_binding_rGRIN1_dn,1,1,"Data from the assay component ERF_LGIC_binding_rGRIN1 was analyzed at the assay endpoint, ERF_LGIC_binding_rGRIN1_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene GRIN1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is ligand-gated (glutamate, Ionotropic).",binding,percent activity,positive,0,NA,loss,protein,transporter,ion channel,"ligand-gated (glutamate, Ionotropic)",0,0,1
2680,2633,ERF_MP_binding_hTSPO_dn,1,1,"Data from the assay component ERF_MP_binding_hTSPO was analyzed at the assay endpoint, ERF_MP_binding_hTSPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene TSPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the membrane protein intended target family, where the subfamily is mitochondrial associated translocator protein.",binding,percent activity,positive,0,PK 11195,loss,protein,receptor,membrane protein,mitochondrial associated translocator protein,0,0,1
2681,2634,ERF_NR_binding_hAR_up,1,1,"Data from the assay component ERF_NR_binding_hAR was analyzed at the assay endpoint, ERF_NR_binding_hAR_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene AR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is androgens.",radioligand binding,percent activity,positive,0,testosterone,gain,protein,receptor,nuclear receptor,androgens,0,0,1
2682,2635,ERF_NR_binding_hFXR_Antagonist,1,1,"Data from the assay component ERF_NR_binding_hFXR_Antagonist was analyzed at the assay endpoint, ERF_NR_binding_hFXR_Antagonist, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NR1H4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is liver X receptor.",binding,percent activity,positive,0,Z-Guggulsterone,loss,protein,receptor,nuclear receptor,liver X receptor,0,0,1
2683,2636,ERF_NR_binding_hGR_up,1,1,"Data from the assay component ERF_NR_binding_hGR was analyzed at the assay endpoint, ERF_NR_binding_hGR_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene NR3C1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",binding,percent activity,positive,0,triamcinolone,gain,protein,receptor,nuclear receptor,steroidal,0,0,1
2684,2637,ERF_NR_binding_hHTR2C_dn,1,1,"Data from the assay component ERF_NR_binding_hHTR2C was analyzed at the assay endpoint, ERF_NR_binding_hHTR2C_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene HTR2C. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is serotonin.",binding,percent activity,positive,0,SB 242084,loss,protein,receptor,gpcr,serotonin,0,0,1
2685,2638,ERF_NR_binding_hPGR_up,1,1,"Data from the assay component ERF_NR_binding_hPGR was analyzed at the assay endpoint, ERF_NR_binding_hPGR_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene PGR. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",binding,percent activity,positive,0,promegestone,gain,protein,receptor,nuclear receptor,steroidal,0,0,1
2686,2639,ERF_NR_binding_hPPARA_up,1,1,"Data from the assay component ERF_NR_binding_hPPARA was analyzed at the assay endpoint, ERF_NR_binding_hPPARA_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene PPARA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",binding,percent activity,positive,0,GW 7647,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2687,2640,ERF_NR_binding_hPPARG_up,1,1,"Data from the assay component ERF_NR_binding_hPPARG was analyzed at the assay endpoint, ERF_NR_binding_hPPARG_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in binding as they relate to gene PPARG. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",binding,percent activity,positive,0,rosiglitazone,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2688,2641,ERF_NR_binding_hRARa_up,1,1,"Data from the assay component ERF_NR_binding_hRARa was analyzed at the assay endpoint, ERF_NR_binding_hRARa_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in radioligand binding as they relate to gene RARA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is retinoic acid receptor.",binding,percent activity,positive,0,9-cis-Retinoic acid,gain,protein,receptor,nuclear receptor,retinoic acid receptor,0,0,1
2689,2642,ERF_NR_hTHRA_Agonist,1,1,"Data from the assay component ERF_NR_hTHRA_Agonist was analyzed at the assay endpoint, ERF_NR_hTHRA_Agonist, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of agonist, gain-of-signal activity can be used to understand changes in protein-protein interaction as they relate to gene THRA. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",agonist,percent activity,positive,0,NA,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2690,2643,ERF_NR_binding_rI2_dn,1,1,"Data from the assay component ERF_NR_binding_rI2 was analyzed at the assay endpoint, ERF_NR_binding_rI2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in radioligand binding as they relate to gene NISCH (homolog). To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is imidazoline receptor.",binding,percent activity,positive,0,idazoxan,loss,protein,receptor,oxidoreductase,imidazoline receptor,0,0,1
2691,2644,ERF_TR_binding_hSLC35B3_dn,1,1,"Data from the assay component ERF_TR_binding_hSLC35B3 was analyzed at the assay endpoint, ERF_TR_binding_hSLC35B3_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in transporter binding as they relate to gene SLC29A1. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is nucleoside transporter.",binding,percent activity,positive,0,nitrobenzylthioinosine,loss,protein,transporter,transporter,nucleoside transporter,0,0,1
2692,2645,ERF_TR_binding_hSLC6A2_dn,1,1,"Data from the assay component ERF_TR_binding_hSLC6A2 was analyzed at the assay endpoint, ERF_TR_binding_hSLC6A2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SLC6A2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is SLC6 / Monoamine.",binding,percent activity,positive,0,protriptyline,loss,protein,transporter,transporter,SLC6 / Monoamine,0,0,1
2693,2646,ERF_TR_binding_hSLC6A3_dn,1,1,"Data from the assay component ERF_TR_binding_hSLC6A3 was analyzed at the assay endpoint, ERF_TR_binding_hSLC6A3_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in binding as they relate to gene SLC6A3. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is SLC6 / Monoamine.",binding,percent activity,positive,0,BTCP,loss,protein,transporter,transporter,SLC6 / Monoamine,0,0,1
2694,2647,ERF_TR_binding_hSLC6A4_dn,1,1,"Data from the assay component ERF_TR_binding_hSLC6A4 was analyzed at the assay endpoint, ERF_TR_binding_hSLC6A4_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene SLC6A4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is SLC6 / Monoamine.",binding,percent activity,positive,0,imipramine,loss,protein,transporter,transporter,SLC6 / Monoamine,0,0,1
2695,2648,ERF_TR_binding_rSLC18A2_dn,1,1,"Data from the assay component ERF_TR_binding_rSLC18A2 was analyzed at the assay endpoint, ERF_TR_binding_rSLC18A2_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in transporter binding as they relate to gene SLC18A2. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is vesicular transporter.",binding,percent activity,positive,0,tetrabenazine,loss,protein,transporter,transporter,vesicular transporter,0,0,1
2696,2649,ERF_TR_binding_rTSPO_dn,1,1,"Data from the assay component ERF_TR_binding_rTSPO was analyzed at the assay endpoint, ERF_TR_binding_rTSPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand changes in transporter binding as they relate to gene TSPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is cholesterol transporter.",binding,percent activity,positive,0,diazepam,loss,protein,transporter,transporter,cholesterol transporter,0,0,1
2697,2650,UKN_HCS_IMR90_UKN2_neural_migration_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2698,2650,UKN_HCS_IMR90_UKN2_neural_migration_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2699,2651,UKN_HCS_IMR90_UKN2_cell_viability_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2700,2651,UKN_HCS_IMR90_UKN2_cell_viability_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2701,2652,UKN_HCS_LUHMES_UKN4_neurite_outgrowth_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2702,2652,UKN_HCS_LUHMES_UKN4_neurite_outgrowth_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2703,2653,UKN_HCS_LUHMES_UKN4_cell_viability_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2704,2653,UKN_HCS_LUHMES_UKN4_cell_viability_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2705,2654,ERFPL_NR_binding_hPPARG_up,1,1,"Data from the assay component ERFPL_NR_binding_hPPARG was analyzed at the assay endpoint, ERFPL_NR_binding_hPPARG_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding receptor, gain-of-signal activity can be used to understand changes in binding receptor as they relate to gene PPARG.To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",binding,percent activity,positive,0,Rosiglitazone,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2707,2655,TAMU_HCS_cardiomyocyte_1.5hr_Percent.Positive.W2,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,percent of positive W2 stained cells/cell count,cell cycle,cell morphology,0,1,1
2709,2656, TAMU_HCS_cardiomyocyte_1.5hr_All.Cells.Mean.Area,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,average cell area,cell cycle,cell morphology,0,1,1
2806,2716,CCTE_Padilla_ZF_144hpf_BEHAV_TOTAL_SUM_dn,0,0,NULL,,percent activity,,0,,,,,,,0,0,1
2807,2716,CCTE_Padilla_ZF_144hpf_BEHAV_TOTAL_SUM_up,0,0,NULL,,percent activity,,0,,,,,,,0,0,1
2711,2657, TAMU_HCS_cardiomyocyte_1.5hr_All.Nuclei.Mean.Area,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,average nuclear area,cell cycle,cell morphology,0,1,1
2804,2715,CCTE_Padilla_ZF_144hpf_BEHAV_LIGHT_SUM_dn,0,0,NULL,,percent activity,,0,,,,,,,0,0,1
2805,2715,CCTE_Padilla_ZF_144hpf_BEHAV_LIGHT_SUM_up,0,0,NULL,,percent activity,,0,,,,,,,0,0,1
2713,2658, TAMU_HCS_cardiomyocyte_1.5hr_All.Nuclei.Mean.Average.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,average nuclear stain intensity/nuclear area,cell cycle,cell morphology,0,1,1
2802,2714,CCTE_Padilla_ZF_144hpf_BEHAV_LIGHT_MAX_dn,0,0,NULL,,percent activity,,0,,,,,,,0,0,1
2803,2714,CCTE_Padilla_ZF_144hpf_BEHAV_LIGHT_MAX_up,0,0,NULL,,percent activity,,0,,,,,,,0,0,1
2715,2659, TAMU_HCS_cardiomyocyte_1.5hr_All.Nuclei.Mean.Integer.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,(total nuclear stain intensity/nuclear area)/cell count,cell cycle,cell morphology,0,1,1
2800,2713,CCTE_Padilla_ZF_144hpf_BEHAV_DARK_SUM_dn,0,0,NULL,,percent activity,,0,,,,,,,0,0,1
2801,2713,CCTE_Padilla_ZF_144hpf_BEHAV_DARK_SUM_up,0,0,NULL,,percent activity,,0,,,,,,,0,0,1
2717,2660, TAMU_HCS_cardiomyocyte_1.5hr_All.W2.Mean.Stain.Area,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,average stained mitochondrial area/cell count,cell cycle,cell morphology,0,1,1
2797,2710,CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten_loss,1,1,"Data from the CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,aphidicolin (10uM),loss,cellular,cellular,cell cycle,proliferation,0,0,1
2798,2712,CCTE_Padilla_ZF_144hpf_BEHAV_DARK_MIN_dn,0,0,NULL,,percent activity,,0,,,,,,,0,0,1
2799,2712,CCTE_Padilla_ZF_144hpf_BEHAV_DARK_MIN_up,0,0,NULL,,percent activity,,0,,,,,,,0,0,1
2719,2661, TAMU_HCS_cardiomyocyte_1.5hr_All.W2.Mean.Stain.Average.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,(average intensity of W2/stained area)/cell count,cell cycle,cell morphology,0,1,1
2795,2711,CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten_loss,1,1,"Data from the CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,aphidicolin (10uM),loss,cellular,cellular,cell cycle,proliferation,0,0,1
2796,2709,CCTE_Mundy_HCI_hNP1_Pro_ObjectCount_loss,1,1,"Data from the CCTE_Mundy_HCI_hNP1_Pro_ObjectCount was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ObjectCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,aphidicolin (10uM),loss,cellular,cellular,cell cycle,proliferation,0,0,1
2721,2662, TAMU_HCS_cardiomyocyte_1.5hr_All.W2.Mean.Stain.Integer.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,(total intensity of W2/stained area)/cell count,cell cycle,cell morphology,0,1,1
2793,2691,CCTE_Mundy_HCI_hNP1_Casp3_7_gain,1,1,"Data from the CCTE_Mundy_HCI_hNP1_Casp3_7 was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Casp3_7_gain in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain -of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,staurosporine (0.1 uM),gain,cellular,cellular,cell cycle,apoptosis,0,0,1
2794,2700,CCTE_Mundy_HCI_hNP1_CellTiter_loss,1,1,"Data from the CCTE_Mundy_HCI_hNP1_CellTiter was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_CellTiter_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss -of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,staurosporine (0.1 uM),loss,cellular,cell count,cell cycle,cell count,0,0,1
2723,2663, TAMU_HCS_cardiomyocyte_1.5hr_Positive.W2,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,positive W2 stained cell count,cell cycle,cell morphology,0,1,1
2791,2693,CCTE_Mundy_HCI_hN2_NOG_NeuriteLength_loss,1,1,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
2792,2692,CCTE_Mundy_HCI_hN2_NOG_NeuronCount_loss,1,1,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
2725,2664, TAMU_HCS_cardiomyocyte_1.5hr_Positive.W2.Mean.Stain.Area,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,average stained area in positive W2 stained cells,cell cycle,cell morphology,0,1,1
2788,2708,CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,sodium orthovanadate (10uM),loss,cellular,cellular,neurodevelopment,synaptogenesis and neurite maturation,0,0,1
2789,2695,CCTE_Mundy_HCI_hN2_NOG_BPCount_loss,1,1,"Data from the CCTE_Mundy_HCI_hN2_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
2790,2694,CCTE_Mundy_HCI_hN2_NOG_NeuriteCount_loss,1,1,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
2727,2665, TAMU_HCS_cardiomyocyte_1.5hr_Positive.W2.Mean.Stain.Average.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,(average intensity of W2 stain/stained area)/ area in positive W2 cells,cell cycle,cell morphology,0,1,1
2786,2703,CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,sodium orthovanadate (10uM),loss,cellular,cellular,neurodevelopment,synaptogenesis and neurite maturation,0,0,1
2787,2701,CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,sodium orthovanadate (10uM),loss,cellular,cellular,neurodevelopment,synaptogenesis and neurite maturation,0,0,1
2729,2666, TAMU_HCS_cardiomyocyte_1.5hr_Positive.W2.Mean.Stain.Integer.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,total intensity of W2 stain area/positive W2 cell count,cell cycle,cell morphology,0,1,1
2785,2704,CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,sodium orthovanadate (10uM),loss,cellular,cellular,neurodevelopment,synaptogenesis and neurite maturation,0,0,1
2731,2667, TAMU_HCS_cardiomyocyte_1.5hr_Total.Cells,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,cell count,cell cycle,cell morphology,0,1,1
2732,2668,TAMU_HCS_cardiomyocyte_24hr_Percent.Positive.W2,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,percent of positive W2 stained cells/cell count,cell cycle,cell morphology,0,1,1
2784,2705,CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,sodium orthovanadate (10uM),loss,cellular,cellular,neurodevelopment,synaptogenesis and neurite maturation,0,0,1
2783,2706,CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,sodium orthovanadate (10uM),loss,cellular,cellular,neurodevelopment,synaptogenesis and neurite maturation,0,0,1
2735,2669, TAMU_HCS_cardiomyocyte_24hr_All.Cells.Mean.Area,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,average cell area,cell cycle,cell morphology,0,1,1
2737,2670, TAMU_HCS_cardiomyocyte_24hr_All.Nuclei.Mean.Area,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,average nuclear area,cell cycle,cell morphology,0,1,1
2738,2671, TAMU_HCS_cardiomyocyte_24hr_All.Nuclei.Mean.Average.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,average nuclear stain intensity/nuclear area,cell cycle,cell morphology,0,1,1
2741,2672, TAMU_HCS_cardiomyocyte_24hr_All.Nuclei.Mean.Integer.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,(total nuclear stain intensity/nuclear area)/cell count,cell cycle,cell morphology,0,1,1
2776,2690,ERF_NR_binding_hFXR_Agonist,0,0,"Data from the assay component ERF_NR_binding_hFXR_Agonist was analyzed at the assay endpoint, ERF_NR_binding_hFXR_Agonist, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand changes in enzymatic activity as they relate to gene NR1H4. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is liver X receptor.",binding,percent activity,positive,0,CDCA,gain,protein,receptor,nuclear receptor,non-steroidal,0,0,1
2743,2673, TAMU_HCS_cardiomyocyte_24hr_All.W2.Mean.Stain.Area,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,average stained mitochondrial area/cell count,cell cycle,cell morphology,0,1,1
2745,2674, TAMU_HCS_cardiomyocyte_24hr_All.W2.Mean.Stain.Average.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,(average intensity of W2/stained area)/cell count,cell cycle,cell morphology,0,1,1
2747,2675, TAMU_HCS_cardiomyocyte_24hr_All.W2.Mean.Stain.Integer.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,(total intensity of W2/stained area)/cell count,cell cycle,cell morphology,0,1,1
2749,2676, TAMU_HCS_cardiomyocyte_24hr_Positive.W2,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,positive W2 stained cell count,cell cycle,cell morphology,0,1,1
2751,2677, TAMU_HCS_cardiomyocyte_24hr_Positive.W2.Mean.Stain.Area,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,average stained area in positive W2 stained cells,cell cycle,cell morphology,0,1,1
2753,2678, TAMU_HCS_cardiomyocyte_24hr_Positive.W2.Mean.Stain.Average.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,(average intensity of W2 stain/stained area)/ area in positive W2 cells,cell cycle,cell morphology,0,1,1
2755,2679, TAMU_HCS_cardiomyocyte_24hr_Positive.W2.Mean.Stain.Integer.Intensity,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,total intensity of W2 stain area/positive W2 cell count,cell cycle,cell morphology,0,1,1
2757,2680, TAMU_HCS_cardiomyocyte_24hr_Total.Cells,0,0,NA,viability,log2_fold_induction,negative,0,NA,loss,cellular,cell count,cell cycle,cell morphology,0,1,1
2758,2681,TAMU_PeakParms_cardiomyocyte_BPM_up,0,0,NA,signaling,percent activity,positive,0,NA,gain,cellular,cellular,cardiomyocyte function,beating,0,0,1
2759,2681,TAMU_PeakParms_cardiomyocyte_BPM_dn,0,0,NA,signaling,percent activity,negative,0,NA,loss,cellular,cellular,cardiomyocyte function,beating,0,0,1
2760,2682,TAMU_Peak.Parms_cardiomyocyte_Decay.Rise.Ratio.Average_up,0,0,NA,signaling,percent activity,negative,0,NA,gain,cellular,cellular,cardiomyocyte function,QT interval,0,0,1
2761,2682,TAMU_Peak.Parms_cardiomyocyte_Decay.Rise.Ratio.Average_dn,0,0,NA,signaling,percent activity,positive,0,NA,loss,cellular,cellular,cardiomyocyte function,QT interval,0,0,1
2762,2683,TAMU_PeakParms_cardiomyocyte_Peak.Amp.Avg_up,0,0,NA,signaling,percent activity,positive,0,NA,gain,cellular,cellular,cardiomyocyte function,amplitude,0,0,1
2763,2683,TAMU_PeakParms_cardiomyocyte_Peak.Amp.Avg_dn,0,0,NA,signaling,percent activity,negative,0,NA,loss,cellular,cellular,cardiomyocyte function,amplitude,0,0,1
2764,2684,TAMU_PeakParms_cardiomyocyte_Peak.Amp.CV_up,0,0,NA,signaling,percent activity,positive,0,NA,gain,cellular,cellular,cardiomyocyte function,amplitude variability,0,0,1
2765,2684,TAMU_PeakParms_cardiomyocyte_Peak.Amp.CV_dn,0,0,NA,signaling,percent activity,negative,0,NA,loss,cellular,cellular,cardiomyocyte function,amplitude variability,0,0,1
2766,2685,TAMU_PeakParms_cardiomyocyte_Peak.Freq.Avg_up,0,0,NA,signaling,percent activity,positive,0,NA,gain,cellular,cellular,cardiomyocyte function,frequency,0,0,1
2767,2685,TAMU_PeakParms_cardiomyocyte_Peak.Freq.Avg_dn,0,0,NA,signaling,percent activity,negative,0,NA,loss,cellular,cellular,cardiomyocyte function,frequency,0,0,1
2768,2686,TAMU_PeakParms_cardiomyocyte_Peak.Spacing.CV_up,0,0,NA,signaling,percent activity,positive,0,NA,gain,cellular,cellular,cardiomyocyte function,irregular beating,0,0,1
2769,2686,TAMU_PeakParms_cardiomyocyte_Peak.Spacing.CV_dn,0,0,NA,signaling,percent activity,negative,0,NA,loss,cellular,cellular,cardiomyocyte function,irregular beating,0,0,1
2770,2687,IUF_NPC1ab_proliferation_BrdU_up,0,0,"Data from the IUF_NPC1ab_proliferation_BrdU component was analyzed at the endpoint IUF_NPC1ab_proliferation_BrdU_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain-of-signal activity can be used to understand cell proliferation effects.",cell proliferation,percent activity,positive,0,media without growth factors,gain,dna,dna-unspecified,cell cycle,proliferation,0,0,1
2771,2687,IUF_NPC1ab_proliferation_BrdU_dn,0,0,"Data from the IUF_NPC1ab_proliferation_BrdU component was analyzed at the endpoint IUF_NPC1ab_proliferation_BrdU_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss-of-signal activity can be used to understand cell proliferation effects.",cell proliferation,percent activity,positive,0,media without growth factors,loss,dna,dna-unspecified,cell cycle,proliferation,0,0,1
2772,2688,IUF_NPC1ab_proliferation_area_up,0,0,"Data from the IUF_NPC1ab_proliferation_area component was analyzed at the endpoint IUF_NPC1ab_proliferation_area_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain-of-signal activity can be used to understand cell proliferation effects.",cell proliferation,percent activity,positive,0,media without growth factors,gain,cellular,cell morphology,cell cycle,proliferation,0,0,1
2773,2688,IUF_NPC1ab_proliferation_area_dn,0,0,"Data from the IUF_NPC1ab_proliferation_area component was analyzed at the endpoint IUF_NPC1ab_proliferation_area_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss-of-signal activity can be used to understand cell proliferation effects.",cell proliferation,percent activity,positive,0,media without growth factors,loss,cellular,cell morphology,cell cycle,proliferation,0,0,1
2774,2689,IUF_NPC1ab_viability_up,0,0,"Data from the IUF_NPC1ab_viability component was analyzed at the endpoint IUF_NPC1ab_viability_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,lysed cells,gain,cellular,mitochondria,cell cycle,cytotoxicity,0,1,1
2775,2689,IUF_NPC1ab_viability_dn,0,0,"Data from the IUF_NPC1ab_viability component was analyzed at the endpoint IUF_NPC1ab_viability_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,lysed cells,loss,cellular,mitochondria,cell cycle,cytotoxicity,0,1,1
2782,2702,CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,sodium orthovanadate (10uM),loss,cellular,cellular,neurodevelopment,synaptogenesis and neurite maturation,0,0,1
2781,2707,CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,sodium orthovanadate (10uM),loss,cellular,cellular,neurodevelopment,synaptogenesis and neurite maturation,0,0,1
2780,2696,CCTE_Mundy_HCI_Cortical_NOG_NeuronCount_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
2779,2697,CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
2778,2698,CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
2777,2699,CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss,1,1,"Data from the CCTE_Mundy_HCI_Cortical_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
2808,2717,UTOR_hL-FABP_binding_Kd_dn,1,1,"Data from the assay component UTOR_hL-FABP_binding was analyzed into 1 assay endpoint. This assay enddpoint, UTOR_hL-FABP_binding_Kd_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, measures of fluorescence for loss-of-signal activity can be used to understand competitive binding of L-FABP. Furthermore, this assay endpoint can be referred to as the primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""fatty acid binding protein"".",binding,percent activity,positive,0,"1,8-ANS",loss,protein,transporter,transporter,fatty acid binding protein,0,0,1
2809,1068,BSK_BT_Bcell_Proliferation_up,1,1,"Data from the assay component BSK_BT_Bcell_Proliferation  was analyzed at the endpoint, BSK_BT_Bcell_Proliferation_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, gain-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,cell cycle,proliferation,0,0,1
2810,1068,BSK_BT_Bcell_Proliferation_down,1,1,"Data from the assay component BSK_BT_Bcell_Proliferation  was analyzed at the endpoint, BSK_BT_Bcell_Proliferation_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,0,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2811,1069,BSK_BT_PBMCCytotoxicity_up,1,1,"Data from the assay component BSK_BT_PBMCCytotoxicity  was analyzed at the endpoint, BSK_BT_PBMCCytotoxicity_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, gain-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2812,1069,BSK_BT_PBMCCytotoxicity_down,1,1,"Data from the assay component BSK_BT_PBMCCytotoxicity  was analyzed at the endpoint, BSK_BT_PBMCCytotoxicity_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",signaling,log10_fold_induction,negative,0,colchicine,loss,cellular,cellular,cell cycle,proliferation,0,0,1
2813,1070,BSK_BT_sIgG_up,1,1,"Data from the assay component BSK_BT_sIgG was analyzed at the endpoint, BSK_BT_sIgG_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'immunoglobulin' intended target family, where the subfamily is 'IgG'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,immunoglobulin,IgG,0,0,1
2814,1070,BSK_BT_sIgG_down,1,1,"Data from the assay component BSK_BT_sIgG was analyzed at the endpoint, BSK_BT_sIgG_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'immunoglobulin' intended target family, where the subfamily is 'IgG'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,immunoglobulin,IgG,0,0,1
2815,1071,BSK_BT_xIL17A_up,1,1,"Data from the assay component BSK_BT_xIL17A was analyzed at the endpoint, BSK_BT_xIL17A_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2816,1071,BSK_BT_xIL17A_down,1,1,"Data from the assay component BSK_BT_xIL17A was analyzed at the endpoint, BSK_BT_xIL17A_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2817,1072,BSK_BT_xIL17F_up,1,1,"Data from the assay component BSK_BT_xIL17F was analyzed at the endpoint, BSK_BT_xIL17F_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2818,1072,BSK_BT_xIL17F_down,1,1,"Data from the assay component BSK_BT_xIL17F was analyzed at the endpoint, BSK_BT_xIL17F_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2819,1073,BSK_BT_xIL2_up,1,1,"Data from the assay component BSK_BT_xIL2 was analyzed at the endpoint, BSK_BT_xIL2_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2820,1073,BSK_BT_xIL2_down,1,1,"Data from the assay component BSK_BT_xIL2 was analyzed at the endpoint, BSK_BT_xIL2_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2821,1074,BSK_BT_xIL6_up,1,1,"Data from the assay component BSK_BT_xIL6 was analyzed at the endpoint, BSK_BT_xIL6_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2822,1074,BSK_BT_xIL6_down,1,1,"Data from the assay component BSK_BT_xIL6 was analyzed at the endpoint, BSK_BT_xIL6_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2823,1075,BSK_BT_xTNFa_up,1,1,"Data from the assay component BSK_BT_xTNFa was analyzed at the endpoint, BSK_BT_xTNFa_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2824,1075,BSK_BT_xTNFa_down,1,1,"Data from the assay component BSK_BT_xTNFa was analyzed at the endpoint, BSK_BT_xTNFa_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  cytokine quantitation reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2825,1081,BSK_MyoF_ACTA1_up,1,1,"Data from the assay component BSK_MyoF_ACTA1 was analyzed at the endpoint, BSK_MyoF_ACTA1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'actin'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,actin,0,0,1
2826,1081,BSK_MyoF_ACTA1_down,1,1,"Data from the assay component BSK_MyoF_ACTA1 was analyzed at the endpoint, BSK_MyoF_ACTA1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'actin'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,actin,0,0,1
2827,1082,BSK_MyoF_bFGF_up,1,1,"Data from the assay component BSK_MyoF_bFGF was analyzed at the endpoint, BSK_MyoF_bFGF_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'growth factor' intended target family, where the subfamily is 'basic fibroblast growth factor '.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,growth factor,basic fibroblast growth factor ,0,0,1
2828,1082,BSK_MyoF_bFGF_down,1,1,"Data from the assay component BSK_MyoF_bFGF was analyzed at the endpoint, BSK_MyoF_bFGF_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'growth factor' intended target family, where the subfamily is 'basic fibroblast growth factor '.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,growth factor,basic fibroblast growth factor ,0,0,1
2829,1083,BSK_MyoF_VCAM1_up,1,1,"Data from the assay component BSK_MyoF_VCAM1 was analyzed at the endpoint, BSK_MyoF_VCAM1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2830,1083,BSK_MyoF_VCAM1_down,1,1,"Data from the assay component BSK_MyoF_VCAM1 was analyzed at the endpoint, BSK_MyoF_VCAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2831,1084,BSK_MyoF_CollagenI_up,1,1,"Data from the assay component BSK_MyoF_CollagenI was analyzed at the endpoint, BSK_MyoF_CollagenI_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,collagen,0,0,1
2832,1084,BSK_MyoF_CollagenI_down,1,1,"Data from the assay component BSK_MyoF_CollagenI was analyzed at the endpoint, BSK_MyoF_CollagenI_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,collagen,0,0,1
2833,1085,BSK_MyoF_CollagenIII_up,1,1,"Data from the assay component BSK_MyoF_CollagenIII was analyzed at the endpoint, BSK_MyoF_CollagenIII_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,collagen,0,0,1
2834,1085,BSK_MyoF_CollagenIII_down,1,1,"Data from the assay component BSK_MyoF_CollagenIII was analyzed at the endpoint, BSK_MyoF_CollagenIII_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,collagen,0,0,1
2835,1086,BSK_MyoF_CollagenIV_up,1,1,"Data from the assay component BSK_MyoF_CollagenIV was analyzed at the endpoint, BSK_MyoF_CollagenIV_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,collagen,0,0,1
2836,1086,BSK_MyoF_CollagenIV_down,1,1,"Data from the assay component BSK_MyoF_CollagenIV was analyzed at the endpoint, BSK_MyoF_CollagenIV_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,collagen,0,0,1
2837,1087,BSK_MyoF_IL8_up,1,1,"Data from the assay component BSK_MyoF_IL8 was analyzed at the endpoint, BSK_MyoF_IL8_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2838,1087,BSK_MyoF_IL8_down,1,1,"Data from the assay component BSK_MyoF_IL8 was analyzed at the endpoint, BSK_MyoF_IL8_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2839,1088,BSK_MyoF_Decorin_up,1,1,"Data from the assay component BSK_MyoF_Decorin was analyzed at the endpoint, BSK_MyoF_Decorin_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'decorin'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,decorin,0,0,1
2840,1088,BSK_MyoF_Decorin_down,1,1,"Data from the assay component BSK_MyoF_Decorin was analyzed at the endpoint, BSK_MyoF_Decorin_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'decorin'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,decorin,0,0,1
2841,1089,BSK_MyoF_MMP1_up,1,1,"Data from the assay component BSK_MyoF_MMP1 was analyzed at the endpoint, BSK_MyoF_MMP1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2842,1089,BSK_MyoF_MMP1_down,1,1,"Data from the assay component BSK_MyoF_MMP1 was analyzed at the endpoint, BSK_MyoF_MMP1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2843,1090,BSK_MyoF_PAI1_up,1,1,"Data from the assay component BSK_MyoF_PAI1 was analyzed at the endpoint, BSK_MyoF_PAI1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
2844,1090,BSK_MyoF_PAI1_down,1,1,"Data from the assay component BSK_MyoF_PAI1 was analyzed at the endpoint, BSK_MyoF_PAI1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
2845,1091,BSK_MyoF_SRB_up,1,1,"Data from the assay component BSK_MyoF_SRB was analyzed at the endpoint, BSK_MyoF_SRB_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
2846,1091,BSK_MyoF_SRB_down,1,1,"Data from the assay component BSK_MyoF_SRB was analyzed at the endpoint, BSK_MyoF_SRB_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2847,1092,BSK_MyoF_TIMP1_up,1,1,"Data from the assay component BSK_MyoF_TIMP1 was analyzed at the endpoint, BSK_MyoF_TIMP1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2848,1092,BSK_MyoF_TIMP1_down,1,1,"Data from the assay component BSK_MyoF_TIMP1 was analyzed at the endpoint, BSK_MyoF_TIMP1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2849,2719,BSK_BF4T_MCP1_up,1,1,"Data from the assay component BSK_BF4T_MCP1 was analyzed at the endpoint, BSK_BF4T_MCP1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2850,2719,BSK_BF4T_MCP1_down,1,1,"Data from the assay component BSK_BF4T_MCP1 was analyzed at the endpoint, BSK_BF4T_MCP1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2851,2720,BSK_BF4T_Eotaxin3_up,1,1,"Data from the assay component BSK_BF4T_Eotaxin3 was analyzed at the endpoint, BSK_BF4T_Eotaxin3_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2852,2720,BSK_BF4T_Eotaxin3_down,1,1,"Data from the assay component BSK_BF4T_Eotaxin3 was analyzed at the endpoint, BSK_BF4T_Eotaxin3_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2853,2721,BSK_BF4T_VCAM1_up,1,1,"Data from the assay component BSK_BF4T_VCAM1 was analyzed at the endpoint, BSK_BF4T_VCAM1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2854,2721,BSK_BF4T_VCAM1_down,1,1,"Data from the assay component BSK_BF4T_VCAM1 was analyzed at the endpoint, BSK_BF4T_VCAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2855,2722,BSK_BF4T_ICAM1_up,1,1,"Data from the assay component BSK_BF4T_ICAM1 was analyzed at the endpoint, BSK_BF4T_ICAM1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2856,2722,BSK_BF4T_ICAM1_down,1,1,"Data from the assay component BSK_BF4T_ICAM1 was analyzed at the endpoint, BSK_BF4T_ICAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2857,2723,BSK_BF4T_CD90_up,1,1,"Data from the assay component BSK_BF4T_CD90 was analyzed at the endpoint, BSK_BF4T_CD90_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2858,2723,BSK_BF4T_CD90_down,1,1,"Data from the assay component BSK_BF4T_CD90 was analyzed at the endpoint, BSK_BF4T_CD90_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2859,2724,BSK_BF4T_IL8_up,1,1,"Data from the assay component BSK_BF4T_IL8 was analyzed at the endpoint, BSK_BF4T_IL8_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2860,2724,BSK_BF4T_IL8_down,1,1,"Data from the assay component BSK_BF4T_IL8 was analyzed at the endpoint, BSK_BF4T_IL8_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2861,2725,BSK_BF4T_IL1a_up,1,1,"Data from the assay component BSK_BF4T_IL1a was analyzed at the endpoint, BSK_BF4T_IL1a_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2862,2725,BSK_BF4T_IL1a_down,1,1,"Data from the assay component BSK_BF4T_IL1a was analyzed at the endpoint, BSK_BF4T_IL1a_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2863,2726,BSK_BF4T_Keratin818_up,1,1,"Data from the assay component BSK_BF4T_Keratin818 was analyzed at the endpoint, BSK_BF4T_Keratin818_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'keratin'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,keratin,0,0,1
2864,2726,BSK_BF4T_Keratin818_down,1,1,"Data from the assay component BSK_BF4T_Keratin818 was analyzed at the endpoint, BSK_BF4T_Keratin818_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'keratin'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,keratin,0,0,1
2865,2727,BSK_BF4T_MMP1_up,1,1,"Data from the assay component BSK_BF4T_MMP1 was analyzed at the endpoint, BSK_BF4T_MMP1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2866,2727,BSK_BF4T_MMP1_down,1,1,"Data from the assay component BSK_BF4T_MMP1 was analyzed at the endpoint, BSK_BF4T_MMP1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2867,2728,BSK_BF4T_MMP3_up,1,1,"Data from the assay component BSK_BF4T_MMP3 was analyzed at the endpoint, BSK_BF4T_MMP3_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2868,2728,BSK_BF4T_MMP3_down,1,1,"Data from the assay component BSK_BF4T_MMP3 was analyzed at the endpoint, BSK_BF4T_MMP3_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2869,2729,BSK_BF4T_MMP9_up,1,1,"Data from the assay component BSK_BF4T_MMP9 was analyzed at the endpoint, BSK_BF4T_MMP9_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2870,2729,BSK_BF4T_MMP9_down,1,1,"Data from the assay component BSK_BF4T_MMP9 was analyzed at the endpoint, BSK_BF4T_MMP9_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2871,2730,BSK_BF4T_PAI1_up,1,1,"Data from the assay component BSK_BF4T_PAI1 was analyzed at the endpoint, BSK_BF4T_PAI1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
2872,2730,BSK_BF4T_PAI1_down,1,1,"Data from the assay component BSK_BF4T_PAI1 was analyzed at the endpoint, BSK_BF4T_PAI1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
2873,2731,BSK_BF4T_SRB_up,1,1,"Data from the assay component BSK_BF4T_SRB  was analyzed at the endpoint, BSK_BF4T_SRB_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
2874,2731,BSK_BF4T_SRB_down,1,1,"Data from the assay component BSK_BF4T_SRB  was analyzed at the endpoint, BSK_BF4T_SRB_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2875,2732,BSK_BF4T_tPA_up,1,1,"Data from the assay component BSK_BF4T_tPA was analyzed at the endpoint, BSK_BF4T_tPA_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,serine protease,0,0,1
2876,2732,BSK_BF4T_tPA_down,1,1,"Data from the assay component BSK_BF4T_tPA was analyzed at the endpoint, BSK_BF4T_tPA_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,serine protease,0,0,1
2877,2733,BSK_BF4T_uPA_up,1,1,"Data from the assay component BSK_BF4T_uPA was analyzed at the endpoint, BSK_BF4T_uPA_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,serine protease,0,0,1
2878,2733,BSK_BF4T_uPA_down,1,1,"Data from the assay component BSK_BF4T_uPA was analyzed at the endpoint, BSK_BF4T_uPA_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,serine protease,0,0,1
2879,2734,BSK_BE3C_ICAM1_up,1,1,"Data from the assay component BSK_BE3C_ICAM1 was analyzed at the endpoint, BSK_BE3C_ICAM1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2880,2734,BSK_BE3C_ICAM1_down,1,1,"Data from the assay component BSK_BE3C_ICAM1 was analyzed at the endpoint, BSK_BE3C_ICAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2881,2735,BSK_BE3C_ITAC_up,1,1,"Data from the assay component BSK_BE3C_ITAC was analyzed at the endpoint, BSK_BE3C_ITAC_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2882,2735,BSK_BE3C_ITAC_down,1,1,"Data from the assay component BSK_BE3C_ITAC was analyzed at the endpoint, BSK_BE3C_ITAC_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2883,2736,BSK_BE3C_IL8_up,1,1,"Data from the assay component BSK_BE3C_IL8 was analyzed at the endpoint, BSK_BE3C_IL8_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2884,2736,BSK_BE3C_IL8_down,1,1,"Data from the assay component BSK_BE3C_IL8 was analyzed at the endpoint, BSK_BE3C_IL8_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2885,2737,BSK_BE3C_EGFR_up,1,1,"Data from the assay component BSK_BE3C_EGFR was analyzed at the endpoint, BSK_BE3C_EGFR_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
2886,2737,BSK_BE3C_EGFR_down,1,1,"Data from the assay component BSK_BE3C_EGFR was analyzed at the endpoint, BSK_BE3C_EGFR_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,receptor,kinase,receptor tyrosine kinase,0,0,1
2887,2738,BSK_BE3C_Keratin818_up,1,1,"Data from the assay component BSK_BE3C_Keratin818 was analyzed at the endpoint, BSK_BE3C_Keratin818_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'keratin'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,keratin,0,0,1
2888,2738,BSK_BE3C_Keratin818_down,1,1,"Data from the assay component BSK_BE3C_Keratin818 was analyzed at the endpoint, BSK_BE3C_Keratin818_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'keratin'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,keratin,0,0,1
2889,2739,BSK_BE3C_MMP9_up,1,1,"Data from the assay component BSK_BE3C_MMP9 was analyzed at the endpoint, BSK_BE3C_MMP9_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2890,2739,BSK_BE3C_MMP9_down,1,1,"Data from the assay component BSK_BE3C_MMP9 was analyzed at the endpoint, BSK_BE3C_MMP9_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2891,2740,BSK_CASM3C_PAI1_up,1,1,"Data from the assay component BSK_CASM3C_PAI1 was analyzed at the endpoint, BSK_CASM3C_PAI1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
2892,2740,BSK_CASM3C_PAI1_down,1,1,"Data from the assay component BSK_CASM3C_PAI1 was analyzed at the endpoint, BSK_CASM3C_PAI1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
2893,2741,BSK_hDFCGF_MCP1_up,1,1,"Data from the assay component BSK_hDFCGF_MCP1 was analyzed at the endpoint, BSK_hDFCGF_MCP1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2894,2741,BSK_hDFCGF_MCP1_down,1,1,"Data from the assay component BSK_hDFCGF_MCP1 was analyzed at the endpoint, BSK_hDFCGF_MCP1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2895,2742,BSK_hDFCGF_ICAM1_up,1,1,"Data from the assay component BSK_hDFCGF_ICAM1 was analyzed at the endpoint, BSK_hDFCGF_ICAM1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2896,2742,BSK_hDFCGF_ICAM1_down,1,1,"Data from the assay component BSK_hDFCGF_ICAM1 was analyzed at the endpoint, BSK_hDFCGF_ICAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2897,2743,BSK_hDFCGF_CollagenI_up,1,1,"Data from the assay component BSK_hDFCGF_CollagenI was analyzed at the endpoint, BSK_hDFCGF_CollagenI_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,collagen,0,0,1
2898,2743,BSK_hDFCGF_CollagenI_down,1,1,"Data from the assay component BSK_hDFCGF_CollagenI was analyzed at the endpoint, BSK_hDFCGF_CollagenI_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,collagen,0,0,1
2899,2744,BSK_hDFCGF_ITAC_up,1,1,"Data from the assay component BSK_hDFCGF_ITAC was analyzed at the endpoint, BSK_hDFCGF_ITAC_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2900,2744,BSK_hDFCGF_ITAC_down,1,1,"Data from the assay component BSK_hDFCGF_ITAC was analyzed at the endpoint, BSK_hDFCGF_ITAC_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2901,2745,BSK_hDFCGF_TIMP2_up,1,1,"Data from the assay component BSK_hDFCGF_TIMP2 was analyzed at the endpoint, BSK_hDFCGF_TIMP2_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2902,2745,BSK_hDFCGF_TIMP2_down,1,1,"Data from the assay component BSK_hDFCGF_TIMP2 was analyzed at the endpoint, BSK_hDFCGF_TIMP2_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,matrix metalloproteinase,0,0,1
2903,2746,BSK_KF3CT_IL8_up,1,1,"Data from the assay component BSK_KF3CT_IL8 was analyzed at the endpoint, BSK_KF3CT_IL8_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2904,2746,BSK_KF3CT_IL8_down,1,1,"Data from the assay component BSK_KF3CT_IL8 was analyzed at the endpoint, BSK_KF3CT_IL8_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2905,2747,BSK_KF3CT_MIG_up,1,1,"Data from the assay component BSK_KF3CT_MIG was analyzed at the endpoint, BSK_KF3CT_MIG_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2906,2747,BSK_KF3CT_MIG_down,1,1,"Data from the assay component BSK_KF3CT_MIG was analyzed at the endpoint, BSK_KF3CT_MIG_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2907,2748,BSK_KF3CT_PAI1_up,1,1,"Data from the assay component BSK_KF3CT_PAI1 was analyzed at the endpoint, BSK_KF3CT_PAI1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
2908,2748,BSK_KF3CT_PAI1_down,1,1,"Data from the assay component BSK_KF3CT_PAI1 was analyzed at the endpoint, BSK_KF3CT_PAI1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,plasmogen activator inhibitor,0,0,1
2909,2749,BSK_IMphg_MCP1_up,1,1,"Data from the assay component BSK_IMphg_MCP1 was analyzed at the endpoint, BSK_IMphg_MCP1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2910,2749,BSK_IMphg_MCP1_down,1,1,"Data from the assay component BSK_IMphg_MCP1 was analyzed at the endpoint, BSK_IMphg_MCP1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,chemotactic factor,0,0,1
2911,2750,BSK_IMphg_MIP1a_up,1,1,"Data from the assay component BSK_IMphg_MIP1a was analyzed at the endpoint, BSK_IMphg_MIP1a_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2912,2750,BSK_IMphg_MIP1a_down,1,1,"Data from the assay component BSK_IMphg_MIP1a was analyzed at the endpoint, BSK_IMphg_MIP1a_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2913,2751,BSK_IMphg_VCAM1_up,1,1,"Data from the assay component BSK_IMphg_VCAM1 was analyzed at the endpoint, BSK_IMphg_VCAM1_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2914,2751,BSK_IMphg_VCAM1_down,1,1,"Data from the assay component BSK_IMphg_VCAM1 was analyzed at the endpoint, BSK_IMphg_VCAM1_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,Immunoglobulin CAM,0,0,1
2915,2752,BSK_IMphg_CD40_up,1,1,"Data from the assay component BSK_IMphg_CD40 was analyzed at the endpoint, BSK_IMphg_CD40_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2916,2752,BSK_IMphg_CD40_down,1,1,"Data from the assay component BSK_IMphg_CD40 was analyzed at the endpoint, BSK_IMphg_CD40_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2917,2753,BSK_IMphg_ESelectin_up,1,1,"Data from the assay component BSK_IMphg_ESelectin was analyzed at the endpoint, BSK_IMphg_ESelectin_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cell adhesion molecules,selectins,0,0,1
2918,2753,BSK_IMphg_ESelectin_down,1,1,"Data from the assay component BSK_IMphg_ESelectin was analyzed at the endpoint, BSK_IMphg_ESelectin_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cell adhesion molecules,selectins,0,0,1
2919,2754,BSK_IMphg_CD69_up,1,1,"Data from the assay component BSK_IMphg_CD69 was analyzed at the endpoint, BSK_IMphg_CD69_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2920,2754,BSK_IMphg_CD69_down,1,1,"Data from the assay component BSK_IMphg_CD69 was analyzed at the endpoint, BSK_IMphg_CD69_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2921,2755,BSK_IMphg_IL8_up,1,1,"Data from the assay component BSK_IMphg_IL8 was analyzed at the endpoint, BSK_IMphg_IL8_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2922,2755,BSK_IMphg_IL8_down,1,1,"Data from the assay component BSK_IMphg_IL8 was analyzed at the endpoint, BSK_IMphg_IL8_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2923,2756,BSK_IMphg_IL1a_up,1,1,"Data from the assay component BSK_IMphg_IL1a was analyzed at the endpoint, BSK_IMphg_IL1a_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2924,2756,BSK_IMphg_IL1a_down,1,1,"Data from the assay component BSK_IMphg_IL1a was analyzed at the endpoint, BSK_IMphg_IL1a_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2925,2757,BSK_IMphg_MCSF_up,1,1,"Data from the assay component BSK_IMphg_MCSF was analyzed at the endpoint, BSK_IMphg_MCSF_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'colony stimulating factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,colony stimulating factor,0,0,1
2926,2757,BSK_IMphg_MCSF_down,1,1,"Data from the assay component BSK_IMphg_MCSF was analyzed at the endpoint, BSK_IMphg_MCSF_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'colony stimulating factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,colony stimulating factor,0,0,1
2927,2758,BSK_IMphg_IL10_up,1,1,"Data from the assay component BSK_IMphg_IL10 was analyzed at the endpoint, BSK_IMphg_IL10_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0,0,1
2928,2758,BSK_IMphg_IL10_down,1,1,"Data from the assay component BSK_IMphg_IL10 was analyzed at the endpoint, BSK_IMphg_IL10_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0,0,1
2929,2759,BSK_IMphg_SRB_up,1,1,"Data from the assay component BSK_IMphg_SRB  was analyzed at the endpoint, BSK_IMphg_SRB_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
2930,2759,BSK_IMphg_SRB_down,1,1,"Data from the assay component BSK_IMphg_SRB  was analyzed at the endpoint, BSK_IMphg_SRB_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2931,2760,BSK_IMphg_SRB.Mphg_up,1,1,"Data from the assay component BSK_IMphg_SRB.Mphg  was analyzed at the endpoint, BSK_IMphg_SRB.Mphg_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,cell morphology,cell conformation,0,0,1
2932,2760,BSK_IMphg_SRB.Mphg_down,1,1,"Data from the assay component BSK_IMphg_SRB.Mphg  was analyzed at the endpoint, BSK_IMphg_SRB.Mphg_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,cell cycle,cytotoxicity,0,1,1
2933,2761,BSK_LPS_Thrombomodulin_up,1,1,"Data from the assay component BSK_LPS_Thrombodulin was analyzed at the endpoint, BSK_LPS_Thrombomodulin_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,gpcr,rhodopsin-like receptor,0,0,1
2934,2761,BSK_LPS_Thrombomodulin_down,1,1,"Data from the assay component BSK_LPS_Thrombodulin was analyzed at the endpoint, BSK_LPS_Thrombomodulin_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,gpcr,rhodopsin-like receptor,0,0,1
2935,2762,BSK_LPS_CD69_up,1,1,"Data from the assay component BSK_LPS_CD69 was analyzed at the endpoint, BSK_LPS_CD69_up, in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, gain-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2936,2762,BSK_LPS_CD69_down,1,1,"Data from the assay component BSK_LPS_CD69 was analyzed at the endpoint, BSK_LPS_CD69_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of binding reporter, loss-of-signal activity can be used to understand protein changes. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,inflammatory factor,0,0,1
2948,2768,IUF_NPC4_neurite_length_120hr_dn,0,0,"Data from the IUF_NPC4_neurite_length_120hr component was analyzed at the endpoint IUF_NPC4_neurite_length_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,NA,loss,cellular,cellular,neurodevelopment,neural progenitor differentiation,0,0,1
2949,2769,IUF_NPC4_neurite_area_120hr_up,0,0,"Data from the IUF_NPC4_neurite_area_120hr component was analyzed at the endpoint IUF_NPC4_neurite_area_120hr_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,NA,gain,cellular,cellular,neurodevelopment,neural progenitor differentiation,0,0,1
2950,2769,IUF_NPC4_neurite_area_120hr_dn,0,0,"Data from the IUF_NPC4_neurite_area_120hr component was analyzed at the endpoint IUF_NPC4_neurite_area_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,NA,loss,cellular,cellular,neurodevelopment,neural progenitor differentiation,0,0,1
2951,2770,IUF_NPC5_oligodendrocyte_diff_120hr_up,0,0,"Data from the IUF_NPC5_oligodendrocyte_diff_120hr component was analyzed at the endpoint IUF_NPC5_oligodendrocyte_diff_120hr_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, gain-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,BMP7,gain,cellular,cellular,neurodevelopment,neural progenitor differentiation,0,0,1
2952,2770,IUF_NPC5_oligodendrocyte_diff_120hr_dn,0,0,"Data from the IUF_NPC5_oligodendrocyte_diff_120hr component was analyzed at the endpoint IUF_NPC5_oligodendrocyte_diff_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss-of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,BMP7,loss,cellular,cellular,neurodevelopment,neural progenitor differentiation,0,0,1
2954,2771,IUF_NPC2-5_cytotoxicity_72hr,0,0,"Data from the IUF_NPC2-5_cytotoxicity_72hr component was analyzed at the endpoint IUF_NPC2-5_cytotoxicity_72hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cytotoxicity effects.",cytotoxicity,percent activity,positive,0,Triton X-100,loss,cellular,enzyme activity,cell cycle,cytotoxicity,0,0,1
2956,2772,IUF_NPC2-5_cytotoxicity_120hr,0,0,"Data from the IUF_NPC2-5_cytotoxicity_120hr component was analyzed at the endpoint IUF_NPC2-5_cytotoxicity_120hr in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cytotoxicity effects.",cytotoxicity,percent activity,positive,0,Triton X-100,loss,cellular,enzyme activity,cell cycle,cytotoxicity,0,0,1
2957,2773,IUF_NPC2-5_count_120hr_up,0,0,"Data from the IUF_NPC2-5_count_120hr component was analyzed at the endpoint IUF_NPC2-5_count_120hr_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,Triton X-100,gain,cellular,cell count,cell cycle,proliferation,0,1,1
2958,2773,IUF_NPC2-5_count_120hr_dn,0,0,"Data from the IUF_NPC2-5_count_120hr component was analyzed at the endpoint IUF_NPC2-5_count_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,Triton X-100,loss,cellular,cell count,cell cycle,proliferation,0,1,1
2959,2774,IUF-NPC2-5_viability_120hr_up,0,0,"Data from the IUF_NPC2-5_viability_120hr component was analyzed at the endpoint IUF-NPC2-5_viability_120hr_up in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,Triton X-100,gain,cellular,mitochondria,cell cycle,cytotoxicity,0,1,1
2960,2774,IUF-NPC2-5_viability_120hr_dn,0,0,"Data from the IUF_NPC2-5_viability_120hr component was analyzed at the endpoint IUF-NPC2-5_viability_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability effects.",viability,percent activity,positive,0,Triton X-100,loss,cellular,mitochondria,cell cycle,cytotoxicity,0,1,1
2961,2775,CCTE_Shafer_MEA_acute_active_electrodes_number_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2962,2775,CCTE_Shafer_MEA_acute_active_electrodes_number_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2963,2776,CCTE_Shafer_MEA_acute_burst_duration_IQR_mean_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2964,2776,CCTE_Shafer_MEA_acute_burst_duration_IQR_mean_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2965,2777,CCTE_Shafer_MEA_acute_burst_duration_IQR_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2966,2777,CCTE_Shafer_MEA_acute_burst_duration_IQR_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2967,2778,CCTE_Shafer_MEA_acute_burst_duration_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2968,2778,CCTE_Shafer_MEA_acute_burst_duration_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2969,2779,CCTE_Shafer_MEA_acute_burst_frequency_mean_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2970,2779,CCTE_Shafer_MEA_acute_burst_frequency_mean_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2971,2780,CCTE_Shafer_MEA_acute_burst_frequency_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2972,2780,CCTE_Shafer_MEA_acute_burst_frequency_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2973,2781,CCTE_Shafer_MEA_acute_bursting_electrodes_number_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2974,2781,CCTE_Shafer_MEA_acute_bursting_electrodes_number_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2975,2782,CCTE_Shafer_MEA_acute_cross_correlation_area_normalized_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2976,2782,CCTE_Shafer_MEA_acute_cross_correlation_area_normalized_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2977,2783,CCTE_Shafer_MEA_acute_cross_correlation_HWHM_normalized_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2978,2783,CCTE_Shafer_MEA_acute_cross_correlation_HWHM_normalized_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2979,2784,CCTE_Shafer_MEA_acute_firing_rate_mean_weighted_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2980,2784,CCTE_Shafer_MEA_acute_firing_rate_mean_weighted_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2981,2788,CCTE_Shafer_MEA_acute_inter-network_burst_interval_CV_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2982,2788,CCTE_Shafer_MEA_acute_inter-network_burst_interval_CV_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2983,2785,CCTE_Shafer_MEA_acute_interburst_interval_CV_mean_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2984,2785,CCTE_Shafer_MEA_acute_interburst_interval_CV_mean_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2985,2786,CCTE_Shafer_MEA_acute_interburst_interval_CV_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2986,2786,CCTE_Shafer_MEA_acute_interburst_interval_CV_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2987,2787,CCTE_Shafer_MEA_acute_interburst_interval_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2988,2787,CCTE_Shafer_MEA_acute_interburst_interval_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2989,2789,CCTE_Shafer_MEA_acute_interspike_interval_CV_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2990,2789,CCTE_Shafer_MEA_acute_interspike_interval_CV_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2991,2790,CCTE_Shafer_MEA_acute_mean_interspike_interval_within_burst_mean_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2992,2790,CCTE_Shafer_MEA_acute_mean_interspike_interval_within_burst_mean_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2993,2791,CCTE_Shafer_MEA_acute_mean_interspike_interval_within_burst_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2994,2791,CCTE_Shafer_MEA_acute_mean_interspike_interval_within_burst_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2995,2792,CCTE_Shafer_MEA_acute_median_interspike_interval_within_burst_mean_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2996,2792,CCTE_Shafer_MEA_acute_median_interspike_interval_within_burst_mean_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2997,2793,CCTE_Shafer_MEA_acute_median_interspike_interval_within_burst_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
2998,2793,CCTE_Shafer_MEA_acute_median_interspike_interval_within_burst_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
2999,2794,CCTE_Shafer_MEA_acute_network_burst_duration_IQR_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3000,2794,CCTE_Shafer_MEA_acute_network_burst_duration_IQR_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3001,2795,CCTE_Shafer_MEA_acute_network_burst_duration_mean_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3002,2795,CCTE_Shafer_MEA_acute_network_burst_duration_mean_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3003,2796,CCTE_Shafer_MEA_acute_network_burst_duration_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3004,2796,CCTE_Shafer_MEA_acute_network_burst_duration_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3005,2797,CCTE_Shafer_MEA_acute_network_burst_frequency_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3006,2797,CCTE_Shafer_MEA_acute_network_burst_frequency_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3007,2798,CCTE_Shafer_MEA_acute_network_burst_number_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3008,2798,CCTE_Shafer_MEA_acute_network_burst_number_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3009,2799,CCTE_Shafer_MEA_acute_per_burst_spike_number_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3010,2799,CCTE_Shafer_MEA_acute_per_burst_spike_number_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3011,2800,CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3012,2800,CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3013,2801,CCTE_Shafer_MEA_acute_per_network_burst_mean_spikes_per_electrode_mean_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3014,2801,CCTE_Shafer_MEA_acute_per_network_burst_mean_spikes_per_electrode_mean_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3015,2802,CCTE_Shafer_MEA_acute_per_network_burst_mean_spikes_per_electrode_std_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3016,2802,CCTE_Shafer_MEA_acute_per_network_burst_mean_spikes_per_electrode_std_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3017,2803,TOX21_msti_p3_activity,0,0,"TOX21_msti_p3_activity used a chemical substrate, (E)-2-(4-mercaptostyryl)-1,3,3-trimethyl-3H-indol-1-ium (MSTI), to identify thiol-reactive chemicals in a chemical reaction format. Covalent binding of the test chemical with MSTI results in a decreased fluorescence intensity of the substrate. Thiol-reactive chemicals are associated with cell stress through effects on proteins and cellular membranes. To identify chemicals with have inherent fluorescence that may interfere with the assay, the TOX21_msti_p3_activity_n assay was performed in parallel consisting of the identical assay protocol but lacking the MSTI substrate.",chemical reporter,percent_activity,positive,0,MLS001163887,loss,chemical,chemical reactivity,NA,stress,0,0,1
3018,2804,TOX21_msti_p3_activity_n,0,0,TOX21_msti_p3_activity_n was run as an assay to identify chemicals with have inherent fluorescence that may interfere with the assay TOX21_msti_p3_activity. TOX21_msti_p3_activity_n assay was performed in parallel consisting of the identical assay protocol to TOX21_msti_p3_activity but lacking the MSTI substrate.,background control,percent_activity,positive,0,NA,loss,chemical,fluorescence,fluorescence,fluorescence,0,0,1
3024,2810,VALA_TUBIPS1_TubuleLength_up,0,0,,,percent_activity,,0,,,,,,,0,0,1
3025,2811,VALA_TUBIPS2_CellCount_dn,0,0,,,log2_fold_induction,,0,,,,,,,0,0,1
3026,2812,VALA_TUBIPS2_TubuleLength_dn,0,0,,,percent_activity,,0,,,,,,,0,0,1
3027,2813,VALA_MIGHUV1_CellCount_dn,0,0,,,log2_fold_induction,,0,,,,,,,0,0,1
3028,2814,VALA_MIGHUV1_WoundArea_up,0,0,,,percent_activity,,0,,,,,,,0,0,1
3029,2815,VALA_MIGHUV2_CellCount_dn,0,0,,,log2_fold_induction,,0,,,,,,,0,0,1
3030,2816,VALA_MIGHUV2_BCatenin_up,0,0,,,percent_activity,,0,,,,,,,0,0,1
3031,2817,VALA_MIGHUV2_WoundArea_up,0,0,,,percent_activity,,0,,,,,,,0,0,1
3032,2818,CCTE_GLTED_hIYD_dn,1,1,"Data from the CCTE_GLTED_hIYD was analyzed at the assay endpoint CCTE_GLTED_hIYD_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand iodotyrosine deiodinase activity.",enzymatic activity,percent inhibition,positive,0,3-Nitro-L-tyrosine (0.05 M NaOH for model inhibitor (MNT)),loss,protein,enzyme,dehalogenase,iodotyrosine deiodinase,0,0,1
3033,2819,CCTE_Shafer_MEA_dev_burst_rate_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3034,2819,CCTE_Shafer_MEA_dev_burst_rate_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3035,2820,CCTE_Shafer_MEA_dev_interburst_interval_mean_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3036,2820,CCTE_Shafer_MEA_dev_interburst_interval_mean_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3037,2821,CCTE_Shafer_MEA_dev_burst_duration_mean_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3038,2821,CCTE_Shafer_MEA_dev_burst_duration_mean_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3039,2822,CCTE_Shafer_MEA_dev_per_burst_interspike_interval_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3040,2822,CCTE_Shafer_MEA_dev_per_burst_interspike_interval_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3041,2823,CCTE_Shafer_MEA_dev_firing_rate_mean_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3042,2823,CCTE_Shafer_MEA_dev_firing_rate_mean_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3043,2824,CCTE_Shafer_MEA_dev_mutual_information_norm_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3044,2824,CCTE_Shafer_MEA_dev_mutual_information_norm_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3045,2825,CCTE_Shafer_MEA_dev_bursting_electrodes_number_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3046,2825,CCTE_Shafer_MEA_dev_bursting_electrodes_number_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3047,2826,CCTE_Shafer_MEA_dev_active_electrodes_number_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3048,2826,CCTE_Shafer_MEA_dev_active_electrodes_number_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3049,2827,CCTE_Shafer_MEA_dev_spike_duration_mean_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3050,2827,CCTE_Shafer_MEA_dev_spike_duration_mean_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3051,2828,CCTE_Shafer_MEA_dev_network_spike_duration_std_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3052,2828,CCTE_Shafer_MEA_dev_network_spike_duration_std_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3053,2829,CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3054,2829,CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3055,2830,CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3056,2830,CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3057,2831,CCTE_Shafer_MEA_dev_network_spike_number_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3058,2831,CCTE_Shafer_MEA_dev_network_spike_number_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3059,2832,CCTE_Shafer_MEA_dev_network_spike_peak_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3060,2832,CCTE_Shafer_MEA_dev_network_spike_peak_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3061,2833,CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3062,2833,CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3063,2834,CCTE_Shafer_MEA_dev_per_burst_spike_percent_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3064,2834,CCTE_Shafer_MEA_dev_per_burst_spike_percent_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3065,2835,CCTE_Shafer_MEA_dev_correlation_coefficient_mean_DIV12_up,0,0,,,percent activity,,0,,,,,,,0,0,1
3066,2835,CCTE_Shafer_MEA_dev_correlation_coefficient_mean_DIV12_dn,0,0,,,percent activity,,0,,,,,,,0,0,1
3067,2836,CCTE_Mundy_HCI_CDI_NOG_BPCount_loss,0,0,"Data from the CCTE_Mundy_HCI_CDI_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_CDI_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
3068,2837,CCTE_Mundy_HCI_CDI_NOG_NeuriteCount_loss,0,0,"Data from the CCTE_Mundy_HCI_CDI_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_CDI_NOG_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
3069,2838,CCTE_Mundy_HCI_CDI_NOG_NeuriteLength_loss,0,0,"Data from the CCTE_Mundy_HCI_CDI_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_CDI_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
3070,2839,CCTE_Mundy_HCI_CDI_NOG_NeuronCount_loss,0,0,"Data from the CCTE_Mundy_HCI_CDI_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_CDI_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",developmental,percent activity,positive,0,Rac 1 inhibitor (10uM),loss,cellular,cellular,neurodevelopment,neurite outgrowth (initiation),0,0,1
